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The use of sulfur in aqueous carbohydrate chemistry 
Carbohydrates play critical roles in a number of biological systems, including cell-cell 
recognition and signalling, regulation of protein transport, and receptor activation. 
Carbohydrates are typically found as glycoconjugates: carbohydrates attached to other 
biomolecules, such as proteins or lipids. Synthetic glycoconjugates have great potential to 
improve the treatments for a wide range of diseases, and can also be effective vaccines. 
Carbohydrates and carbohydrate mimics can also interact with a wide range of biological 
pathways, meaning that techniques for the synthesis of a range of carbohydrate and 
carbohydrate-derived species are in high demand. However, the modification of carbohydrates 
and the synthesis of glycoconjugates is often challenging, requiring multiple 
protection/deprotection steps, and so simple, widely applicable methods for the modification 
of carbohydrates and the synthesis of glycoconjugates are highly desirable. 
 
Sulfur is a versatile element: it is more nucleophilic than oxygen, can exist in a wide range of 
oxidation states, and functional groups containing sulfur are capable of carrying out a number 
of unique reactions including the thiol-ene click reaction, a wide range of redox reactions, and 
a number of nucleophilic substitution reactions. 
 
The work in this thesis focuses on the application of a number of sulfur’s unique features to 
the preparation of glycoconjugates and glycosidase inhibitors without the use of protecting 
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The following abbreviations have been used in this thesis: 
General abbreviations 
[α] Specific rotation 
ABq AB quartet (NMR spectroscopy) 
Ac Acetyl 
ADMP 2-Azido-1,3-dimethylimidazolinium hexafluorophosphate 
Ar Generic aromatic functional group 
ASGPR Asialoglycoprotein receptor 
Bn Benzyl 
Boc tert-Butyloxycarbonyl 
BSA Bovine serum albumin 
c Concentration 
°C Degrees celcius 
calcd. Calculated 
CDMBI 2-Chloro-1,3-dimethyl-1H-benzimidazolium chloride 
CHES N-Cyclohexyl-2-aminoethanesulfonic acid 
CuAAC Copper-catalysed azide-alkyne cycloaddition 
d Doublet (NMR spectroscopy) 
δ Chemical shift (NMR spectroscopy) 
Da Daltons 





dGMIIb Golgi α-mannosidase II 




DNA Deoxyribonucleic acid 
E. coli Escherichia coli 
Endo H Endo-β-N-acetylglucosaminidase from Streptomyces plicatus 




ESI-TOF Electrospray ionisation-time of flight detector 
Et al. Et alia 
Et Ethyl 
FAD Flavin adenine dinucleotide 
FMN Flavin mononucleotide 
Fmoc 9-Fluorenylmethoxycarbonyl 
g Gram(s) 










HIB Haemophilius influenza type B 
HILIC Hydrophilic interaction liquid chromatography 
HIV Human immunodeficiency virus 
hυ Electromagnetic radiation 
HPLC High-performance liquid chromatography 
HRMS High resolution mass spectrometry 
Hz Hertz 
J Coupling constant (NMR spectroscopy) 
I Inhibitor 
IC50 Half maximal inhibitory concentration 
i.e. Id est 
IgG Immunoglobulin G 
IME 2-Imino-2-methoxyethyl 
iPr Isopropyl 
Ka Acid dissociation constant 
Ki Inhibition constant 
Km Michaelis constant 
Km
app Apparent Michaelis constant 
KLH Keyhole limpet hemocyanin 
L Litre(s) 
LC-MS Liquid chromatography-mass spectrometry 
lit. Literature 
m metre(s) 





M Mole(s) per litre 
M Molecular mass ion (mass spectrometry) 
Man D-Mannose 
ManNAc N-Acetyl-D-Mannosamine 
mCPBA meta-Chloroperoxybenzoic acid 
Me Methyl 
MHC Major histocompatibility complex 
min Minute(s) 
mol Mole(s) 
m.p. Melting point 
MS Mass spectrometry 
MUC1 Mucin 1 
m/z Mass to charge ratio 
υ Initial reaction rate (enzyme kinetics) 
NADPH Nicotinamide adenine dinucleotide phosphate 
υmax Infrared spectroscopy peak 
NMR Nuclear magnetic resonance 












ppm Parts per million 
q Quartet (NMR spectroscopy) 
quant. Quantitative 
R Generic organic group, unless specified 
Rf Retention factor 
RNA Ribonucleic acid 
RT Room temperature 
s Second(s) 
s Singlet (NMR spectroscopy) 
S Substrate (enzyme kinetics) 
sat. Saturated 
SN2 Bimolecular nucleophilic substitution 




t.l.c. Thin layer chromatography 
TMS Trimethylsilyl 










VNTR Variable number tandem repeat 
Amino Acids 
Ala A Alanine 
Arg R Arginine 
Asn N Asparagine 
Asp D Aspartic acid 
Cys C Cysteine 
DHA  Dehydroalanine 
Gln Q Glutamine 
Glu E Glutamic acid 
Gly G Glycine 
HAG  Homoallylglycine 
His H Histidine 
HPG  Homopropargylglycine 
Ile I Isoleucine 
Lys K Lysine 
Met M Methionine 
Phe F Phenylalanine 
Pro P Proline 
Ser S Serine 
Thr T Threonine 
Trp W Tryptophan 
Tyr Y Tyrosine 
Val V Valine 




A note on atom labelling 
Carbohydrates have been named in accordance with IUPAC conventions,1 and numbered 
according to carbohydrate convention. The monosaccharide components of oligosaccharides 
are distinguished by a lower case letter, starting at the reducing terminus. 
 
Figure I: Atom labelling for flavins and flavinium salts. 










1. McNaught, A. D., Carbohydr. Res. 1997, 297 (1), 1-92. 
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Chapter 1: Introduction 
1.1 Carbohydrates overview 
Carbohydrates are a class of biomolecules critical to living organisms.1 Carbohydrates are 
found as polymers composed of monosaccharide units, which combine to form 
oligosaccharides (short carbohydrate chains) and larger polysaccharides (such as cellulose). 
Unlike other biopolymers, such as DNA, RNA, and proteins, structural diversity in 
carbohydrates is derived from variation in both the monomers used for construction of the 
carbohydrate and the position(s) and stereochemistry of chain extension from these monomers. 
Most monosaccharides have at least three positions from which the carbohydrate chain can be 
extended, leading to massive potential structural diversity even for short oligosaccharide 




Living organisms take advantage of the structural diversity of carbohydrates through the use 
of glycoconjugates. Glycoconjugates consist of one or more carbohydrates covalently bonded 
to another biomolecule, such as a protein or lipid. The structural diversity of carbohydrates 
leads to a correspondingly diverse set of roles for glycoconjugates. 
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1.2.1 N-Linked glycans 
N-Linked glycans are one of the two most common types of protein glycosylation. There are 
three main types of N-linked glycans (Figure 1.1), which share a common pentasaccharide 
core but differ in the sugars attached to this core.5  
 
Figure 1.1: Examples of the various types of N-linked glycans. 




High mannose N-linked glycans are composed of the core pentasaccharide with many mannose 
units attached, while complex N-linked glycans have a variety of different sugar units attached 
to the pentasaccharide core. Meanwhile, hybrid N-linked glycans contain one branch of the 
high-mannose type (which can itself have one or more branches) and one branch of the complex 
type. N-Linked glycans are almost exclusively found attached to protein asparagine residues 
which match the consensus sequence Asn-X-Ser/Thr, where X is any amino acid except 
proline.6 The biosynthesis of N-linked glycans begins with the assembly of a 
Glc3Man9GlcNAc2 oligosaccharide attached to dolichol phosphate. The entire oligosaccharide 
is then transferred to the protein by a glycosyl transferase, and is trimmed and extended as 
required.7 
 
1.2.2 O-Linked glycans 
Along with N-linked glycans, O-linked glycans make up the majority of protein glycosylation.8, 
9 O-Linked glycans are attached to serine and threonine residues, and unlike N-linked glycans 
only share a common N-acetylgalactosamine (GalNAc) residue before diversifying, leading to 
a greater variety of core structures. O-linked glycans are commonly found attached to mucins, 
proteins characterised by the presence of a repeated section of amino acids, which are typically 
found as part of mucous secretions and as transmembrane proteins. Unlike N-linked glycans, 
O-linked glycans are biosynthesised in a stepwise manner by the sequential addition of 
monosaccharide units to the growing oligosaccharide. Abnormal O-glycosylation has been 
linked to some forms of cancer.10 
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1.3 Glycoconjugates in protein folding 
One of the most important roles of the glycans of N-linked glycoproteins is in protein folding.11 
Glycoproteins are typically at least partially dependent on the attachment of appropriate 
N-linked glycans in order to fold correctly, although the degree to which the glycans are 
required varies. In extreme situations the lack of glycans on proteins which are normally 
glycosylated results in misfolding and protein aggregation.12-14 In other cases the lack of 
glycans results in an increase in misfolding relative to the glycosylated form15 or temperature-
dependent misfolding.16 The glycan requirement is not necessarily specific to a single site, 
rather, one or more of a number of glycans may be required. In this case removal of any 
individual glycan does not significantly impact protein folding, but removal of multiple glycans 
can result in misfolding.13, 17 There is also a subset of glycoproteins in which folding is entirely 
unaffected by the removal of the associated glycans.18, 19  
 
The role of the glycan component of glycoproteins in protein folding is therefore highly 
variable and unpredictable. The glycans may or may not be essential for correct protein folding, 
and in the former case all glycans or only some of them may be required.  
 
1.3.1 The calnexin-calreticulin cycle 
The calnexin-calreticulin cycle is one of the major pathways by which N-linked glycans have 
an influence on protein folding (Figure 1.2).20, 21  




Figure 1.2: The calnexin-calreticulin cycle. 
Briefly, calnexin and calreticulin are lectins which bind unfolded or misfolded proteins bearing 
a monoglucosylated high mannose N-linked glycan and act as chaperones to ensure correct 
folding occurs. Once folding is complete the glucose unit is removed by glucosidase II. 
However, a glucosyl transferase which recognises misfolded proteins can attach another 
glucose unit to the free high-mannose N-linked glycan, allowing misfolded proteins to re-enter 
the calnexin-calreticulin cycle in a process which repeats until the protein is correctly folded 
or degrades. 
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1.4 Glycan effects on protein stability 
As well as assisting in the folding of proteins, glycosylation can impact on the stability of 
folded glycoproteins, both in vitro and in vivo. Enzymatic removal of the glycans of 
glycoproteins or removal of potential glycosylation sites by site-directed mutagenesis can result 
in a lowering of the melting temperature of the protein, which indicates a decrease in the 
thermal stability of the protein tertiary structure.22-24  
 
For example, the removal of the glycans attached to Asn52 and Asn78 of the α subunit of 
human chorionic gonadotropin resulted in a small but significant decrease in the melting 
temperature of the protein.25  
 
A similar effect was observed when ribonuclease A was compared to ribonuclease B, which 
differ only in that ribonuclease B is glycosylated with a high-mannose oligosaccharide at 
Asn34, while ribonuclease A is not glycosylated.26 Ribonuclease A and B were found to unfold 
at similar rates, but ribonuclease B displayed a slightly higher melting temperature.  
 
A study of ovomucoid first domain, a glycoprotein which bears two complex oligosaccharides, 
revealed that glycosylation increases the melting temperature of the protein, and that this 
increase is primarily due to entropic effects.27 The smaller decrease in entropy between the 
unfolded and folded protein is proposed to be due to an increase in order in the unfolded 
glycosylated protein, resulting a smaller decrease in disorder when protein folding occurs. 
 




Modification of proteins that are not naturally glycosylated can also result in an increase in the 
thermal stability of the protein. Glycation of β-lactoglobulin with glucose or fructose via the 
Maillard reaction resulted in an increase in melting temperature of 5 °C and 6 °C respectively.28 
In this case the attachment of carbohydrates to the protein increases the stability of the protein’s 
secondary structure. 
 
In addition to simply increasing the melting temperature of a protein, glycosylation can have a 
number of other effects on the in vitro properties of glycoproteins, including imparting 
resistance to degradation by proteases,29 an increase or decrease in protein solubility,30 and an 
increase in the protein’s resistance to chemically induced unfolding.31 The glycosylation of 
proteins is a promising technique for improving the physical properties of proteins. 
 
1.5 Glycan effects on protein transport 
The precise glycans attached to a glycoprotein can have an impact on the movement of the 
glycoprotein in vivo. For example, the removal of terminal sialic acid residues from complex 
N-linked glycans results in the rapid clearance of ceruloplasmin by the liver,32 a process which 
depends on the binding of terminal galactose residues to the asialoglycoprotein receptor 
(ASGPR). The ASGPR is responsible for the clearance of a wide range of desialylated 
glycoproteins,33, 34 including erythropoietin (EPO). Treatment of EPO with a neuraminidase 
results in the removal of terminal sialic acid residues from the three complex glycans attached 
to EPO, and is accompanied by inactivation of EPO in vivo,35 due to the binding of desialylated 
EPO to the ASGPR and subsequent clearance.36 
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The two mannose-6-phosphate receptors bind selectively to terminal mannose-6-phosphate 
sugars and are responsible for the transport of a variety of hydrolases and other proteins to the 
lysosome.37, 38 Attachment of mannose-6-phosphate sugars to proteins results in enhanced 
localisation of the enzyme in the lysosome, providing a means of targeting the lysosome in 
enzyme replacement therapy.39, 40 The attachment of mannose-6-phosphate is not required to 
be via a natural linkage; localisation is still observed if a non-natural linkage between protein 
and mannose-6-phosphate is used.39, 41 
 
The mannose receptor family42 is a group of proteins which bind a wide variety of glycans, 
including sulfated glycans,43 and glycans possessing terminal mannose or fucose residues.44 
The mannose receptor is responsible for the binding of hormones such as the sulfated 
glycoprotein hormone lutropin,45 the clearance of sulfated glycoproteins,46 and the binding of 
high-mannose glycoproteins.47 The mannose receptor also plays a role in the immune system. 
 
1.6 Carbohydrates in self-recognition and immunity 
Glycans and glycoproteins are vital components of the immune system.48 Major 
histocompatibility complexes (MHCs) are cell surface proteins which bind to glycopeptide 
antigens and present them for recognition by T cells.49, 50 There are two classes of MHCs: class 
I, which present antigens derived from inside the cell, and class II, which present antigens 
derived from outside the cell. The highest immunogenic activity is observed when both the 
glycan and peptide antigen components are present.51 Recognition of a non-self antigen results 
in an immune response and subsequent generation of memory T cells. Memory T cells cause a 
rapid immune response upon any further antigen detection, which is reflected in immunity to 
the pathogen the antigen is taken from.52 




In addition, the mannose receptor plays a number of roles in the innate immune system.42 For 
example, macrophages utilise the mannose receptor to recognise some foreign objects, as 
human cell surface glycans do not typically possess terminal mannose residues and therefore 
cells bearing a high number of mannose residues would be expected to be foreign.53  
 
1.6.1 Glycoconjugate vaccines 
As antigens require both the glycan and peptide component for optimal presentation by MHCs, 
glycocoproteins or glycopeptides are ideal vaccine candidates.54, 55  
 
Figure 1.3: Structure of a bacterial cell which produces a polysaccharide capsule 
Many bacteria produce a cell capsule constructed from densely packed polysaccharides 
(Figure 1.3), ideal for use as an antigen. The first glycoconjugate vaccine was developed by 
Robbins and co-workers in 1980 against Haemophilus influenza type B (HIB).56 The vaccine 
was composed of HIB capsular polysaccharide conjugated to bovine serum albumin (BSA) via 
carbodiimide chemistry, and resulted in a significant immune response, while neither BSA nor 
polysaccharide alone resulted in any immune response. HIB polysaccharide conjugated to 
tetanus toxoid is still used as a vaccine against HIB.57 
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A number of other diseases have also been targeted by glycoconjugate vaccines. A cholera 
vaccine composed of cholera capsule polysaccharide conjugated to cholera toxin displayed 
significantly higher immunogenic activity than either of the components alone.58 Similarly, a 
vaccine against Shigella flexneri was prepared by the conjugation of capsule polysaccharide to 
tetanus toxoid.59 A vaccine targeting Streptococcus pneumoniae composed of 7 different types 
of capsular polysaccharide fragments, each conjugated to diphtheria CRM197 toxin, is effective 
against pneumonia.60 
 
The cell wall of the yeast Candida albicans provided another vaccine target.61 Conjugation of 
a trimannose component of Candida albicans’ cell wall to a short peptide resulted in an active 
anti-fungal vaccine, and conjugation of the same trimannose unit to tetanus toxoid also resulted 
in an immune response.  
 
As viruses co-opt the biochemical machinery of the host cell in order to reproduce, the 
glycosylation patterns of viral particles are typically much closer to those of the host, meaning 
that a carbohydrate-focused vaccine against viruses is much more difficult to produce than for 
bacteria or fungi.62 As an example, the human immunodeficiency virus (HIV) is contained 
within a protein shell which is glycosylated to an extreme degree by high-mannose N-linked 
glycans (Figure 1.4).63 High-mannose N-linked glycans are native to the human host, and so 
do not trigger an immune reaction, and the unique peptide sequences to which they are attached 
are beneath the thick carbohydrate layer, and so are not detected. 





Figure 1.4: External structure of an HIV particle. 
Despite these challenges, some progress has been made towards a carbohydrate-based HIV 
vaccine by mimicking the high-density of high-mannose glycans found on the surface of HIV 
particles - a feature not naturally found on human glycoproteins. High-mannose clusters based 
on a galactose support, 64 a short cyclic peptide support,65 and other branched structures66-69 
showed improved receptor binding and/or immunogenic activity over singly glycosylated 
structures. The use of viral scaffolds to provide multivalency has also been explored with mixed 
success.70, 71 Viruses are clearly more complex vaccine targets than bacteria, however 
carbohydrate-based vaccines have still shown some potential in provoking an immune 
response. 
 
In addition to vaccination against pathogens, carbohydrate-based vaccines have also shown 
some potential as anti-cancer vaccines. Tumour cells often display altered glycosylation 
patterns relative to non-tumour cells, including increased sialylation, fucosylation, branching 
Chapter 1: Introduction 
12 
 
of N-linked glycans, and truncation of O-linked glycans.10, 72 Promoting an immune response 
against these non-self glycans has shown some promise in the development of cancer vaccines. 
One of the earliest examples was published in 1997 by Ragupathi et al.,73 who demonstrated 
that the conjugation of globo H, a hexasaccharide associated with some cancers, to keyhole 
limpet hemocyanin (KLH) resulted in the production of anti-globo H antibodies. Other 
examples of anti-cancer vaccines based on carbohydrates conjugated to KLH include the sialyl 
Lewisy conjugate,74 the sTn conjugate,75 and the 5′-N-phenylacetyl sTn conjugate,76 among 
many others.77, 78 Many of these vaccines have reached clinical trials.79 
 
One feature often observed in tumour cells is the overexpression and aberrant glycosylation of 
mucins.80 Mucins are highly O-glycosylated proteins found in mucous layers and as 
transmembrane proteins. Alterations in O-linked glycan structure combined with a conserved 
repeating peptide unit meant that short mucin glycopeptides would be expected to be ideal 
candidates for a cancer vaccine. Investigation by von Mensdorff-Pouilly and co-workers 
revealed that this is indeed the case, and that the presence of both the peptide and glycan 
component resulted in greatly enhanced immunogenic activity.81 Subsequently a number of 
investigations into mucin glycopeptide vaccines have been carried out, frequently resulting in 
promising immune responses.82-84 
 
Carbohydrate-based vaccines have shown promise for the immunisation against and treatment 
of a number of conditions, and further exploration of this field has the potential to yield 
valuable pharmaceuticals. 
 




1.7 Synthesis of glycoproteins and glycopeptides 
The preparation of glycoproteins is a complex field, due to the extremely wide variety of 
glycans, linkages, and substrates which exist. There are a number of general modifications for 
the synthesis of glycoproteins, which can broadly be divided into two categories: 
indiscriminate, where there is no selectivity towards a particular site, and selective, where 
glycosylation only occurs in one or more pre-selected positions.85-88 
 
1.7.1 Indiscriminate glycoprotein synthesis 
The indiscriminate synthesis of glycoproteins is typically easier to carry out than selective 
glycosylation, however the glycoproteins produced are also less useful, as glycosylation of 
each particular molecule is random rather than well defined, which in turn results in more 
variation in the properties of the glycoprotein between batches. In addition, it is often difficult 
to control the precise degree of glycosylation, meaning that under- or, more commonly, over-
glycosylation, particularly of key catalytic or binding residues, can be an issue. Also, a well-
defined structure is necessary for the use of glycoproteins in biomedical applications.86 Despite 
these drawbacks, indiscriminate glycosylation methods are more widely applied, due to their 
relative ease and low cost. The majority of indiscriminate glycosylation methods take 
advantage of nucleophilic residues, primarily the amine groups of lysine, in order to modify a 
large number of residues, and are carried out to modify the physical properties (for example, 
solubility or stability) of the desired conjugate. 
 




Scheme 1.1: Modification of protein with aryldiazonium salts. 
The first reported indiscriminate preparation of a glycoprotein was in 1929 by Goebel and 
Avery,89 who prepared the aryldiazonium salts of glucose and galactose and coupled them to 
horse serum globulin (Scheme 1.1). Aryldiazonium salts couple to a wide variety of amino 
acid side chains, including tyrosine, histidine, and lysine,90 and therefore provide very little 
control over the point(s) of attachment of glycans even relative to other indiscriminate 
glycosylation methods. 
 





Scheme 1.2: The use of cyanogen bromide to prepare glycoproteins. 
Cyanogen bromide has been a popular reagent for indiscriminate glycosylation in the past,91-93 
however it has since fallen out of favour due to the harsh conditions required and the hazards 
associated with the use of cyanogen bromide. In addition, the conjugation reaction is not 
selective for a single product, resulting in a mixture of possible linkages (Scheme 1.2). 
 
One of the most common procedures for the coupling of carbohydrates to lysine residues is the 
use of reductive amination. The simplest method of reductive amination relies on the 
equilibrium which exists between the cyclic hemiacetal and open-chain aldehyde or ketone for 
all carbohydrates with a free reducing terminus (Scheme 1.3).94-97 




Scheme 1.3: Protein modification by reductive amination. 
Under mildly basic conditions the open-chain carbonyl can react in an equilibrium process with 
the amine group of a lysine residue to form an imine, which is then reduced in situ by sodium 
cyanoborohydride to form a stable secondary amine linkage. Protein modification by reductive 
amination is ubiquitous, but suffers from the drawback of destroying the natural conformation 
of the monosaccharide at the reducing terminus of the glycan. Reductive amination may also 
be carried out at positions other than the reducing terminus of the carbohydrate through the 
oxidation of other positions, for example by periodate cleavage of sugar rings98 or by enzymatic 
oxidation.99 Glycation followed by Amadori rearrangement shares some features with 
reductive amination, but notably relies upon the rearrangement of the imine generated as 
opposed to its reduction. Glycation has found some use in glycoconjugation reactions,100, 101 
however, the glycoconjugates produced by glycation and rearrangement also tend to be 




significantly less stable than those produced by reductive amination, and as a result glycation 
has not seen significant use in the synthesis of glycoproteins. 
 
Scheme 1.4: Carbodiimide-mediated coupling between glyco-carboxylic acids and lysine 
residues. 
Carbodiimide chemistry has been used to couple carbohydrates to proteins, either via the 
coupling of the carboxylate groups of glucuronic or hyaluronic acid to the lysine residues of a 
protein (Scheme 1.4),102, 103 or the coupling of amino sugars to the carboxylate groups of 
aspartic and glutamic acid residues.104-106 The use of carbodiimide chemistry is limited as either 
carboxylate or amine functionality is required as part of the sugar, and most natural glycans do 
not possess these functional groups in appropriate sites for conjugation, limiting the potential 
carbohydrate substrates. 
 
N-Hydroxysuccinimide esters have also been used to generate glycoproteins through the use of 
activated esters (Scheme 1.5).107, 108 In this case glycosylamines were accessed through 
reaction of free reducing sugars with ammonium carbonate, followed by attachment to the 
lysine residues of a protein through a double-ended succinimide ester linker.  
 




Scheme 1.5: Preparation of glycoproteins using a double-ended N-hydroxysuccinimide ester. 
2-Imino-2-methoxyethyl thioglycosides (IME thioglycosides) selectively react with lysine 
residues to produce amidine-linked glycoproteins (Scheme 1.6).109-112 IME thioglycosides are 
typically prepared by the reaction of cyanomethyl thioglycosides with sodium methoxide in an 
equilibrium process. The preparation of cyanomethyl thioglycosides is more involved than 
other indiscriminate glycosylation reagents, requiring the protection of the sugar, conversion 
to the glycosyl bromide, formation of the glycosyl thiol, reaction of the glycosyl thiol with 
chloroacetonitrile, and deprotection.109 The complexity involved in generating the required 
cyanomethyl thioglycoside can be reduced for synthetic oligosaccharides by introducing the 
required cyanomethyl functionality during the synthesis, while the glycan target is protected,113 
but IME thioglycosides still represent a more challenging synthetic target than other 
indiscriminate glycosylating agents, limiting their application. However, IME thioglycosides 
also represent a more gentle approach to indiscriminate glycosylation than most other methods, 
maintaining the natural glycan structure. 
 





Scheme 1.6: The use of IME thioglycosides to prepare glycoproteins. 
 
1.7.2 Site-selective glycoprotein synthesis 
Well-defined glycoproteins represent more valuable targets than indiscriminately glycosylated 
glycoproteins. Glycosylation at specific sites is often required for biological activity of 
glycoproteins, and even in cases where the exact positioning of the glycan is unimportant well-
defined glycoproteins are significantly simpler to study, and their synthesis is generally more 
consistent. However, selectively modifying one or more specified amino acids is often 
challenging. Site-selective glycoprotein synthesis can be divided into two broad categories: 
enzymatic glycosylation, which relies on the use of glycosyl hydrolases and transferases to 
modify existing glycosylation sites,85 and synthetic glycosylation.86, 88 Synthetic site-selective 
glycoprotein synthesis is primarily targeted at amino acids that are not naturally abundant: 
either proteogenic amino acids naturally found in low concentrations, such as cysteine, or non-
proteogenic amino acids. 
 
Enzymatic remodelling of glycoproteins relies upon the vast array of carbohydrate processing 
enzymes which exist in nature and which can, under the right conditions, be applied to 
Chapter 1: Introduction 
20 
 
selectively trim, transfer, and extend the oligosaccharides attached to a protein.85, 114 A typical 
procedure begins with either the trimming of the glycan components of the desired protein 
down to a single monosaccharide using an endohexosaminidase enzyme, such as Endo H,115, 
116 or by total synthesis of the desired protein or peptide, with monosaccharide residues at the 
desired positions.117 The desired glycans can be obtained by natural extraction118, 119 or total 
synthesis,40 and then converted to a glycosyl oxazoline. The glycosyl oxazoline and 
monosaccharide-modified peptide or protein are then used as substrates for a glycosynthase 
enzyme120 in order to link the two together. Enzymatic remodelling in this fashion has been 
used to access a wide range of glycoproteins, including mannosylated glycopeptides for use as 
vaccines,121 glycosylated pramlintide for the treatment of diabetes,117 remodelled IgG 
antibodies as promising anti-inflammatories,122 and glycan-modified enzymes for the treatment 
of lysosomal storage diseases.123 Enzymatic glycan remodelling has a number of advantages 
over the chemical synthesis of glycoproteins, including exceptional selectivity, compatibility 
with a wide range of glycan and protein structures, and often high reaction efficiency. However, 
enzymatic remodelling is for the most part restricted to natural glycosylation sites and 
structures, and the activity of glycosynthase enzymes on different proteins and glycans can be 
variable. 
 
Targeting of non-proteogenic amino acids for the chemical synthesis of glycoproteins offers a 
number of advantages, most significant of which is that the reactive functional groups, such as 
alkenes, alkynes, and azides, are not normally found in proteins and peptides, and therefore 
perfect selectivity can be achieved.  
 





Scheme 1.7: Synthesis of glycoproteins via CuAAC. 
Copper-catalysed azide-alkyne 1,3-dipolar cycloaddition (CuAAC) is an extremely versatile 
reaction which couples azides to alkynes selectively, cleanly, efficiently, and under a wide 
range of conditions.124, 125 Glycosyl azides have proven to be an effective means of attaching 
carbohydrates to proteins or peptides through the preparation of peptides or proteins containing 
unnatural homopropargylglycine (HPG) residues (Scheme 1.7).126-128 CuAAC is an effective 
means of attaching glycans to proteins with minimal side reactions and high conversions. The 
primary difficulty in the use of CuAAC to prepare glycoproteins or glycopeptides is the 
introduction of HPG to the protein or peptide of interest. Peptides can be obtained with relative 
ease through chemical synthesis,127 but the incorporation of HPG into proteins is challenging, 
and relies upon the reassignment of the methionine triplet codon to HPG in protein 
biosynthesis.126, 129, 130 
 
It is also possible to carry out CuAAC to conjugate glycans to proteins in the reverse direction; 
i.e. with a carbohydrate alkyne and a protein or peptide azide, in a reaction which is functionally 
very similar to and shares almost all of the benefits and drawbacks of the previously discussed 
method.131 Furthermore, the synthesis of a glycan alkyne is in most cases more challenging 
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than the synthesis of a glycosyl azide, meaning that the previously discussed method of 
coupling a glycosyl azide to a protein or peptide alkyne is preferred. 
 
Modification of cysteine residues is one of the leading techniques for glycoprotein synthesis, 
as cysteine is a proteogenic amino acid and therefore relatively easily introduced into a protein 
by site-directed mutagenesis, but free cysteine is relatively uncommon in most proteins as it is 
most often found in disulfide bonds, and therefore undesired side reactions are much simpler 
to avoid as compared to other proteogenic amino acids.  
 
Scheme 1.8: Conversion of cysteine to DHA and reaction with glycosyl thiol to form 
glycoproteins. 
Conversion of cysteine residues to dehydroalanine (DHA) allows for a conjugate addition 
reaction to take place with an appropriate nucleophile. Bernardes et al. have demonstrated that 
O-mesitylenesulfonylhydroxylamine selectively converts cysteine residues into DHA, which 
then reacts with thiols, including glycosyl thiols, to produce thioether-linked glycoproteins 
(Scheme 1.8).132 Glycan-DHA conjugates are stable and have similar structures to natural 
linkages, making them ideal for the preparation of glycoproteins.126, 133, 134 There are, however, 
no reports of the preparation of glycan-DHA conjugates larger than disaccharides. 
 





Scheme 1.9: The use of iodoacetamides to prepare glycoconjugates. 
Iodoacetamides are another example of a reagent that exploits the increased nucleophilicity of 
thiols relative to other biological functional groups. Glycosyl iodoacetamides react with 
cysteine residues to produce glycoproteins (Scheme 1.9).135, 136 Glycoproteins prepared in this 
way have amide functionality at the anomeric centre, a characteristic of natural N-linked 
glycans which is not often reproduced in synthetic glycoproteins. However, the reaction of 
iodoacetamides with cysteine residues is comparatively low yielding, meaning it is difficult to 
purify the resultant mixture of glycosylated and non-glycosylated protein. Side reactions with 
lysine residues are also possible.137 
 
Scheme 1.10: Use of thiosulfonates and selenyl sulfides to prepare glycoproteins. 
Cysteine can also be selectively modified through the formation of asymmetric disulfides. A 
number of reagents have been developed to carry out this transformation, most notably glycosyl 
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phenyl-138 and methylthiosulfonates,139 and glycosyl selenyl sulfides140 (Scheme 1.10). Both 
rely upon the attachment of a good leaving group to the sulfur of a glycosyl thiol, resulting in 
a species which reacts selectively with other thiols, such as the cysteines of proteins or peptides, 
to produce asymmetric disulfides. In the case of the selenyl sulfide method, it is also possible 
to prepare protein or peptide selenyl sulfide,141 and indeed this is believed to be the intermediate 
even when glycosyl selenyl sulfides are used as a reagent. For both thiosulfonates and selenyl 
sulfides the reaction is perfectly selective for cysteine residues, and the main drawback is that 
preparation of the glycan component can be challenging for larger oligosaccharides. Glycosyl 
selenyl sulfides are prepared from a glycosyl thiol, which either requires protection and 
deprotection of the sugar, or the use of Lawesson’s reagent, which is incompatible with 
2-acetamido sugars,141 a major component of most natural glycans. Protecting groups are also 
required for the preparation of glycosyl thiosulfonates; a method does not currently exist for 
the preparation of unprotected glycosyl thiosulfonates. 
 
Photocatalysed thiol-ene click chemistry has recently developed as another method for the 
preparation of glycoproteins.142, 143 In the presence of an appropriate radical initiator and UV 
light thiols form thiyl radicals, highly reactive and useful synthetic intermediates.144 In 
particular, thiyl radicals react with alkenes and alkynes to form stable thioether linkages. As 
with CuAAC, there are two possible ways to use thiol-ene click chemistry to generate 
glycoproteins: either by coupling of a glycosyl thiol and protein or peptide alkene (Scheme 
1.11, a)), or coupling of a sugar alkene to protein or peptide thiol (Scheme 1.11, b)). 





Scheme 1.11: Preparation of glycoproteins by photocatalysed thiol-ene click chemistry. 
The first method is generally preferred, primarily because, while synthesis of a glycosyl thiol 
does require protection and deprotection of the sugar, the difficulty in preparing glycosyl thiols 
of larger carbohydrates is outweighed by the difficulty of attaching an alkene to the same. As 
a result, proteins or peptides incorporating alkenes must be prepared. This is accomplished in 
a similar fashion to the preparation of proteins or peptides containing alkynes; that is, through 
chemical synthesis or the reassignment of the methionine codon to homoallylglycine (HAG). 
The reaction of carbohydrate alkenes with protein or peptide thiols is attractive from a protein 
and peptide synthesis perspective, as it would allow coupling to natural cysteine residues, but 
currently the preparation of carbohydrate alkenes for larger oligosaccharides provides too great 
a hurdle. Both methods have been used to prepare glycosylated versions of large proteins. 
Notably, Davis and co-workers prepared virus particles glycosylated at 180 sites through 
method a),145 while Dondoni and co-workers prepared BSA glycosylated with mannose 
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tetraacetate sugars in three positions via method b).146 As a final note, thiol-ene click chemistry 
can be extended to alkynes, which allows for two glycosylations at each position. 
 
A wide array of procedures currently exist for indiscriminate and site-selective glycoprotein 
synthesis, however in most cases one or more flaws or difficulties exist that prevent widespread 
application. In many cases the key issue is preparation of the reactive oligosaccharide or 
biomolecule without resorting to extended synthetic procedures or complex biological 
processes. A method which bypasses both these hurdles would allow for the significantly wider 
application of glycoproteins and glycopeptides. 
 
1.8 DMC and the aqueous modification of carbohydrates 
One of the principal issues in the preparation of glycoconjugates is that where modification of 
the carbohydrate moiety is required this modification is almost invariably accompanied by 
protection and deprotection steps. Methods that do not utilise protection and deprotection steps 
are often characterised by low yields, poor selectivities, or are inapplicable to structurally 
defined oligosaccharides. Reactions which selectively modify oligosaccharides effectively 
without requiring protecting groups are therefore highly desirable.  
 
Recently, 2-chloro-1,3-dimethylimidazolinium chloride (DMC, Figure 1.5) has emerged as a 
reagent for the selective modification of the anomeric centre of carbohydrates in water without 
the use of protecting groups. 
  





Figure 1.5: 2-Chloro-1,3-dimethylimidazolinium chloride (DMC). 
DMC exploits the subtle difference in pKa between the anomeric hydroxyl group and all other 
hydroxyl groups of carbohydrates. The anomeric hydroxyl group is more acidic than other 
oligosaccharide alcohols due to the anomeric effect, and is also more acidic than water.147 The 
anomeric hydroxyl group of glucose, for example, has a pKa of approximately 12, in 
comparison to values greater than 14 for water and other alcohols. Appropriate selection of 
base therefore allows the selective activation of the anomeric hydroxyl group in the presence 
of both other oligosaccharide alcohols and also in the presence of water. The use of a good 
nucleophile which can out-compete water then allows selective modification of the anomeric 
centre,128 to form 1,2-trans glycosides. The strength of the nucleophile is critical, as water is 
present in massive excess and so can potentially outcompete even potent nucleophiles. With 
this in mind, the use of D2O as a solvent results in reduced hydrolysis as compared to water, 
presumably due to the reduced dissociation constant of D2O.
148 
Scheme 1.12: Activation of 2-acetamido sugars by DMC. 
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The mechanism of activation by DMC is still not fully understood. Activation of 2-acetamido 
sugars is the simpler case, and is known to proceed via a 1,2-oxazoline, which can subsequently 
be opened by acid (Scheme 1.12).149 Indeed, DMC has quickly become established as the most 
widely used reagent for the formation of 1,2-oxazolines from unprotected oligosaccharides 
comprising 2-acetamido sugars at the reducing terminus.40, 150  
 
The activation of 2-hydroxy sugars is more complex. In all cases where the sugar contains a 
2-hydroxyl group 1,2-trans glycosides are formed, with glucose giving primarily β products 
and mannose giving primarily α products,151 implying that the 2-hydroxy group is participating 
in some manner. Shoda et al. report that 2-deoxy glucose can be activated by DMC and 
subsequently allowed to react to produce product, albeit with lowered selectivity, although a 
yield has not been quoted.151, 152 Two possible mechanisms have been proposed to account for 
these observations. 
Scheme 1.13: Shoda’s proposed DMC activation mechanism.152 
The first of these mechanisms was proposed by Shoda when he originally developed DMC in 
2009 (Scheme 1.13).152, 153 In this proposed mechanism, activation of the β anomer by DMC 




results in the formation of a 1,2-anhydrosugar intermediate, which is then opened by a 
nucleophile to produce the observed product. It is also possible for direct reaction between a 
nucleophile and the DMC-sugar intermediate to occur, although given that reaction with DMC 
and subsequent substitution is invariably selective for the 1,2-trans product it must be assumed 
that the rate of reaction for the mechanism involving participation of the 2-hydroxyl group is 
significantly greater than the rate of direct attack on the DMC-sugar intermediate. 
 
Scheme 1.14: DMC activation mechanism proposed by Novoa et al.154 
An alternative mechanism for activation of sugars by DMC was proposed by Novoa et al. 
(Scheme 1.14).154 Similarly to Shoda’s mechanism, the 2-hydroxyl group participates, 
however, in this case a 5-membered acetal ring is formed, which is then opened by a 
nucleophile to produce product. In this case the 1,2-trans starting anomer cannot possibly react 
to give product. NMR data purportedly showing the α DMC-glucose intermediate before attack 
by the 2-hydroxyl group is provided as evidence of this mechanism, however there is minimal 
characterisation of this intermediate, and the DMC-glucose acetal was not observed.  
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Upon performing a similar low temperature NMR experiment to Novoa et al., Shoda and co-
workers unsurprisingly observed the same peaks. However, a more detailed investigation 
indicated that the peaks observed most likely correspond to 1,2-anhydroglucose,155 rather than 
the α DMC-glucose intermediate suggested by Novoa et al., implying that DMC activation of 
a 2-hydroxy sugar results in the formation of a highly reactive 1,2-anhydrosugar, which then 
reacts selectively with a nucleophile. Although the observation of 1,2-anhydroglucose provides 
a strong indication of the activation mechanism, a number of mysteries remain, including why 
alteration of the solvent has a significant effect on the formation of byproducts such as 
1,6-anhydroglucose, and why, if direct hydrolysis of the DMC-sugar intermediate is also 
possible, nucleophilic attack on DMC-activated 2-hydroxy sugars is invariably perfectly 
selective. 
 
Nevertheless, DMC is undeniably a versatile reagent for the modification of unprotected 
oligosaccharides. Since the first use of DMC to activate unprotected oligosaccharides a wide 
variety of nucleophiles have been examined for attack upon the activated intermediate. 
 
As discussed previously, simultaneously one of the most simple and useful applications of 
DMC is the preparation of 1,2-oxazolines, first demonstrated by Shoda et al. in 2009.149 
1,2-Oxazolines are both useful synthetic intermediates and substrates for endo-β-N-
acetylglucosaminidase (ENGase) enzymes, which have been widely used in the preparation of 
glycoconjugates (Section 1.7.2). The formation of a 1,2-oxazoline is an inevitable consequence 
of the DMC activation of 2-acetamido sugars. As the formation of 1,2-oxazoline is currently 
the most widespread use of DMC activation, attempts to improve this reaction are ongoing. 





Figure 1.6: 2-Chloro-1,3-dimethyl-1H-benzimidazolium chloride (CDMBI). 
Notably, 2-chloro-1,3-dimethyl-1H-benzimidazolium chloride (CDMBI, Figure 1.6) is 
significantly less hygroscopic than DMC, and the side product of the activation reaction, 1,3-
dimethylbenzimidazolone, is almost completely insoluble in water.156 As a result, the urea 
byproduct of the reaction can easily be removed by filtration. As the urea product has been 
reported to inhibit synthetic reactions catalysed by ENGases it therefore becomes possible to 
use the crude oxazoline as an ENGase substrate, which is not the case with DMC. The most 
significant issue with CDMBI is that its synthesis is longer than that of DMC, and significantly 
lower yielding. 
 
Another possible intramolecular reaction that can occur upon DMC activation is the formation 
of 1,6-anhydrosugar as a result of the attack of the 6-hydroxyl group on the DMC-sugar 
intermediate.153 1,6-Anhydrosugar does not form if 2-acetamido sugars, sugars with an axial 
2-hydroxyl group, or sugars without a 6-hydroxyl group are activated by DMC, but in all other 
cases 1,6-anhydrosugar is invariably observed as a byproduct of DMC-mediated activation. 
 
Strong external nucleophiles can also react with sugars activated by DMC. As discussed 
previously, the nucleophile must be able to outcompete water or the DMC intermediate will 
simply hydrolyse, which provides a limit on the nucleophiles that can be used.  




Scheme 1.15: Preparation of glycosyl azides by Shoda and co-workers.151 
A stereotypical strong nucleophile, azide was one of the first nucleophiles to be applied to 
DMC-mediated substitution reactions (Scheme 1.15).151 Azide proved to be an effective 
nucleophile, provided a massive excess of sodium azide was used, affording unprotected 
glycosyl azides in moderate to high yields. The formation of 1,6-anhydrosugar, the main side-
product of the reaction, was minimised by changing the base used from triethylamine to 
diisopropylethylamine or 2,6-lutidine, although in the hands of the Fairbanks group the use of 
alternative amine bases was never successful. The reaction of 2-acetamido sugars did produce 
glycosyl azides in high yields, but an extended reaction time (36-48 h) was required, 
presumably due to the difficulty of opening the 1,2-oxazoline intermediate. Glycosyl azides 
are useful because they are ideal substrates for CuAAC (Section 1.7.2), so a process which 
gives unprotected glycosyl azides without requiring any other modification or protection of the 
oligosaccharide substrate is therefore of great benefit for the preparation of glycoconjugates. 
 
Figure 1.7: 2-Azido-1,3-dimethylimidazolinium chloride, ADMP. 
Improving on this method, Lim developed the reagent 2-azido-1,3-dimethylimidazolinium 
hexafluorophosphate (ADMP, Figure 1.7).128 ADMP generates azide in situ, both removing 
the need to work with highly toxic sodium azide and reducing the number of equivalents of 
azide required from 10 to 3. In addition, Lim showed that an acidic workup of the ADMP 




reaction of 2-acetamido sugars rapidly opens the 1,2-oxazoline intermediate that is formed 
competitively and forms glycosyl azide product without requiring the extended reaction times 
used by Shoda et al. Furthermore, Lim demonstrated that CuAAC can be carried out in one pot 
on crude glycosyl azide, providing a rapid means of generating glycoconjugates from a variety 
of free reducing sugars. 
 
Scheme 1.16: Preparation of unprotected thioglycosides using DMC. 
Sulfur-containing species are also widely used for their nucleophilicity, and therefore have also 
been examined for their reactivity with DMC-activated sugars. Again, the first example was 
provided by Shoda and co-workers, who demonstrated that DMC activation of 2-hydroxy 
sugars in the presence of aryl thiols resulted in the selective formation of unprotected aryl 
thioglycosides (Scheme 1.16),152, 157 species which are useful as O-glycoside analogues and, 
when protected, as donors for glycosylation reactions. In all cases the reaction was very high 
yielding, although it was not applied to any carbohydrates larger than a disaccharide.  
 
Scheme 1.17: Formation of DMC-thiol adduct. 
While DMC-mediated activation and substitution is effective for more acidic thiols such as aryl 
thiols, less acidic thiols show a tendency to form DMC adducts which interfere with the 
reaction efficiency (Scheme 1.17).154 In order to avoid this side reaction, Novoa et al. 
developed a procedure based upon pre-activation of the oligosaccharide with DMC, followed 
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by addition of thiol once the sugar was fully activated. In this manner they carried out the 
DMC-mediated activation and nucleophilic substitution using the thiol of a cysteine residue of 
a peptide on a solid phase support as a nucleophile in order to prepare a glycopeptides. 
Moderate yields were observed for one reaction cycle, but by iteratively adding activated sugar 
they were able to obtain a quantitative yield for glycosylated peptide over three cycles. 
 
DMC has a potential for modifying unprotected sugars that has just barely begun to be tapped. 
Further investigation into DMC could allow the direct preparation of all manner of unprotected 
carbohydrate derivatives, and from them a wide variety of glycoconjugates. 
  





Sulfur is widely used in carbohydrate chemistry, most commonly in the form of thioglycosides. 
Thioglycosides were first prepared over 90 years ago by Schneider et al.158 by the reaction of 
two equivalents of ethanethiol with glucose in the presence of a stoichiometric amount of 
mercuric chloride (Scheme 1.18). 
 
Scheme 1.18: The preparation of thioglycosides by Schneider et al. 
In modern times thioglycosides are typically prepared by the reaction of peracetylated sugars 
with a thiol in the presence of a Lewis acid (Scheme 1.19), most commonly BF3.OEt2,
159 but a 
number of other Lewis acids such as SnCl4,
160 ZrCl4,
161 and MoO2Cl2
162 have also been used.  
 
Scheme 1.19: Preparation of thioglycosides by the reaction of peracetylated monosaccharides 
with a Lewis acid and a thiol. 
Thioglycosides are stable to a wide range of conditions, and are frequently used as glycosyl 
donors in glycosylation reactions, as they can be activated in a large number of ways, including 
with methyl triflate,163, 164 N-iodosuccinimide together with a variety of other species,165, 166 
and various other conditions.167, 168 However, in many cases they are less reactive than other 
glycosyl donors, such as trichloroacetimidates.169  
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1.10 Glycosyl sulfoxides 
Although thioglycosides are only moderately reactive in glycosylation reactions, they are 
special in that they can be converted to glycosyl sulfoxides, which display significantly greater 
activity than the corresponding thioglycoside. Glycosyl sulfoxides were first used in 
glycosylation reactions by Kahne et al.170 in 1989. They proved significantly more active than 
other glycosyl donors of the time. For example, the glycosylation of an extremely sterically 
demanding steroid unit (Scheme 1.20) was accomplished with a yield of 85%, while other 
attempts to synthesise similar species gave yields for the crucial glycosylation step of 40% or 
less.171 
 
Scheme 1.20: Glycosylation of a a sterically demanding steroid unit by Kahne et al.170 
 
1.10.1 Applications of glycosyl sulfoxides 
Since they were first reported glycosyl sulfoxides have been used in glycosylation reactions 
where their increased reactivity or other unique properties are important. Crich and co-workers 
have repeatedly used glycosyl sulfoxides in their syntheses of β-mannans.172-175 In these 
syntheses the increased propensity of glycosyl sulfoxides to give the β-anomer when used in 
glycosylation reactions makes them ideal for the synthesis of chains of β-linked mannose units, 




which are otherwise very difficult to access. This selectivity is proposed to be due to the 
formation of an α-glycosyl triflate when a glycosyl sulfoxide is activated by triflic anhydride,176 
which is subsequently selectively attacked in an SN2 reaction to give a β-glycoside product.  
 
Crich has also exploited both the increased reactivity and β selectivity of glycosyl sulfoxides 
by using them in the preparation of β-mannosyl phosphoisoprenoids.172, 177 This class of 
molecule had in the past proved to be very difficult to prepare,178 but using glycosyl sulfoxides 
as the glycosyl donors allowed their preparation in moderate yields with good selectivity, an 
improvement over other methods. Glycosyl sulfoxides are key to the preparation of these 
biologically relevant molecules. 
 
Like thioglycosides, glycosyl sulfoxides can be activated with a wide range of different 
activating agents. The first and most common activating agent used is triflic anhydride,170 but 
reagents such as triflic acid179 and trimethylsilyl triflate180 have also been used. Significantly, 
because the reactivity of glycosyl sulfoxides is both much greater than that of thioglycosides 
and dependent on the aglycon unit of the sulfoxide, careful tuning of the reaction conditions 
allows selective reaction of sulfoxides both in the presence of thioglycosides180, 181 and in the 
presence of other glycosyl sulfoxides.  




Scheme 1.21: One pot synthesis of the trisaccharide component of cylcamycin by  
Kahne et al. 179 
This is most elegantly demonstrated in the synthesis of the cyclamycin trisaccharide by Kahne 
et al.179 (Scheme 1.21). In this synthesis three monosaccharide units were combined and 
activated in one pot to produce a trisaccharide with a thioglycoside at its reducing terminus. 
This was possible because the rate limiting step in glycosylation using glycosyl sulfoxides is 
triflation of the glycosyl sulfoxide, and therefore alteration of the electron donating ability of 
the aglycon, for example by adding an electron donating methoxy group to the phenyl ring, 
increases the rate of activation and hence the rate of glycosylation. This therefore allows 
selective activation of p-methoxyphenyl glycosyl sulfoxides in the presence of phenyl 
sulfoxides provided the conditions are carefully controlled. In addition, the use of a silyl 
protecting group which is stable at low temperatures (as used in the activation of 
p-methoxyphenyl glycosyl sulfoxides), but not at higher temperatures (as used in the activation 
of phenyl glycosyl sulfoxides) allows the in situ deprotection of a hydroxyl group in order to 
carry out the second glycosylation reaction selectively with respect to the glycosyl acceptor. 




Furthermore, this synthesis could be carried out with a thioglycoside at the reducing terminus, 
allowing for further glycosylation if required, without any further modification of the structure. 
As can be seen from this synthesis, glycosyl sulfoxides are versatile reagents that can be subtly 
modified in order to afford significant control over a reaction. 
 
Scheme 1.22: Use of glycosyl sulfoxides to generate glycosyl carbanions and subsequent 
reactions of glycosyl carbanions. 
In addition to glycosylation reactions, glycosyl sulfoxides can be used in a number of other 
reactions. Treatment of glycosyl sulfoxides with an alkyl lithium such as n-butyl lithium or t-
butyl lithium generates a glycosyl carbanion which can then either react with an electrophile, 
for example to synthesise a C-glycoside,182 or eliminate to produce a glycal183 (Scheme 1.22).  
 
Scheme 1.23: Thermal rearrangement of glycosyl sulfoxides. 
Upon heating, sulfoxides undergo β-elimination to form a sulfenic acid and an alkene (Scheme 
1.23). Depending on which direction β-elimination occurs in this can produce two different 
classes of products. Typically glycosyl sulfoxides will β-eliminate to form 2-hydroxy or 2-
amino glycals, which are useful synthetic intermediates.184 If aromatic glycosyl sulfoxides are 
Chapter 1: Introduction 
40 
 
used this is the only potential elimination pathway. Alkyl glycosyl sulfoxides, however, may 
also β-eliminate towards the aglycon, producing glycosyl sulfenic acids. This process has been 
studied in depth by Aversa et al.,185-187 who determined that through careful choice of the 
aglycon group glycosyl sulfenic acids could be generated by heating glycosyl sulfoxides, and 
subsequently be reacted in situ with either alkynes to generate α,β-unsaturated sulfoxides, or 
with thiols to generate mixed disulfides. 
 
Sulfoxides have also found use as glycosidase inhibitors. Glycosidases are an extremely 
widespread category of enzymes which catalyse the hydrolysis of glycosidic linkages.188, 189 
As glycosidases are involved in such a wide variety of processes, inhibitors of glycosidases 
have a correspondingly wide variety of applications, including glycogen phosphorylase 
inhibitors for the treatment of type 2 diabetes,190 neuraminidase inhibitors for the treatment of 
influenza,191 inhibitors of glycosphingolipid formation for the treatment of Gaucher’s 
disease,192 and many more.193 
 
1.11 Glycosidase mechanisms  
Most glycosidase enzymes share one of two general mechanisms (Scheme 1.24).194 Inverting 
glycosidases rely upon acid-catalysed activation of the glycoside to be cleaved while 
simultaneously activating water for attack by base catalysis. This results in a one-step 
mechanism whereby the stereochemistry at the anomeric centre is inverted. The transition state 
of this mechanism involves the build-up of positive charge on the endocyclic sugar oxygen, 
and protonation of the exocyclic sugar oxygen, followed by a build-up of negative charge.195 
A water molecule is also present in the active site of the enzyme.  





Scheme 1.24: General mechanism for inverting (a)) and retaining (b)) glycosidases. 
Retaining glycosidases display a similar active site to inverting glycosidases, but carry out the 
hydrolysis reaction slightly differently. The glycoside is again activated by protonation of the 
exocyclic oxygen, however in this case the nucleophile is not water but a deprotonated 
carboxylic acid residue. A covalent enzyme-carbohydrate intermediate is then formed. The 
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former catalytic acid is now deprotonated and can therefore act as a catalytic base to activate 
water for attack and hydrolysis of the covalent intermediate to form the hydrolysed product. 
Due to the double inversion of stereochemistry, the reactant and product share the same 
stereochemistry at the anomeric centre. 
 
The first transition state for retaining glycosidases is similar to that of inverting glycosidases, 
in that there is again protonation of the exocyclic oxygen and a build-up of positive charge on 
the endocyclic oxygen. However, there is no water molecule present in the active site of the 
enzyme, with a covalent intermediate being formed instead. This naturally leads to a second 
transition state, in which the covalent intermediate is hydrolysed by a water molecule to give 
hydrolysed product. This process is base-catalysed, as the catalytic residue assists in 
deprotonating the water so it can attack the anomeric centre of the sugar. Again, there is a 
significant build-up of positive charge on the endocyclic oxygen. 
 
Binding of the carbohydrate substrate in the active site also results in significant distortion of 
the carbohydrate structure.196 Crystallographic studies have shown that the ring is distorted 
from a standard 4C1 chair conformation to a 
1S3 skew-boat conformation.
197 Leaving group 
(aglycon) binding is essential for this to take place, as species which do not bind in the leaving 
group pocket have been shown to be undistorted. 
 
  




1.12 Glycosidase inhibitors 
The concept that enzymes have the highest affinity for the transition state of a reaction in order 
to lower the energy of activation of the reaction is well established.198 One possible logical 
approach to inhibitor design is therefore to design species which mimic the transition state of 
the reaction, as this is the species to which the enzyme binds most strongly. Most glycosidase 
inhibitors reflect this design philosophy, although in a number of cases detailed studies have 
indicated that binding is at most partially due to the compound in question being a transition 
state mimic. Other interactions both within and external to the enzyme active site can result in 
inhibitors which bind strongly to an enzyme, and in many cases this is true for glycosidase 
inhibitors, which often form strong salt bridge interactions with catalytic residues. 
 
1.12.1 Inhibitors containing endocyclic heteroatoms 
 
Figure 1.8: Amine-based glucosidase inhibitors. 
As noted previously there is significant build-up of positive charge on the endocyclic oxygen, 
and so mimicking this feature might be expected to be a step towards more potent inhibitors. 
Commonly, a positively charged heteroatom is introduced in place of the endocyclic oxygen 
or the anomeric carbon, a feature which could be expected to mimic this partial positive charge. 
Furthermore, glycosidase active sites contain multiple carboxylate residues, and charged 
species would be expected to form strong interactions with these residues. This can be seen in 
potent glycosidase inhibitors such as 1-deoxynojirimycin 1.1199, 200 and castanospermine 1.2,201 
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both glucosidase inhibitors (Figure 1.8). Protonation of the ring nitrogen, which occurs fully 
at physiological pH, creates a positive charge where the endocyclic oxygen would be, 
increasing the binding affinity of the molecule for the glycosidase. Isofagomine 1.3 was 
developed based on a similar principle, but with a nitrogen atom in place of the anomeric 
carbon, and is also a strong inhibitor of glucosidases.202 
Nitrogen is not the only atom that has been used in this role. Sulfur has been investigated in 




Inhibition of α-glucosidase from Bacillus 







Figure 1.9: 5-Thiosugars and derivatives prepared by Le Merrer et al. and their inhibition of 
α-glucosidase from Bacillus stearothermophilus.203 
Sulfides are not expected to be good glycosidase inhibitors, as they will generally share both 
the geometry and non-polarised bonds of the starting material, rather than the transition state. 




They are also uncharged, and as a result do not interact strongly with the catalytic carboxylate 
residues. This is borne out by experiment, whereby the preparation and inhibition testing of 5-
thio analogues of 1-deoxynojirimycin and similar structures (Figure 1.9) by Le Merrer et al.203 
revealed that thioether compounds 1.4, 1.5, and 1.6 displayed only modest inhibition against a 
panel of glycosidase enzymes, with minimal inhibition even at a concentration of 1 mM. In this 
case, a limited study of the effect of oxidation of the sulfur demonstrated a limited effect on 
the inhibition of the compound in question, with both sulfoxide 1.7 and sulfone 1.8 displaying 
similar inhibition percentages. Sulfoxide 1.7 did demonstrate slightly improved inhibition, but 
the increase was minimal. 
 
Figure 1.10: The structure of salacinol 
Salacinol (Figure 1.10) is a natural product derived from the roots and stems of Salacia 
reticulate.204 It is a strong glucosidase inhibitor, displaying comparable inhibition of rat 
intestinal maltase and sucrase to acarbose, a leading glucosidase inhibitor used for the treatment 
of type-2 diabetes.205 In addition, salacinol displayed greatly increased inhibition of isomaltase 
over acarbose. The presence of a positively charged sulfonium ion is presumably a significant 
factor in salacinol’s strong binding to glucosidases.  




Figure 1.11: Binding of salacinol to the active site of NtMGAM. Adapted from the work of 
Nakamura et al.206 
Salacinol has since been synthesised207 and its docking to the N-terminal catalytic domain of 
maltase-glucoamylase (NtMGAM) has been studied (Figure 1.11).206 As would be expected, 
the hydroxyl groups form a network of hydrogen bonds, presumably mimicking interactions 
formed by the natural substrate. The sulfonium ion forms a salt bridge with an aspartate residue, 
a feature consistent with iminosugar inhibitors. Investigation has suggested that perhaps this 
interaction is less representative of transition state mimicry and more an example of fortuitous 
binding, whereby the inhibitor takes advantage of different interactions to the natural substrate, 
and therefore is not a transition state mimic.208 This is logical, as while there is a build-up of 
positive charge in the transition state, it is only partial, not a full charge as is observed in 
sulfonium or iminosugars. While fortuitous binders are no less effective for not being transition 
state mimics, they are typically harder to discover in a logical manner, and modification will 
not necessarily result in predictable variation in binding affinity.  
 
Strong hydrogen bonding interactions or salt bridges are characteristic of glycosidase inhibitors 
that are not transition state mimics.208 Multiple carboxylate residues are invariably present in 




the active site of glycosidase enzymes to act as catalytic acids, bases, or nucleophiles, and 
therefore charged compounds that depend on interactions with these residues often show 
inhibition of a wide variety of glycosidases, despite not being transition state mimics. 
 
1.12.2 Inhibitors containing exocyclic heteroatoms 
As the exocyclic oxygen is protonated during the glycosidase-catalysed hydrolysis of 
glycosides, the exocyclic oxygen may also develop a partial positive charge, depending on the 
time of protonation on the reaction co-ordinate relative to carbon-oxygen bond cleavage. In 
addition, a positive charge can help create salt bridge interactions within the enzyme active 
site, as discussed previously. Molecules bearing a positive charge or partial positive charge in 
the position of the exocyclic oxygen have therefore also been investigated.  
 
Figure 1.12: The structure of Mannostatins A and B. 
For example, Mannostatin A (1.9, Figure 1.12) and its sulfoxide Mannostatin B (1.10) have 
been shown to be strong inhibitors of rat epididymis mannosidase, both displaying Kis of 
48 nM.209 In this case modelling has suggested that the significant interaction is hydrogen 
bonding of the amine group with the general acid/base aspartic acid residue.210 Again, the 
mannostatins do not appear to be true transition state mimics, instead inhibiting due to strong 
hydrogen bonding interactions. However, the five-membered ring is proposed to be a good 
mimic for the distorted six-membered ring of the transition state.  








Figure 1.13: Inhibitors developed by Robina et al. and their inhibition of β-glucosidase from 
Caldocellum saccharolyticum.211 
 Glycosyl sulfoxides have also been investigated as glycosidase inhibitors featuring a polarised 
exocyclic group. Robina et al. investigated 2-phthalamido derivatives 1.11-1.14 as inhibitors 
of β-glucosidases (Figure 1.13).211 Thioglycoside 1.11, its sulfoxide 1.12, and chlorinated 
sulfoxide 1.14 displayed moderate inhibition at a 1 mM concentration, with chlorinated 
sulfoxide 1.14 being the most effective inhibitor. Curiously, 1.14 inhibits uncompetitively at 
substrate concentrations below 1 mM. Uncompetitive inhibition is when the inhibitor only 
binds to the enzyme substrate complex, implying that 1.14 does not occupy the sugar’s position 
in the enzyme active site. It is possible that 1.14 is binding in another location in the active site, 
or is binding elsewhere in the molecule. 
Compound 
Inhibition of β-glucosidase from Caldocellum 










Compound IC50 for dGMIIb (mM) 
1.15 No inhibition 
1.16 No inhibition 





Figure 1.14: Inhibitors of dGMIIb developed by Poláková et al.212 
Mannose thioglycosides, sulfoxides, and sulfones 1.15-1.20 were investigated by Poláková et 
al. as inhibitors of golgi α-mannosidase II (dGMIIb).212 Compounds 1.18, 1.19, and 1.20 
displayed moderate inhibition of dGMIIb, with IC50 values between 1.5 and 2.5 mM 
(Figure 1.14). The other compounds did not inhibit dGMIIb, indicating that inhibitory activity 
was enhanced by oxidation of the sulfur atom, and also by increasing the flexibility of the alkyl 
chain. Docking studies showed that a hydrogen bond between the catalytic acid residue of the 
mannosidase and an oxygen of the sulfoxide or sulfone plays a role in the binding of the 
inhibitor to the mannosidase, similarly to iminosugars.  




Figure 1.15: Thiodisaccharide sulfoxides investigated by Colomer et al.213 
Colomer et al. investigated thiodisaccharide sulfoxide diastereoisomers 1.21 R and 1.21 S 
(Figure 1.15) as inhibitors of β-galactosidase from E. coli.213 Both displayed moderate Kis of 
0.45 mM and 0.19 mM respectively. Interestingly, 1.21 S was also shown to be a substrate for 
the glycosidase. 
 
While species such as sulfoxides do not normally constitute transition state mimics, they have 
been shown to be able to interact with catalytic residues in the active site of glycosidase 
enzymes. These interactions are another potential route to the inhibition of glycosidases, as 
shown by the widespread use of iminosugars and similar structures as glycosidase inhibitors.214  
 
1.13 Synthesis of glycosyl sulfoxides 
Glycosyl sulfoxides show wide utility in chemical reactions, both in their traditional role as 
glycosyl donors and in other sequences, and in addition show some promise as glycosidase 
inhibitors. However, their use is limited by the difficulty of preparing them. The most common 
procedure for preparing glycosyl sulfoxides is Kahne’s original procedure, oxidation of the 
corresponding thioglycoside with mCPBA.170 mCPBA is relatively inexpensive and safe to 
work with, and is therefore widely used as an organic oxidising agent, but the use of mCPBA 
in the synthesis of glycosyl sulfoxides has some notable drawbacks.215 Firstly, careful control 




of the oxidation conditions is required to avoid over-oxidation of the thioglycoside to the 
unreactive glycosyl sulfone. This typically means the reaction must be carried out at low 
temperatures, and with a carefully controlled concentration of mCPBA. In addition to the 
reduced yield resulting from over- or under-oxidation, glycosyl sulfoxides can be difficult to 
separate from both the starting thioglycoside and undesired sulfone due to their similar 
polarities, and therefore even a small amount of impurity can be a significant issue, particularly 
when compared to glycosyl donors such as trichloroacetimidates,169 which display comparable 
activity to glycosyl sulfoxides in most cases. In addition, the use of mCPBA as an oxidant 
results in the formation of a significant amount of m-chlorobenzoic acid as a byproduct, which 
can again be difficult to separate from the glycosyl sulfoxide. Trichloroacetimidates and other 
glycosyl donors, including thioglycosides, are typically preferred over glycosyl sulfoxides even 
for difficult glycosylation reactions as the increased efficiency of glycosylation when using 
glycosyl sulfoxides is countered by the increased difficulty of preparing them. The use of 
glycosyl sulfoxides in glycosylation reactions is in large part restricted to cases where other 
glycosyl donors have failed, and other reactions in which glycosyl sulfoxides are used typically 
find limited application. 
 
Since the first use of glycosyl sulfoxides, a number of attempts have been made to develop 
alternative oxidation methods. The most widely used was developed by Kakarla et al.215 and 
relies upon the ability of silica gel to act as an adsorbent for peroxy oxidising agents, increasing 
the rate at which they react.216 The treatment of thioglycosides with hydrogen peroxide, acetic 
anhydride, and silica gel in dichloromethane resulted in the oxidation of sulfides to sulfoxides, 
while producing little to no sulfone. This method avoids a number of the drawbacks associated 
with the use of mCPBA, as significantly less care is required to avoid over-oxidation: the 
reaction can be carried out at room temperature, and the reagent system demonstrates a reduced 
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propensity to overoxidise to the sulfone. Separation of the reagents and byproducts is also 
significantly easier, as all reagents used may be filtered off or are water soluble. The most 
significant drawback of this method is that the reagent system used is significantly less active 
than mCPBA: extended reaction times are required, and less reactive thioglycosides typically 
display a low conversion to glycosyl sulfoxide. mCPBA reacts significantly more quickly, and 
will oxidise a wider variety of thioglycosides efficiently. 
 
These two methods have both been modified in order to attempt to overcome their limitations. 
Agnihotri et al.217 demonstrated that the use of potassium fluoride as an additive to the mCPBA 
oxidation of thioglycosides results in complete selectivity for sulfoxide, avoiding any oxidation 
to sulfone. Requiring limited control over reaction conditions and causing very rapid oxidation 
to sulfoxide (<10 minutes), this procedure is a significant improvement over unmodified 
mCPBA oxidation. However, m-chlorobenzoic acid will still be produced, and therefore 
purification of the products will still be challenging. 
 
An attempt was made by Chen et al. to modify Kakarla’s H2O2/Ac2O/SiO2 procedure by 
substituting other peroxy oxidising agents for hydrogen peroxide.218 tert-Butyl hydroperoxide 
and oxone® were both tested, and both proved to be less reactive than hydrogen peroxide by a 
significant margin. Extended reaction times are therefore required (>20 h in almost all cases, 
and up to 42 h) even for relatively electron-rich, and therefore easily oxidised, thioglycosides. 
The conditions may be useful for selective oxidations when more than one thioether is present, 
and avoid the use of hydrogen peroxide, which can be dangerous, but otherwise are inferior to 
Kakarla’s original conditions.  
 




A number of unrelated methods have also been reported for the oxidation of thioglycosides to 
glycosyl sulfoxides. Fluorinating reagents, including Selectfluor®219 and 1-fluoropyridinium 
triflates,220 produce glycosyl sulfoxides in very high yields by first fluorinating the sulfur of 
the thioglycoside, forming a sulfur-fluorine species which is subsequently hydrolysed to form 
a glycosyl sulfoxide. Selectfluor® produced glycosyl sulfoxides for a number of thioglycosides 
cleanly and in high yields, but it is noted the reaction produces hydrofluoric acid, and strong 
acids can often cause the decomposition of larger oligosaccharides. In addition, the fluorinating 
reagents themselves are highly reactive, and could potentially damage less robust structures. 
The use of fluorinating reagents for the oxidation of larger oligosaccharides is therefore likely 
to be limited. 
 
Chen et al. explored the use of microwave irradiation to accelerate the oxidation of 
thioglycosides.221 Investigation revealed that magnesium monoperoxyphthalate was the most 
effective oxidant under these conditions, proving slightly more effective than sodium periodate 
adsorbed on silica gel and oxone®. The conditions developed resulted in significantly more 
rapid reaction than Kakarla’s H2O2/Ac2O/SiO2 conditions, with oxidation taking less than 1 h 
even for less reactive thioglycosides. However, microwave irradiation is not widely used, and 
while selectivity for the sulfoxide was observed any excess magnesium monoperoxyphthalate 
caused the formation of sulfone, which means that careful control is required to avoid over-
oxidation. 
 
Huang et al. examined the use of porphyrin catalysts and sodium hypochlorite as oxidant.222 
Manganese-porphyrin complexes proved to be moderately effective as catalysts, providing a 
number of thioglycosides in good yields. However, the yields were lower than those obtainable 
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by other methods, the more effective catalysts are not readily commercially available, and the 
reaction must be carried out under phase-transfer conditions, which means that the reaction is 
less effective for less polar sugars. However, the method is highly selective for the production 
of single sulfoxide diastereoisomers as compared to other oxidation methods, which is useful 
when a single sulfoxide diastereoisomer is required, for example for use as a glycosidase 
inhibitor. 
 
Very recently Wang et al. developed a method based on hydrogen peroxide and phenol,223 
either using phenol as the solvent or dissolved in acetic acid. These conditions were effective 
for more reactive substrates, but suffered from low conversions when less reactive substrates 
(such as nitrophenyl thioglycosides) were used. In addition, the highly acidic conditions proved 
detrimental when thioglycosides with acid-labile protecting groups, such as acetals and silyl 
protecting groups, were used as substrates, generally resulting in low yields of the 
corresponding glycosyl sulfoxide. Also, separation of phenol from the product of the reaction 
was reportedly difficult. 
A number of varied techniques for the oxidation of thioglycosides to glycosyl sulfoxides have 
been explored, but at this time none have succeeded in all areas. No one method provides an 
efficient reaction with simple purification and no over-oxidation to sulfone. Glycosyl 
sulfoxides therefore find only limited application, as often other species will fill similar roles 
more efficiently or with less complexity (for example, trichloroacetimidates or even 
thioglycosides for glycosylation reactions). A simple, clean method for the synthesis of 
glycosyl sulfoxides would allow more widespread utilisation of reactions they are involved in, 
and make the development of new applications more attractive. 
 




1.14 Methods of sulfide oxidation to sulfoxide 
The oxidation of sulfides to sulfoxides has been very well explored. Metal catalysed reactions 
are very widely used,224-227 and although they are undoubtedly effective, often metal catalysts 
are expensive, unsustainable, and difficult to work with. There are also a number of reports of 
oxidations catalysed by entirely organic reagents and simple oxidising reagents.228-231 Ideally 
the conditions applied to the oxidation of thioglycosides would be compatible with a range of 
conditions and functional groups, oxidise thioglycosides rapidly and selectively to the 
sulfoxide, use a simple to acquire and work with catalyst, and result in little or no byproducts. 
Hydrogen peroxide or oxygen would be preferred as an oxidant, as both are readily available, 
easy to work with, and produce only water as a byproduct.  
 
1.14.1 Flavinium salt-catalysed oxidations 
 
Figure 1.16: Flavinium salt catalyst used by Murahashi (1.22)232 and riboflavin (1.23). Flavin 
atom numbering scheme shown on 1.22. 
In 1989 Murahashi reported the use of a flavinium salt species (1.22, Figure 1.16) to catalyse 
the oxidation of sulfur and nitrogen-containing molecules.232 Flavins are found in nature as 
cofactors for oxidase, oxygenase, and dehydrogenase enzymes, normally as flavin adenine 
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dinucleotide (FAD) or flavin mononucleotide (FMN),233 and this is therefore an example of 
biomimetic catalysis. Both FAD and FMN are biosynthesised from riboflavin (vitamin B2, 
1.23),234 and all three biomolecules, as well as Murahashi’s catalyst, contain a similar core 
structure, which is responsible for the catalytic activity. As would be expected, they also rely 
upon similar reactive intermediates in order to carry out catalysis. A catalytic cycle for 1.22 is 
shown in Scheme 1.25.235 The 4a-hydroperoxy adduct 1.25 is believed to be the reactive 
intermediate responsible for the key oxidation step, as upon isolation and use in a non-catalytic 
reaction 1.25 was demonstrated to react more than 4 orders of magnitude faster than hydrogen 
peroxide with amines to convert them to their N-oxides.236 Note that the labelling of atoms in 
all flavins and related species is displayed in Figure 1.16. 
 
Scheme 1.25: Catalytic cycle for flavin oxidation catalysts. 
A notable feature of this cycle is that the precise mechanism differs depending on the oxidising 
species. In nature, molecular oxygen is the most readily available species for regenerating 1.25. 
In oxygenases, in order to generate reactive intermediate 1.25 using molecular oxygen the 
oxidised form of flavinium salt 1.22 is first reduced to species 1.24, typically by NADPH,237 




which then undergoes a single electron transfer process to form a biradical complex.238 The 
flavin and superoxide radicals then combine to produce 1.25.  
 
This sequence of reactions can be bypassed if hydrogen peroxide is used to regenerate 1.25. 
Peroxide can directly attack flavinium salt 1.22 at position 4a to form 1.25, without the need 
for electron transfer from a reducing agent.232 In this case the rate limiting step in this catalytic 
cycle is believed to be loss of water from species 1.26 to regenerate catalyst 1.22.232  
 
Since the first report on the use of flavinium salt 1.22 as a catalyst a number of groups have 
investigated the use of flavinium salts as catalysts for oxidation reactions. In addition to the 
amine and sulfide substrates investigated by Murahashi,232 flavinium salts have since also been 
used to hydroxylate aromatics,239 oxidatively hydroxylate boronic acids,240 and carry out 
Baeyer-Villiger oxidations.241, 242 However, amines and sulfides remain the most common 
substrates. 
 
The flavinium salt catalysts in use today for oxidations fall into three broad categories based 
on their nitrogen substitution pattern. All three have alkyl substituents on two of N1, N5 and 
N10, and this has been shown to be necessary for activity.241 
 
Figure 1.17: N5,N10 substituted flavinium salts. 
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The first type to be developed were the N5,N10 substituted flavinium salts (Figure 1.17).232 
This class of catalysts is the most similar to FAD of the three, with an extra substituent 
(typically an ethyl group) on N5. N3 is also generally methylated.  
 
The standard method of preparing N5,N10 flavinium salts is condensation of alloxan with a 
1,2-diamino benzene derivative 1.27 to give flavin 1.28, followed by methylation of N3 with 
methyl iodide to produce substituted flavin 1.29, and then reductive amination of N10 and salt 
exchange to afford flavinium salt 1.30 (Scheme 1.26).243 
 
Scheme 1.26: Preparation of N5,N10 substituted flavinium salts. 
This method can be modified by altering the substituents on the 1,2-diaminobenzene or the 
aldehyde used for the reductive amination, allowing both subtle and significant modification 
to the structure of the catalyst. There are limited systematic comparisons of the activity of 
differentially substituted N5,N10 substituted flavinium salts. N5 is invariably ethyl substituted, 
but a variety of substituents for N10 have been examined, including short232 and long244 alkyl 
chains, aromatic groups,241, 245 chiral groups,246 and dimeric structures.247, 248  




Catalyst 1.32 has been prepared by Imada et al.242 (Scheme 1.27). Flavinium salt 1.32 is 
significant because instead of constructing the flavin skeleton from discrete building blocks, 
its synthesis instead begins with riboflavin 1.23, the precursor to FAD. While this does make 
modification of the structure of 1.32 more difficult, the use of a widely available biomolecule 
as a starting material means that the majority of the required structure is already in place, and 
potentially makes 1.32 or similar structures less costly to produce on a large scale. 
 
Scheme 1.27: Preparation of catalyst 1.32 from riboflavin by Imada et al.242 
Riboflavin 1.23 is first converted to the diacetal under acidic conditions and methylated on N3 
to afford intermediate 1.31. Then, as previously seen in Scheme 1.26, a reductive amination is 
performed to ethylate N5, and the counterion is exchanged for perchlorate to produce flavinium 
salt catalyst 1.32. Catalyst 1.32 has been shown to be active in the hydrogen peroxide oxidation 
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of sulfoxides, producing sulfoxides selectively and in high yields, similarly to other N5,N10 
substituted flavinium salt catalysts.  
 
Molecular oxygen oxidations have been examined exclusively for N5,N10 substituted flavinium 
salt catalysts. Salt 1.22 is the most commonly used catalyst for these reactions, and was used 
in the first oxygen oxidation of amines and sulfides catalysed by a flavinium salt by Imada.235 
A co-reductant is also required (Scheme 1.25), of which a variety have been found to be 
effective, including hydrazine,235, zinc dust,242 ascorbic acid,249 and formic acid.250  
 
Scheme 1.28: Preparation of dihydroalloxazine 1.36 by Bergstad et al.251 
N1,N5 Substituted flavinium salts were first applied to catalytic oxidation reactions by Bergstad 
et al. Notably, instead of flavinium salts they elected to prepare 5,10-dihydroalloxazine 1.36 
(Scheme 1.28).251 Dihydroalloxazines are not catalytically active in hydrogen peroxide 
oxidations, but they are part of the catalytic cycle of flavins in oxygen oxidations. They are 
readily oxidised by air to flavin hydroperoxides. Indeed, Bergstad noted that purification of 
1.36 was difficult for this very reason, and therefore air oxidation allows dihydroalloxazines to 




enter the peroxide catalytic cycle (Scheme 1.29). The catalytic cycle is otherwise much the 
same as N5,N10 substituted flavinium salts; involving the condensation of a diamine with 
alloxan to produce intermediate 1.34, followed by methylation to afford 1.35 and reductive 
amination to give dihydroalloxazine 1.36. 
 
Scheme 1.29: Catalytic cycle for N1,N5 substituted 5,10-dihydroalloxazines. 
Catalyst 1.36 was first prepared for use in the oxidation of tertiary amines to N-oxides. Rate 
enhancements of between 30 and 80 times were observed compared to the uncatalysed reaction.  
  




Figure 1.18: Structural comparison of dihydroalloxazine 1.36 and dihydroisoalloxazine 1.37. 
Dihydroisoalloxazine 1.37 (Figure 1.18) displayed minimal or no activity in oxidation 
reactions, a curious finding as it would be expected to be oxidised by air to flavinium salt 1.22, 
which has previously been shown to have high activity in oxidation reactions. This result was 
explained by Ménová and Cibulka, who proposed that the effect was due to differing rate-
determining steps for the two reactions.252 The rate determining step for catalysts such as 
dihydroalloxazine 1.36 has been shown to be elimination of water, while the rate-determining 
step in the reaction of dihydroisoalloxazines 1.37 is postulated to be attack of peroxide on the 
alloxazine cation. Basic conditions would be expected to increase the rate of reaction in the 
case of alloxazines, as basic conditions increase the nucleophilicity of the hydrogen peroxide. 
Meanwhile, acidic conditions would be expected to increase the rate of reaction in the case of 
isoalloxazines, as acidic conditions mean that the leaving water molecule is more easily 
protonated in the rate determining step. Flavinium salts generate one equivalent of acid upon 
first reacting with hydrogen peroxide, while dihydroalloxazines or isoalloxazines do not 
generate an equivalent of acid upon reaction with oxygen. Therefore, the use of a 
dihydroalloxazine is favoured, while the use of N5,N10 substituted flavinium salts is also 
favoured. Furthermore, addition of acid can allow N1,N5 flavinium salts to be active catalysts, 
while addition of base allows dihydroisoalloxazines to be active catalysts. A direct comparison 
between dihydroalloxazines and dihydroisoalloxazines is not useful for comparing the two 
types of catalyst, and the same is true of a comparison between the flavinium salts. All can 




display significant catalytic activity under appropriate conditions, which vary depending on the 
rate determining step in the catalytic cycle. 
 
Figure 1.19: N1,N10 bridged flavinium salt. 
The final type of flavinium salt catalysts that have been studied are N1,N10 bridged flavinium 
salts (Figure 1.19), completing the possible set of disubstitutions on N1, N5, and N10. The first 
set of N1,N10 bridged flavinium salts was prepared by Li et al. as models for natural enzyme 
systems.253 Subsequently, N1,N10 bridged flavinium salts as catalysts for the oxidation of 
sulfides were examined simultaneously by Marsh et al.254 and Zurek et al..255 Of the structures 
examined in these two papers, flavinium salt 1.42 is the simplest. 
 
Scheme 1.30: Preparation of N1,N10 bridged flavin catalysts by Marsh and Carbery.254 
The preparation of these catalysts begins in a similar way to that of N5,N10 substituted flavinium 
salts, with the preparation of a 1,2-diaminobenzene derivative 1.41, and subsequent 
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condensation with alloxan (Scheme 1.30). Thionyl chloride is used to perform the cyclisation. 
Notably, this sequence only requires two purification steps. 
 
Scheme 1.31: Catalytic cycle for N1,N10 bridged flavinium salts. 
Mechanistically, N1,N10 flavinium salts behave similarly to other types of flavinium salts, but 
not identically. The key difference is that N1,N10 bridged flavinium salts form a 10a peroxy 
adduct (1.42, Scheme 1.31), instead of the 4a adduct formed by N1,N5 and N5,N10 substituted 
flavinium salts. This is expected, based on the fact that the positive charge in the molecule is 
to be found on N10, not N5. 
 
In summary, there are a range of available flavin and flavinium salt catalysts, and a significant 
proportion of them have been shown to be highly active catalysts in clean, biomimetic 
oxidation reactions using either hydrogen peroxide or molecular oxygen as an oxidising agent. 








1.15 Thesis outline 
The primary aim of the research detailed within this thesis was to develop new reactions by 
which carbohydrate structures could be modified under aqueous conditions without the use of 
protecting groups using sulfur as a key reaction component. 
 
Chapters 2, 3, and 4 detail the preparation of a variety of glycoconjugates from unprotected 
reducing sugars.  
 
Chapter 2 demonstrates the use of DMC to prepare 1-cyanomethyl thioglycosides, and the 
indiscriminate modification of lysozyme using these reagents, allowing the production of 
glycoproteins. 
 
Chapter 3 describes the preparation of glycosyl thiols in an aqueous environment through the 
use of DMC, and the application of the thiol-ene click reaction to selectively modify alkene-
containing species with these glycosyl thiols.  
 
Chapter 4 illustrates the use of a bifunctional alkene-alkyne linker to couple unprotected 
carbohydrates to thiols, including the cysteine residues of synthetic peptides. 
 
Chapter 5 of this thesis details the preparation of glycosyl sulfoxides from carbohydrates 
through the use of a biomimetic flavinium salt catalyst system, and investigation of the 
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Chapter 2: The aqueous preparation of cyanomethyl thioglycosides 
and their use in the preparation of glycoproteins 
2.1 Cyanomethyl thioglycosides 
As discussed previously (Section 1.7.1), cyanomethyl thioglycosides are an effective way of 
indiscriminately glycosylating a protein while still maintaining the entire intact carbohydrate 
structure and are additionally completely selective for lysine residues. However, the 
preparation of cyanomethyl thioglycosides and their conjugation to protein requires a number 
of synthetic steps, and is therefore difficult to carry out with larger oligosaccharide substrates.1 
 
Scheme 2.1: Typical route for the preparation and conjugation of cyanomethyl thioglycosides.1 
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Currently, the preparation of cyanomethyl glycosides and their conjugation to proteins is an 
extended process (Scheme 2.1). The carbohydrate is first acetylated with acetic anhydride, then 
converted to the glycosyl bromide. The glycosyl bromide is reacted with thiourea to produce 
the isothiouronium salt, which is then cleaved with sodium metabisulfite to give the glycosyl 
thiol, which is subsequently converted to the cyanomethyl thioglycoside by reaction with 
chloroacetonitrile. Simultaneous acetate deprotection and equilibration to form the 2-imino-2-
methoxyethyl 1-thioglycoside (IME thioglycoside) is followed by conjugation to a protein 
using the crude reaction mixture. While this method is relatively effective for smaller 
oligosaccharides, the multiple protection and deprotection steps become extremely challenging 
for larger oligosaccharides. A method which bypasses the requirement for protection and 
deprotection would facilitate the preparation of glycoproteins using larger oligosaccharides via 
IME thioglycoside chemistry. 
 
2.2 The use of DMC for preparing cyanomethyl thioglycosides 
As discussed previously (Section 1.8), DMC (2.1) is a highly effective reagent for the 
modification of the anomeric centre of unprotected carbohydrates with strongly nucleophilic 
reagents in an aqueous environment.2, 3 Thiols are good nucleophiles, and indeed have been 
used in DMC-mediated reactions in the past.3-5 It therefore seemed logical that the use of 
mercaptoacetonitrile (2.2) as a nucleophile together with DMC activation of the anomeric 
centre could serve to generate cyanomethyl thioglycosides, which could then be used as 
reagents for lysine modification without requiring protection of the carbohydrate at any stage 
(Scheme 2.2). 
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Scheme 2.2: Retrosynthesis of cyanomethyl thioglycosides using DMC. 
In addition to establishing that thiols can be effective nucleophiles for reaction with sugars in 
a DMC-mediated process, Shoda3 and Winssinger5 furthermore both observed that more acidic 
thiols display greater reactivity in the DMC reaction, due to the tendency of more basic thiols 
to react with DMC preferentially over the carbohydrate anomeric hydroxyl group. 
Mercaptoacetonitrile would be expected to be relatively acidic due to the presence of the 
electron-withdrawing nitrile group, providing further support for the potential reaction of 
mercaptoacetonitrile with DMC-activated sugars.  
 
2.3 Reagent preparation: DMC and mercaptoacetonitrile 
Both DMC6 and mercaptoacetonitrile7, 8 have been previously prepared, and so both were 
prepared according to the relevant literature procedures.  
 
Scheme 2.3: Preparation of DMC. 
DMC (2.1) was prepared in 45% yield by reaction of 1,3-dimethylimidazolidinone with oxalyl 
chloride at 50 °C.6 
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Scheme 2.4: Preparation of mercaptoacetonitrile. 
At first, mercaptoacetonitrile (2.2) was prepared by reaction of chloroacetonitrile with sodium 
hydrosulfide hydrate at -20 °C according to the method of Mathias and Shimanski 
(Scheme 2.4).7 While this reaction does produce mercaptoacetonitrile, it is low-yielding and 
inconsistent, presumably due to dimerization via reaction of mercaptoacetonitrile product with 
chloroacetonitrile starting material, dimerization via disulfide formation, and polymerisation 
of mercaptoacetonitrile.9 Careful control of the reaction temperature was required, as low 
temperatures resulted in the freezing of the reaction mixture, and high temperatures resulted in 
minimal product formation. Rapid addition of chloroacetonitrile is also required, but the 
reaction is exothermic, again resulting in challenges for temperature control. The removal of 
significant impurities was also difficult, as mercaptoacetonitrile is unstable at high 
temperatures, meaning that distillation is not straightforward. 
 
An alternative route for the preparation of mercaptoacetonitrile was therefore examined. 
Gaumont et al. prepared mercaptoacetonitrile by reaction of thioacetic acid with 
chloroacetonitrile, using triethylamine as a base to form a thioester which was then deprotected 
under acidic conditions to afford mercaptoacetonitrile (Scheme 2.4).8 This method has the 
advantage of at no point generating a reactive thiolate anion, and therefore being significantly 
less likely to produce byproducts. Mercaptoacetonitrile was prepared by this method in 82% 
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yield. Furthermore, the reaction was significantly cleaner, making purification far less 
challenging.  
 
2.4 Investigation of conditions for the preparation of cyanomethyl 
thioglycosides 
In order to investigate the conditions for the preparation of unprotected cyanomethyl 
thioglycosides from reducing sugars using DMC, glucose was selected as a model substrate for 
2-hydroxy sugars. As a starting point, standard DMC activation conditions were used 
(Scheme 2.5).3 
 
Scheme 2.5: Conditions for the DMC activation of glucose and subsequent nucleophilic 
substitution with mercaptoacetonitrile. 
These conditions resulted in a small but noticeable conversion of 30% to cyanomethyl 
thioglucoside 2.4, as determined by 1H NMR spectroscopy, with the remainder of the material 
being glucose 2.3. The order of addition of reagents is typically important in DMC-mediated 
reactions, and in this case glucose 2.3, triethylamine, and mercaptoacetonitrile were mixed in 
D2O, followed by the portionwise addition of DMC. Notably, no 1,6-anhydroglucose was 
produced, which is a common byproduct of reactions of 2-hydroxy sugars with DMC.10 
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Variation of the order of addition of the reagents significantly affected the course of the 
reaction. Mixing glucose 2.3, DMC, and mercaptoacetonitrile in D2O and then adding 
triethylamine resulted in 39% conversion to 2.4, a slight improvement, with the remainder 
again being glucose 2.3. Alternatively, addition of the reactants in the order glucose 2.3, 
triethylamine, DMC, and then adding the mercaptoacetonitrile resulted in 40% conversion to 
2.4, but also produced 23% of 1,6-anhydroglucose. The use of a 1:1 mixture of D2O:acetonitrile 
as the solvent resulted in no conversion to product, and only glucose 2.3 starting material was 
observed. However, the addition of DMC to the reaction mixture last as a solution in 
mercaptoacetonitrile resulted in a noticeable increase in conversion to 53%. It was further 
determined upon repetition of the reaction that dropwise addition of the DMC-
mercaptoacetonitrile solution was critical to obtain a high conversion, with reduced conversion 
to product 2.4 observed when the DMC-mercaptoacetonitrile solution was added more rapidly.  
 
From these results, it would appear that mercaptoacetonitrile is unstable under the basic 
aqueous conditions of the DMC-mediated reaction, and therefore adding it to the reaction as 
late as possible results in a greater conversion to product, as there is less time for the 
mercaptoacetonitrile to decompose.  
 
In order to further improve the conversion to product, the number of equivalents of reagents 
was doubled, to 6 equivalents of DMC, 20 equivalents of mercaptoacetonitrile, and 20 
equivalents of triethylamine. Pleasingly, this resulted in a conversion of glucose 2.3 to 
cyanomethyl thioglycoside 2.4 of 83%, and an isolated yield of product 2.4 of 65%. 
Furthermore, when water was used as a solvent a conversion of glucose 2.3 to product 2.4 of 
91% and an isolated yield of 89% were obtained. The variation in yield between the deuterated 
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and non-deuterated solvent is most likely due to experimental variation rather than any 
meaningful effect given the apparently random nature of the variation. As discussed previously, 
rate of addition of the reagents had a strong effect on the conversion to product, and subtle 
changes in the rate of addition could explain variations in conversion to product 
 
Scheme 2.6: Testing of the substrate scope of DMC-mediated cyanomethyl thioglycoside 
synthesis. 
 
Table 2.1: Substrate scope of DMC-mediated cyanomethyl thioglycoside synthesis. 
With reaction conditions for 2-hydroxy sugars in hand, attention then turned to the substrate 
scope of the reaction. The reaction was shown to be effective and gave the corresponding 
cyanomethyl thioglycosides in moderate to high yield with a variety of 2-hydroxy sugars, using 
both D2O and H2O as solvent (Table 2.1). When D2O was used a solvent a degree of H/D 
exchange was observed at the aglycon CH2, presumably because of the increased acidity of the 













Maltotriose 2.8 D2O 90% 
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hydrogens at this position due to the adjacent nitrile group. Cyanomethyl thiogalactoside 2.6 
was produced in relatively low yield, an observation consistent with previous DMC-mediated 
reactions of galactose using thiols as a nucleophile.4, 5 Substituent orientation in carbohydrates 
can have an effect on the rate of substitution reactions at the anomeric centre.11 This effect is 
proposed to be due to different electron donating abilities of axial and equatorial hydroxyl 
groups.12 It therefore seems reasonable that a similar effect is in play here, as all proposed DMC 
reaction mechanisms proceed via strained bicyclic intermediates. 
 
Scheme 2.7: Conditions for the DMC reaction of GlcNAc and mercaptoacetonitrile. 
Attention then turned to the application of the DMC-mediated reaction to 2-acetamido sugars. 
In a standard DMC-mediated reaction for 2-acetamido sugars, the sugar is first activated by 
DMC in order to form a 1,2-oxazoline, which is then opened by addition of acid in the presence 
of the nucleophile (Scheme 2.7).6 Unfortunately, these conditions gave a conversion of 
N-acetylglucosamine (GlcNAc) 2.9 to cyanomethyl thioglycoside 2.10 of only 16%, with the 
remainder of the material being the starting material. Further investigation revealed that a 
comparable conversion to 2.10 was achieved when the acid was not added, in which case the 
remainder of the material was found to be 1,2-oxazoline. As discussed previously, 
mercaptoacetonitrile is unstable under the basic aqueous conditions of the DMC reaction, and 
therefore one conclusion is that all of the cyanomethyl thioglycoside 2.10 that forms does so 
by direct attack of mercaptoacetonitrile on the DMC-sugar intermediate, rather than by opening 
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of the 1,2-oxazoline; i.e., by the time acid is added all the mercaptoacetonitrile has 
decomposed. Furthermore, the addition of mercaptoacetonitrile as a solution in concentrated 
HCl to preformed oxazoline did not result in any product, a result which can be explained by 
the reduced nucleophilicity of the thiol species found under acidic conditions as compared to 
the thiolate anion that is present under basic conditions.  
 
Due to the inevitability of significant oxazoline formation by the rapid intramolecular attack of 
the 2-acetamido group at the anomeric centre, and the mutual incompatibility of oxazoline ring 
opening and high nucleophilicity of mercaptoacetonitrile, a viable reaction for the formation 
of cyanomethyl thioglycosides of 2-acetamido sugars by activation with DMC and reaction 
with mercaptoacetonitrile was deemed unlikely. Therefore at this point 2-acetamido sugars as 
substrates were abandoned to focus on the development of the more effective reaction of 2-
hydroxy sugars.  
 
2.5 Preparation of IME thioglycosides 
With a selection of cyanomethyl thioglycosides of 2-hydroxy sugars in hand, attention then 
turned to the formation of the corresponding IME thioglycosides. IME Thioglycosides are 
typically prepared by the reaction of the corresponding cyanomethyl glycosides with sodium 
methoxide in an equilibrium process, which typically yields around 40% conversion to IME 
thioglycoside (Scheme 2.8).1 In other examples of the preparation of IME thioglycosides the 
sodium methoxide also serves to deprotect the sugar, but in the case of unprotected 
cyanomethyl thioglycosides deprotection is not necessary. The IME thioglycoside-
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cyanomethyl thioglycoside mixture is used typically as a crude mixture to modify proteins; the 
remaining cyanomethyl thioglycoside is not removed. 
 
Scheme 2.8: Preparation of IME thioglycosides. 
 
Table 2.2: Preparation of IME thioglycosides. 
As expected, in all cases the preparation of IME thioglycosides (Scheme 2.8) resulted in the 
formation of a mixture of the IME thioglycoside and the corresponding cyanomethyl 
thioglycoside starting material (Table 2.2). Some variation in conversion to IME thioglycoside 






Glucoside 2.4 2.11 35% 
Mannoside 2.5 2.12 22% 
Galactoside 2.6 2.13 50% 
Lactoside 2.7 2.14 85% 
Maltotrioside 2.8 2.15 60% 
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2.6 Protein modification using IME thioglycosides 
 
Scheme 2.9: Protein modification with IME thioglycosides. 
With a selection of IME thioglycosides in hand, attention turned to the modification of a model 
protein. Modification of protein lysines with IME reagents is typically carried out at pH 8.5 in 
a sodium borate buffer (Scheme 2.9); the amidination reaction being more effective at higher 
pH.13 The use of an even higher pH results in greater modification, but also risks denaturing 
the protein. 
 
Figure 2.1: Structure of BSA.14 
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BSA (Figure 2.1) was the first protein examined, and unfortunately did not prove suitable. 
While it appeared that modification had occurred, MS analysis did not provide suitable 
characterisation data. Amidination produces a statistical distribution of modified protein: not 
every lysine residue is modified and the exact modification positions are random, leading to a 
wide range of possible product masses. This problem was compounded by the relatively high 
molecular weight of BSA (approximately 66.4 kDa), which also results in a high number of 
lysine residues, 59 in all, any of which can be modified. As a result, the data obtained upon MS 
analysis of the reaction of BSA with IME thioglucoside 2.4 did not clearly provide evidence 
of conjugate formation, although it appeared that all BSA had been consumed. 
 
Figure 2.2: Structure of hen egg white lysozyme.15 
With this methodological limitation in mind, a smaller protein was chosen for exemplification. 
Hen egg white lysozyme is a simple protein with a molecular weight of approximately 14.3 
kDa and only 6 lysine residues, meaning that characterisation of any conjugate generated was 
expected to be significantly simpler. 
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Figure 2.3: Deconvoluted HRMS of lysozyme modified with glucose reagent 2.11. 
Gratifyingly, this proved to be the case, and reaction of various IME thioglycosides with 
lysozyme resulted in significant modification. In all cases 50 µL of the IME thioglycoside 
equilibrium mixture, with a combined sugar concentration of 0.1 M, was added to 0.070 µmol 
of lysozyme in pH 8.5 borate buffer (Scheme 2.10), representing between 2 and 10 equivalents 
of IME glycoside per lysine residue, depending on the equilibrium of the cyanomethyl 
thioglycoside-IME thioglycoside equilibrium for the sugar in question. Characterisation of the 
modified lysozyme was carried out by MS analysis (Figure 2.3), allowing identification and 
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Scheme 2.10: Modification of lysozyme with IME thioglycosides. 
IME Thioglycoside 
Number of Sugar Units Attached 
0 1 2 3 4 5 6 Mean 
Glucoside 2.11 - - - - 26% 48% 26% 5.0 
Mannoside 2.12 9% 33% 38% 18% 2% - - 1.7 
Galactoside 2.13 - - - 1% 28% 46% 25% 5.0 
Lactoside 2.14 3% 9% 27% 35% 16% 9% - 2.8 
Maltotrioside 2.15 4% 26% 43% 21% 7% <1% - 2.0 
 
Table 2.3: Modification of lysozyme with IME thioglycosides. 
In all cases, multiple sugar sugars units were observed to be conjugated to lysozyme 
(Table 2.3). Glucose and galactose IME thioglycosides 2.11 and 2.13 both modified the 
majority of the lysozyme’s six lysine residues, while the use of the mannose, lactose, and 
maltotriose IME thioglycosides 2.12, 2.14, and 2.15 resulted in at least some modification in 
all cases. Modification with mannoside 2.12 resulted in reduced modification relative to 
glucoside 2.11 and galactoside 2.13, an observation for which the most likely explanation is 
the reduced conversion of cyanomethyl thioglycoside to IME thioglycoside. This explanation 
was supported by the increased conjugation observed upon the addition of further equivalents 
of IME thioglycoside; a second addition of IME thioglycoside resulted in an increase in the 
average number of attached sugars to 3.8. 
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Figure 2.4: Structure of lysozyme with lysine residues highlighted in blue. 
Meanwhile, the lower modification observed for lactoside 2.14 and maltotrioside 2.15 may to 
be due to greater steric hindrance resulting from the larger glycans. As the modification 
reaction competes with imidate hydrolysis, any reduction in reaction rate is accompanied by a 
corresponding drop in conjugation yield. This proposal is supported by the progressive decline 
in the observed average number of sugars attached to the protein as the sugar itself becomes 
larger. While lysozyme is not a large protein and the lysine residues are relatively exposed 




A procedure was developed for the preparation of cyanomethyl thioglycosides from 
unprotected reducing sugars in water, and was applied to a range of 2-hydroxy sugars. The 
cyanomethyl thioglycosides produced by this reaction were then converted to the 
corresponding IME thioglycosides and conjugated to hen egg white lysozyme, demonstrating 
the utility of this method for the preparation of glycoproteins. The method developed is 
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significantly less complex than existing procedures, and should enable the more widespread 
use of IME thioglycosides for the preparation of glycoproteins. 
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Chapter 3: The aqueous preparation of glycosyl thiols and their use 
in the thiol-ene click reaction 
3.1 The site-selective preparation of glycoproteins and glycopeptides 
As discussed in Section 1.7.2, the preparation of glycoproteins and glycopeptides in a site-
selective manner is typically more useful than non-specific approaches, as the biological 
activity of these glycoconjugates can be strongly tied to the position(s) of glycosylation and 
the structures of attached glycans. However, the most significant drawback associated with the 
site-selective preparation of glycoproteins is that this is far more synthetically challenging than 
making indiscriminately glycosylated glycoconjugates. In particular, the chemical synthesis of 
glycoproteins and glycopeptides almost invariably requires protection and deprotection of the 
sugar, a process that is particularly complex when applied to larger oligosaccharides. In recent 
years some attempts have been made to overcome this particular hurdle, and one of the most 
promising of these is the use of DMC to modify unprotected carbohydrates (Section 1.8). 
 
3.2 The search for alternative nucleophiles for reaction with DMC-activated 
sugars 
Three categories of nucleophiles have been applied to the DMC-mediated activation of sugars 
(Section 1.8): intramolecular nucleophiles, including 2-acetamido groups for the formation of 
oxazolines1 and 6-hydroxyl groups for the preparation of 1,6-anhydrosugars,2 azide for the 
formation of glycosyl azides,3, 4 and thiols, mainly aryl thiols5-7 but also alkyl thiols.8 These 
nucleophiles are significantly more nucleophilic than water, and thus selective substitution at 
the anomeric centre is possible even when water is used as a solvent. As reported in Chapter 2, 




mercaptoacetonitrile is another example of a nucleophile which can out-compete water, and is 
therefore able to effectively attack a DMC-sugar intermediate. However, cyanomethyl 
thioglycosides are only useful for indiscriminate glycosylation of protein lysines.9 An 
investigation therefore began into DMC-mediated reactions with other nucleophiles which may 
allow the transformation of unprotected sugars into reagents that could subsequently be used 
to carry out site selective glycosylation of proteins or peptides.  
 
Sulfur containing compounds are well-known as effective nucleophiles, and as discussed 
previously thiols have previously been used as nucleophiles in DMC-mediated reactions.5, 8 
Sulfur is also often used for the site-selective production of glycoconjugates, by methods which 
include asymmetric disulfide formation, either via glycosyl selenyl sulfides10, 11 or glycosyl 
phenylthiosulfonates,12 the nucleophilic addition of glycosyl thiols to DHA,13 and the thiol-ene 
click chemistry of glycosyl thiols14 (Section 1.7.2). However, to date the preparation of the 
sulfur-containing reagents required as substrates for these reactions has almost invariably 
required protection of the sugar.  
 
3.3 DMC-mediated preparation of glycosyl phenylthiosulfonates 
Glycosyl phenylthiosulfonates have been shown to be highly effective reagents for the 
modification of cysteine residues of proteins.12 However, they are prepared by reaction of 
sodium phenylthiosulfonate with the relevant glycosyl bromide, and therefore protection of the 
sugar is required (Scheme 3.1). Furthermore, glycosyl phenylthiosulfonates cannot be easily 
deprotected. 






Scheme 3.1: Current preparation and application of glycosyl phenylthiosulfonates. 
A method to prepare glycosyl phenylthiosulfonates without the use of any protecting groups 
would therefore greatly expand their utility. With this in mind, a DMC-mediated reaction to 
prepare glycosyl phenylthiosulfonates was proposed (Scheme 3.2). 
 
Scheme 3.2: Retrosynthesis for the preparation of glycosyl phenylthiosulfonates using DMC. 
Sodium phenylthiosulfonate 3.1 was prepared via the reaction of sodium benzenesulfinate with 
elemental sulfur in pyridine as per the previously published procedure (Scheme 3.3).12 
 
Scheme 3.3: Preparation of sodium phenylthiosulfonate. 
 
 





Scheme 3.4: Attempted preparation of glycosyl phenylthiosulfonates via DMC-mediated 
reaction with unprotected GlcNAc 3.2. 
Unfortunately, phenylthiosulfonate did not prove to be an effective nucleophile in DMC-
mediated reactions. When GlcNAc 3.2 was used as a substrate with 3 equivalents of DMC, 10 
equivalents of triethylamine as a base, and 10 equivalents of sodium phenylthiosulfonate 3.1 
as a nucleophile (Scheme 3.4) none of the desired product 3.3 was detected by 1H NMR 
spectroscopy of the crude reaction mixture; only starting material was observed, formed by 
hydrolysis of the oxazoline intermediate. The use of glucose as a staring material under similar 
reaction conditions resulted in the formation of 1,6-anhydroglucose, a common byproduct of 
the DMC-mediated activation of 2-hydroxy sugars.2 The fact that none of the desired product 
was detected in either case implies that the phenylthiosulfonate anion is not a strong enough 
nucleophile to outcompete water when attacking the activated sugar intermediate, and therefore 
the synthesis of glycosyl phenylthiosulfonates via DMC-mediated reaction using water as a 
solvent seems unlikely to be successful. Furthermore, glycosyl phenylthiosulfonates have been 
observed to decompose when deprotected.15 With these two points in mind, the preparation of 
glycosyl phenylthiosulfonates via a DMC-mediated reaction seemed unlikely to be successful, 
and so other potential nucleophiles were investigated. 
 
  





3.4 DMC-mediated preparation of glycosyl thiols 
Similarly to glycosyl phenylthiosulfonates, glycosyl thiols are typically prepared by reaction 
of a glycosyl bromide, but with either thiourea as a nucleophile, which can be cleaved with 
sodium metabisulfite to afford the desired glycosyl thiol,9 or thioacetate as a nucleophile, which 
can be deprotected with sodium methoxide16 (Scheme 3.5). Again, protecting groups are 
required, and the preparation of glycosyl thiols of larger oligosaccharides is therefore 
challenging. 
 
Scheme 3.5: Current preparation of glycosyl thiols. 
It is also possible to prepare unprotected glycosyl thiols by direct reaction of unprotected 
reducing sugars with Lawesson’s reagent,11 but an apparent incompatibility with 2-acetamido 
groups renders this method unusable for N- and O-linked glycans, which comprise the majority 
of the oligosaccharides of glycoproteins. 





Scheme 3.6: DMC-mediated reactions of thioacetic acid and sugars. 
Thioacetate could be expected to attack the DMC-activated sugar intermediate (Section 1.8), 
and as was observed by another member of the Fairbanks group17 this is indeed the case. When 
this reaction was carried out on GlcNAc 3.2 the product formed was glycosyl thioacetate 3.4 
(Scheme 3.6), which could be readily deprotected to form a glycosyl thiol (Scheme 3.5). 
However, the order of reagent addition was significant, and it was found that addition of 
thioacetic acid at the beginning of the reaction as opposed to after 30 min resulted in the 
formation of the 1-O-acetyl sugar 3.3 instead of the 1-S-thioacetyl sugar 3.4.18 
 
3.5 Purification of glycosyl thioacetate 3.4 
The use of 3 equivalents of DMC, 10 equivalents of triethylamine, 15 equivalents of thioacetic 
acid, and water as a solvent for the reaction of thioacetic acid with GlcNAc (Scheme 3.6) 
provided near-quantitative conversion to thioacetate product 3.4. However, purification of the 
product was extremely challenging, as the thioacetate was both highly polar and relatively 
prone to hydrolysis, and at the same time a mixture of salts was present, most notably 
triethylammonium chloride. Purification by HPLC would be expected to provide pure product, 
but could only be applied on a small scale, limiting the applicability of the reaction. 
 





Normal phase flash column chromatography did not result in adequate separation between 
glycosyl thioacetate 3.4 and triethylammonium chloride, and, as a result, both co-eluted using 
a range of solvents. Similarly, reverse phase flash column chromatography using C18 silica 
and HILIC flash column chromatography19 also resulted in co-elution of 3.4 and 
triethylammonium chloride. In all cases separation of all other impurities was possible, but 
triethylammonium chloride could not be removed. 
 
In the past Lim et al. solved the problem of triethylammonium salt removal by the use of a 
column of Amberlite® IR-120 (Na+ form) ion exchange resin.4 An attempt to remove the 
triethylammonium chloride with an Amberlite® IR-120 column resulted in partial 
decomposition of thioacetate and a reduced and inconsistent yield, presumably due to base-
catalysed hydrolysis of the thioacetate 3.4 to form the glycosyl thiol 3.5.  
 
Scheme 3.7: Deprotection of thioacetate 3.4. 
Deprotection of the thioacetate using sodium hydroxide (Scheme 3.7) was also explored as a 
means of purification, as glycosyl thiol 3.5 was the ultimate goal. Treatment with a strong base 
was also expected to deprotonate the triethylammonium cation, which would then allow the 
removal of triethylamine in vacuo. Testing on a small quantity of purified glycosyl thioacetate 
3.3 revealed that sodium hydroxide was effective for this deprotection step. Notably, a 
stoichiometric, rather than catalytic, quantity of base was required to deprotect the thioacetate, 




as the glycosyl thiolate produced by the reaction is not sufficiently basic to deprotonate water 
and thus continue the catalytic cycle.  
 
Treatment of the crude glycosyl thioacetate 3.4 with sodium hydroxide did facilitate the 
removal of triethylammonium chloride. However, significant quantities of sodium acetate, 
sodium thioacetate, and sodium chloride remained as impurities. Flash column 
chromatography was not effective for removal of these impurities, as glycosyl thiol 3.5 
displayed a tendency to bind strongly to silica, which resulted in a low isolated yield of product. 
 
Investigation of different workup procedures to remove all the salt impurities met with more 
success. Following the reaction, extraction with dichloromethane followed by trituration with 
ethyl acetate removed all by-products except triethylammonium chloride. Subsequent 
deacetylation with sodium methoxide and trituration with methanol then afforded clean 
glycosyl thiol 3.5.  
Scheme 3.8: Purification of glycosyl thioacetate 3.4 via acetylation. 
As the method detailed above is rather involved, and does not include a chromatography or 
recrystallization step and therefore may not always provide high purity product, an alternative 
method was also investigated. Full protection of the sugar significantly increased the ease of 
purification, and could be carried out in one pot. Protection can be avoided if necessary, for 
example in the preparation of glycosyl thiols where only a small amount of sugar is available 





and minimising the number of steps is therefore desirable in order to maximise the yield, by 
purification of the glycosyl thioacetate by HPLC. Crude glycosyl thioacetate 3.4 was acetylated 
with acetic anhydride in pyridine20 to afford acetylated glycosyl thioacetate 3.6 in a pleasingly 
high yield of 88% from GlcNAc. Purification was then easily accomplished by normal phase 
flash column chromatography. 
 
Scheme 3.9: Deacetylation of peracetylated glycosyl thioacetate 3.6. 
Finally, deprotection was easily accomplished in quantitative yield by treatment of acetylated 
glycosyl thioacetate 3.6 with sodium in methanol (Scheme 3.9),21 giving an overall yield of 
88% for the preparation of glycosyl thiol 3.5 from GlcNAc 3.2. 
 
3.6 Attempted extension of the DMC-mediated reaction of sugars with 
thioacetic acid to 2-hydroxy sugars 
The most notable difference between 2-acetamido and 2-hydroxy sugars in DMC-mediated 
reactions is that while 2-acetamido sugars react via a relatively stable 1,2-oxazoline 
intermediate,1 the intermediate in the reaction of 2-hydroxy sugars is very unstable, and has 
never been conclusively observed (Section 1.8). This leads to a number of practical differences 
in the application of DMC activation to the two varieties of sugars. Firstly, when the 2-hydroxy 
group is equatorial the corresponding 1,6-anhydrosugar is invariably formed as a by-product. 
Secondly, because the intermediate in the reaction of 2-hydroxy sugars is significantly less 




stable than that formed during the reaction of 2-acetamido sugars, the addition of an acid to 
open the cyclic intermediate4, 6 is not required.  
 
Scheme 3.10: DMC-mediated reaction of thioacetic acid and glucose. 
Unfortunately, the reaction of glucose 3.7 under the conditions employed for GlcNAc 3.2 
(Scheme 3.6) resulted in the formation of no thioacetate 3.8; rather, 1,6-anhydroglucose 3.9 
was isolated in a 40% yield, with the remainder of the material being unreacted glucose 3.7 
(Scheme 3.10). Increasing or decreasing the activation time between the addition of DMC and 
the addition of the thioacetic acid did not lead to the formation of any product, presumably 
because upon the addition of thioacetic acid no further sugar activation by DMC occurs due to 
the then acidic conditions. Under basic conditions DMC reacts preferentially with thioacetate 
rather than glucose 3.7 to form a DMC-thioacetate intermediate, which then reacts with sugars 
to produce glycosyl acetates.18 
 
As a consequence of these results, investigation into the formation of anomeric thioacetates of 
2-hydroxy sugars was halted, as it was judged to be unlikely to be successful. However, this is 
only a minor drawback of this method of preparing glycosyl thioacetates for use in conjugation 
reactions, because, as discussed previously, the majority of natural glycans have 2-acetamido 
sugars at the reducing terminus. 
 





3.7 Conversion of a range of 2-acetamido sugars into their glycosyl 
thioacetates 
With optimised conditions in hand, the DMC-thioacetic acid reaction was tested on a range of 
2-acetamido sugars. 
Scheme 3.11: Preparation of the glycosyl thiol of N-acetylgalactosamine. 
N-Acetylgalactosamine (GalNAc) thiol 3.12 was prepared from GalNAc 3.10 by a similar 
procedure to that used to make GlcNAc thiol 3.5 (Scheme 3.11) and purification was attempted 
via a workup, as previously (Section 3.5). Unfortunately, this did not result in clean thiol 3.12, 
meaning that the sequence of washes that had been developed for the synthesis of GlcNAc thiol 
3.5 is not generally applicable, and implying that a new procedure would have to be developed 
for each sugar examined. Furthermore, the reaction of N-acetylgalactosamine to form 
thioacetate 3.11 did not go to completion under the standard reaction conditions, and a number 
of minor sugar impurities were present. The remaining starting material and other sugar 
impurities were not removed by the workup procedure, exposing one of the key limitations of 
the workup method. The reaction was therefore exemplified with monosaccharides via the 
protection/purification/deprotection strategy outlined in Schemes 3.8 and 3.9, whilst larger 
oligosaccharides were purified by HPLC. 





Scheme 3.12: Preparation of glycosyl thioacetates. 
 
Table 3.1: Preparation of glycosyl thioacetates. aPurified by acetylation followed by flash 
column chromatography. bPurified by HPLC. 
Pleasingly, high yields of the glycosyl thioacetate were obtained in all cases except for GalNAc 
thioacetate 3.13. As discussed in Section 2.4, activation of galactosyl sugars by DMC results 
in relatively low conversion to product and the formation of a number of unidentified 
byproducts, so this result was not unexpected. The glycosyl thioacetate of 
N,N’-diacetylchitobiose (3.15) was formed in high yield without difficulty, confirming that the 
reaction is applicable to sugars larger than a monosaccharide. 














The selection of glycosyl thioacetates were then deprotected using previously established 
conditions (Scheme 3.13). Thioacetates 3.6, 3.13, and 3.15 were deprotected in quantitative 
yield using either sodium in methanol or sodium hydroxide in water (Table 3.2).  
 
Scheme 3.13: Preparation of glycosyl thiols. 
Starting Material Product Yield 
3.6 3.5 
quant.a 
3.13     3.16 
quant.a 
  3.14       3.17 
decomp.a 
 
                                   3.15 
 
                                       3.18 
quant.b 
 
Table 3.2: Preparation of glycosyl thiols. aMethod a). bMethod b). 
Unfortunately, N-acetylmannosamine (ManNAc) thioacetate 3.14 was not readily deprotected 
under these conditions. While the acetyl groups were indeed removed, a number of other 
products were formed, including disulfide 3.19 (Scheme 3.14). Attempts to carry out the 
deacetylation reaction in the presence of reducing agents, including dithiothreitol and 




TCEP,22, 23 did not significantly improve the conversion to product, and as established 
previously the purification of unprotected glycosyl thiols is challenging so separation of 
glycosyl thiol 3.17 from disulfide 3.19 is not possible. ManNAc thiol 3.17 was not an attractive 
target: the primary biological role of ManNAc is the biosynthesis of N-acetylneuraminic acid,24 
and it is not found in natural glycoprotein structures. Attempts to optimise the reaction for 
ManNAc were therefore abandoned. 
 
Scheme 3.14: Deprotection and oxidation of ManNAc thiol 3.14. 
 
3.8 Preparation of glycoconjugates 
A number of options exist for the site-selective preparation of glycoconjugates from glycosyl 
thiols. These include the production of glycoproteins and glycopeptides by the attachment of 
glycosyl thiols to cysteine residues through the use of selenyl sulfides,10 the reaction of glycosyl 
thiols with DHA,13 and the use of photocatalysed thiol-ene click chemistry to attach glycosyl 
thiols to alkenes.14 Of these methods, selenyl sulfide chemistry was selected for initial 
exemplification, due to the apparent ease of applying it to larger structures, including proteins. 
 
  





3.8.1 Preparation of glycoconjugates via selenyl sulfide chemistry 
As discussed in Section 1.7.2, glycosyl selenyl sulfides are effective reagents for the 
modification of thiols, including the cysteine residues of proteins.  
 
Scheme 3.15: Use of glycosyl selenyl sulfides to prepare glycoconjugates. 
In order to prepare glycoconjugates using glycosyl selenyl sulfides, one of the thiols is first 
reacted with phenylselenyl bromide, and the resulting selenyl sulfide is reacted with the desired 
thiol to produce a glycoconjugate (Scheme 3.15).10  
 
Scheme 3.16: Preparation of GlcNAc selenyl sulfide 3.20. 
The glycosyl selenyl sulfide 3.20 of GlcNAc thiol 3.5 was prepared in 64% yield following the 
literature method (Scheme 3.16).10 The dropwise addition of a solution of 3.5 to a solution of 
phenylselenyl bromide proved to be critical to obtaining even a moderate yield of product. Any 
other order of addition resulted in the formation of a very small amount of product due to 
formation of disulfide by reaction between glycosyl thiol 3.5 and product 3.20. 
 




Two asymmetric disulfides were then prepared using glycosyl selenyl sulfide 3.20 as one 
component in order to test the selenyl sulfide methodology (Scheme 3.17). 
 
Scheme 3.17: Reaction of selenyl sulfide 3.20 with thiols. 
 
Table 3.3: Reactions of selenyl sulfide 3.20 with thiols.  
Selenyl sulfide 3.20 reacted with ethanethiol and dipeptide 3.22 to give the corresponding 
disulfide products 3.21 and 3.23 in yields of 95% and 77% respectively. In both cases 3 
equivalents of sugar 3.20 were used, and therefore the yield was calculated with respect to the 
thiol.  















Figure 3.1: Crystal structure of GABARAPL2, with Cys15 highlighted in yellow. 
Having demonstrated that glycosyl selenyl sulfide reactions could successfully be carried out 
with a glycosyl thiol prepared via the DMC activation of a free sugar, the next goal was to 
attach GlcNAc to a protein via selenyl sulfide chemistry. Gamma-aminobutyric acid receptor-
associated protein-like 2 (GABARAPL2) which was available in the University of Canterbury 
Biochemistry Department, was selected for exemplification. GABARAPL2 has a single 
cysteine (Figure 3.1, Cys15, highlighted in yellow),25 and was expressed by Dr. Akshita 
Wason. BSA also contains a single free cysteine residue, but was not used as a test protein as 
previous studies with glycosyl selenyl sulfides showed that modification of the single cysteine 
of BSA not involved in a disulfide bond was challenging.10 





Scheme 3.18: Preparation of a GABARAPL2 glycoprotein. 
Modification of GABARAPL2 was carried out using the literature conditions (Scheme 3.18).10 
First, selenyl sulfide protein 3.24 was prepared by reaction of GABARAPL2 with 
phenylselenyl bromide in pH 9.5 CHES buffer, and then glycoprotein 3.25 was prepared by 
reaction of glycosyl thiol 3.5 with selenyl sulfide protein 3.24. While this reaction proved 
successful in the first instance, the results varied considerably between trials. In many cases 
neither product nor starting material was observed upon MS analysis. Variation of buffer, 
purification technique, and MS conditions did not provide greater consistency. It appeared that 
GABARAPL2 shows a tendency to aggregate, and for this reason tended to produce 
inconsistent results. Conditions to avoid this aggregation could not be found. 
 
As no suitable protein was available for the application of glycosyl thiols to the selenyl sulfide 
reaction, and furthermore the preparation of glycosyl selenyl sulfides was found to be 





inconsistent, a different method for the preparation of glycoconjugates using glycosyl thiols 
was investigated. 
 
3.8.2 Preparation of glycoconjugates via thiol-ene click chemistry 
Photocatalysed thiol-ene click chemistry is a versatile reaction for the coupling of alkenes and 
thiols (Scheme 3.19).14 It can be performed with a wide variety of thiols and alkenes, in a wide 
variety of solvents, and provides thioether-linked products in high yields and with good 
selectivity. Alkenes are not typically found as part of proteins or peptides, and so represent an 
attractive functional group for the site-selective modification of these species, as has previously 
been demonstrated (Section 1.7.2).26 
 
Scheme 3.19: Mechanism of the photocatalysed thiol-ene click reaction. 
With the aim of applying the thiol-ene click reaction to the preparation of glycoconjugates, 
suitable initial conditions were investigated. 2,2-Dimethoxy-2-phenylacetophenone (DMPA) 
was selected as the initiator,27 as it has previously been applied to the thiol-ene click reaction 
between sugars and proteins,28 and is readily available. Water was selected as a solvent, as it is 
both benign and readily dissolves unprotected glycosyl thiols. 3-Buten-1-ol was chosen as a 
test alkene, as it is water-soluble, simple, and readily available. 
  









Table 3.4: Photocatalysed thiol-ene click reaction of 3.5. 
The photocatalysed thiol-ene click reaction proved to be highly effective when applied to 
GlcNAc thiol 3.5 (Scheme 3.20). Thioether 3.26 was obtained with a conversion to product (as 
determined by 1H NMR spectroscopy) of 89% and an isolated yield of 61% (Table 3.4); the 
lower isolated yield reflects the difficulty of purifying amphiphilic 3.26 by flash column 
chromatography. A control reaction in which no DMPA was added resulted in only minor 
conversion to product, confirming that the thiol-ene reaction requires a radical initiator in order 
to proceed. 
 
3.8.2.1 Exemplification: variation of glycosyl thiol 
With confirmation that the thiol-ene click reaction worked extremely effectively when a 
glycosyl thiol and 3-buten-1-ol were used as substrates, it was extended to the other glycosyl 
thiols that had been prepared previously (Section 3.5). Yields of glycoconjugate product 
between 60% and 65% were obtained for all sugar substrates (Scheme 3.21, Table 3.5), 
although, as for 3.26, the conversion to product was significantly higher in all cases. 
  
Experiment DMPA Equivalents Conversion Isolated Yield 
Standard 0.1 89% 61% 
Control 0 8% - 






Scheme 3.21: Thiol-ene reaction of glycosyl thiols. 
Glycosyl Thiol Product Yield 
3.5 3.26 
61% 
    3.16     3.27 
61% 
 
                                       3.18 
 
                                                   3.28 
64% 
 
Table 3.5: Thiol-ene click reaction of 3-buten-1-ol and glycosyl thiols 3.5, 3.16, and 3.18. 
 
  




3.8.2.2 Exemplification: variation of alkene 
As the glycosyl thiol substrate could demonstrably be changed without altering the efficiency 
of the thiol-ene click reaction, variation in the alkene substrate was then examined. 
 
In order to carry out this investigation, a selection of biologically relevant alkenes were 
prepared (Scheme 3.22). 6-O-Allyl galactose 3.31, to be used for the preparation of a 
disaccharide mimic, was prepared in two steps from commercially available diacetone 
galactose 3.29, by allylation at position 6 using potassium hydroxide and allyl bromide to 
afford protected allylated galactose 3.30, followed by deprotection of the two acetonides under 
acidic conditions to afford unprotected allyl galactose 3.31.29 
 
Scheme 3.22: Preparation of alkene substrates. 





Two protected amino acid alkenes based on cysteine 3.3230 and serine 3.3431 were also 
prepared to demonstrate the use of glycosyl thiols in preparing glycopeptides. N-Protection is 
important, as it would allow the use of the conjugated amino acids in subsequent solid phase 
peptide synthesis. Fmoc-Protected allyl cysteine 3.33 was prepared by allylation of cysteine 
hydrochloride 3.32 using ammonium hydroxide as a base, followed by Fmoc protection using 
Fmoc chloride, with sodium bicarbonate as a base. Boc-Protected allyl serine 3.35 was 
prepared by Boc protection of serine 3.34 using Boc anhydride and sodium hydroxide, followed 
by allylation with allyl bromide and sodium hydride. 
  





Scheme 3.23: Testing of the alkene substrate scope of the thiol-ene click reaction. 
 
Table 3.6: Variation of the alkene in the thiol-ene click reaction. 

























With this selection of alkenes available, testing of the thiol-ene click reaction commenced 
(Scheme 3.23). For 6-O-allyl galactose 3.31 the reaction proved effective (Table 3.6), and 
gave the disaccharide mimic 3.36 in 73% yield. Unfortunately, allyl cysteine 3.33 did not prove 
suitable for the thiol-ene click reaction, with a number of decomposition products observed in 
the crude reaction mixture, a result consistent with a previous study by Fiore et al.,32 who 
reported that the use of an allyl linker attached to cysteine led to the formation of a number of 
by-products derived from the coupling of various thiyl radicals. However, allyl serine 3.35 
produced glycosyl amino acid 3.38 in an impressively high yield of 91%, demonstrating the 
potential that thiol-ene click chemistry has for the preparation of glycopeptides and 
glycoproteins. 
 
The thiol-ene click reaction has been shown to be an effective reaction for the formation of 
simple glycoconjugates. However, most interesting natural glycoconjugates are significantly 
larger than those examined up to this point in this thesis, and therefore attention turned to the 
preparation of a more complex, biologically relevant glycopeptide. 
 
  




3.9 Application of the thiol-ene click reaction to a model biological system 
While insertion of an alkene into a protein is complex,26 insertion of an alkene into a synthetic 
peptide is relatively simple. With this in mind, the next goal was the attachment of a glycosyl 
thiol to a peptide. Peptide 3.39, with a single allylglycine residue at position 3 (Figure 3.2), 
was prepared and generously provided by Zaid Anso of the Brimble group. The peptide 
selected, a section of the rat pancreatic hormone preptin,33 was a readily available peptide with 
a single allylglycine residue, making it suitable for use as a model peptide. 
 
Figure 3.2: Modified preptin 3.39 containing a single allylglycine residue for use in the thiol-
ene click reaction. 
Firstly, the thiol-ene reaction of GlcNAc thiol 3.5 with peptide 3.39 was examined. Pleasingly, 
the use of 5 equivalents of DMPA in water with a large excess of thiol 3.5 and irradiation at 
254 nm resulted in quantitative conversion to product glycopeptide 3.40 as assessed by HPLC 
(Scheme 3.24). The product was also characterised by LC-MS, confirming the complete 
conversion of peptide 3.39 to glycopeptide 3.40.  






Scheme 3.24: Preparation of glycopeptide 3.40 via thiol-ene click reaction. 
  




While attachment of a monosaccharide demonstrated that the thiol-ene click reaction was 
effective for larger alkene substrates, most glycopeptides and glycoproteins also contain large 
oligosaccharides. The next step was therefore to prepare and attach a large oligosaccharide to 
peptide 3.39. 
 
Figure 3.3: Complex biantennary glycan isolated from hens’ egg yolks. 
Sialoglycan 3.41 (Figure 3.3) is readily isolated from hens’ egg yolks,34, 35 and therefore 
represents a suitable oligosaccharide for exemplification of the methodology developed in this 
chapter. The sample of sialoglycan 3.41 used in this study was prepared by Dr. Vivek 
Poonthiyil. 
 
The DMC-mediated reaction between thioacetic acid and sialoglycan 3.41 proved successful 
(Scheme 3.25). However a greater number of equivalents of DMC, triethylamine, and 
thioacetic acid were required.  






Scheme 3.25: Preparation of sialoglycan glycosyl thioacetate 3.42. 




The reaction appeared to be less efficient on sialoglycan 3.41 than on mono- and disaccharides, 
and this was partially attributed to the fact that the rate of addition of both DMC and thioacetic 
acid to the reaction mixture required careful control: rapid addition at either of these stages 
typically led to an incomplete reaction. Such control of the rate of addition was practically 
challenging for the addition of very small volumes, and therefore the use of a greater quantity 
of reagents led to a more efficient reaction. As all the reagents were readily available, 
increasing the quantities did not present a significant hurdle. Using this method, glycosyl 
thioacetate 3.42 was obtained in 60% yield. 
 
The next step was to deprotect sialoglycan thioacetate 3.42 and then attach it to peptide 3.39. 
Again, the reaction proved straightforward (Scheme 3.26). Thioacetate 3.42 was de-protected 
with aqueous sodium hydroxide to afford glycosyl thiol 3.43, which was then reacted with 
peptide 3.39 without further purification to afford glycopeptide 3.44 in quantitative yield, as 
determined by HPLC. A relatively large excess of thiol 3.43 (800 equivalents) was required in 
order to ensure complete conversion: the use of a reduced number of equivalents of thiol 3.43 
resulted in some conversion to glycopeptide, but a significant amount of unreacted peptide 3.39 
remained, as observed by mass spectrometry. This is likely to be due to disulfide formation, a 
side reaction caused by the combination of two thiyl radicals, which is more likely to have a 
significant effect on the reaction when the relative rate of the reaction between the thiyl radical 
and alkene is slow, as would be expected for the two large, sterically hindered species examined 
here. Nevertheless, it has been demonstrated that thiol-ene click chemistry is effective for the 
preparation of complex glycopeptides. 
 






Scheme 3.26: Application of the thiol-ene click reaction to the preparation of a complex 
glycopeptide.  
 





DMC was applied to the preparation of glycosyl thiols in aqueous conditions without the use 
of protecting groups. The use of 3 equivalents of DMC, 10 equivalents of triethylamine, and 
15 equivalents of thioacetic acid proved effective in most cases for 2-acetamido sugars, while 
2-hydroxy sugars proved unsuitable for the reaction. Furthermore, the glycosyl thiols prepared 
via this method were then used to prepare glycoconjugates, culminating in the attachment of a 
decasaccharide to a 16mer peptide, demonstrating that the methodology developed in this 
chapter provides a simple, robust means of site-selectively modifying glycopeptides.  
Future studies could include the attachment of glycosyl thiols to a protein via thiol-ene click 
chemistry, and the preparation of more biologically relevant glycopeptides with a view towards 
testing any impact of the unnatural thioether linker on their biological activity. 
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Chapter 4: Allyl propargyl ether as a bifunctional linker for the 
preparation of glycoconjugates 
4.1 Limitations of current methods for glycoconjugate preparation 
As discussed previously, most methods for the preparation of glycoproteins and glycopeptides 
suffer from one or more significant limitations, the most common of which is that synthesis of 
either the glycan or protein component presents a substantial challenge (Scheme 4.1).  
 
Scheme 4.1: Methods of preparing glycoproteins. 
Only a limited range of functional groups, represented by the standard proteogenic amino acids, 
can simply be introduced into a protein. Functional groups such as alkenes and alkynes are 




more difficult to introduce into a protein,1 as they are not contained in the side chains of any of 
the amino acids that are coded for in standard protein biosynthesis. While an alkene or alkyne 
can be introduced into a protein it is non-trivial to do so.2 In contrast, it is relatively easy to 
introduce reactive functional groups such as thiols through site-directed mutagenesis. Thiols 
are an effective handle for the site-selective modification of proteins, as they are both reactive 
and relatively uncommon, as most cysteine residues form disulfide linkages. 
 
Selective chemical modification of large oligosaccharides also presents a significant challenge. 
As discussed previously (Section 1.8), DMC provides an effective means of modifying the 
reducing terminus of large carbohydrates without resorting to protecting groups. However, only 
a small variety of nucleophiles have been demonstrated to attack DMC-activated sugars, and 
introducing functional groups that can react with thiols, such as alkenes and alkynes, is at 
present non-trivial.3, 4 While DMC-mediated reactions can be used to couple unprotected 
reducing sugars and thiols,5, 6 the substrate scope is often limited, both in terms of thiol and 
sugar. 
 
As no method currently exists in which preparation of both the sugar and protein component is 
simple, general site-selective preparation of glycoproteins remains a challenge.  
 
  




4.2 A bifunctional linker 
Click reactions are perhaps the most useful reactions for the modification of proteins, being 
both robust and selective, but no single click reaction allows the simple preparation of 
glycoproteins without challenging alteration of either the sugar or the protein component. 
However, it is possible to imagine that a combination of click reactions could be effective for 
the preparation of glycoproteins. For example, CuAAC and thiol-ene click chemistry occur 
under different conditions, and, most significantly, alkenes are entirely unreactive in CuAAC. 
However, the reverse is not true; alkynes can react in thiol-ene click reactions.7 Therefore, if 
CuAAC was used to attach an alkene to a carbohydrate, it would then be possible to prepare a 
glycoprotein or glycopeptide using a thiol-ene click reaction (Scheme 4.2) in a second step. 
This process would require minimal manipulation of the carbohydrate, and only the 
introduction of a cysteine residue into the protein or peptide. 
Scheme 4.2: The use of a bifunctional linker to prepare a glycoprotein. 
The CuAAC reaction can be easily carried out on complex reducing sugars in one pot using 
the method previously developed by Lim in the Fairbanks group,8 while the thiol-ene click 
reaction has previously been demonstrated to be effective for the preparation a variety of 
glycoconjugates.9  





Scheme 4.3: Attachment of an alkene to a carbohydrate by Shoda via CuAAC.4 
The use of CuAAC to introduce an alkene is similar to the method developed by Shoda to 
create glycopolymers (Scheme 4.3),4 but the use of a reagent with an alkyne at one end and an 
alkene at the other to prepare glycoconjugates through the thiol-ene click reaction has not been 
attempted. 
 
4.3 Choice of linker 
 
Figure 4.1: Potential bifunctional linkers. 
In his previous study, Shoda used propargyl acrylamide 4.1 (Figure 4.1) as a linker molecule 
which contains both an alkene and an alkyne.4 While this does contain both an alkene and an 
alkyne, the use of an acrylamide linker was presumably due to the subsequent use of the sugar-
linker conjugates for polymerisation reactions, where acrylamide monomers are widespread. 
Linker 4.1 is commercially available, but not from major suppliers. It can be prepared, but 
either expensive reagents or multiple steps are required.10, 11 




A number of other linkers were therefore considered. The ideal linker would be simple, readily 
available, and easily modifiable. An alkyl linker such as 4.2 is simple, but presents a significant 
challenge to synthesise. An ether linker such as 4.3 is simple to prepare using standard 
techniques in a manner that allows variation,12, 13 and is stable under biological conditions. 
Furthermore, linker 4.3 is readily commercially available.  
 
Scheme 4.4: Preparation of ether linkers. 
With a view to testing the effectiveness of linkers of various lengths in CuAAC and the 
subsequent thiol-ene reaction, three propargyl ether based-linkers 4.3-4.5 were prepared, which 
differed in the length of the alkyl chain between the alkene and oxygen. All were prepared 
using a broadly similar procedure in which an alkyl bromide was reacted with an alcohol in the 
presence of a base. Allyl propargyl ether 4.3 was prepared following a literature procedure,12 
in which propargyl alcohol was reacted with allyl bromide using sodium hydride as the base 
(Scheme 4.4). An attempt to prepare butenyl propargyl ether 4.4 via the same method proved 
unsuccessful, as only a small amount of product was formed. An alternative literature 
procedure, in which potassium hydroxide was used as the base, propargyl bromide was used 
as the electrophile, and 3-buten-1-ol was used as the nucleophile, was successful.13 This 
procedure afforded butenyl linker 4.4 in 35% yield. An analogous procedure using 4-penten-
1-ol as the nucleophile afforded pentenyl linker 4.5 in a yield of 48%. Both ethers are volatile, 




and the low yield of product can be explained by the difficulty of completely separating solvent 
from the product ether.  
 
4.4 One pot preparation of sugar-linker conjugates 
Scheme 4.5: One pot conversion of reducing sugars to glycosyl azides followed by CuAAC. 
With a selection of linkers available the next step was to conjugate a simple sugar to a linker. 
As discussed previously (Section 1.7.2), Lim developed the one-pot conversion of unprotected 
reducing sugars to glycosyl azides and their use in CuAAC in the Fairbanks group 
(Scheme 4.5),8 and this methodology was ideal for applying to the linkers developed here. 
 
Scheme 4.6: Preparation of ADMP. 
With the aim of applying this reaction to linkers 4.3-4.5, ADMP 4.7 was prepared from DMC 
2.1 following the literature procedure (Scheme 4.6).8 First, DMC 2.1 was stirred with sodium 
hexafluorophosphate to afford hexafluorophosphate salt 4.6 in 55% yield, which was then 
reacted with sodium azide to produce ADMP 4.7 in 85% yield. 
















H2O 0.015 0.2 1 trace 
H2O 0.1 0.2 1 18% 
tBuOH:H2O  
2:1 
0.1 0.2 1 68% 
tBuOH:H2O  
2:1 
0.1 0.2 2 72% 
tBuOH:H2O  
2:1 
0.2 0.4 2 86% 
 
Table 4.1: Optimisation of the CuAAC click reaction. 
With all the required starting materials in hand, the reaction of GlcNAc 4.8 and linker 4.3 to 
produce glycosyl triazole 4.9 was examined (Scheme 4.7). As a starting point, the conditions 
of Lim were applied (Table 4.1), namely 3 equivalents of ADMP 4.7 and 5 equivalents of 
triethylamine in water at 0 °C, followed by the addition of 1 M hydrochloric acid, stirring at 
pH 2 for 10 min, neutralisation, then the addition of 1 equivalent of alkyne 4.3, 0.015 
equivalents of copper sulfate, and 0.2 equivalents of sodium ascorbate and heating in water at 
50 °C.8 Only a trace amount of product was formed under these conditions. Increasing the 
number of equivalents of copper sulfate resulted in the formation of a measurable amount of 
product, with a conversion to product 4.9 of 18% (as measured by 1H NMR spectroscopy). 
Reasoning that perhaps the low conversion to product was due to the insolubility of the non-




polar ether 4.3 in water, a water/tert-butanol mixture was tested as a solvent, a change which 
resulted in a significantly higher conversion to 4.9 of 68%. Increasing the number of 
equivalents of all reagents again resulted in an increase in conversion to product, with the 
highest conversion to product of 86% observed when 0.2 equivalents of copper sulfate, 0.4 
equivalents of sodium ascorbate, and 2 equivalents of alkyne 4.3 were used. 
 
Using these optimised conditions, an isolated yield of GlcNAc-linker conjugate 4.9 of 79% 
was obtained for this reaction. Purification was straightforward using ion exchange filtration 
followed by flash column chromatography. However it was observed that an impurity which 
does not produce any signals in either 1H or 13C NMR spectra was a common contaminant. 
Careful purification was required to ensure that this contaminant was indeed removed. The 
observation of peaks in 19F and 31P NMR spectra of some samples of 4.9 corresponding to the 
hexafluorophosphate anion suggested that the impurity was sodium hexafluorophosphate, and 
19F and 31P NMR spectroscopy were used to confirm that all sodium hexafluorophosphate was 
removed from purified samples of 4.9. The use of an internal standard when taking 1H NMR 
spectra of 4.9 further confirmed that all non-NMR active impurities had been removed. 
 
  




4.4.1 Variation of the sugar substrate 
Having demonstrated that the CuAAC click reaction component of the sequential double click 
reaction approach could be successfully carried out, a variety of carbohydrates were then 
attached to linker 4.3 (Scheme 4.8, Table 4.2). 
 
Scheme 4.8: Attachment of sugars to alkyne 4.3. 
Pleasingly, in most cases the conditions developed for the attachment of GlcNAc to linker 4.3 
worked equally well for other sugars. Treatment with 1 M hydrochloric acid was only required 
for 2-acetamido sugars in order to open the 1,2-oxazoline that formed competitively upon 













Table 4.2: Attachment of various sugars to linker 4.3. aAddition of 1 M HCl was required to 
open oxazoline intermediate. bReaction time: 40 h.  
The use of GalNAc as a substrate resulted in a reduced yield of product 4.10 of 44%, but as 
discussed previously (Section 2.4) this observation is consistent with previous DMC- and 
Sugar Product Isolated Yield 
  4.9 
79%a 
     4.10 
44%a 
  4.11 
66% 
 
       4.12 
80%b 
                             4.13 
41% 
(85% conversion to 
1,6-
anhydrogalactose) 
   4.14 
75% 




ADMP-mediated reactions where GalNAc or galactose has been used as a substrate. Glucose 
and mannose both produced the desired click product in moderate to high yields, (66% and 
80% respectively). The click reaction of mannose required an extended reaction time. 
Wilkinson and co-workers previously observed that α-glycosyl azides react more slowly than 
β-glycosyl azides in CuAAC click reactions.14 This observation was later examined in more 
detail by Dedola et al.,15 who concluded that the difference in reactivity between the two was 
significant, as α-glycosyl azides reportedly react more than three times more slowly in CuAAC 
than β-azides. The difference in reaction rates has been proposed to be due to the anomeric 
effect, which results in a decrease in the molecular orbital coefficient in the HOMO of the p-
orbital of the anomeric nitrogen of the azide functional group. Practically, this altering of the 
azide molecular orbitals lowers the affinity of the anomeric nitrogen for copper(I) ions, 
resulting in a reduced reaction rate.16  
 
Unfortunately, galactose did not prove compatible with the ADMP-mediated reaction. Rapid 
formation of 1,6-anhydrogalactose 4.13 was observed instead of the formation of the desired 
galactosyl azide. 1,6-Anhydrogalactose 4.13 was the major product, and formed in a ratio of 
approximately 6:1 with the desired click product. The use of galactose in a reaction mediated 
by either DMC or ADMP to produce a galactosyl azide has never been reported,8, 17 presumably 
due to the unavoidable formation of 1,6-anhydrogalactose 4.13. As previous investigations 
using similar methodology apparently did not succeed in this area, galactose was abandoned as 
a substrate for this reaction. More promisingly, reaction of isomaltose with linker 4.3 produced 
the desired product 4.14 in 75% yield, proving that the reaction is effective with sugars larger 
than a monosaccharide. 
 




4.4.2 Variation of the bifunctional linker 
 
Scheme 4.9: Attachment of linkers of a range of lengths to GlcNAc 4.8. 
Variation of the linker used would allow fine-tuning of the properties of any glycoconjugates 
prepared by the sequence of click reactions described in this chapter. In order to demonstrate 
that the linker could be varied without drastically altering the nature of the click reaction, the 
extended linkers 4.4 and 4.5 were examined (Scheme 4.9).  
Linker Product Isolated Yield 
 
4.3 











Table 4.3: Attachment of linkers of a range of lengths to GlcNAc 4.8. 
Pleasingly, variation of the linker length resulted in uniformly high conversions in all cases 
(Table 4.3). The lowest yield was observed for the reaction of butenyl linker 4.4. However the 




conversion to product as assessed by 1H NMR spectroscopy of the crude reaction mixture was 
>90% in all cases, implying that the issue in this case was purification of the product 4.15 rather 
than incomplete reaction.  
 
4.5 Application of the thiol-ene click reaction to the glycosyl triazoles 
With conditions established for the attachment of carbohydrates to one end of the bifunctional 
linker, the next step was to confirm that it is then possible to attach a thiol to the other end of 
the linker. Cysteine was selected for initial studies, as the primary application envisaged for 
this reaction was the conjugation of sugars to the cysteine residues of peptides or proteins.  
 
Scheme 4.10: Thiol-ene click reaction of alkene 4.9 with cysteine. 
The initial conditions selected were those that previously proved effective for the thiol-ene 
click reaction of glycosyl thiols (Section 3.8.2), i.e. 1 equivalent of cysteine, 0.1 equivalents 
of DMPA, water as the solvent, irradiation at 254 nm, and a reaction time of 6 h (Scheme 4.10). 
Disappointingly, a low conversion to product 4.17 was observed for this substrate combination 
(Table 4.4). 
  













6 h 1 0.1 No H2O 25% 
16 h 1 0.1 No H2O 37% 
6 h 0.5 0.1 No H2O 30%
a 
6 h 2 0.1 No H2O 37% 
6 h 1 1 No H2O 32% 
6 h 1 0.1 Yes H2O 42% 





Table 4.4: Testing of conditions for the thiol-ene click reaction of 4.9 with cysteine. 
aConversion calculated with respect to cysteine. bpH 4.0 0.2 M Sodium acetate buffer 
Increasing the number of equivalents of either cysteine or alkene, or increasing the reaction 
time, resulted in only a slight improvement. Increasing the number of equivalents of the radical 
initiator DMPA used did not significantly improve the conversion, even when a stoichiometric 
amount of initiator was used. Carrying out the reaction under N2 resulted in a slight 
improvement, but the reaction remained low-yielding. The use of a pH 4.0 sodium acetate 
buffer as a solvent has previously been shown to increase the efficiency of the thiol-ene click 
reaction,18 and while in this case a slight improvement was observed, the conversion to product 
remained disappointingly low. Testing of the reaction mixture with Ellman’s reagent confirmed 
that while some oxidation to cystine occurred over the course of the reaction (approximately 
20% of the added cysteine was converted to cystine), the major issue was simply the low 
reactivity of cysteine with alkene 4.8, as a significant portion of unreacted cysteine remained. 
 
With the low reactivity of cysteine in mind, the next step was to investigate the reactivity of 
other, similar, thiols. Fmoc-Protected cysteine 4.19 was prepared by deprotection of 




commercially available Fmoc-S-tritylcysteine 4.18 using trifluoroacetic acid and 
triisopropylsilane (Scheme 4.11).  
 
Scheme 4.11: Preparation of Fmoc-protected cysteine. 
An initial investigation demonstrated that Fmoc-cysteine 4.19 was significantly more reactive 
than cysteine in the thiol-ene click reaction (Scheme 4.12). 0.1 Equivalents of DMPA and 1 
equivalent of Fmoc-cysteine 4.19 were used, and the reaction was irradiated at 254 nm for 6 h. 
A tert-butanol/water mixture (2:1) was used as the solvent because Fmoc-cysteine 4.19 is 
insoluble in water alone. 
 
Scheme 4.12: Thiol-ene click reaction using Fmoc-cysteine. 
However, the reaction proved highly inconsistent, with the conversion to product varying 
between 50% and >95% for no discernible reason. An investigation into the oxidation 
behaviour of Fmoc-cysteine 4.19 under the reaction conditions revealed that Fmoc-cysteine 
4.19 was completely oxidised to disulfide under the reaction conditions, in a process that was 
significantly accelerated by radical initiator DMPA and irradiation with UV light. Previous 
studies have shown that the free-radical oxidation of thiols is accelerated by the presence of 




oxygen,19 and therefore a test oxidation reaction under an atmosphere of nitrogen was carried 
out, which resulted in reduced oxidation of Fmoc-cysteine. This observation implied that if the 
thiol-ene click reaction was carried out under an atmosphere of nitrogen the thiol-ene click 
reaction would be more effective and consistent, and this did indeed prove to be the case. The 
use of two equivalents of Fmoc-cysteine 4.19 resulted in complete conversion to glyco-amino 
acid 4.20. 
 
Scheme 4.13: Purification of glycoconjugate 4.17 after Fmoc deprotection. 
Purification of glyco-amino acid 4.20 was challenging due to its amphiphilic nature, so in order 
to simplify the process the Fmoc protecting group was removed and the product 4.17 was 
purified by reverse phase flash column chromatography (Scheme 4.13). An overall yield of 
71% was obtained for the transformation from alkene 4.9. 
 




The above experiments revealed two potential issues with the thiol-ene click reaction of alkene 
4.9 and amino acid thiols: either the thiol did not react at a high enough rate with the alkene, 
or the thiol was easily oxidised to disulfide. While no means of overcoming the first issue has 
been discovered, the second was relatively easily avoided by conducting the reaction under an 
atmosphere of nitrogen and using excess thiol. With this in mind, a small selection of other 
thiols were investigated for their utility in this thiol-ene click reaction (Scheme 4.14). The use 
of a pH 4.0 0.2 M sodium acetate buffer resulted in an increase in conversion to product in 
some cases. 
 
Scheme 4.14: Thiol variation in the thiol-ene click reaction of alkene 4.9. 
In all cases a moderate to high yield was obtained (Table 4.5). The variation in the number of 
equivalents of thiol used reflected the ease of oxidation of the thiol starting material; if the thiol 
was more readily oxidised a greater number of equivalents of thiol were required to ensure that 
the majority of the sugar alkene reacted.  
 
The highest conversion and yield of isolated product was obtained when glutathione 4.17 was 
used as the thiol, a promising result because glutathione was closer to the intended thiol targets 
of this research, namely peptides and proteins. The fact that the tripeptide glutathione showed 
significantly greater activity in the thiol-ene click reaction with alkene 4.9 as compared to 
single amino acids suggested that the bifunctional click reagent approach should also be useful 
for the preparation of glycopeptides and glycoproteins. 












































1 quant. quant. 
 
Table 4.5: Variation of thiol in the thiol-ene click reaction of alkene 4.9. 
  




4.5.1 Variation of the sugar alkene in the thiol-ene click reaction 
Having demonstrated that the thiol-ene click reaction could be applied to sugar alkenes 
prepared via CuAAC, the next step was to confirm that the thiol-ene click reaction was effective 
using the alkene-containing sugars prepared in this manner. Glutathione 4.22 was selected as a 
model thiol substrate, as it was both a highly efficient in the thiol-ene click reaction and 
representative of larger peptide thiols, which are more interesting targets from a biological 
perspective. 
 
Scheme 4.15: Variation of the sugar-alkene substrate in the thiol-ene click reaction. 
The thiol-ene click reaction with glutathione 4.17 (Scheme 4.15) proved effective with all of 
the sugar alkenes that had been prepared (Table 4.6). The isolated yields of the glycopeptides 
produced varied from moderate to very high.  
  

























Table 4.6: Thiol-ene click reaction of various sugar-alkenes with glutathione 4.17. 
  




4.5.2 Variation of the linker length in the thiol-ene click reaction 
 
Scheme 4.16: Variation of the linker length in the thiol-ene click reaction. 
As expected, the thiol-ene click reaction proved effective when an extended linker was used 
(Scheme 4.16, Table 4.7); butyl-linked glycopeptide 4.28 and pentyl-linked glycopeptide 4.29 
were both obtained in moderate yield. The reduced yield in comparison to propyl-linked 
glycopeptide 4.16 was most likely due to the increased hydrophobicity of the linker resulting 
in greater losses during purification, as the conversion to product as determined by 1H NMR 
of the crude reaction mixture was very high in all cases. 
 
As variation of the sugar and thiol components of the reaction, as well as the linker length, had 
been tolerated in the reaction sequence developed, it appeared that the use of a bifunctional 
click linker represented a versatile technique for the conjugation of unprotected reducing sugars 
to thiols.  
  




Starting material Product 
Isolated 
Yield 















Table 4.7: Variation of the linker length in the thiol-ene click reaction. 
  




4.6 Preparation of MUC1 glycopeptides 
The use of a bifunctional linker has been shown to be a versatile method for the preparation of 
small glycopeptides. However, preparation of a more biologically relevant example was 
necessary in order to demonstrate its true utility. 
 
As discussed in Section 1.2.2 and Section 1.6.1, mucins are a class of glycoproteins commonly 
found as a component of mucous secretions and as transmembrane proteins.20 Abnormal 
glycosylation of mucins is linked to some cancers,21 and the preparation of mucin 
glycoconjugates is therefore of great interest for the design of anti-cancer vaccines.22 Mucins 
contain a variable number tandem repeat (VNTR) domain composed of a repeating peptide unit 
which is heavily O-glycosylated, and short glycosylated peptides therefore represent prime 
vaccine targets.22 The repeated peptide unit of MUC1, VTSAPDTRPAPGSTAPPAHG 
(Figure 4.2),23 has five potential O-glycosylation sites, highlighted in red. Glycosylation of 
one or more of these sites increases the immunogenic activity of the peptide,22 and MUC1 was 
therefore thought to be an ideal target for modification by the double click reaction 
methodology developed in this chapter. 





Figure 4.2: MUC1 VNTR domain repeat peptide unit, with O-glycosylation sites highlighted 
in red. 
In order to modify the MUC1 repeat peptide with the double click method a cysteine needed 
to be introduced at one of the O-glycosylation sites. The threonine residue at position 7 was 
selected for replacement (Figure 4.3), as studies have shown that glycosylation at this position 
is significant for the immunogenic activity of the peptide.22 Peptide 4.30 was therefore prepared 
by Dr Geoff Williams of the Brimble group at the University of Auckland using standard solid 
phase peptide synthesis. 





Figure 4.3: MUC1 20mer peptide with a cysteine inserted at position 7, highlighted in red. 
The Tn antigen (α-GalNAc) is overexpressed on mucins in a variety of cancers,24 therefore the 
GalNAc derivative 4.17 represents a suitable sugar for attachment to peptide 4.30 in order to 
prepare a biologically relevant glycopeptide. 
 
Pleasingly, the thiol-ene click reaction of peptide thiol 4.30 and GalNAc alkene 4.17 
(Scheme 4.17) proved effective, producing glycopeptide 4.31 in 80% yield, as determined by 
HPLC. An excess of GalNAc alkene 4.19 was required to ensure significant glycosylation of 
the peptide. The use of a 20mer peptide in the thiol-ene click reaction demonstrated that the 
use of two sequential click reactions on a bifunctional linker was an effective method for the 
preparation of biologically relevant glycoconjugates. 





Scheme 4.17: Attachment of GalNAc triazole 4.10 to modified MUC1 20mer peptide 4.30. 





Scheme 4.18: Conjugation of complex biantennary glycan 4.32 to bifunctional linker 4.3. 




Having demonstrated that a monosaccharide could be successfully attached to a 20mer peptide, 
the next objective was to demonstrate that the sequential click reaction methodology could be 
applied to larger oligosaccharides. As previously (Section 3.9), the complex biantennary 
glycan 4.32 (Scheme 4.18) was selected as a model oligosaccharide substrate.  
 
Sialoglycan 4.32 was prepared from hens’ egg yolks25, 26 by Dr Vivek Poonthiyil. Preparation 
of the glycosyl azide and subsequent attachment to linker 4.3 was carried out in a similar 
manner to all other conjugates prepared in this chapter (Scheme 4.18). As anticipated, a large 
excess of reagents was required to ensure complete conversion to glycosyl triazole 4.33, which 
was isolated by HPLC in 94% yield.  
 
However, attachment of sialoglycan alkene 4.33 to the modified MUC1 20mer peptide 4.30 
(Scheme 4.19) proved challenging. The initial conditions selected (20 equivalents of 
sialoglycan-linker conjugate 4.33 and 0.1 equivalents of initiator DMPA with a reaction time 
of 4 h) resulted in no observable conversion to the desired product 4.34 (Table 4.8), as 
determined by HRMS. Increasing the concentration of reagents resulted in the formation of 
peptide disulfide, indicating that while radical initiation and chain transfer to thiol had 
occurred, recombination of the thiyl radicals produced was preferred over reaction with the 
linker alkene. The addition of TCEP to reduce any disulfide formed in situ27, 28 reduced the 
peptide disulfide, but no product was observed.  





Scheme 4.19: Attempted attachment of sialoglycan alkene 4.33 to modified MUC1 20mer 
peptide 4.30. 
  





of 4.33 (mM) 
Concentration 
of 4.31 (mM) 
Concentration 
of DMPA (mM) 
Concentration 
of TCEP (mM) 
Result 
12 0.6 0.06 0 No reaction 
120 6 0.6 0 Peptide disulfide 
120 6 0.6 60 No reaction 
120 0.6 0.6 60 Trace 4.34 
120 0.6a 0.6 60 Trace 4.34 
 
Table 4.8: Thiol-ene reaction of sialoglycan-linker conjugate 4.33 with modified MUC1 
peptide 4.30. aAdded over 4 h via syringe pump. 
Increasing the number of equivalents of reagents used and lowering the concentration of 
peptide 4.31 used resulted in the formation of a trace amount of product, as observed by HRMS, 
presumably because the lower concentration of peptide 4.31 leads to a correspondingly lower 
thiyl radical concentration, and therefore the rate of radical recombination is reduced. It was 
reasoned that perhaps adding the peptide over an extended period of time via a syringe pump 
would lead to a further increase in product yield, but disappointingly this was not the case. 
 
It was reasoned that perhaps the low conversion to product when both the sugar and peptide 
were large structures (as compared to previous examples in this chapter) was due to the slow 
hydrogen atom abstraction from another molecule of thiol by the thiol-ene conjugate (Scheme 
4.20, Step III).  





Scheme 4.20: Mechanism of the thiol-ene reaction. 
The radical in the thiol-ene conjugate is between the bulky oligosaccharide and the large 
peptide (4.37), and must be approached by a sterically hindered peptide thiol (4.35) in order to 
abstract a hydrogen atom (Step III). Step II is reversible and therefore unless thiol-ene 
conjugate 4.37 abstracts a hydrogen atom it may decompose into its components. The rate at 
which thiyl radicals combine to form disulfide 4.39 is non-negligible, as demonstrated by the 
formation of peptide disulfide, and so presumably the reduced rate of Step III leads to the 
preferential formation of peptide disulfide. 
 
With this hypothesis, methods for increasing the rate of hydrogen abstraction by the thiol-ene 
conjugate radical were explored. Of these, the most promising was the use of a radical chain 
transfer agent. The most well-known example of a radical chain transfer agent is tributyltin 
hydride.29 However tin reagents are highly toxic and tin contaminants are notoriously difficult 
to remove.30 One alternative to tributyltin hydride is tris(trimethylsilyl)silane (TTMSS).31-33 
While neither tributyltin hydride nor TTMSS have been studied in the context of thiol-ene click 




reactions, TTMSS has been demonstrated to act as a chain transfer agent in the addition of 
radicals to alkenes32 and it has been demonstrated TTMSS can, under the correct conditions, 
abstract a hydrogen atom from a thiol.34  
TTMSS equivalents 
relative to peptide 4.30 
Result 
0 Trace 4.34 
0.1 Trace 4.34 
1 Trace 4.34 
 
Table 4.9: Addition of TTMSS to the thiol-ene reaction between peptide 4.30 and sialoglycan 
alkene 4.33. 
Addition of TTMSS had no discernible effect on the thiol-ene click reaction between the 
modified MUC1 20mer peptide 4.30 and sialoglycan alkene 4.33 (Scheme 4.21, Table 4.9), 
implying either that TTMSS was not capable of donating a hydrogen atom to the peptide-
oligosaccharide conjugate, that the TTMSS radical was not capable of abstracting a hydrogen 
atom from the cysteine residue of peptide 4.30 or that TTMSS directly reduced the thiol of 
peptide 4.30 too rapidly.  
 
Due to the lack of progress in producing even a small quantity of sialoglycan glycoconjugate 
by this method, direct attachment of sialoglycan alkene 4.33 to peptide 4.30 was abandoned 
due to time constraints. 





Scheme 4.21: Addition of TTMSS to the thiol-ene reaction between peptide 4.30 and 
sialoglycan-linker conjugate 4.33. 
  




4.6.1 Sialoglycan attachment using a glycosynthase 
While the direct attachment of a large oligosaccharide to modified MUC1 peptide 4.30 had not 
been possible, a sequence of reactions could be used to accomplish the same goal. 
Glycosynthase enzymes are modified glycosidase enzymes which are capable of catalysing the 
formation of a glycosidic bond.35 Notably, Endo M N175Q, a mutant of Endo M, can catalyse 
the attachment of complex biantennary sialoglycan oxazoline to a wide variety of substrates, 
whilst it has no hydrolytic activity towards the product.36, 37 If a peptide with a single GlcNAc 
attached could be prepared using two sequential click reactions then a sialoglycan oxazoline 
could be attached to the peptide using Endo M N175Q as a catalyst. In general, this method 
would allow the attachment of a GlcNAc “handle” to a peptide, which could then be further 
functionalised using mutant ENGase enzymes.  
 
In order to test this proposal, GlcNAc alkene 4.9 was attached to modified MUC1 peptide 4.30 
(Scheme 4.22). Using the same conditions that had been used for the attachment of GalNAc, 
the GlcNAc-peptide conjugate 4.40 was obtained in 77% yield, as determined by HPLC.  





Scheme 4.22: Attachment of GlcNAc alkene 4.9 to the modified MUC1 20mer peptide 4.30. 





Scheme 4.23: Preparation of sialoglycan oxazoline 4.41. 
Sialoglycan oxazoline 4.41 was prepared using DMC 2.1 in a yield of 63% by following the 
literature procedure (Scheme 4.23).38 A large excess of reagents was required to ensure 
complete reaction of sialoglycan 4.32. 




With both substrates in hand, the glycosynthase-catalysed glycosylation reaction of oxazoline 
4.41 and GlcNAc conjugate 4.40 was examined. Pleasingly, the conditions reported by 
Tomabechi et al. (Scheme 4.24)37 for the use of Endo M N175Q to catalyse similar reactions 
proved successful with only minor alterations (10 mU of Endo M N175Q was used instead of 
2 mU), and afforded the desired glycopeptide 4.42 in a yield of 40% as determined by HPLC.  
 
Thus, while it had not been possible to attach the large oligosaccharide directly to the MUC1 
20mer through the use of two sequential click reactions using the conditions so far investigated, 
it was demonstrated that following the introduction of GlcNAc as a handle by double click 
chemistry the attachment of a larger N-glycan structure could be achieved by the use of an 
ENGase-catalysed reaction. 
 





Scheme 4.24: Preparation of sialoglycan-modified MUC1 peptide glycopeptide 4.37. 
 
  





The use of a bifunctional linker to prepare glycoconjugates was demonstrated to be an effective 
means of attaching monosaccharide units and small oligosaccharide chains to a variety of 
substrates. Sugar-linker conjugates were prepared via CuAAC for a wide range of small sugars, 
and a number of different linkers. These sugar linker conjugates could then be attached to thiols 
via thiol-ene click chemistry. A small number of thiols were investigated, and it was 
determined that the effectiveness of the reaction largely hinged on the reactivity of the thiol. 
The reaction sequence could be applied to large, biologically relevant thiols, as demonstrated 
by the attachment of a GalNAc alkene to a modified MUC1 20mer peptide. However, while 
larger oligosaccharides could be attached to a linker, the subsequent thiol-ene click reaction 
proved challenging. In order to avoid the difficulties associated with this reaction, it was 
demonstrated that glycoconjugates containing larger oligosaccharides could be prepared by 
first attaching a GlcNAc residue to the peptide using two sequential click reactions, and then 
attaching by an oligosaccharide to the GlcNAc residue using an ENGase enzyme. While not 
being able to directly attach a large oligosaccharide is a current limitation of the methodology, 
the attachment of a GlcNAc handle followed by the use of a glycosynthase enzyme bypasses 
the problematic step. 
 
Only a small subset of linkers were tested in this study. Therefore, in future it would be 
worthwhile to expand the set of linkers tested, with a view to increasing the effectiveness of 
the reaction sequence, particularly with larger substrates. Also, the linker structure differs 
significantly from natural glycoconjugate linkages, and therefore it would be beneficial to carry 
out studies of the biological activity of compounds produced in this manner, again investigating 
the effect of varying the linker. 
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Chapter 5: Flavinium salt-catalysed synthesis of glycosyl 
sulfoxides and investigation of their activity as glycosidase 
inhibitors 
5.1 Flavinium salts 
In recent years there has been an intense focus on “green chemistry”,1 developing reactions 
which are less harmful to the environment. The application of flavinium salts (Section 
1.14.1) appears to represent a real possibility to improve the synthesis of glycosyl sulfoxides, 
as it has been demonstrated to be clean, producing only water as a byproduct, and efficient, 
oxidising a wide range of sulfides to sulfoxides.2-4 The use of hydrogen peroxide as an 
oxidant is desirable because it is both atom-economic,5 and produces only environmentally 
benign water as a byproduct, while the use of water as a solvent is preferred over organic 
solvents because it is environmentally benign. 
 
Figure 5.1: Flavin species that have previously been examined as catalysts for the oxidation of 
sulfides. 
The activities of the various types of flavin species (Figure 5.1), N5,N10 substituted flavinium 
salts (5.1),2 N1,N5 substituted dihydroalloxazines (5.2),3 and N1,N10 bridged flavinium salts 
(5.3),4 are broadly comparable, although direct comparisons are scarce. Therefore, N1,N10 
substituted flavinium salts were selected for testing as catalysts for the oxidation of 
thioglycosides to glycosyl sulfoxides, as their preparation is simpler and shorter, a beneficial 
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feature if such catalysts are to be used on a large scale. Furthermore, they are easily tuneable, 
notably by modification of either the aromatic ring or the bridging chain,4, 6 and they have been 
shown to be more stable than some of the alternatives, notably N1,N5 substituted flavinium 
salts.3 
 
5.2 Preparation of catalyst 5.7 
 
Scheme 5.1: Preparation of flavinium salt catalyst 5.7. 
The N1,N10 bridged flavinium salt 5.7 was prepared according to the literature procedure 
(Scheme 5.1).7 1-Chloro-2-nitrobenzene was converted to compound 5.4 via nucleophilic 
aromatic substitution by ethanolamine, using potassium carbonate as a base. The nitro- group 
of 5.4 was converted to an amine by catalytic reduction, with palladium on carbon as a catalyst 
and ammonium formate as the hydrogen source. Condensation of diamine 5.5 with alloxan 5.6 
catalysed by boric acid and acetic acid, followed by conversion of the free hydroxyl group to a 
chloride using thionyl chloride and then in-situ nucleophilic substitution of the chloride by N1 
afforded catalyst 5.7.  
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5.3 Preparation of the test substrate 
 
Scheme 5.2: Preparation of tolyl thioglycoside 5.9. 
Tolyl thioglycoside 5.9 was chosen as a test substrate for the oxidation reaction, as it is 
unprotected and therefore expected to be more easily oxidised in an aqueous environment than 
protected sulfoxides. Thioglycoside 5.9 was prepared by Zemplén deacetylation8 of the known 
acetyl-protected tolyl thioglycoside 5.89 (Scheme 5.2), which had previously been synthesised 
by another member of the Fairbanks group.  
 
5.4 Investigation of the oxidation reaction 
With catalyst 5.7 and model substrate 5.9 in hand, investigation of the oxidation reaction 
commenced (Scheme 5.3). A loading of 1.8% of catalyst 5.7 was used, as this loading has 
previously been shown to catalyse oxidation reactions effectively.4 Only 1.2 equivalents of 
hydrogen peroxide were used, as peroxide is potentially explosive and therefore minimising 
the amount used is desirable. Screening of reaction solvents revealed that methanol was most 
effective, the use of which resulted in 78% conversion to product as determined by 1H NMR 
spectroscopy (Table 5.1). The use of acetonitrile resulted in the production of significant 
quantities of impurities. Water would be an ideal solvent for this reaction, as it is 
environmentally benign and readily available, and would therefore further complement the 
conditions required. Unfortunately tolyl thioglycoside 5.9 was not soluble in water. Methanol 
was therefore arrived upon as the optimal solvent for the oxidation of tolyl thioglycoside 5.9.  
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Scheme 5.3: Oxidation of tolyl thioglycoside 5.9 to glycosyl sulfoxide 5.10 catalysed by 
flavinium salt 5.7. 
Solvent Catalyst Loading Reaction time (h) Conversion 
H2O 1.8% 6 0% 
MeCN 1.8% 6 Impurities 
MeOH 1.8% 6 78% 
MeOH 5% 6 87% 
MeOH 10% 6 84% 
MeOH 20% 6 92% 
MeOH 5% 4 69% 
MeOH 5% 8 86% 
 
Table 5.1: Optimisation of oxidation of tolyl glycoside 5.9 to glycosyl sulfoxide 5.10. 
Next, other reaction parameters were systematically varied. Increasing the catalyst loading 
resulted in a small increase in conversion. At a loading of 5% catalyst 87% conversion to 
product was observed; an increase of 9% over the oxidation reaction with a catalyst loading of 
1.8%. Increasing the catalyst loading to 10% resulted in 84% conversion to product, and further 
increasing the catalyst loading to 20% gave a conversion of 92%. However, the increase in 
conversion upon increasing the amount of catalyst above 5% loading was slight, and appears 
to be within the experimental margin of error. Therefore, 5% was selected as a suitable catalyst 
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loading for further optimisation and exemplification. Six hours was found was found to be the 
optimum reaction time; reactions run for less time had significantly lower conversions, whilst 
the use of more extended reaction times resulted in no significant change in conversion. 
 
Purification of sulfoxide 5.10 proved challenging, as it is insoluble in a number of common 
chromatography solvents, non-crystalline, and unstable to both acid and heat. Purification was 
eventually accomplished with a yield of 74% by pre-absorption of 5.10 onto Florisil®, followed 
by rapid flash column chromatography with CH2Cl2:MeOH (7:1) as the solvent. 
 
5.5 Oxidation of protected thioglycosides 
Having demonstrated that flavin 5.7 is an effective catalyst for the hydrogen peroxide-mediated 
oxidation of unprotected tolyl thioglycosides, attention turned to protected thioglycosides. 
Benzylated tolyl thioglycoside 5.119 was prepared using standard conditions, by reaction of 
unprotected tolyl thioglycoside 5.9 with benzyl bromide, in the presence of sodium hydride as 
a base (Scheme 5.4). Acetylated tolyl thioglycoside 5.89 was already available, and together 
these protecting groups represent those most commonly used in carbohydrate chemistry. 
 
Scheme 5.4: Preparation of benzylated tolyl thioglycoside 5.11. 
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Scheme 5.5: Oxidation of protected tolyl thioglycosides catalysed by flavinium salt 5.7. 
Compound Solvent Temperature Reaction Time (h) Conversion 
5.8 H2O RT 6 - 
5.8 MeOH RT 6 - 
5.8 MeOH Reflux 6 22% 
5.8 DCM RT 6 - 
5.8 MeCN RT 6 30% 
5.8 MeCN Reflux 6 Decomp. 
5.8 MeCN RT 72 45% 
5.11 MeCN RT 6 <10% 
 
Table 5.2: Testing of the hydrogen peroxide-mediated oxidation of protected tolyl 
thioglycosides catalysed by flavinium salt 5.7.  
First, the conditions established for unprotected tolyl thioglycoside 5.9 were applied to 
acetylated tolyl thioglycoside 5.8 (Scheme 5.5). Unfortunately, it quickly became apparent that 
the reaction was significantly less effective with protected thioglycosides (Table 5.2). 
Acetylated thioglycoside 5.8 is insoluble in water and only sparingly soluble in methanol, and 
therefore perhaps unsurprisingly no reaction was observed in either of these solvents. Heating 
the reaction to reflux in methanol increased the rate of reaction, but after six hours only 22% 
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conversion to 5.12 was observed. The use of dichloromethane as a solvent again resulted in no 
reaction. Both catalyst 5.7 and hydrogen peroxide are insoluble in dichloromethane, leading to 
a heterogeneous system. This is consistent with previous studies of N1,N10 bridged flavinium 
catalysts, where it was reported that the use of dichloromethane as a reaction solvent resulted 
in irreproducible results due to heterogeneity of the reaction mixture.4 
 
The use of acetonitrile as a reaction solvent resulted in a more promising 30% conversion of 
5.8 into 5.12 after six hours at room temperature. As heating the reaction to reflux increased 
the rate of the corresponding reaction in methanol, refluxing the acetonitrile reaction was 
attempted. Unfortunately, analysis of the reaction mixture showed that a complex mixture of 
products had been formed. Sulfoxides are known to be unstable when heated, decomposing 
into highly reactive sulfenic acids.10, 11 Indeed, in the course of this work even heating glycosyl 
sulfoxides in vacuo while concentrating the crude reaction mixture was observed to be 
sufficient to result in violent decomposition.  
 
Extending the reaction time did result in an increase in conversion. After 72 hours only 45% 
conversion to product was observed, which, while an improvement, is far from ideal. 
 
Application of identical conditions to the benzylated tolyl thioglycoside 5.11 gave a reduced 
conversion to the corresponding product 5.13. Further optimisation attempts were therefore 
focused on acetylated thioglycoside 5.8. 
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Scheme 5.6: Optimisation of the oxidation of acetylated tolyl thioglycoside 5.8. 
Loading of 5.7 H2O2 equivalents Conversion 
5% 1.2 30% 
10% 1.2 39% 
20% 1.2 39% 
5% 2.4 63% 
5% 7.2 94% 
 
Table 5.3: Variation of reaction conversion with catalyst loading and the quantity of hydrogen 
peroxide for oxidation of acetylated tolyl thioglycoside 5.8. 
Due to the significantly lower conversion to product observed for protected tolyl 
thioglycosides, the catalyst loading and hydrogen peroxide concentration were reinvestigated 
(Table 5.3). Increasing the loading of catalyst 5.7 resulted in only a small increase in 
conversion, consistent with previous results. However, increasing the number of equivalents of 
hydrogen peroxide used did result in a more effective reaction, increasing the conversion of 
thioglycoside 5.8 to sulfoxide 5.12 to 94% when 7.2 equivalents of peroxide were used. 
However, given that hydrogen peroxide is a potentially explosive compound, and furthermore 
that the atom economy benefits of using peroxide as an oxidant are diminished when 7.2 
equivalents are required, existing peroxide oxidation procedures, such as those catalysed by 
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silica,12 were deemed more effective and benign. Therefore, this protocol was not further 
applied to protected sugars, as it was not judged to be an improvement on existing 
methodology.  
 
5.5.1 Modification of the flavinium catalyst 
Unlike the reactions of N1,N5 substituted and N5,N10 substituted flavinium salts13-15 there has 
been no thorough mechanistic study of oxidation reactions catalysed by N1,N10 bridged 
flavinium salts. However, electron-withdrawing subsituents attached to C7 and/or C8 have 
been shown to increase their catalytic activity,4 implying that the rate-determining step is the 
elimination of water from the 10a adduct to regenerate the flavinium salt. Variation of these 
substituents could therefore provide a route to enhancing the oxidation of protected 
thioglycosides.  
 
Scheme 5.7: Preparation of chlorine-substituted catalyst 5.17.7 
With the aim of testing this hypothesis, the chlorinated flavinium salt 5.17 was prepared 
according to the literature procedure.7 An analogous reaction sequence to that used previously 
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was applied to 1,4-dichloro-2-nitrobenzene 5.14. Regioselective nucleophilic aromatic 
substitution was carried out with ethanolamine using potassium carbonate as a base to obtain 
compound 5.15. Reduction of the nitro group to afford diamine 5.16 was carried out using 
mossy tin16 and hydrochloric acid in order to avoid dehalogenation. Diamine 5.16 was then 
condensed with alloxan 5.6 using boric acid as a catalyst. Ring-closure by conversion of the 
free hydroxyl group to a chloride followed by nucleophilic substitution afforded flavinium salt 
5.17.  
 
Scheme 5.8: Oxidation of protected tolyl thioglycosides catalysed by flavinium salt 5.17. 
Compound H2O2 equivalents Conversion 
5.8 1.2 38% 
5.8 2.4 42% 
5.8 3.6 47% 
5.11 1.2 <10% 
 
Table 5.4: Oxidation of protected tolyl thioglycosides catalysed by chlorinated flavinium salt 
5.17.  
Testing of flavinium salt 5.17 did reveal a small increase in conversion of the acetylated 
thioglycoside 5.8 to the sulfoxide 5.12 (Scheme 5.8, Table 5.4). However, even the use of 3.6 
equivalents of hydrogen peroxide only resulted in 47% conversion, significantly below existing 
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procedures. Similarly, no significant improvement for the conversion of benzylated tolyl 
thioglycoside 5.11 to sulfoxide 5.13 was observed. 
 
With these results in mind, further investigation into the use of flavinium catalysts to catalyse 
the oxidation of protected thioglycosides were discontinued, as no conditions that were an 
improvement over pre-existing methods had been found. It was believed that solubility effects 
contributed to the poor performance of protected sugars in the flavinium salt catalysed reaction; 
in most of the solvents tested at least one of the protected sugar, hydrogen peroxide, or the 
flavinium salt catalyst was insoluble, or only partially soluble. 
 
5.6 Substrate scope: variation of the aglycon 
While protected sugars are required for the majority of applications of glycosyl sulfoxides, 
such as their use as glycosyl donors, there are some exceptions. Notably, glycosidase inhibitors 
possess free hydroxyl groups, as the natural substrates of these enzymes are themselves 
unprotected. Therefore, the substrate scope of the reaction of unprotected thioglycosides was 
investigated. 
 
Scheme 5.9: Preparation of unprotected thioglucosides 5.22-5.24. 
Firstly, the aglycon was varied. A selection of common thioglucosides were prepared following 
the standard procedure (Scheme 5.9).17 Peracetyl-β-glucose 5.1818 was converted to the 
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corresponding ethyl, phenyl, and para-methoxyphenyl thioglucosides 5.19-5.21 by activation 
with boron trifluoride in the presence of the relevant thiol. These reactions afforded protected 
ethyl-,18 phenyl-,19 and para-methoxyphenyl-20 thioglucosides (5.19-5.21) in moderate to high 
yields. Deacetylation was then carried out under Zemplén conditions to afford the unprotected 
thioglucosides 5.22-5.2419-21 in high yields.  
 
Scheme 5.10: Oxidation of various unprotected thioglycosides to glycosyl sulfoxides catalysed 
by flavinium salt 5.7. 
Compound Solvent Conversion Isolated yield 
5.9 MeOH 87% 74% 
5.22 MeOH 93% 76% 
5.22 H2O >99% 71% 
5.23 MeOH 30% - 
5.24 MeOH 64% - 
 
Table 5.5: Oxidation of various unprotected thioglucosides to glycosyl sulfoxides catalysed by 
5.3. 
Testing revealed that ethyl thioglycoside 5.22 (93% conversion) was slightly more efficiently 
oxidised to sulfoxide than tolyl thioglycoside 5.9 (87% conversion). On the other hand, para-
Chapter 5: Flavinium salt-catalysed synthesis of glycosyl sulfoxides and investigation of their  
activity as glycosidase inhibitors 
191 
 
methoxyphenyl thioglycoside 5.24 was a less effective substrate (64% conversion) and phenyl 
thioglycoside 5.23 was a poor substrate with only a very low 30% conversion to sulfoxide. 
Only tolyl glycosyl sulfoxide 5.10 and ethyl glycosyl sulfoxide 5.25 were isolable, due to the 
difficulty separating the unreacted thioglycoside starting material from the glycosyl sulfoxide. 
Again, purification proved challenging due to the high polarity and relative instability of the 
glycosyl sulfoxides when exposed to silica, but was accomplished by pre-absorbing the 
sulfoxides onto Florisil® before purifying by rapid flash column chromatography. 
 
Interestingly, both the more electron-rich (para-methoxyphenyl- as compared to tolyl- groups) 
and the less electron-rich (phenyl- as compared to tolyl- groups) substrates were found to be 
less effective substrates than the tolyl thioglycoside. The precise reasons for this were not 
investigated, but one possible explanation is as follows: if a more electron-rich species reacts 
at a reduced rate then it is logical that the increased build-up of negative charge on the sulfur 
atom interferes with its ability to attack the flavinium peroxide species. On the other hand, for 
less electron-rich species attack on the flavinium peroxide species becomes more challenging 
due to the greatly reduced electron density at sulfur.  
 
It was observed that ethyl thioglucoside 5.22 is soluble in water, unlike tolyl thioglucoside 5.9. 
The efficiency of the reaction in water as the solvent was therefore investigated for ethyl 
thioglucoside 5.22. Pleasingly, the use of water as a solvent led to the complete conversion of 
5.22 to sulfoxide 5.25 (as observed by 1H NMR spectroscopy). As water is the solvent of choice 
for this reaction, and also gives higher conversions in this case, ethyl thioglycosides were used 
for the remaining studies.  
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5.7 Substrate scope: variation of the sugar
 
Scheme 5.11: Preparation of ethyl thioglycosides. 
The ethyl thioglycosides of mannose (5.30), galactose (5.34), GlcNAc (5.38), and lactose 
(5.40) were prepared using similar methodology to that followed previously (Scheme 5.11). 
Mannose ethyl thioglycoside 5.30 was prepared in an identical manner to glucose ethyl 
thioglycoside 5.22, by first reacting α-mannose pentaacetate 5.2822 with boron trifluoride in 
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the presence of ethanethiol to afford protected thioglycoside 5.29,23 and then deprotecting 
under Zemplén conditions to afford manno ethyl thioglycoside 5.30.24 The galacto 
thioglycoside 5.34 was prepared similarly, however β-galactose pentaacetate 5.32 first had to 
be prepared, by acetylation of galactose 5.31 with acetic anhydride.25 Subsequent conversion 
to thioglycoside 5.3326 and deprotection21 was carried out as previously. The ethyl 
thioglycoside of GlcNAc 5.38 was prepared starting from the 2-phthalamido tetraacetate 
compound 5.35, which was converted to the ethyl thioglycoside using boron trifluoride and 
ethanethiol as before to afford thioglycoside 5.36.23 The phthlamide group was then removed 
using hydrazine hydrate in ethanol and the resulting free amine acetylated with acetic anhydride 
to obtain fully acetylated thioglycoside 5.37.21 Zemplén deacetylation of 5.37 afforded 
unprotected GlcNAc ethyl thioglycoside 5.38.21 Lactose ethyl thioglycoside 5.40 was prepared 
from β-lactose octaacetate 5.3927 by treatment with boron trifluoride and ethanethiol as 
before.28 The resulting protected thioglycoside could not be completely purified; a small 
amount of the α-thioglycoside was inseparable from the β anomer. Deprotection under 
Zemplén conditions and subsequent recrystallization afforded pure β-ethyl thioglycoside 
5.40.28 
 
Pleasingly, in almost all cases high conversions were observed for the oxidation of the ethyl 
thioglycosides catalysed by flavinium salt 5.7 (Scheme 5.12, Table 5.6). The only exception 
was the GlcNAc ethyl thioglycoside 5.38. NMR analysis of the crude reaction mixture showed 
both the presence of a significant amount of unreacted starting material and a number of 
products. As demonstrated previously protection of the thioglycoside significantly alters its 
reactivity in this reaction, and the poor performance of 5.38 would appear to indicate that 
protection or alteration of OH-2 in particular has a significant effect on the reactivity of the 
thioglycoside. This is perhaps unsurprising, as OH-2 is the hydroxyl group physically closest 
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to the anomeric centre. This is reinforced by the excellent reactivity of lactose thioglycoside 
5.40. Lactose thioglycoside 5.40 is insoluble in methanol, accounting for the low reactivity 
when methanol is used as a reaction solvent. Modification of a more remote hydroxyl group 
clearly does not have a significant effect on the reactivity of the thioglycoside substrate. 
 
Scheme 5.12: Oxidation of ethyl thioglycosides to glycosyl sulfoxides. 
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Compound Solvent Conversion Yield 
5.22 MeOH 93% 76% 
5.22 H2O >99% 71% 
5.30 MeOH 93% 70% 
5.30 H2O >99% 49% 
5.34 MeOH >99% 66% 
5.34 H2O 88% 63% 
5.38 MeOH Mixture - 
5.38 H2O Mixture - 
5.40 MeOH - - 
5.40 H2O >99% 43% 
 
Table 5.6: Oxidation of ethyl thioglycosides catalysed by 5.7. In all cases a 5% loading of 5.7, 
1.2 eq. H2O2, and a reaction time of 6 h were used (Scheme 5.12). 
The manno glycosyl sulfoxide 5.41 was unique in that it was obtained as a single 
diastereoisomer; all the other sulfoxides were formed as approximately 1:1 mixtures of the two 
sulfoxide diastereoisomers. The single diastereoisomer formed is believed to be the RS 
diastereoisomer, as the preference for formation of the RS diastereoisomer in oxidation 
reactions of α-thioglycosides has been noted previously.29, 30 The explanation given for this 
phenomenon is that the favoured conformation of the thioglycoside α-anomer is one in which 
one lone pair of sulfur stabilises that conformation via the exo-anomeric effect, while the bulky 
thioglycoside substituent (the ethyl group in this case) is in the sterically favoured exo 
configuration. These two conditions lead to one favoured rotational conformer (Scheme 5.13). 
Oxidation then requires attack of one of the lone pairs on sulfur on the oxidising agent, in this 
case the flavinium-peroxide species. The pro-S lone pair is sterically hindered by the pyranose 
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ring, and so it is the pro-R lone pair that attacks preferentially, so forming a single 
diastereoisomer.29 In addition, the conformer shown would also be expected to be the most 
reactive, as the perpendicular C-O and S-O dipoles would be expected to minimise the 
transition state energy. Thus, the conformation shown would be expected to be the most 
abundant and the most reactive. 
 
Scheme 5.13: Mechanism of the selective formation of the RS diastereoisomer of the manno 
ethyl glycosyl sulfoxide 5.41. 
As previously, the yields were in all cases lower than would be expected given the high 
conversions, and again this was due to difficulties in purifying the highly polar and relatively 
unstable glycosyl sulfoxide products. Beyond the difficulties of purification the relatively low 
stability of sulfoxides is rarely a factor in their use, as they are typically prepared and then used 
almost immediately. Nevertheless, once purified the glycosyl sulfoxides prepared here were 
found to be stable for weeks when stored at -20 °C. 
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5.8 Investigation of glycosyl sulfoxides as potential glycosidase inhibitors 
5.8.1 Conditions 
 
Figure 5.2: Sulfoxides selected for testing as glycosidase inhibitors. 
A selection of the synthesised glycosyl sulfoxides were then tested as inhibitors of a variety of 
common glycosidase enzymes. The glycosyl sulfoxides selected were the gluco, manno, and 
galacto ethyl sulfoxides 5.25, 5.41, and 5.42 (Figure 5.2), which are potential inhibitors of β-
glucosidases, α-mannosidases, and β-galactosidases respectively. The ethyl glycosyl sulfoxide 
series was the most easily prepared of the sulfoxides investigated, and they have a simple 
aglycon which would be expected to have minimal steric issues when the inhibitor is bound to 
an enzyme. It was thought that they therefore represented a good starting point from which 
modifications can be made if interesting inhibitory behaviour was discovered. 
 
The glycosidase enzymes selected for these inhibition studies were a β-glucosidase from 
almonds,31-33 a jack bean α-mannosidase,34-36 and a β-galactosidase from E. coli.37-39 All are 
well studied enzymes and are commercially available. 
 
Chapter 5: Flavinium salt-catalysed synthesis of glycosyl sulfoxides and investigation of their  




Figure 5.3: Nitrophenyl glycosides used for glycosidase inhibition studies. 
Nitrophenyl glycosides 5.45, 5.46, and 5.47 (Figure 5.3) were chosen as hydrolytic substrates 
for the inhibition studies. Nitrophenyl glycosides are typically used for real time monitoring of 
the rate of the glycosidase catalysed hydrolysis reactions,40, 41 as the nitrophenyl glycoside itself 
exhibits minimal or no absorption between 400 nm and 450 nm, while the o- or p-
nitrophenolate ion produced by the hydrolysis reaction absorbs strongly in this region.  
 
5.8.2 Kinetic model 
One of two values is typically used to represent the strength of an enzyme inhibitor: either IC50, 
the concentration of inhibitor required for the activity of the enzyme to be reduced by 50%, or 
Ki, the dissociation constant of the enzyme substrate complex.
42 The most significant difference 
between the two measurements is that Ki is by definition independent of substrate 
concentration, while IC50 is typically substrate concentration-dependent. Exceptions to the 
substrate-dependence of IC50 do exist, if the inhibitor is un- or non-competitive and certain 
conditions are met.42 The substrate-independence of Ki means that Ki is normally a more useful 
measurement for comparing data between various studies. However, determination of Ki does 
require the collection of significantly more data than determination of IC50, as initial rate values 
must be collected over a range of substrate and inhibitor concentrations.  
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A modified version of Michaelis-Menten enzyme kinetics is used to determine Ki.
43 
                                                            𝜐 =
𝑉𝑚𝑎𝑥[𝑆]
𝐾𝑚+[𝑆]
                                                             (1) 
Equation 1 is the standard Michaelis-Menten equation for an enzyme-catalysed reaction 
involving a single substrate. For a competitive inhibitor it can be assumed that Km is modified 
by some factor that is dependent on Ki and the concentration of inhibitor, to give a lower 
apparent Km value, Km
app (Equation 2). 
                                                      𝐾𝑚
𝑎𝑝𝑝
= 𝐾𝑚 (1 +
[𝐼]
𝐾𝑖
)                                                     (2) 
Substituting this value for Km
app into equation 1 gives equation 3, which describes the initial 
rate in terms of Vmax, [S], [I], Km, and Ki. 






                                        (3) 
If measurements of the initial rate of reaction are taken at varying concentrations of both 
substrate and inhibitor Equation 3 can be fitted to the experimental data to give values for Vmax, 
Km, and Ki. The fitting of Equation 3 is best achieved by direct fitting to the data using the 
method of least squares.44 It is possible to convert Equation 3 into a linear form analogous to 
the Lineweaver-Burk plot (equation 4).45 












                                                 (4) 
The use of a linear plot results in a significantly higher error in fitted values, and therefore 
linear fitting to Equation 4 is not suitable for calculating Ki or Km.
44 However, the use of a 
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linear plot does allow for more effective visual analysis of the data. In order to fit the data 
obtained in this study, the program GraFit 5 was used. 
 
There are three common types of reversible enzyme inhibition.46 The glycosyl sulfoxides 
examined here are expected to be competitive inhibitors, which means that substrate and 
inhibitor both bind to the enzyme active site, and therefore only one of the two can be bound 
at a time. Competitive inhibitors raise the apparent Km of the enzyme, by reducing the 
concentration of enzyme available for reaction, but result in no change in Vmax,, as the rate at 
which the available enzyme can process substrate remains unchanged. The type of inhibition 
is readily determined by observation of the Lineweaver-Burk plot. If the inhibition observed is 
competitive then the lines corresponding to various inhibitor concentrations will share a 





In non-competitive inhibition the substrate and inhibitor bind to the enzyme in an independent 
manner, that is, both, one of, or neither of the substrate and inhibitor may be bound to the 
enzyme at one time. Non-competitive inhibition results in no change in apparent Km, but a 
lowering of Vmax, as substrate binding is not affected by the binding of inhibitor but the rate at 
which the enzyme can process substrate is reduced. In the case of non-competitive inhibition, 
when inhibitor concentration is varied the Lineweaver-Burk plot displays a series of lines with 
a common x-intercept, corresponding to the constant apparent Km value. Mixed inhibition is 
related to non-competitive inhibition, and is when the strength of substrate binding to the 
uninhibited enzyme is different to the strength of substrate binding to the enzyme-inhibitor 
complex. When inhibitor concentration is varied the Lineweaver-Burk plot of the activity of 
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an enzyme inhibited by a mixed inhibitor displays a series of lines with a common intercept 
that is on neither the x- nor the y-axis. 
 
The third common type of reversible inhibition is uncompetitive inhibition. An uncompetitive 
inhibitor only binds to the enzyme-substrate complex, not to the free enzyme. Uncompetitive 
inhibition results in a decrease in the rate at which the enzyme can process substrate and also 
results in a decrease in the apparent Km of the enzyme, as the formation of enzyme-substrate-
inhibitor complex effectively lowers the concentration of the enzyme substrate complex, 
increasing the amount of substrate which can bind to the enzyme. The Lineweaver-Burk plot 
of the activity of an uncompetitively inhibited enzyme displays a series of parallel lines, as 
both Ki and Vmax vary when inhibitor concentration is varied.  
 
While the glycosyl sulfoxides examined in this study were expected to be competitive 
inhibitors, uncompetitive inhibition of glycosidase enzymes by some glycosyl sulfoxides has 
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5.8.3 Inhibition testing 
The first sulfoxide tested was the gluco sulfoxide 5.25, which was assayed against β-
glucosidase from almonds. The study was carried out at pH 6.8 in a phosphate buffer (0.05 M) 
at 25 °C.41 
 
 Value Error 
Vmax 0.191 s-1 ±0.08 s-1 
Km 7.7 mM ±1.0 mM 
Ki - - 
 
Figure 5.4: Lack of inhibition of β-glucosidase from almonds by gluco sulfoxide 5.25. 
Unfortunately, 5.25 did not inhibit the β-glucosidase from almonds at an inhibitor 
concentration of 1 mM (Figure 5.4). The value of Km obtained is broadly consistent with 
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Next, manno sulfoxide 5.41 was tested against the α-mannosidase from jack beans. The 








 Value Error 
Vmax 0.062 s-1 ±0.002 s-1 
Km 4.0 mM ±0.3 mM 
Ki 17 mM ±1 mM 
 
Figure 5.5: Inhibition of jack bean α-mannosidase by manno sulfoxide 5.41. 
The manno sulfoxide 5.41 gave slightly more promising results (Figure 5.5). Inhibition of jack 
bean α-mannosidase was observed at an inhibitor concentration of 1 mM, and further testing 
revealed a Ki for 5.41 of 17 mM. Again, the measured value of Km of 4.0 mM was broadly 
consistent with the previously reported value of 2.5 mM.49 Millimolar level inhibition of 
lysosomal and golgi α-mannosidases by α-mannosyl sulfoxides was previously reported by 
Poláková et al.,50 results similar to those demonstrated here. In addition, the common y-
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intercept at varying inhibitor concentrations on the Lineweaver-Burk plot indicated that the 
inhibition was competitive. 
The galacto sulfoxide 5.42 was assayed against the β-galactosidase from E. coli, at pH 7.0 in 








 Value Error 
Vmax 0.22 s-1 ±0.01 s-1 
Km 0.24 mM ±0.03 mM 
Ki 2.1 mM ±0.02 mM 
 
Figure 5.6: Inhibition of the β-galactosidase from E. coli by galacto sulfoxide 5.42. 
Pleasingly, galacto sulfoxide 5.42 also demonstrated mild inhibitory activity against the 
corresponding glycosidase, with a Ki of 2.1 mM obtained (Figure 5.6). The Km value of 0.24 
mM is consistent with previously reported values.52 However, similarly to manno sulfoxide 
5.41, the galacto sulfoxide 5.42 displayed only moderate activity against the corresponding 
glycosidase. Again, the inhibition was competitive. 
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5.8.4 Inhibition testing of single sulfoxide diastereoisomers 
One notable feature of the gluco and galacto sulfoxides tested is that they were mixtures of 
diastereoisomers, and, as enzyme active sites are chiral environments, it is likely that the 
inhibitory activities of the two diastereoisomers are in fact different. Therefore, the two 
diastereoisomers of each of the gluco and galacto sulfoxides were separated and the Kis of the 
individual diastereoisomers were measured. 
 
Figure 5.7: Sulfoxide diastereoisomers separated by HPLC. 
Both sets of diastereoisomers were separated by HPLC, as the sulfoxides are non-crystalline 
and were not separable by flash column chromatography, resulting in four new potential 
glycosidase inhibitors: gluco sulfoxides 5.25 SS and RS, and galacto sulfoxides 5.42 SS and RS. 
Determining which diastereoisomer was which was non-trivial, as they were not literature 
compounds, and so NMR spectra, optical rotation values, and other data were not available for 
comparison. There was also no significant preference for the formation of one diastereoisomer 
over the other, as was the case for the manno sulfoxide 5.41. 
 
Four techniques have been used to assign the configuration of glycosyl sulfoxides. X-Ray 
crystallography is the most reliable, and has often been used to verify the results of other 
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methods.30, 53 Unfortunately, none of the sulfoxides obtained in this study produced large 
enough crystals for examination by this method. Chiral shift reagents have been used to 
distinguish sulfoxide diastereoisomers, although the difference between the two isomers in that 
case was less than 0.02 ppm for the single sulfoxide studied.53 Circular dichroism has also been 
applied to a small group of sulfoxides in a study by Sanhueza et al.54 While circular dichroism 
is effective a simpler method was preferable, ideally using NMR data already collected, as 
there are noticeable differences in the NMR spectra of the diastereoisomers.  
 
Khair has reported that differences in chemical shift between the two diastereoisomers of ethyl 
glycosyl sulfoxides can reliably be used to assign the configuration of the sulfur.55 Notably, the 
peak corresponding to C-1 of the RS sulfoxide is shifted upfield relative to that of the SS 
sulfoxide. In addition, the peak or peaks corresponding to the CH2 group of the ethyl substituent 
display significantly higher separation in the RS substituent as compared to the SS substituent 
(roughly 160 Hz as compared to roughly 20 Hz). These effects are relatively consistent and are 
due to the varying degree to which conformers displaying the exo-anomeric effect are present 
in solution for the RS and SS diastereoisomers.
56 The RS diastereoisomer favours only the 
conformation in which the exo-anomeric effect is present, resulting in greater shielding of C-
1. 
 
In the case of 5.25 and 5.42 the separation of the CH2 peaks was not useful to distinguish the 
two diastereoisomers, as in all cases the separation between the peaks was approximately 50 
Hz. However, the chemical shift C-1 varied in a manner consistent with the above method for 
distinguishing diastereoisomers, and so assignments were made on the basis of these chemical 
shifts. 
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5.25 RS 5.25 SS 
Value Error Value Error 
Vmax 0.162 s-1 ±0.006 s-1 0.153 s-1 ±0.003 s-1 
Km 8.3 mM ±0.9 mM 7.0 mM ±0.4 mM 
Ki - - - - 
 
Figure 5.8: Inhibition testing of gluco sulfoxides against the β-glucosidase from almonds. 
Glucosyl sulfoxides 5.25 RS and SS were again assayed against β-glucosidase from almonds 
using the same conditions as previously. While the diastereoisomeric mixture did not potently 
inhibit the glucosidase, it is possible that one of the individual sulfoxides could display 
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significantly higher inhibitory activity than the other. Again, no statistically significant 
inhibition of β-glucosidase from almonds was observed at a 1 mM inhibitor concentration for 
either diastereoisomer (Figure 5.8). 
 
Galacto sulfoxide 5.42 was previously shown to inhibit the β-galactosidase from E. coli. 
Testing of the individual diastereoisomers revealed that the inhibitory activity of sulfoxide 5.42 
did indeed vary with the stereochemistry of the sulfoxide. 
 
The results of the inhibition studies of the two diastereoisomers of 5.42 on the β-galactosidase 
from E. coli (Figure 5.9) indicated that both diastereoisomers inhibited the β-galactosidase, 
but that 5.42 SS was more active than 5.42 RS, with Kis of 1.0 mM and 1.7 mM respectively. 
This observation is consistent with a previously reported study in which the SS isomer of a 
sulfoxide-linked disaccharide was found to display greater inhibitory activity against the β-
galactosidase from E. coli than the RS isomer, with Kis of 0.19 mM and 0.45 mM respectively.
57 
Again these values represent only moderate inhibition which, while it may have some 
mechanistic interest, is of limited use in the design of potent glycosidase inhibitors. 
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 5.42 RS 5.42 SS 
Value Error Value Error 
Vmax 0.143 s-1 ±0.004 s-1 0.021 s-1 ±0.01 s-1 
Km 0.20 mM ±0.02 mM 0.17 mM ±0.02 mM 
Ki 1.7 mM ±0.1 mM 1.0 mM ±0.1 mM 
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In summary, a biomimetic oxidation process for the oxidation of unprotected thioglycosides to 
glycosyl sulfoxides was developed and applied to a range of thioglycosides. A selection of the 
glycosyl sulfoxides produced in this way were examined as inhibitors of glycosidase enzymes, 
where they displayed only moderate inhibitory activity.  
 
A number of potential future avenues of exploration remain open. Firstly, only a very small 
subset of flavinium salt catalysts was examined in this study. Modification of the salt may 
provide a catalyst which is better able to catalyse the oxidation of protected thioglycosides in 
non-polar solvents. Secondly, the selection of an alternate catalyst may allow the use of oxygen 
as an oxidant, avoiding the requirement for potentially hazardous hydrogen peroxide. Finally, 
examination of a wider selection of glycosyl sulfoxides may potentially reveal more effective 
inhibitors of glycosidases. Notably, the ethyl aglycon is unlikely to interact favourably with 
any part of the enzyme active site, and selection of a more suitable aglycon could enhance the 
inhibitory activity of the sulfoxide significantly. 
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Chapter 6: Experimental 
General experimental section 
All reactions involving moisture sensitive reagents were performed under an atmosphere of 
argon or nitrogen via standard vacuum Schlenk line techniques. All glassware for such 
reactions was flame-dried and cooled under an atmosphere of argon. Reactions conducted 
at -20 °C were cooled by means of an acetonitrile/dry ice bath; those conducted at 0 °C were 
cooled by means of an ice bath. Solvent was removed under reduced pressure using a BuchiTM 
rotary evaporator. HPLC-grade solvents were used for reactions, and in case of moisture-
sensitive reactions solvents were dried by literature procedures and freshly distilled as required. 
Petroleum ether (Petrol) refers to the fraction of light petroleum ether boiling in the range 
40-60 °C. Reagents were used as supplied without further purification unless otherwise stated. 
Thin Layer Chromatography (t.l.c.) was carried out on Merck Silica Gel 60F254 aluminium-
backed plates. Visualisation of the plates was achieved using a UV lamp (λmax = 254 or 
365 nm), and/or ammonium molybdate (5% in 2 M aqueous H2SO4) and/or potassium 
permanganate (60 mM in aqueous 0.5 M potassium carbonate and 2.5 mM sodium hydroxide) 
and /or aniline-diphenylamine-85% phosphoric acid (4 mL: 4 g: 20 mL) in acetone (96 mL). 
Flash column chromatography was carried out using Sorbsil C60 40/60 silica. Melting points 
were recorded on an Electrothermal melting point apparatus and are uncorrected. Proton and 
carbon nuclear magnetic resonance (1H, 13C) spectra were recorded on Agilent 400–MR 
instrument operating for 1H NMR at 400 MHz, and at 100.5 MHz for 13C NMR, or an Agilent 
600–MR instrument operating for 1H NMR at 600 MHz, and at 150 MHz for 13C NMR. All 
chemical shifts are quoted on the δ-scale in ppm using residual solvent as an internal standard. 
1H and 13C spectra were assigned using COSY, DEPT, HSQC, HMBC, and TOCSY. High 
resolution mass spectra were recorded by on either a DIONEX Ultimate 3000 or Bruker MaXis 
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4G spectrometer, operated in high resolution positive ion electrospray mode. Optical rotations 
were measured on a Perkin-Elmer 241 polarimeter with a 1 cm3 cell with a path length of 1 dm, 
and are quoted in units of °.cm2.g-1. Concentrations (c) are given in g/100 cm3, solvent and 
temperature are recorded. Infrared spectra were recorded on a Bruker FTIR spectrometer with 
Alpha’s Platinum ATR single reflection diamond where the neat samples were recorded. 
 
Lysozyme from hens’ egg white, BSA, β-glucosidase from almonds, β-galactosidase from 
Eschericia coli, and α-mannosidase from jack beans were purchased from Sigma-Aldrich and 
used as received. N-butoxycarbonyl-L-cysteine-L-threonine methyl ester 3.22 was prepared by 
Patrycja Gołębiowska. GABARAPL2 was prepared by Dr. Akshita Wason. Peptide 3.39 was 
prepared by Zaid Anso. Sialoglycan 3.41 was prepared by Dr. Vivek Poonthiyil. Modified 
MUC1 peptide 4.30 was prepared by Dr. Geoff Williams. Endo M N175Q was purchased from 
Tokyo Chemical Industry and used as recieved. p-Tolyl-2,3,4,6-O-acetyl-1-thio-β-D-
glucopyranoside 5.8, 1,3,4,6-tetra-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 
5.35, and 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-1,2,3,6-tetra-O-acetyl-β-D-
glucopyranoside 5.39 were prepared by previous members of the Fairbanks group. 
 
  
Chapter 6: Experimental 
217 
 
Experimental section for Chapter 2 
2-Chloro-1,3-dimethylimidazolinium chloride 2.11 
 
1,3-Dimethylimidazolidinone (50 mL, 475 mmol) was dissolved in toluene (500 mL) and 
stirred at 50 °C under an N2 atmosphere. Oxalyl chloride (51 mL, 594 mmol) was added 
dropwise. After 3 h, the flask was allowed to cool to RT and stirred overnight. After 18 h, the 
precipitate was filtered, washed with cold toluene and recrystallized (MeCN/Et2O). The white 
solid was filtered and dried under vacuum to yield 2-chloro-1,3-dimethylimidazolidinium 
chloride 2.1 (37.27 g, 45 %) as a white powdery solid; m.p. 65-70 °C [lit. 95-100 °C]1; H (400 
MHz, CD3CN) 3.15 (6H, s, 2 x CH3), 3.98 (4H, s, 2 x CH2); C (100.5 MHz, CD3CN) 34.3, 
49.9; HRMS (ESI-TOF): calcd. for C5H10ClN2





A solution of sodium hydrosulfide hydrate (25.3 g, 0.27 mol) in water (43 mL) was cooled to 
-20 °C and stirred under an atmosphere of nitrogen. Chloroacetonitrile (21.6 mL, 0.24 mol) 
was added rapidly and the reaction was stirred at -20 °C for 5 h, at which point NaCl was 
observed to precipitate from the reaction mixture. The reaction was then warmed to RT over 1 
h and H2SO4 (conc., 3 mL) was added to bring the reaction mixture to pH 1. The solution was 
then diluted with water (20 mL), and extracted with CH2Cl2 (3 x 100 mL). The combined 
organic extracts were concentrated in vacuo and the crude product was purified by flash column 
chromatography (petrol:ethyl acetate, 5:1) to afford mercaptoacetonitrile 2.2 (3.62 g, 21%) as 
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a yellow liquid; υmax (neat) 2247 cm
-1 (C≡N); H (400 MHz, CDCl3)
2 2.37 (1H, t, J 8.2 Hz, 
SH), 3.29 (2H, d, J 8.2 Hz, CH2); C (100.5 MHz, CDCl3) 9.6 (t, CH2), 118.2 (s, CN). 
 
Method 23 
Chloroacetonitrile (6.3 mL, 0.1 mol) and thioacetic acid (7.05 mL, 0.1 mol) were dissolved in 
CH2Cl2 (70 mL) and cooled to -30 °C under an atmosphere of N2. Triethylamine (16.7 mL, 
0.12 mol) was added dropwise over 0.5 h. The reaction was stirred at -30 °C for another 1 h, 
and then gradually warmed to RT. Water (5 mL) was added, and the organic layer was washed 
with acetic acid (10%, 2 x 15 mL) followed by water (2 x 15 mL). The organic layer was dried 
(MgSO4), filtered, and concentrated in vacuo. The liquid produced was dissolved in MeOH 
(100 mL) and Amberlyst® 15 (H+ form, 3 g) was added. The reaction was heated to reflux 
under an atmosphere of N2 and stirred for 20 h. The reaction was filtered, Amberlyst
® 15 (H+ 
form, 0.3 g) was added, and the mixture was concentrated in vacuo at RT to afford 
mercaptoacetonitrile 2.2 (5.96 g, 82%) as a pale yellow liquid, identical in all respects to that 
produced by Method 1. 
 
Cyanomethyl 1-thio-β-D-glucopyranoside 2.4 
 
D-Glucose 2.3 (200 mg, 1.11 mmol) was dissolved in water (4 mL). Triethylamine (2.5 mL, 
34 mmol) was added, the reaction was cooled to 0 °C, and stirred. 2-Chloro-1,3-
dimethylimidazolinium chloride 2.1 (0.92 g, 5.5 mmol) was dissolved in mercaptoacetonitrile 
2.2 (1.3 g, 17.8 mmol) and the resulting solution was added dropwise to the aqueous D-glucose 
solution over 2 min. The reaction was stirred at 0 °C for 0.5 h, and was then diluted with water 
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(5 mL) and washed with CH2Cl2 (5 x 10 mL). The aqueous layer was filtered through a column 
of Amberlite® IR-120 (Na+ form, produced by treating the H+ form with 1 M aqueous NaOH 
solution and then washing with water until pH 7), lyophilised, pre-absorbed onto silica, and 
purified by flash column chromatography (CHCl3:MeOH, 5:1) to afford cyanomethyl 1-thio-
β-D-glucopyranoside 2.4 (232 mg, 89%) as a pale yellow oil; [α]D
20 -67 (c, 1.0 in MeOH) [lit. 
[α]D
22 -60.2 (c, 5.05 in water)]4 ; υmax (neat) 2248 cm
-1 (C≡N); H (400 MHz, D2O) 3.26 - 3.35 
(2H, m, H-2 & H-3), 3.37 - 3.44 (2H, m, H-4 & H-5), 3.57, 3.68 (2H, ABq, J 17.6 Hz, CH2CN) 
3.61 (1H, dd, J5,6 5.5 Hz, J6,6’ 12.1 Hz, H-6), 3.79 (1H, dd, J5,6’ 1.8 Hz, J6,6’ 12.3 Hz, H-6’), 
4.60 (1H, d, J1,2 9.8 Hz, H-1); C (100.5 MHz, D2O) 14.4 (t, CH2CN), 60.7 (t, C-6), 69.2 (d, 
C-2), 71.8 (d, C-3), 77.0, 80.0 (2 x d, C-4 & C-5), 84.4 (d, C-1), 118.6 (s, CH2CN); HRMS 
(ESI-TOF): calcd. for C8H13NO5SNa
+: 258.0407. Found: 258.0414 (MNa+). 
 
Cyanomethyl 1-thio-α-D-mannopyranoside 2.5 
 
D-Mannose (100 mg, 0.56 mmol) was dissolved in water (2 mL). Triethylamine (1.2 mL, 
11.1 mmol) was added, the reaction was cooled to 0 °C, and stirred. 2-Chloro-1,3-
dimethylimidazolinium chloride 2.1 (0.56 g, 3.3 mmol) was dissolved in mercaptoacetonitrile 
2.2 (0.8 g, 11.1 mmol) and the resulting solution was added dropwise to the aqueous D-mannose 
solution over 2 min. The reaction was stirred at 0 °C for 0.5 h, and was then diluted with water 
(2 mL) and washed with CH2Cl2 (5 x 10 mL). The aqueous layer was filtered through a column 
of Amberlite® IR-120 (Na+ form, produced by treating the H+ form with 1 M aqueous NaOH 
solution and then washing with water until pH 7), lyophilised, pre-absorbed onto silica, and 
purified by flash column chromatography (CHCl3:MeOH, 5:1) to afford cyanomethyl 1-thio-
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α-D-mannopyranoside 2.5 (103 mg, 78%) as a yellow oil; [α]D
20 +80 (c, 1.0 in MeOH); υmax 
(neat) 3327 cm-1 (OH), 2255 cm-1 (CN); H (400 MHz, D2O) 3.49, 3.54 (2H, ABq, J 17.6 Hz, 
SCH2CN), 3.71 - 3.76 (2H, m, H-3 & H-4), 3.80 (2H, dd, J5,6 5.5 Hz, J6,6’ 12.5 Hz, H-6), 
3.88 (2H, dd, J5,6’ 2.0 Hz, J6,6’ 12.1 Hz, H-6’), 3.91 - 3.97 (1H, m, H-5), 4.08 (1H, d, J2,3 1.2 Hz, 
H-2), 5.47 (1H, s, H-1); C (100.5 MHz, D2O) 15.3 (t, SCH2CN), 60.4 (t, C-6), 66.7 (d, C-3), 
70.8 (d, C-2), 71.0 (d, C-4), 73.5 (d, C-5), 84.8 (d, C-1), 118.2 (s, SCH2CN); HRMS (ESI-
TOF): calcd. for C8H13NO5SNa
+: 258.0407. Found: 258.0401 (MNa+). 
 
Cyanomethyl 1-thio-β-D-galactopyranoside 2.6 
 
D-Galactose (200 mg, 1.11 mmol) was dissolved in water (4 mL). Triethylamine (2.4 mL, 
33 mmol) was added, the reaction was cooled to 0 °C, and stirred. 2-Chloro-1,3-
dimethylimidazolinium chloride 2.1 (1.12 g, 6.7 mmol) was dissolved in mercaptoacetonitrile 
2.2 (1.6 g, 22 mmol) and the resulting solution was added dropwise to the aqueous D-galactose 
solution over 2 min. The reaction was stirred at 0 °C for 0.5 h, and was then diluted with water 
(5 mL) and washed with CH2Cl2 (5 x 10 mL). The aqueous layer was filtered through a column 
of Amberlite® IR-120 (Na+ form, produced by treating the H+ form with 1 M aqueous NaOH 
solution and then washing with water until pH 7), lyophilised, pre-absorbed onto silica, and 
purified by flash column chromatography (CHCl3:MeOH, 5:1) to afford cyanomethyl 1-thio-
β-D-galactopyranoside 2.6 (106 mg, 41%) as a pale yellow oil; [α]D
20 +13 (c, 0.1 in MeOH) 
[lit. [α]D
20 -51.5 (c, 5.05 in water)]4; υmax (neat) 2252 cm
-1 (C≡N); H (400 MHz, D2O) 3.50 - 
3.68 (5H, m, H-2, H-4, H-5, H-6 & H-6’), 3.57, 3.69 (2H, ABq, J 17.6 Hz, CH2) 3.87 (1H, d, 
J2,3 3.1 Hz, H-3), 4.54 (1H, d, J1,2 9.4 Hz, H-1); C (100.5 MHz, D2O) 14.5 (t, CH2CN), 61.0 
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(t, H-6), 68.6 (d, C-3), 69.2 (d, C-2), 73.8, 79.1 (2 x d, C-4 & C-5), 84.9 (d, C-1), 118.6 (s, 
CH2CN); HRMS (ESI-TOF): calcd. for C8H13NO5SNa
+: 258.0407. Found: 258.0413 (MNa+). 
 
Cyanomethyl β-D-galactopyranosyl-(1→4)-1-thio-β-D-glucopyranoside 2.7 
 
β-D-Galactopyranosyl-(1→4)-D-glucopyranose (103 mg, 0.3 mmol) was dissolved in water 
(2 mL). Triethylamine (0.84 mL, 6 mmol) was added, the reaction was cooled to 0 °C, and 
stirred. 2-Chloro-1,3-dimethylimidazolinium chloride 2.1 (0.303 g, 1.8 mmol) was dissolved 
in mercaptoacetonitrile 2.2 (0.439 g, 6 mmol) and the resulting solution was added dropwise 
to the aqueous β-D-galactopyranosyl-(1→4)-D-glucopyranose solution over 2 min. The 
reaction was stirred at 0 °C for 0.5 h, and was then diluted with water (2 mL) and washed with 
CH2Cl2 (5 x 10 mL). The aqueous layer was filtered through a column of Amberlite
® IR-120 
(Na+ form, produced by treating the H+ form with 1 M aqueous NaOH solution and then 
washing with water until pH 7), lyophilised, pre-absorbed onto silica, and purified by flash 
column chromatography (CHCl3:MeOH, 5:1) to afford cyanomethyl β-D-galactopyranosyl-
(1→4)-1-thio-β-D-glucopyranoside 2.7 (77 mg, 65%) as a yellow oil; [α]D
20 -25 (c, 0.1 in 
MeOH); υmax (neat) 3298 cm
-1 (OH), 2251 cm-1 (CN); H (400 MHz, CD3OD) 3.37 (1H, t, 
J 9.8 Hz, H-2a), 3.42 - 3.65 (6H, m, H-3a, H-4a, H-5a, H-2b, H-3b & H-5b), 3.66 - 3.88 (6H, m, 
CH2, H-6b, H-4b, H-6b & H-6’b), 3.94 (1H, dd, J5,6 2.0 Hz, J6,6’ 12.1 Hz, H-6’a), 4.37 (1H, d, 
J1,2 7.4 Hz, H-1b), 4.60 (1H, d, J1,2 9.4 Hz, H-1a); C (100.5 MHz, CD3OD) 13.1 (t, CH2CN), 
60.5 (t, C-6a), 61.1 (t, C-6b), 68.9 (d, C-4b), 71.1, 72.6, 73.3, 75.6, 76.4, 78.8, 79.4 (7 x d, C-2a, 
C-3a, C-4a, C-5a, C-2b, C-3b & C-5b), 83.9 (d, C-1a), 103.6 (d, C-1b), 117.3 (s, CH2CN); HRMS 
(ESI-TOF): calcd. for C14H24NO10S
+: 398.1115. Found: 398.1109 (MH+). 






α-D-Glucopyranosyl-(1→4)-α-D-glucopyranosyl-(1→4)-β-D-glucopyranose (101 mg, 
0.2 mmol) was dissolved in D2O (1.3 mL). Triethylamine (0.56 mL, 4 mmol) was added, the 
reaction was cooled to 0 °C, and stirred. 2-Chloro-1,3-dimethylimidazolinium chloride 2.1 
(0.202 g, 1.2 mmol) was dissolved in mercaptoacetonitrile 2.2 (0.292 g, 4 mmol) and the 
resulting solution was added dropwise to the aqueous α-D-glucopyranosyl-(1→4)-α-D-
glucopyranosyl-(1→4)-β-D-glucopyranose solution over 2 min. The reaction was stirred at 0 
°C for 0.5 h, and was then diluted with water (2 mL) and washed with CH2Cl2 (5 x 10 mL). 
The aqueous layer was filtered through a column of Amberlite® IR-120 (Na+ form, produced 
by treating the H+ form with 1 M aqueous NaOH solution and then washing with water until 
pH 7), lyophilised, pre-absorbed onto silica, and purified by flash column chromatography 
(CHCl3:MeOH, 5:1) to afford cyanomethyl α-D-glucopyranosyl-(1→4)-α-D-glucopyranosyl-
(1→4)-1-thio-β-D-glucopyranoside 2.8 (77 mg, 65%) as a yellow oil; [α]D
20 +54 (c, 1.0 in 
MeOH); υmax (neat) 3279 cm
-1 (OH), 2248 cm-1 (CN); H (600 MHz, CD3OD) 3.26 (1H, t, 
J 9.2 Hz, H-4b), 3.33 (1H, t, J 9.6 Hz, H-2a), 3.42 - 3.47 (2H, m, H-5a & H-2b), 3.48 - 3.53 (2H, 
m, H-2c & H-5c), 3.57 (1H, t, J 9.2 Hz, H-4a), 3.61 (1H, t, J 9.4 Hz, H-3b), 3.63 - 3.70 (3H, m, 
H-3a, H-5b & H-6b), 3.73 - 3.84 (6H, m, H-6a, H-6’b, H-4c, H-6c & CH2), 3.84 - 3.88 (2H, m, 
H-3c & H-6’c), 3.90 (1H, dd, J 12.4 Hz, J 2.0 Hz, H-6’a), 4.59 (1H, d, J1,2 9.6 Hz, H-1a), 5.15 
(1H, d, J1,2 3.7 Hz, H-1b), 5.19 (1H, d, J1,2 3.9 Hz, H-1c); C (151 MHz, CD3OD) 13.0 (t, 
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SCH2CN), 60.7 (t, C-6c), 60.9 (t, C-6a), 61.3 (t, C-6b), 70.1 (d, C-4b), 71.9 (d, C-4c), 72.4 (d, 
C-5c), 72.5 (d, C-2a), 72.8 (d, C-5b), 73.4 (d, C-3c), 73.5 (d, C-3b), 73.6 (d, C-5a), 77.8 (d, C-
3a), 79.3 (d, C-4a), 79.4 (d, C-2b), 79.9 (d, C-2c), 83.9 (d, C-1a), 101.2 (d, C-1c), 101.5 (d, C-
1b), 117.2 (SCH2CN); HRMS (ESI-TOF): calcd. for C20H33NO15SNa
+: 582.14633. Found: 
582.1461 (MNa+). 
 
2-Imino-2-methoxyethyl 1-thio-β-D-glucopyranoside 2.114 
 
Sodium metal (8 mg, 0.36 mmol) was dissolved in MeOH (3.6 mL). Cyanomethyl 1-thio-β-D-
glucopyranoside 2.4 (83.6 mg, 0.36 mmol) was added and the reaction mixture was stirred for 
64 h. The reaction mixture was then concentrated in vacuo and analysed by 1H NMR to reveal 
the formation of 2-imino-2-methoxyethyl 1-thio-β-D-glucopyranoside 2.11 (35% conversion). 
The crude material was subsequently used without purification for conjugation experiments; 
υmax (neat) 1654 cm
-1 (C=N); δH (400 MHz, CD3OD) 3.17 - 3.41 (4H, m, H-2, H-3, H-4 & H-
5)), 3.63 (1H, dd, J5,6 5.5 Hz, J6,6’ 12.9 Hz, H-6), 3.85 (1H, d, J6,6’ 12.9 Hz, H-6’) 4.32 Hz (1H, 
d, J 10.2 Hz, H-1) ; C (100.5 MHz, CD3OD) 61.5 (t, C-6), 70.1 (d, C-2), 73.0 (d, C-3), 78.3, 
80.9 (2 x d, C-4 & C-5), 85.2 (d, C-1); HRMS (ESI-TOF): calcd. for C9H18NO6S
+: 268.0849. 
Found: 268.0860 (MH+). 
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2-Imino-2-methoxyethyl 1-thio-α-D-mannopyranoside 2.124 
 
Sodium metal (13.7 mg, 0.60 mmol) was dissolved in MeOH (6 mL). Cyanomethyl 1-thio-α-
D-mannopyranoside 2.5 (140 mg, 0.60 mmol) was added and the reaction mixture was stirred 
for 64 h. The reaction mixture was then concentrated in vacuo and analysed by 1H NMR to 
reveal the formation of 2-imino-2-methoxyethyl 1-thio-α-D-mannopyranoside 2.12 (22% 
conversion). The crude material was subsequently used without purification for conjugation 
experiments; υmax (neat) 3311 cm
-1 (OH), 1649 cm-1 (C=NH); H (400 MHz, CD3OD) 3.59 - 
3.84 (5H, H-3, H-4, H-6 & CH2), 3.87 (1H, d, J6,6’ 13.7 Hz, H-6’), 3.91 (2H, m, H-2 & H-5), 
5.33 (1H, s, H-1); C (100.5 MHz, D2O) 61.3 (t, C-6), 66.9 (d, C-3), 70.1 (d, C-2), 71.0 (d, C-
4), 73.8 (d, C-5), 85.7 (d, C-1); HRMS (ESI-TOF): calcd. for C9H18NO6S
+: 268.0849. Found: 
268.0848 (MH+). 
 
2-Imino-2-methoxyethyl 1-thio-β-D-galactopyranoside 2.134 
 
Sodium metal (5 mg, 0.22 mmol) was dissolved in MeOH (2.5 mL). Cyanomethyl 1-thio-β-D-
galactopyranoside 2.6 (52 mg, 0.22 mmol) was added and the reaction mixture was stirred for 
64 h. The reaction mixture was then concentrated in vacuo and analysed by 1H NMR to reveal 
the formation of 2-imino-2-methoxyethyl 1-thio-β-D-galactopyranoside 2.13 (50% 
conversion). The crude material was subsequently used without purification for the conjugation 
experiments; υmax (neat) 1651 cm
-1 (C=N); H (400 MHz, CD3OD)
5 3.40 - 3.61 (3H, m, H-2, 
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H-4 & H-5), 3.64 - 3.77 (3H, m, CH2, H-6 & H-6’), 3.86 (1H, d, J2,3 10.6 Hz, J3,4 3.1 Hz, H-3) 
4.27 (1H, d, J1,2 9.4 Hz, H-1); C (100.5 MHz, CD3OD) 61.3 (t, C-6), 69.2 (d, C-3), 70.0 (d, C-
2), 74.9, 79.4 (2 x d, C-4 & C-5), 85.8 (d, C-1); HRMS (ESI-TOF): calcd. for C9H18NO6S
+: 
268.0849. Found: 268.0853 (MH+). 
 
2-Imino-2-methoxyethyl β-D-galactopyranosyl-(1→4)-1-thio-β-D-glucopyranoside 2.144 
 
Sodium metal (7.6 mg, 0.33 mmol) was dissolved in MeOH (3.3 mL). Cyanomethyl β-D-
galactopyranosyl-(1→4)-1-thio-β-D-glucopyranoside 2.7 (130 mg, 0.33 mmol) was added and 
the reaction mixture was stirred for 64 h. The reaction mixture was then concentrated in vacuo 
and analysed by 1H NMR to reveal the formation of 2-imino-2-methoxyethyl β-D-
galactopyranosyl-(1→4)-1-thio-β-D-glucopyranoside 2.14 (85% conversion). The crude 
material was subsequently used without purification for conjugation experiments; υmax (neat) 
3279 cm-1 (OH), 1652 cm-1 (C=NH); δH (400 MHz, CD3OD) 4.35 (1H, d, J 7.4 Hz, H-1b), 4.42 
(1H, d, J 7.4 Hz, H-1a); C (100.5 MHz, CD3OD) 60.5 (t, C-6a), 60.5 (t, CH2), 61.2 (t, C-6b), 
69.2 (d, C-4b), 71.1, 72.2, 73.6, 75.8, 76.5, 78.7, 79.3 (7 x d, C-2a, C-3a, C-4a, C-5a, C-2b, C-3b 
& C-5b), 85.1 (d, C-1a), 103.8 (d, C-1b)) HRMS (ESI-TOF): calcd. for C15H28NO11S
+: 
430.1378. Found: 430.1392 (MH+). 
 
  






Sodium metal (4 mg, 0.17 mmol) was dissolved in MeOH (1.7 mL). cyanomethyl α-D-
glucopyranosyl-(1→4)-α-D-glucopyranosyl-(1→4)-1-thio-β-D-glucopyranoside 2.8 (97 mg, 
0.17 mmol) was added and the reaction mixture was stirred for 64 h. The reaction mixture was 
then concentrated in vacuo and analysed by 1H NMR to reveal the formation of 2-imino-2-
methoxyethyl α-D-glucopyranosyl-(1→4)-α-D-glucopyranosyl-(1→4)-1-thio-β-D-
glucopyranoside 2.15 (60% conversion). The crude material was subsequently used without 
purification for conjugation experiments; υmax (neat) 3289 cm
-1 (OH), 1652 cm-1 (C=NH); 
H (400 MHz, D2O) 4.69 (1H, d, J1,2 10.6 Hz, H-1a), 5.29 - 5.35 (2H, m, H-1b & H-1c); HRMS 
(ESI-TOF): calcd. for C21H38NO16S
+: 592.1906. Found: 592.1907 (MH+). 
 




Lysozyme (1 mg, 0.070 µmol) was dissolved in sodium borate buffer (0.2 mL, 0.2 M, pH 8.5). 
A portion of the 2-imino-2-methoxyethyl 1-thio-β-D-glucopyranoside 2.11 crude reaction 
mixture (50 µL, approximately 1.8 µmol of 2.11) was added to the lysozyme solution and the 
reaction was stirred. After 5 h the reaction was dialysed against water (2 x 500 mL), and 
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filtered; HRMS (ESI-TOF): 15246, 54% (calcd. for lysozyme-(C(NH)CH2SC6H11O5)4: 
15247), 15481, 100% (calcd. for lysozyme-(C(NH)CH2SC6H11O5)5: 15482), 15715, 54% 
(calcd. for lysozyme-(C(NH)CH2SC6H11O5)6: 15717). 
 






Lysozyme (1 mg, 0.070 µmol) was dissolved in sodium borate buffer (0.2 mL, 0.2 M, pH 8.5). 
A portion of the 2-imino-2-methoxyethyl 1-thio-α-D-mannopyranoside 62 crude reaction 
mixture (50 µL, approximately 1.1 µmol of 62) was added to the lysozyme solution and the 
reaction was stirred. After 5 h the reaction was dialysed against water (2 x 500 mL), and 
filtered; HRMS (ESI-TOF): 14305, 25% (calcd. for lysozyme: 14307), 14540, 87% (calcd. for 
lysozyme-(C(NH)CH2SC6H11O5): 14542), 14775, 100% (calcd. for lysozyme-
(C(NH)CH2SC6H11O5)2: 14777), 15011, 47% (calcd. for lysozyme-(C(NH)CH2SC6H11O5)3: 
15012), 15247, 6% (calcd. for lysozyme-(C(NH)CH2SC6H11O5)4: 15247). 
 
Method 2 
Lysozyme (1 mg, 0.070 µmol) was dissolved in sodium borate buffer (0.2 mL, 0.2 M, pH 8.5). 
A portion of the 2-imino-2-methoxyethyl 1-thio-α-D-mannopyranoside 62 crude reaction 
mixture (100 µL, approximately 2.2 µmol of 62) was added to the lysozyme solution and the 
reaction was stirred. After 5 h the reaction was dialysed against water (2 x 500 mL), and 
filtered; HRMS (ESI-TOF): 14775, 2% (calcd. for lysozyme-(C(NH)CH2SC6H11O5)2: 14777) 
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15011, 78% (calcd. for lysozyme-(C(NH)CH2SC6H11O5)3: 15013), 15249, 100% (calcd. for 
lysozyme-(C(NH)CH2SC6H11O5)4: 15247), 15482, 40% (calcd. for lysozyme-
(C(NH)CH2SC6H11O5)5: 15482), 15717, 2% (calcd. for lysozyme-(C(NH)CH2SC6H11O5)6: 
15717). 
 




Lysozyme (1 mg, 0.070 µmol) was dissolved in sodium borate buffer (0.2 mL, 0.2 M, pH 8.5). 
A portion of the 2-imino-2-methoxyethyl 1-thio-β-D-galactopyranoside 2.13 crude reaction 
mixture (50 µL, approximately 2.2 µmol of 2.13) was added to the lysozyme solution and the 
reaction was stirred. After 5 h the reaction was dialysed against water (2 x 500 mL), and 
filtered; HRMS (ESI-TOF): 15010, 2% (calcd. for lysozyme-(C(NH)CH2SC6H11O5)3: 15012), 
15246, 61% (calcd. for lysozyme-(C(NH)CH2SC6H11O5)4: 15247), 15481, 100% (calcd. for 
lysozyme-(C(NH)CH2SC6H11O5)5: 15482), 15717, 54% (calcd. for lysozyme-
(C(NH)CH2SC6H11O5)6: 15717). 
 
Conjugation of 2-imino-2-methoxyethyl β-D-galactopyranosyl-(1→4)-1-thio-β-D-




Lysozyme (1 mg, 0.070 µmol) was dissolved in sodium borate buffer (0.2 mL, 0.2 M, pH 8.5). 
A portion of the 2-imino-2-methoxyethyl β-D-galactopyranosyl-(1→4)-1-thio-β-D-
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glucopyranoside 2.14 crude reaction mixture (50 µL, approximately 1.7 µmol of 2.14) was 
added to the lysozyme solution and the reaction was stirred. After 5 h the reaction was dialysed 
against water (2 x 500 mL), and filtered; HRMS (ESI-TOF): 14307, 9% (calcd. for lysozyme: 
14307), 14703, 25% (calcd. for lysozyme-(C(NH)CH2SC12H21O10): 14704), 15099, 78% 
(calcd. for lysozyme-(C(NH)CH2SC12H21O10)2: 15101), 15497, 100% (calcd. for lysozyme-
(C(NH)CH2SC12H21O10)3: 15498), 15894, 47% (calcd. for lysozyme-
(C(NH)CH2SC12H21O10)4: 15895), 16293, 27% (calcd. for lysozyme-
(C(NH)CH2SC12H21O10)5: 16292). 
 
Conjugation of 2-imino-2-methoxyethyl α-D-glucopyranosyl-(1→4)-α-D-glucopyranosyl-
(1→4)-1-thio-β-D-glucopyranoside 2.15 to lysozyme 
         
Lysozyme (1 mg, 0.070 µmol) was dissolved in sodium borate buffer (0.2 mL, 0.2 M, pH 8.5). 
A portion of crude 2-imino-2-methoxyethyl α-D-glucopyranosyl-(1→4)-α-D-glucopyranosyl-
(1→4)-1-thio-β-D-glucopyranoside 2.15 (3 mg, approximately 3 µmol of 2.15) was added to 
the lysozyme solution and the reaction was stirred. After 5 h the reaction was dialysed against 
water (2 x 500 mL), and filtered; HRMS (ESI-TOF): 14305, 9% (calcd. for lysozyme: 14307), 
14864, 61% (calcd. for lysozyme-(C(NH)CH2SC18H31O15): 14866), 150424, 100% (calcd. for 
lysozyme-(C(NH)CH2SC18H31O15)2: 15425), 15983, 50% (calcd. for lysozyme-
(C(NH)CH2SC18H31O15)3: 15984), 16543, 15% (calcd. for lysozyme-
(C(NH)CH2SC18H31O15)4: 16543), 17103, 1% (calcd. for lysozyme-(C(NH)CH2SC18H31O15)5: 
17102). 
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Experimental section for Chapter 3 
Sodium phenylthiosulfonate 3.16 
 
Sodium benzenesulfinate (8.21 g, 50 mmol) and elemental sulfur (1.60 g, 50 mmol) were 
dissolved in pyridine (50 mL) under an atmosphere of nitrogen. The reaction was stirred at 
room temperature for 1 h, then the mixture was filtered and the precipitate was washed with 
Et2O (50 mL). The precipitate was recrystallised from EtOH to afford sodium 
phenylthiosulfonate 3.1 (7.67 g, 78%) as a white crystalline solid; m.p. 295-296 °C (EtOH) [lit. 
305-306 °C (EtOH)]6; H (400 MHz, DMSO-d6)
6 7.28 - 7.39 (3H, m, 2 x m-H & p-H), 7.75 




N-Acetyl-D-glucosamine 3.2 (500 mg, 2.26 mmol) and triethylamine (3.1 mL, 22.6 mmol) 
were stirred in water (10 mL) and cooled to 0 °C. 2-Chloro-1,3-dimethylimidazolinium 
chloride 2.1 (1.2 g, 6.78 mmol) was added. After 0.5 h, t.l.c. (CHCl3:MeOH, 2:1) indicated 
complete consumption of starting material (Rf 0.2) and the formation of a major product 
(Rf 0.6). Thioacetic acid (2.4 mL, 33.9 mmol) was added dropwise and the reaction mixture 
was allowed to stir for an additional 0.5 h at 0 °C. The reaction mixture was then diluted with 
water (10 mL) and washed with CH2Cl2 (5 x 20 mL). The aqueous layer was concentrated in 
vacuo and the resulting solid dissolved in the minimum amount of water and filtered through 
a column of Amberlite® IR-120 (Na+ form, produced by treating the H+ form with 1 M aqueous 
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NaOH solution and then washing with water until pH 7). The solution was concentrated in 
vacuo, dissolved in the minimum amount of water, and purified by flash column 
chromatography (CHCl3:MeOH 5:1) to afford 1-thioacetyl-acetamido-2-deoxy-β-D-
glucopyranoside 3.4 (0.361 g, 57%) as a white solid; m.p. 179-181 °C (CHCl3); [α]D
20 +27 (c, 
1.0 in MeOH); υmax (neat) 3237 cm
-1 (OH), 1688 cm-1 (SC=O), 1649 cm-1 (NHC=O); 
H (400 MHz, D2O) 1.89 (3H, m, NHC(O)CH3), 2.31 (3H, s, SC(O)CH3), 3.39 (1H, t, J 9.0 Hz, 
H-4), 3.45 - 3.49 (1H, m, H-5), 3.52 (1H, t, J 9.0 Hz, H-3), 3.62 (1H, dd, J5,6 5.5 Hz, 
J6,6’ 12.5 Hz, H-6), 3.74 - 3.83 (2H, m, H-2 & H-6’), 5.10 (1H, d, J1,2 10.6 Hz, H-1); 
C (100.5 MHz, D2O) 22.0 (q, NHC(O)CH3), 30.2 (q, SC(O)CH3), 53.4 (d, C-2), 60.5 (t, C-6), 
69.4 (d, C-4), 74.9 (d, C-3), 80.3 (d, C-5), 80.9 (d, C-1), 174.5 (s, NHC(O)CH3), 197.6 (s, 
SC(O)CH3); HRMS (ESI-TOF): calcd. for C10H18NO6S





1-Thioacetyl-acetamido-2-deoxy-β-D-glucopyranoside 3.4 (279 mg, 1 mmol) was dissolved in 
aqueous NaOH (1 M, 3 mL) and stirred for 1 h. Amberlite® IR-120 (H+) was then added until 
pH 7 was reached. The solution was then filtered and concentrated in vacuo to afford 1-thio-2-
acetamido-2-deoxy-β-D-glucopyranose 3.5 (236 mg, quant.) as a white solid; m.p. 174-175 °C 
(ethyl acetate/MeOH) [lit. 177-179 °C (ethyl acetate/MeOH)]7; [α]D
20 -6 (c, 1.0 in MeOH) 
[lit. [α]D
22 -10.4 (c, 1.0 in MeOH)]7; υmax (neat) 3286 cm
-1 (OH, NH), 2531 cm-1 (SH), 
1634 cm-1 (NHC=O); H (400 MHz, D2O) 1.96 (3H, s, NHC(O)CH3), 3.35 - 3.48 (3H, m, H-3, 
H-4 & H-5), 3.59 - 3.70 (2H, m, H-2 & H-6), 3.78 - 3.84 (1H, m, H-6’), 4.60 (1H, d, J1,2 9.8 Hz, 
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H-1); C (100.5 MHz, D2O) 22.2 (q, NHC(O)CH3), 58.0 (d, C-2), 60.8 (t, C-6), 69.7 (d, C-4), 
75.0 (d, C-3), 79.1 (d, C-1), 80.1 (d, C-5), 174.6 (s, NHC(O)CH3); HRMS (ESI-TOF): calcd. 
for C8H16NO5SNa
+: 260.0563. Found: 260.0560 (MNa+). 
 
Method 2 
N-Acetyl-D-glucosamine 3.2 (500 mg, 2.26 mmol) and triethylamine (3.1 mL, 22.6 mmol) 
were stirred in water (10 mL) and the mixture cooled to 0 °C. 2-Chloro-1,3-
dimethylimidazolinium chloride 2.1 (1.2 g, 6.78 mmol) was added. After 0.5 h, thioacetic acid 
(2.4 mL, 33.9 mmol) was added dropwise, and the reaction mixture was allowed to stir for an 
additional 0.5 h at 0 °C. The reaction mixture was then diluted with water (10 mL) and washed 
with CH2Cl2 (5 x 20 mL). The aqueous layer was concentrated in vacuo and the residue 
triturated with ethyl acetate (3 x 50 mL). The solid was then filtered off and dissolved in 
aqueous NaOH (1 M, 30 mL). The solution was stirred at RT for 1 h and then concentrated in 
vacuo. The residue was dissolved in water (50 mL) and Amberlite® IR-120 (H+) was added 
until pH 7 was reached. The mixture was then filtered, and the filtrate was concentrated in 
vacuo. EtOH (50 mL) was added to the residue and the mixture was stirred. The mixture was 
filtered and the filtrate was concentrated in vacuo to afford 1-thio-2-acetamido-2-deoxy-β-D-




Sodium metal (25.4 mg, 1.1 mmol) was added to MeOH (5 mL) and stirred. 1-Thioacetyl-
3,4,6-tri-O-acetyl-2-deoxy-2-acetamido-β-D-glucopyranoside 3.6 (203 mg, 0.50 mmol) was 
added and the reaction mixture was stirred for 0.5 h, at which point t.l.c. (ethyl acetate:petrol 
2:1) indicated complete consumption of starting material (Rf 0.2) and formation of a single 
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product (Rf 0). Dowex
® 50WX8 (H+) ion exchange resin was added portion-wise until the 
reaction reached neutral pH. The mixture was then filtered and concentrated in vacuo to afford 
1-thio-2-acetamido-2-deoxy-β-D-glucopyranose 3.5 (122 mg, quant.) as a white solid, identical 




N-Acetyl-D-glucosamine 3.2 (500 mg, 2.26 mmol) and triethylamine (3.1 mL, 22.6 mmol) 
were stirred in water (10 mL), and cooled to 0 °C. 2-Chloro-1,3-dimethylimidazolinium 
chloride 2.1 (1.2 g, 6.78 mmol) was added. After 0.5 h, thioacetic acid (2.4 mL, 33.9 mmol) 
was added dropwise, and the reaction mixture was allowed to stir for an additional 0.5 h at 0 
°C. The reaction mixture was then diluted with water (10 mL) and washed with DCM (5 x 20 
mL). The aqueous layer was concentrated in vacuo and the solid suspended in pyridine (7 mL) 
under an atmosphere of nitrogen. The mixture was stirred at RT and acetic anhydride (7 mL, 
74.1 mmol) was added. The reaction was stirred for 12 h, after which time t.l.c. (petrol:ethyl 
acetate 2:1)  indicated the formation of a single major product (Rf 0.8). Water (10 mL) was 
added, and the mixture was then washed with CH2Cl2 (3 x 100 mL). The combined organic 
extracts were washed with aqueous HCl (1 M, 100 mL), NaHCO3 (sat. aqueous soln., 100 mL), 
water (100 mL) and brine (100 mL), dried (MgSO4), filtered, and concentrated in vacuo. The 
residue was recrystallised (CH2Cl2/petrol) to afford 1-thioacetyl-3,4,6-tri-O-acetyl-2-deoxy-2-
acetamido-β-D-glucopyranoside 3.6 (0.807 g, 88%) as a colourless crystalline solid; m.p. 190-
191 °C (CH2Cl2/petrol) [lit. 186-188 °C (CH2Cl2/petrol)]
8; [α]D
20 +20 (c, 1.0 in CHCl3) [lit. 
[α]D
20 +12.1 (c, 2.2 in CHCl3)]
9; υmax (neat) 1739 cm
-1 (OC=O), 1699 cm-1 (SC=O), 1661 cm-
1 (NHC=O); H (400 MHz, CDCl3) 1.92 (3H, s, NHC(O)CH3), 2.03 (6H, s, 2 x C(O)CH3), 2.08 
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(3H, s, C(O)CH3), 2.37 (3H, s, SC(O)CH3), 3.75 - 3.81 (1H, m, H-5), 4.09 (1H, dd,  J6,6’ 11.7 
Hz, H-6), 4.23 (1H, dd, J6,6’ 12.7 Hz, J5,6’ 4.5 Hz, H-6’), 4.35 (1H, aq, J 9.9 Hz, H-2), 5.05 - 
5.18 (3H, m, H-1, H-3 & H-4), 5.65 (1H, d, JNH,2 9.8 Hz, NHC(O)CH3); C (100.5 MHz, CDCl3) 
20.6 (q, C(O)CH3), 20.6 (q, C(O)CH3), 20.7 (q, C(O)CH3), 23.1 (q, NHC(O)CH3), 30.8 (q, 
SC(O)CH3), 52.3 (d, C-2), 61.8 (t, C-6), 67.7 (d, C-3), 74.0 (d, C-4), 76.6 (d, C-5), 81.6 (d, C-
1), 169.2 (s, C(O)CH3), 170.0 (s, C(O)CH3), 170.7 (s, C(O)CH3), 171.3 (s, C(O)CH3), 193.7 
(s, SC(O)CH3); HRMS (ESI-TOF): calcd. for C16H24NO9S





Glucose 3.7 (180 mg, 1.0 mmol) and triethylamine (1.37 mL, 10 mmol) were stirred in water 
(4.4 mL) and cooled to 0 °C. 2-Chloro-1,3-dimethylimidazolinium chloride 2.1 (504 mg, 
3.0 mmol) was added. After 0.5 h, thioacetic acid (1.06 mL, 15 mmol) was added dropwise 
and the reaction mixture was stirred for an additional 0.5 h at 0 °C. The reaction mixture was 
then diluted with water (5 mL) and washed with CH2Cl2 (5 x 10 mL). The aqueous layer was 
filtered through a column of Amberlite® IR-120 (Na+ form, produced by treating the H+ form 
with 1 M aqueous NaOH solution and then washing with water until pH 7). The solution was 
concentrated in vacuo, dissolved in the minimum amount of water, and purified by flash 
column chromatography (CHCl3:MeOH 5:1) to afford 1,6-anhydro-β-D-glucose 3.9 (65 mg, 
40%) as a colourless oil; H (400 MHz, D2O)
10 3.50 (1H, s, H-2), 3.63 - 3.68 (2H, m, H-3 & 
H-4), 3.73 (1H, dd, J5,6 5.9 Hz, J6,6’ 7.8 Hz, H-6), 4.07 (1H, d, J6,6’ 7.8 Hz, H-6’), 4.61 (1H, d, 
J5,6 5.9 Hz, H-5), 5.43 (1H, s, H-1); C (100.5 MHz, D2O) 65.1 (t, C-6), 70.1 (d, C-2), 70.8 (d, 
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C-4), 72.4 (d, C-3), 76.2 (d, C-5), 101.4 (d, C-1); HRMS (ESI-TOF): calcd. for C6H10O5Na
+: 




N-Acetyl-D-galactosamine 3.10 (500 mg, 2.26 mmol) and triethylamine (3.1 mL, 22.6 mmol) 
were stirred in water (10 mL) and the mixture was cooled to 0 °C. 2-Chloro-1,3-
dimethylimidazolinium chloride 2.1 (1.2 g, 6.78 mmol) was added. After 0.5 h, thioacetic acid 
(2.4 mL, 33.9 mmol) was added dropwise and the reaction mixture was allowed to stir at 0 °C 
for an additional 0.5 h. The reaction mixture was then diluted with water (10 mL) and washed 
with CH2Cl2 (5 x 20 mL). The aqueous layer was concentrated in vacuo and the solid stirred in 
pyridine (7 mL) under an atmosphere of nitrogen. Acetic anhydride (7 mL, 74.1 mmol) was 
added and the mixture was stirred for 12 h, after which time t.l.c. (ethyl acetate:petrol, 2:1) 
indicated the formation of a single product (Rf 0.1). Water (10 mL) was added, and the mixture 
was then washed with CH2Cl2 (3 x 100 mL). The combined organic extracts were washed with 
aqueous HCl (1 M, 100 mL), NaHCO3 (sat. aqueous soln., 100 mL), water (100 mL) and brine 
(100 mL), dried (MgSO4), filtered, and concentrated in vacuo. The residue was pre-absorbed 
onto silica and purified by flash column chromatography (ethyl acetate:petrol, 2:1) to afford 
1-thioacetyl-3,4,6-tri-O-acetyl-2-deoxy-2-acetamido-β-D-galactopyranoside 3.13 (511 mg, 
56%) as a colourless solid; m.p. 185-187 °C (CH2Cl2/Et2O) [lit. 197-198 °C (CH2Cl2/Et2O)];
11 
[α]D
20 +20 (c, 1.0 in CHCl3) [lit. +11.3 (c, 1.0 in CHCl3)]
11; υmax (neat) 1738 cm
-1 (OC=O),  
1701 cm-1 (SC=O), 1645 cm-1 (NHC=O); H (400 MHz, CDCl3)
11 1.92 (3H, s, C(O)CH3), 2.01 
(3H, s, C(O)CH3), 2.04 (3H, s, C(O)CH3), 2.16 (3H, s, C(O)CH3), 2.38 (3H, s, SC(O)CH3), 
3.98 - 4.16 (3H, m, H-5, H-6 & H-6’), 4.52 (1H, q, J 10.6 Hz, H-2), 5.05 (1H, dd, J2,3 10.8 Hz, 
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J3,4 3.3 Hz, H-3), 5.15 (1H, d, J1,2 10.6 Hz, H-1), 5.36 - 5.45 (2H, m, NHC(O)CH3 & H-4); 
C (100.5 MHz, CDCl3) 20.6 (q, C(O)CH3), 20.7 (q, C(O)CH3), 20.7 (q, C(O)CH3), 23.2 (q, 
C(O)CH3), 30.8 (q, SC(O)CH3), 48.7 (d, C-2), 61.4 (t, C-6), 66.7 (d, C-4), 71.6 (d, C-3), 75.3 
(d, C-5), 82.1 (d, C-1), 170.1 (s, C(O)CH3), 170.2 (s, C(O)CH3), 170.4 (s, C(O)CH3), 170.8 (s, 
C(O)CH3), 193.7 (s, SC(O)CH3); HRMS (ESI-TOF): calcd. for C16H24NO9S
+: 406.1172. 




N-Acetyl-D-mannosamine (500 mg, 2.26 mmol) and triethylamine (3.1 mL, 22.6 mmol) were 
stirred in D2O (10 mL) and the mixture was cooled to 0 °C. 2-Chloro-1,3-
dimethylimidazolinium chloride 2.1 (1.2 g, 6.78 mmol) was added. After 0.5 h, thioacetic acid 
(2.4 mL, 33.9 mmol) was added dropwise, and the reaction mixture was allowed to stir at 0 °C 
for an additional 0.5 h. The reaction mixture was then diluted with water (10 mL) and washed 
with CH2Cl2 (5 x 20 mL). The aqueous layer was concentrated in vacuo and the residue stirred 
in pyridine (7 mL) under an atmosphere of nitrogen. Acetic anhydride (7 mL, 74.1 mmol) was 
added and the mixture was stirred for 12 h, after which time t.l.c. (petrol:ethyl acetate, 2:1) 
indicated the formation of a single major product (Rf 0.8). Water (10 mL) was added, and the 
mixture was then washed with CH2Cl2 (3 x 100 mL). The combined organic extracts were 
washed with aqueous aqueous HCl (1 M, 100 mL), NaHCO3 (sat. aqueous soln., 100 mL), 
water (100 mL) and brine (100 mL), dried (MgSO4), filtered, and concentrated in vacuo. The 
residue was purified by flash column chromatography (ethyl acetate:petrol, 3:2) to afford 
1-thioacetyl-3,4,6-tri-O-acetyl-2-deoxy-2-acetamido-α-D-mannopyranoside 3.14 (0.807 g, 
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88%) as a colourless oil; [α]D
20 +55 (c, 1.0 in CHCl3); υmax (neat) 1740 cm
-1 (OC=O), 1711 cm-1 
(SC=O), 1684 cm-1 (NHC=O); H (400 MHz, CDCl3) 1.99 (3H, s, C(O)CH3), 2.05 (3H, s, 
C(O)CH3), 2.06 (3H, s, C(O)CH3), 2.08 (3H, s, C(O)CH3), 2.41 (3H, s, SC(O)CH3), 3.96 - 4.06 
(2H, m, H-5 & H-6), 4.28 (1H, dd, J5,6’ 4.7 Hz, J6,6’ 12.1, H-6’), 4.65 - 4.70 (1H, m, H-2), 5.04 
(1H, dd, J3,4 9.8 Hz, J2,3 3.9 Hz, H-3), 5.15 (1H, t, J 9.8 Hz, H-4), 5.85 (1H, d, J1,2 1.6 Hz, H-1), 
6.02 (1H, d, J 8.6 Hz, NHC(O)CH3); C (100.5 MHz, CDCl3) 20.6 (q, C(O)CH3), 20.6 (q, 
C(O)CH3), 20.7 (q, C(O)CH3), 23.2 (q, C(O)CH3), 31.2 (q, SC(O)CH3), 51.4 (d, C-2), 62.1 (t, 
C-6), 65.7 (d, C-4), 70.1 (d, C-3), 72.0 (d, C-5), 81.1 (d, C-1), 169.7 (s, C(O)CH3), 169.9 (s, 
C(O)CH3), 170.0 (s, C(O)CH3), 170.5 (s, C(O)CH3), 190.8 (s, SC(O)CH3); HRMS (ESI-TOF): 
calcd. for C16H24NO9S




N,N’-Diacetylchitobiose (9.8 mg, 0.023 mmol) and triethylamine (32 µL, 0.23 mmol) were 
stirred in D2O (92 µL) and cooled to 0 °C. 2-Chloro-1,3-dimethylimidazolinium chloride 2.1 
(11.8 mg, 0.069 mmol) was added. After 0.5 h, thioacetic acid (24 µL, 0.345 mmol) was added 
dropwise and the reaction mixture was allowed to stir for an additional 1 h at 0 °C. The reaction 
was purified by HPLC (column: Luna 5u C18 (100 Å) column (Phenomenex); gradient: 100% 
water for 15 min, followed by an increase to 100% MeOH over 5 min; column oven: 40 °C; 
flow rate: 2 mL/min; detection: UV 210 nm) to afford 1-thioacetyl-N,N’-diacetylchitobiose 
3.15 (10.3 mg, 93%) as a white powder; υmax (neat) 3270 cm
-1 (OH), 1697 cm-1 (SC=O), 
1649 cm-1 (NHC=O); [α]D +0.1 (c, 0.5 in water); H (400 MHz, D2O) 1.97 (3H, s, 
NHC(O)CH3), 2.05 (3H, s, NHC(O)CH3), 2.39 (3H, s, SC(O)CH3), 3.43 - 3.50 (2H, m, H-3a & 
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H-3b), 3.55 (1H, t, J 9.1 Hz, H-4b), 3.58 - 3.68 (3H, m, H-4a, H-5a & H-6a), 3.69 - 3.84 (4H, m, 
H-2b, H-5b, H-6’a & H-6b), 3.86 - 3.96 (2H, H-2a & H-6’b), 4.57 (1H, d, J 8.6 Hz, H-1b), 5.18 
(1H, d, J 11.0 Hz, H-1a); C (100.5 MHz, D2O) 21.9 (q, NHC(O)CH3), 22.0 (q, NHC(O)CH3), 
30.1 (q, SC(O)CH3), 52.8 (d, C-2a), 55.5 (d, C-2b), 59.9 (t, C-6a), 60.5 (t, C-6b), 69.6 (d, C-3a), 
73.4 (d, C-4b), 73.5 (d, C-5b), 75.8 (d, C-3b), 78.6, 78.9 (2 x d, C-4a & C-5a), 80.8 (d, C-1a), 
101.3 (d, C-1b), 174.5 (s, 2 x NHC(O)CH3), 197.4 (s, SC(O)CH3); HRMS (ESI-TOF): calcd. 
for C18H31N2O11S




Sodium metal (25.4 mg, 1.1 mmol) was added to MeOH (5 mL) and stirred. 1-Thioacetyl-
3,4,6-tri-O-acetyl-2-deoxy-2-acetamido-β-D-galactopyranoside 3.13 (179 mg, 0.44 mmol) was 
added and the mixture was stirred for 0.5 h, at which point t.l.c. (ethyl acetate:petrol, 2:1) 
indicated complete consumption of starting material (Rf 0.1) and formation of a single product 
(Rf 0). Dowex
® 50WX8 (H+) ion exchange resin was added portion-wise until the reaction 
reached neutral pH. The reaction was then filtered and concentrated in vacuo to afford 1-thio-
2-acetamido-2-deoxy-β-D-galactopyranose 3.16 (108 mg, quant.) as a white amorphous solid; 
[α]D
20 +29 (c, 0.9 in MeOH); υmax (neat) 3275 cm
-1 (b, OH, NH), 2545 cm-1 (SH), 1625 cm-1 
(NHC=O); H (400 MHz, D2O) 1.94 (3H, s, C(O)CH3), 3.56 - 3.67 (4H, m, H-3, H-5, H-6 & 
H-6’), 3.80 - 3.88 (2H, m, H-2 & H-4), 4.50 (1H, d, J1,2 10.2 Hz, H-1); C (100.5 MHz, D2O) 
22.2 (q, C(O)CH3), 54.6 (d, C-2), 61.1 (t, C-6), 67.8 (d, C-4), 71.8 (d, C-3), 79.3 (d, C-1), 79.3 
(d, C-5), 174.8 (s, C(O)CH3); HRMS (ESI-TOF): calcd. for C8H15NO5S
+: 238.0744. Found: 
238.0745 (MH+). 





1-Thioacetyl-N,N’-diacetylchitobiose 3.15 (2.2 mg, 4.6 µmol) was dissolved in aqueous NaOH 
(1 M, 1.5 mL) and stirred for 1 h. Amberlite® IR-120 (H+) was then added until pH 7 was 
reached. The solution was then filtered and lyophilised to afford 1-thio-N,N’-diacetylchitobiose 
3.18 (2.0 mg, quant.) as a white powder; [α]D
20 -5 (c, 0.28 in water); H (400 MHz, D2O)
12 2.02 
(3H, s, NHC(O)CH3), 2.04 (3H, s, NHC(O)CH3), 3.42 - 3.57 (4H, m, H-3a, H-4a, H-5a & H-
3b), 3.57 - 3.67 (3H, m, H-4b, H-5b & H-6a), 3.68 - 3.76 (3H, m, H-2a, H-2b & H-6b), 3.81 (1H, 
dd, J5,6 1.2 Hz, J6,6’ 12.1 Hz, H-6a’), 3.89 (1H, dd, J5,6’ 12.3 Hz, J6,6’ 1.6 Hz, H-6b’), 4.56 (1H, 
d, J1b,2b 8.2 Hz, H-1b), 4.65 (1H, d, J1a,2a 9.8 Hz, H-1a); C (100.5 MHz, D2O) 22.0 (q, 
NHC(O)CH3), 22.1 (q, NHC(O)CH3), 55.5 (d, C-2b), 57.2 (d, C-2a), 60.1 (t, C-6), 60.5 (t, C-
6), 69.6 (d, C-3a), 73.4 (d, C-3b), 73.5 (d, C-5a), 75.8 (d, C-5b), 78.6 (d, C-4a), 78.8 (d, H-1a), 
79.0 (d, C-4b), 101.3 (d, H-1b), 174.5 (s, 2 x q, NHC(O)CH3); HRMS (ESI-TOF): calcd. for 
C16H29N2O10S
+: 441.1537. Found: 441.1544 (MH+). 
 
Phenyl 2-acetamido-2-deoxy-1-selenylsulfide-β-D-glucopyranoside 3.207 
 
Phenylselenyl bromide (216 mg, 0.92 mmol) was dissolved in 1,4-dioxane (4 mL) and stirred 
at room temperature under and atmosphere of nitrogen. 1-Thio-2-acetamido-2-deoxy-β-D-
glucopyranose 3.5 (200 mg, 0.84 mmol) was dissolved in MeOH (15 mL) and added dropwise 
to the reaction mixture, which was then stirred for 2 min. At this point, t.l.c. (ethyl 
acetate:MeOH 9:1) indicated the formation of a major product (Rf 0.4). The reaction was 
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concentrated in vacuo, pre-absorbed onto silica and purified by flash column chromatography 
(ethyl acetate:MeOH, 9:1) to afford phenyl 2-acetamido-2-deoxy-1-selenylsulfide-β-D-
glucopyranoside 3.20 (210 mg, 64%) as a white amorphous solid; [α]D
20 -109 (c, 1.1 in MeOH) 
[lit. [α]D
22 -174 (c, 1.0 in MeOH)]7; υmax (neat) 3258 cm
-1 (OH, NH), 1652 cm-1 (NHC=O); 
H (400 MHz, CD3OD)
7 1.94 (3H, s, C(O)CH3), 3.28 - 3.39 (2H, m, H-4 & H-5), 3.44 - 3.54 
(1H, m, H-3), 3.63 (1H, dd, J6,6’ 12.1 Hz, J5,6 5.1 Hz, H-6), 3.78 - 3.90 (2H, m, H-2 & H-6’), 
4.63 (1H, d, J1,2 10.2 Hz, H-1), 7.23 - 7.33 (3H, m, 3 x Ar-H), 7.68 - 7.73 (2H, m, 2 x Ar-H); 
C (100.5 MHz, CD3OD) 21.5 (q, C(O)CH3), 55.8 (d, C-2), 61.6 (t, C-6), 70.4 (d, C-4), 75.6 
(d, C-3), 80.9 (d, C-5), 89.1 (d, C-1), 127.2, 128.7, 130.4 (3 x d, 3 x Ar-C), 132.6 (s, Ar-C), 
172.1 (s, C(O)CH3); HRMS (ESI-TOF): calcd. for C14H20NO5S
80Se+: 394.0222. Found: 
394.0217 (MH+). 
 
Ethyl 2-acetamido-2-deoxy-1-disulfide-β-D-glucopyranoside 3.217 
 
Phenyl 2-acetamido-2-deoxy-1-selenylsulfide-β-D-glucopyranoside 3.20 (140 mg, 0.4 mmol) 
was dissolved in MeOH (10 mL) and stirred under an atmosphere of nitrogen. A solution of 
ethanethiol (10 µL, 0.13 mmol) and triethylamine (55 µL, 0.4 mmol) in MeOH (5 mL) was 
added dropwise to the reaction over 1 h. After 1 h, t.l.c. (ethyl acetate:MeOH, 9:1) indicated 
the formation of a major product (Rf 0.2). The mixture was concentrated in vacuo and the 
residue was purified by flash column chromatography (ethyl acetate:MeOH, 9:1) to afford ethyl 
2-acetamido-2-deoxy-1-disulfide-β-D-glucopyranoside 3.21 (36.7 mg, 95%) as a white 
amorphous solid; υmax (neat)
7 3271 cm-1 (b, OH, NH), 1650 cm-1 (C=O); H (400 MHz, 
CD3OD)
7 1.29 (3H, t, J 7.4 Hz, SCH2CH3), 1.96 (3H, s, C(O)CH3), 2.76 - 2.88 (2H, m, 
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SCH2CH3), 3.29 - 3.38 (2H, m, H-4 & H-5), 3.44 - 3.51 (1H, m, H-3), 3.64 - 3.70 (1H, dd, 
J5,6 5.5 Hz, J6,6’ 12.1 Hz , H-6), 3.79 - 3.90 (2H, m, H-2 & H-6’), 4.53 (1H, d, J1,2 10.6 Hz, 
H-1); C (100.5 MHz, CD3OD) 13.4 (q, SCH2CH3), 21.5 (q, C(O)CH3), 33.2 (t, SCH2CH3), 
54.5 (d, C-2), 61.6 (t, C-6), 70.4 (d, C-4), 75.8 (d, C-3), 81.1 (d, C-5), 91.1 (d, C-1), 172.0 (s, 
C(O)CH3); HRMS (ESI-TOF): calcd. for C10H19NO5S2
+: 298.0777. Found: 298.0778 (MH+). 
 
N-Butoxycarbonyl-L-cysteinyl-(S-2-acetamido-2-deoxy-1-β-D-glucopyranosyl disulfide)-
L-threonine methyl ester 3.237 
 
Phenyl 2-acetamido-2-deoxy-1-selenylsulfide-β-D-glucopyranoside 3.20 (70 mg, 0.2 mmol) 
was dissolved in MeOH (8 mL) and stirred under an atmosphere of nitrogen. A solution of 
N-butoxycarbonyl-L-cysteine-L-threonine methyl ester 3.22 (22 mg, 0.07 mmol) and 
triethylamine (10 µL, 0.1 mmol) in MeOH (5 mL) was added dropwise. After 10 min, t.l.c. 
(ethyl acetate:MeOH, 9:1) indicated the formation of a major product (Rf 0.4). The reaction 
mixture was concentrated in vacuo and the residue was purified by flash column 
chromatography (ethyl acetate:MeOH, 9:1) to afford N-butoxy-L-cysteinyl-(S-2-acetamido-2-
deoxy-1-β-D-glucopyranosyl disulfide)-L-threonine methyl ester 3.23 (30.8 mg, 77%) as a 
white amorphous solid; υmax (neat)
7 3331 cm-1 (b, OH, NH), 1735 cm-1 (C=O), 1655 cm-1 
(C(O)NH); H (400 MHz, CD3OD)
7 1.17 (3H, d, J 6.3 Hz, CHCH3), 1.46 (9H, s, C(CH3)3), 
1.96 (3H, s, C(O)CH3), 2.94 (1H, dd, JCH,H 13.5 Hz, JCH,αH 9.2 Hz, CHHCys), 3.33 - 3.44 (3H, 
m, CHHCys, H-4 & H-5), 3.51 (1H, t, J 9.0 Hz, H-3), 3.75 (3H, s, OMe), 3.87 - 4.01 (2H, m, 
H-2 & H-6), 4.26 - 4.35 (1H, m, CHCH3), 4.46 (1H, d, J 3.1 Hz, αHThr), 4.57 (1H, d, 
J1,2 10.2 Hz, H-1), 4.59 - 4.68 (1H, m, αHCys); C (100.5 MHz, CD3OD) 18.9 (q, CHCH3), 
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21.7 (q, C(O)CH3), 27.3 (C(CH3)3), 41.1 (t, CH2), 51.6 (q, OCH3), 53.9 (d, αCCys), 54.0 (d, 
C-2), 57.9 (d, αCThr), 61.2 (t, C-6), 67.1 (d, CHCH3), 70.1 (d, C-4), 75.7 (d, C-3), 79.7 (s, 
CH(CH3)3), 81.0 (d, C-5), 89.3 (d, H-1), 156.4, 172.1, 172.2, 172.7 (4 x d, 4 x C(O)); HRMS 
(ESI-TOF): calcd. for C21H38N3O11S2




A solution of GABARAPL2 (0.3 mg) in CHES buffer (0.5 mL, 70 mM, pH 9.5) was prepared. 
Phenylselenyl bromide (2.6 mg, 0.011 mmol) was dissolved in MeCN (200 µL), of which 20 
µL was added to the GABARAPL2 solution. The mixture was stirred for 1 h, then filtered 
through a 0.2 µm filter and dialysed against water (2 x 500 mL) to afford GABARAPL2-Cys-





A solution of 1-thio-2-acetamido-2-deoxy-β-D-glucopyranose 3.5 (1 mg) in water (200 µL) 
was prepared and 50 µL was added to a solution of GABARAPL2-Cys-17-SePh 3.24 (0.3 mg) 
in CHES buffer (1.0 mL, 70 mM, pH 9.5). The reaction was stirred for 1 h and then purified 
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using a Sephadex G-25 HiTrapTM desalting column to afford GABARAPL2-Cys-17-SGlcNAc 
3.25; HRMS (ESI-TOF): calcd. for (GABARAPL2-Cys-17-SGlcNAc)K+: 14084. Found: 
14084 (MK+). 
 
4-Hydroxybutyl 1-thio-2-deoxy-2-acetamido-β-D-glucopyranoside 3.26 
 
1-Thio-2-deoxy-2-acetamido-β-D-glucopyranoside 3.5 (200 mg, 0.84 mmol) and 3-buten-1-ol 
(65 µL, 0.76 mmol) were dissolved in water (7 mL). 2,2-Dimethoxy-2-phenylacetophenone 
(19.6 mg, 0.076 mmol) was added, and the reaction mixture was stirred and irradiated in a 
Rayonet photoreactor (wavelength: 254 nm) for 2 h. The reaction mixture was then 
concentrated in vacuo and the residue purified by flash column chromatography (CHCl3:MeOH 
5:1) to afford 4-hydroxybutyl 1-thio-2-deoxy-2-acetamido-β-D-glucopyranoside 3.26 
(142.4 mg, 61%) as a colourless solid; [α]D
20 -29 (c, 1.0 in MeOH); υmax (neat) 1620 cm
-1 
(C=O); H (400 MHz, D2O) 1.43 - 1.58 (4H, m, 2 x CH2), 1.90 (3H, s, C(O)CH3) 2.51 - 2.71 
(2H, m, CH2S), 3.29-3.34 (2H, m, H-4 & H-5), 3.36 - 3.44 (1H, m, H-3), 3.47 (2H, t, J 6.1 Hz, 
CH2OH), 3.55 - 3.65 (2H, m, H-2 & H-6), 3.77 (1H, d, J6,6’ 12.5 Hz, H-6’), 4.47 (1H, d, 
J1,2 10.2 Hz, H-1); C (100.5 MHz, D2O) 22.1 (t, C(O)CH3), 25.5 (t, CH2CH2OH), 29.9 (t, 
CH2S), 30.3 (t, SCH2CH2), 54.7 (d, C-2), 60.8 (t, C-6), 61.1 (t, CH2OH), 69.7 (d, C-4), 75.1 (d, 
C-3), 79.8 (d, C-5), 84.2 (d, C-1), 174.3 (s, C(O)CH3); HRMS (ESI-TOF): calcd. for 
C12H23NO6SNa
+: 332.1138. Found: 332.1146 (MNa+). 
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4-Hydroxybutyl 1-thio-2-deoxy-2-acetamido-β-D-galactopyranoside 3.27 
 
1-Thio-2-deoxy-2-acetamido-β-D-galactopyranoside 3.16 (131.3 mg, 0.55 mmol) and 3-buten-
1-ol (43 µL, 0.50 mmol) were dissolved in water (5 mL). 2,2-Dimethoxy-2-
phenylacetophenone (12.9 mg, 0.050 mmol) was added, and the reaction mixture was stirred 
and irradiated in a Rayonet photoreactor (wavelength: 254 nm) for 2 h. The reaction mixture 
was then concentrated in vacuo and the residue purified by flash column chromatography 
(CHCl3:MeOH 5:1) to afford 4-hydroxybutyl 1-thio-2-deoxy-2-acetamido-β-D-
galactopyranoside 3.27 (95 mg, 61%) as a colourless solid; [α]D
20 +2 (c, 1.0 in MeOH); 
υmax (neat) 1627 cm
-1 (C=O); H (400 MHz, D2O) 1.56 - 1.69 (4H, m, 2 x CH2), 2.01 (3H, s, 
C(O)CH3), 2.64 - 2.81 (2H, m, CH2S), 3.59 (2H, t, J 6.1 Hz, CH2OH), 3.64 - 3.79 (4H, m, H-3, 
H-5, H-6 & H-6’), 3.89 - 3.95 (1H, m, H-2), 3.96 (1H, d, J4,5 3.1 Hz, H-4), 4.52 (1H, d, 
J1,2 10.6 Hz, H-1); C (100.5 MHz, D2O) 22.1 (q, C(O)CH3), 25.5 (t, CH2CH2S), 29.9 (CH2S), 
30.3 (CH2CH2OH), 51.3 (d, C-2), 61.0 (t, C-6), 61.1 (t, CH2OH), 67.8 (d, C-4), 72.0 (d, C-3), 
78.9 (d, C-5), 84.6 (d, C-1), 174.5 (s, C(O)CH3); HRMS (ESI-TOF): calcd. for 
C12H23NO6SNa
+: 332.1138. Found: 332.1141 (MNa+). 
 
4-Hydroxybutyl 1-thio-N,N’-diacetylchitobiose 3.28 
 
1-Thio-N,N’-diacetylchitobiose 3.18 (7.7 mg, 0.017 mmol) and 3-buten-1-ol (1.5 µL, 
0.017 mmol) were dissolved in water (200 µL). 2,2-Dimethoxy-2-phenylacetophenone 
(0.5 mg, 0.002 mmol) was added, and the reaction mixture was stirred and irradiated in a 
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Rayonet photoreactor (wavelength: 254 nm) for 2 h. The reaction was purified by HPLC 
(column: Jupiter 10u C18 (90 Å) column (Phenomenex); gradient: 100% water for 15 min, 
followed by an increase to 100% MeOH over 5 min; column oven: 40 °C; flow rate: 2 mL/min; 
detection: UV 210 nm) to afford 4-hydroxybutyl 1-thio-N,N’-diacetylchitobiose 3.28 (5.6 mg, 
64%) as a white powder; υmax(neat) 3288 cm
-1 (OH), 1643 cm-1 (NHC=O); [α]D
20 -13 (c, 0.3 in 
H2O); H (400 MHz, D2O) 1.45-1.58 (4H, m, 2 x CH2), 1.91 (3H, s, C(O)CH3), 1.94 (3H, s, 
C(O)CH3), 2.50 - 2.70 (2H, m, CH2S), 3.33 - 3.67 (12H, m), 3.72 (1H, dd, J5,6’ 0.8 Hz, 
J6,6’ 12.1 Hz, H-6a’), 3.80 (1H, d, J6,6’ 11.7 Hz, H-6b’), 4.42 - 4.53 (2H, m, H-1a & H-1b); 
C (100.5 MHz, D2O) 22.0 (q, C(O)CH3), 22.1 (q, C(O)CH3), 25.5 (t, SCH2CH2), 30.0 (t, 
SCH2), 30.3 (t, CH2CH2OH), 54.2 (d, C-2a), 55.5 (d, C-2b), 60.2 (t, C-6a), 60.5 (t, C-6b), 61.1 
(t, OCH2), 69.6, 73.4, 73.7, 75.8, 78.4, 79.2 (6 x d), 84.2 (C-1a), 101.4 (C-1b), 174.3 (s, 
C(O)CH3), 174.5 (s, C(O)CH3); HRMS (ESI-TOF): calcd. for C20H37N2O11S
+: 513.2113. 




1,2:3,4-Di-O-isopropylidene-α-D-galactopyranoside 3.29 (1.185 g, 4.55 mmol) and allyl 
bromide (0.86 mL, 10 mmol) were dissolved in dry MeCN (5 mL) under an atmosphere of 
nitrogen. Potassium hydroxide (0.56 g, 10 mmol) was suspended in the reaction mixture and 
the reaction was stirred for 21 h, at which point t.l.c. (petrol:ethyl acetate 3:1) indicated 
complete consumption of starting material (Rf 0.1) and formation of a single product (Rf 0.6). 
The reaction was concentrated in vacuo, the residue dissolved in CH2Cl2 (15 mL), and washed 
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with water (15 mL). The aqueous phase was washed with CH2Cl2 (3 x 15 mL) and the combined 
organic extracts were dried (MgSO4) and concentrated in vacuo. The product was purified by 
flash column chromatography (petrol:ethyl acetate 3:1) to afford 6-O-allyl-1,2:3,4-di-O-
isopropylidene-α-D-galactopyranoside 3.30 (1.28 g, 94%) as a colourless oil; [α]D
20 -69 (c, 1.0 
in CHCl3) [lit. [α]D -71.8 (c, 1.0 in CHCl3)]
14; H (400 MHz, CDCl3)
15 1.31 (3H, s, CH3), 1.32 
(3H, s, CH3), 1.43 (3H, s, CH3), 1.52 (3H, s, CH3), 3.53 - 3.67 (2H, m, CH2CH=CH2), 3.93 - 
3.99 (1H, m, H-5), 4.00 - 4.05 (2H, m, H-6 & H-6’), 4.25 (1H, dd, J3,4 8.0, J4,5 1.8 Hz, H-4), 
4.29 (1H, dd, J1,2 4.9 Hz, J2,3 2.5 Hz, H-2), 4.58 (1H, dd, J2,3 2.3 Hz, J3,4 7.8 Hz, H-3), 5.13 - 
5.18 (1H, m, CH2CH=CHaHb), 5.26 (1H, dq, J 17.2 Hz, J 1.6 Hz, CH2CH=CHaHb), 5.52 (1H, 
d, J1,2 4.7 Hz, H-1), 5.90 (1H, ddt, J 17.2 Hz, J 10.4 Hz, J 5.8 Hz, CH2CH=CH2); 
C (100.5 MHz, CDCl3) 24.4 (q, CH3), 24.9 (q, CH3), 25.9 (q, CH3), 26.0 (q, CH3), 66.8 (d, 
C-5), 68.8 (t, CH2CH=CH2), 70.5 (d, C-2), 70.6 (d, C-3), 71.2 (d, C-4), 72.3 (t, C-6), 96.3 (d, 
C-1), 108.5 (s, C(CH3)2), 109.2 (s, C(CH3)2), 117.0 (t, CH2CH=CH2), 134.8 (d, CH2CH=CH2); 
HRMS (ESI-TOF): calcd. for C15H24O6Na




6-O-Allyl-1,2:3,4-di-O-isopropylidene-α-D-galactopyranoside 3.30 (1.12 g, 3.73 mmol) was 
dissolved in water (50 mL). Amberlite® IR-120 (H+, 4.0 g) was added, and the reaction was 
heated to 80 °C and stirred for 16 h. The reaction was then cooled to RT and lyophilised to 
afford 6-O-allyl-D-galactopyranoside 3.31 (0.84 g, quant.) as a colourless oil (1:1.3 α:β); 
H (400 MHz, D2O) 3.46 (1H, dd, J1,2 7.8 Hz, J3,4 9.8 Hz, H-2β), 3.62 (1H, dd, J2,3 10.2 Hz, 
J3,4 3.5 Hz, H-3β), 3.64 - 3.67 (3.5H, m, H-6α, H-6’α, H-6β & H-6’β), 3.75 - 3.85 (2.5H, m, 
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H-2α, H-3α & H-5β), 3.88 (1H, d, J3,4 3.5 Hz, H-4β), 3.94 (0.8H, d, J3,4 3.1 Hz, H-4α), 4.03 - 
4.09 (3.6H, m, 2 x CH2CH=CH2), 4.19 (0.8H, t, J 6.3 Hz, H-5α), 4.55 (1H, d, J1,2 7.8 Hz, H-1β), 
5.23 (0.8H, d, J1,2 3.9 Hz, H-1α), 5.26 (1.8H, d, J 10.6 Hz, 2 x CH2CH=CHaHb), 5.32 (1.8H, d, 
J 17.2 Hz, 2 x CH2CH=CHaHb), 5.86 - 6.01 (1.8H, m, 2 x CH2CH=CH2); C (100.5 MHz, D2O) 
68.2 (d, C-2α), 68.6 (d, C-3α), 68.9 (d, C-5α), 69.0 (d, C-4β), 69.2, 69.4 (2 x t, C-6α & C-6β), 
69.5 (d, C-4α), 71.7 (d, C-2β), 71.9, 72.0 (2 x t, CH2CH=CH2α & CH2CH=CH2β), 72.6 (d, 
C-3β), 73.3 (d, C-5β), 92.2 (d, C-1α), 96.3 (d, C-1β), 118.5 (t, CH2CH=CH2α & 
CH2CH=CH2β), 133.5, 133.5 (2 x d, CH2CH=CH2α & CH2CH=CH2β); HRMS (ESI-TOF): 
calcd. for C9H16O6Na




An aqueous solution of ammonium hydroxide (2 M, 18 mL, 21 mmol) was added to EtOH 
(15 mL), followed by L-cysteine monohydrate hydrochloride 3.32 (1.05 g, 6 mmol). Allyl 
bromide (0.78 mL, 9 mmol) was then added and the reaction was stirred for 20 h, at which 
point t.l.c. (CHCl3:MeOH 5:1) indicated complete consumption of starting material (Rf 0) and 
formation of a single product (Rf 0.1). The reaction was concentrated in vacuo and the white 
solid produced was washed with EtOH (2 x 10 mL). The crude solid was dissolved in water 
(15 mL), cooled to 0 °C, and NaHCO3 (1.01 g, 12 mmol) was added. FmocCl (2.33 g, 9 mmol) 
was dissolved in 1,4-dioxane (20 mL) and the resulting solution was then added to the reaction 
mixture. The reaction mixture was allowed to warm to RT, and stirred for 20 h. The reaction 
was then diluted with water (15 mL), acidified to pH 1 by the dropwise addition of H2SO4 
(conc.), and extracted with ethyl acetate (4 x 30 mL). The combined organic extracts were 
concentrated in vacuo and the residue produced was purified by flash column chromatography 




iPrOH:AcOH 97:2:1) to afford N-[(9-fluorenylmethoxy)carbonyl]-S-allyl-L-cysteine 
3.33 (103 mg, 5%) as a white solid; [α]D
20 +12 (c, 1.0 in CHCl3) [lit. [α]D -12.2 (c, 1.0 in 
CHCl2)]
16; υmax (neat) 1692 cm
-1 (C=O); H (400 MHz, CDCl3)
16 2.88 - 3.04 (2H, m, Cys-Hβ), 
3.15 (2H, d, J 6.7 Hz, CH2CH=CH2), 4.23 (1H, t, J 6.8 Hz, Fmoc CHCH2), 4.42 (2H, d, 
J 6.3 Hz, Fmoc CHCH2), 4.56 - 4.63 (1H, m, Cys-Hα), 5.11 (2H, d, J 10.6 Hz, CH2CH=CH2), 
5.57 (1H, d, J 7.0 Hz, NH), 5.67 - 5.82 (1H, m, CH2CH=CH2), 7.31 (2H, t, J 7.4 Hz, 2 x Ar-H), 
7.39 (2H, t, J 7.4 Hz, 2 x Ar-H), 7.59 (2H, d, J 6.3 Hz, 2 x Ar-H), 7.76 (2H, d, J 7.8 Hz, 
2 x Ar-H); C (100.5 MHz, CDCl3)
16 32.5 (t, Cys-Cβ), 35.3 (t, CH2CH=CH2), 47.1 
(Fmoc CHCH2), 52.4 (d, Cys-Cβ), 67.3 (t, Fmoc CHCH2), 118.1 (t, CH2CH=CH2), 120.0, 
125.0, 127.1, 127.7 (4 x d, 4 x Ar-C), 133.5, 141.3 (2 x s, 2 x Ar-C), 143.6; HRMS (ESI-TOF): 
calcd. for C21H22NO4S




L-Serine 3.34 (500 mg, 4.76 mmol) was dissolved in a mixture of 1,4-dioxane (12 mL) and 
aqueous NaOH (1 M, 5.7 mL) at 0 °C. Di-tert-butyl dicarbonate (1.25 g, 5.71 mmol) was added 
portionwise to the reaction, and the reaction was then warmed to RT and stirred for 24 h. The 
reaction was concentrated in vacuo to remove the 1,4-dioxane and the aqueous layer was 
washed with Et2O (10 mL), acidified to pH 2-3 with H2SO4 (1 M, 10 mL), and extracted with 
ethyl acetate (3 x 10 mL). The combined organic extracts were dried (MgSO4), filtered and 
concentrated in vacuo. The residue was dissolved in anhydrous DMF (30 mL) and NaH (60% 
dispersion in mineral oil, 460 mg, 11.4 mmol) was added at 0 °C under an atmosphere of 
nitrogen. Allyl bromide (0.49 mL, 5.71 mmol) was added dropwise to the mixture and the 
reaction was stirred at RT for 5 h. The reaction was concentrated in vacuo and the residue was 
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partitioned between ethyl acetate (50 mL) and water (50 mL). The aqueous layer was acidified 
with HCl (1 M, 20 mL) and extracted with ethyl acetate (3 x 50 mL). The combined organic 
extracts were washed with water (50 mL), followed by brine (50 mL). The organic layer was 
dried (MgSO4), filtered, and concentrated in vacuo to afford N-tert-butoxycarbonyl-O-allyl-L-
serine 3.35 (0.982 g, 84%) as a colourless oil; [α]D
20 +16 (c, 1.0 in CHCl3) [lit. [α]D +9.2 (c, 1.1 
in CH2Cl2)]
18; υmax (neat) 1712 cm
-1 (C=O); H (400 MHz, CDCl3)
18 1.44 (9H, s, 3 x CH3), 
3.67 (1H, dd, J 9.4 Hz, J 3.1 Hz, CHCHH’), 3.89 (1H, d, J 8.2 Hz, CHCHH’), 4.00 (2H, d, 
J 5.5 Hz, OCH2CH=CH2), 4.44 (1H, br. s., CHCH2), 5.18 (1H, d, J 10.6 Hz, 
OCH2CH=CHZHE), 5.25 (1H, d, J 17.2 Hz, OCH2CH=CHZHE), 5.41 (1H, d, J 7.4 Hz, NH), 
5.76 - 5.93 (1H, m, OCH2CH=CH2); C (100.5 MHz, CDCl3)
18 28.3 (q, 3 x CH3), 53.8 (d, 
CHCH2), 69.6 (t, CHCH2), 72.4 (t, OCH2CH=CH2), 80.3 (s, C(CH3)3), 117.7 (t, CH2CH=CH2), 
133.9 (d, CH2CH=CH2), 155.7 (s, OC(O)NH), 175.1 (s, C(O)OH); HRMS (ESI-TOF): calcd. 
for C11H19NO5Na





1-Thio-2-deoxy-2-acetamido-β-D-glucopyranoside 3.5 (104 mg, 0.44 mmol) and 6-O-allyl-D-
galactopyranoside 3.36 (88 mg, 0.4 mmol) were dissolved in water (4 mL). 2,2-Dimethoxy-2-
phenylacetophenone (10.3 mg, 0.04 mmol) was added, and the reaction mixture was stirred 
and irradiated in a Rayonet photoreactor (wavelength: 254 nm) for 2 h. The reaction mixture 
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was then concentrated in vacuo and the residue purified by flash column chromatography 
(CHCl3:MeOH 5:1) to afford 6-O-(2-[1-thio-2-deoxy-2-acetamido-β-D-glucopyranoside]-
ethyl)-D-galactopyranoside 3.36 (133.1 mg, 73 %) as a colourless solid (α:β, 1:1.7); υmax (neat) 
3265 cm-1 (br. s, OH), 1637 cm-1 (C=O); H (400 MHz, D2O) 1.82 - 1.95 (5.4H, m, 2 x 
SCH2CH2CH2O), 2.02 (8.1H, s, 2 x C(O)CH3), 2.62 - 2.86 (5.4H, m, 2 x SCH2CH2CH2O), 3.41 
- 3.96 (20.4H, m, H-21α, H-31α, H-41α, H-61α, H-6’1α, H-21β, H-31β, H-41β, H-51β, H-61β, 
H-6’1β, H-22, H-32, H-42, H-52, H-62, H-6’2 & 2 x SCH2CH2CH2O), 4.19 (1H, t, J 5.5 Hz, 
H-51α), 4.55 (1H, d, J1,2 7.8 Hz, H-11β), 4.60 (1.6H, d, J1,2 10.6 Hz, 2 x H-12), 5.23 (0.6H, d, 
J1,2 3.5 Hz, H-11α); C (100.5 MHz, D2O) 22.1 (q, C(O)CH3), 26.9 (t, SCH2CH2CH2O), 28.9 
(t, SCH2CH2CH2O), 54.7 (d, C-22), 60.8 (t, C-62), 68.2, 68.5, 68.9, 69.0, 69.4, 69.5, 69.6, 69.7, 
69.8, 71.7, 72.7, 73.2, 75.1, 79.8 (d, C-52), 84.3, 84.4 (2 x d, 2 x C-12), 92.2 (d, C-11α), 96.3 
(d, C-11β), 174.3 (s, C(O)CH3); HRMS (ESI-TOF): calcd. for C17H32NO11S






1-Thio-2-deoxy-2-acetamido-β-D-glucopyranoside 3.5 (52 mg, 0.22 mmol) and N-tert-
butoxycarbonyl-O-allyl-L-serine 3.35 (49 mg, 0.2 mmol) were dissolved in a 1:1 mixture of 
water and MeOH (2 mL). 2,2-Dimethoxy-2-phenylacetophenone (5.1 mg, 0.02 mmol) was 
added, and the reaction mixture was stirred and irradiated in a Rayonet photoreactor 
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(wavelength: 254 nm) for 2 h. The reaction mixture was then concentrated in vacuo and the 
residue purified by flash column chromatography (CHCl3:MeOH 5:1) to afford N-tert-
butoxycarbonyl-O-(2-[1-thio-2-deoxy-2-acetamido-β-D-glucopyranoside]-ethyl)-L-serine 
3.38 (88 mg, 91%) as a colourless oil; [α]D
20 0 (c, 1.0 in CHCl3); υmax (neat) 3306 cm
-1 (OH), 
1737 cm-1 (HOC=O), 1648 cm-1 (NHC=O); H (400 MHz, CD3OD) 1.44 (9H, s, C(CH3)3), 1.78 
- 1.89 (2H, m, SCH2CH2CH2O), 1.98 (3H, s, NHC(O)CH3), 2.64 - 2.84 (2H, m, 
SCH2CH2CH2O), 3.26-3.37 (2H, m, H-4 & H-5), 3.45 (1H, t, J 8.4 Hz, H-3), 3.50 - 3.59 (2H, 
m, SCH2CH2CH2O), 3.63 - 3.81 (4H, m, H-2, H-6 & CHCH2), 3.87 (1H, d, J6,6’ 12.1 Hz, H-6’), 
4.21 (1H, br. s, CHCH2) 4.48 (1H, d, J 10.2 Hz, H-1); C (100.5 MHz, CD3OD) 21.6 (q, 
NHC(O)CH3), 26.3 (t, SCH2CH2CH2O), 27.3 (q, C(CH3)3), 29.4 (t, SCH2CH2CH2O), 54.5 (d, 
CHCH2), 54.8 (d, C-2), 61.5 (t, C-6), 69.3 (t, SCH2CH2CH2O), 70.4 (t, CHCH2), 70.6 (d, C-4), 
76.0 (d, C-3), 80.6 (d, C-5), 84.4 (d, C-1); HRMS (ESI-TOF): calcd. for C19H35N2O10S
+: 
483.2007. Found: 483.2012 (MH+). 
 
  





Peptide 3.39 (1.0 mg, 0.55 µmol) and 1-thio-2-acetamido-2-deoxy-β-D-glucopyranose 3.5 
(6.5 mg, 27 µmol) were dissolved in DMF (100 µL). 2,2-Dimethoxy-2-phenylacetophenone 
(0.7 mg, 2.8 µmol) was added, and the reaction mixture was stirred and irradiated in a Rayonet 
photoreactor (wavelength: 254 nm) for 2 h. The reaction was analysed by LCMS (column: 
Jupiter 5u C18 (300 Å) column (Phenomenex); gradient: 5% MeCN in water for 15 min, 
followed by an increase to 75% MeCN over 30 min; column oven: 40 °C; flow rate: 
0.5 mL/min; detection: UV 210 nm) to reveal the presence of neoglycopeptide 3.40 (>95%); 
tR = 33.2 min; HRMS (ESI-TOF): calcd. for C90H138N21O32S
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Sialoglycan thioacetate 3.42 
 
Sialoglycan 3.41 (5.1 mg, 2.5 µmol) was dissolved in D2O (100 µL). Triethylamine (35.0 µL, 
250 µmol) was added and the reaction mixture was cooled to 0 °C and stirred. A solution of 
2-chloro-1,3-dimethylimidazolinium chloride 2.1 (12.6 mg, 75 µmol) in D2O (50 µL) was then 
added dropwise. The reaction mixture was stirred at 0 °C for 2 h. A solution of thioacetic acid 
(26.4 µL, 375 µmol) in MeCN (75 µL) was added dropwise to the reaction mixture. The 
reaction mixture was stirred for 1 h and then purified by HPLC (tR = 14.8 min; column: 
XBridge® Glycan BEH Amide 3.5µm (130 Å) column; gradient: 10% water in MeCN for 
7 min, followed by an increase to 40% water over 5 min, followed by 40% water in MeCN for 
5 min; column oven: 40 °C; flow rate: 1 mL/min; detection: UV 210 nm) to afford sialoglycan 
thioacetate 3.42 (3.1 mg, 60%) as a white powder; H (400 MHz, D2O) 2.35 (3H, s, SC(O)H3), 
5.17 (1H, d, J1,2 11.0 Hz, H-1a); δC (100.5 MHz, D2O) 30.0 (q, SC(O)CH3), 80.8 (d, C-1a); 
HRMS (ESI-TOF): calcd. for C78H128N5O57S
+: 2078.6986. Found: 2078.7007 (MH+). 
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Sialoglycan neoglycopeptide 3.44 
 
Sialoglycan thioacetate 3.42 (1.5 mg, 0.75 µmol) was dissolved in aqueous NaOH (1 M, 5 mL) 
and stirred for 2 h. Amberlite® IR-120 (H+) was added until pH 7 was reached, and the reaction 
mixture was then filtered and concentrated in vacuo. The resulting colourless solid was 
dissolved in water (40 µL). Peptide 3.39 (0.5 mg, 0.28 µmol) was dissolved in DMF (100 µL). 
10 µL of the resulting solution was diluted with water (150 µL). 5 µL of the diluted peptide 
solution was added to the sialoglycan solution. 2,2-Dimethoxy-2-phenylacetophenone (1 mg, 
3.9 µmol) was dissolved in DMF (200 µL), and 1 µL of this solution was added to the reaction 
mixture. The mixture was then stirred and irradiated in a Rayonet photoreactor (wavelength: 
254 nm) for 4 h, and then analysed by LCMS (column: Jupiter 5u C18 (300 Å) column 
(Phenomenex); gradient: 5% MeCN in water for 15 min, followed by an increase to 75% 
MeCN over 30 min; column oven: 40 °C; flow rate: 0.5 mL/min; detection: UV 235 nm) to 
reveal the presence of sialoglycan neoglycopeptide 3.44 (>95%); tR = 32.1 min; HRMS (ESI-
TOF): calcd. for C158H248N25O83S
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Experimental section for Chapter 4 
3-Allyloxy-1-propyne 4.319 
 
NaH (60% suspension in mineral oil, 9 g, 225 mmol) was washed with diethyl ether (100 mL 
x 4) and dissolved in DMF/Et2O (200 mL, 10:1) at 0 °C under an atmosphere of nitrogen. 
Propargyl alcohol (5.76 mL, 86 mmol) was added dropwise and the reaction was stirred for 1 
h. Allyl bromide (7.38 mL, 99 mmol) was dissolved in Et2O (45 mL) and the resulting solution 
was added dropwise to the reaction. The reaction was then stirred at 0 °C for 5 h, then quenched 
with brine (500 mL). The organic layer was washed with water (500 mL), dried (MgSO4), 
filtered through silica, and carefully concentrated in vacuo (700 mbar, 40 °C) to afford 
3-allylloxy-1-propyne 4.3 (7.24 g, 87%) as a pale yellow oil; H (400 MHz, CDCl3)
20 2.40 (1H, 
d, J 1.2 Hz, CH2C≡CH), 4.03 (2H, d, J 5.9 Hz, CH2=CHCH2), 4.11 (2H, d, J 2.3 Hz, 
CH2C≡CH), 5.18 (1H, d, J 10.2 Hz, CHEHZ=CH), 5.27 (1H, d, J 17.2 Hz, CHEHZ=CH), 5.86 
(1H, ddt, JE 16.9 Hz, JZ 11.1 Hz, 2 x J 5.6 Hz, CH2=CHCH2); C (100.5 MHz, CDCl3)
20 57.0 
(t, CH2C≡CH), 70.6 (t, CH2=CHCH2), 74.3 (d, CH2C≡CH), 79.6 (s, CH2C≡CH), 117.9 (t, 




Potassium hydroxide (5.05 g, 90 mmol) was suspended in DMSO (60 mL) at 0 °C. 3-Buten-
1-ol (2.58 mL, 30 mmol) was added and the reaction mixture was stirred for 10 min. Propargyl 
bromide (2.27 mL, 30 mmol) was added and the reaction was stirred at RT for 3 h, then diluted 
with water (120 mL) and extracted with Et2O (3 x 60 mL). The combined organic extracts were 
washed with water (4 x 50 mL), washed with brine (50 mL), dried (MgSO4), filtered, and 
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concentrated in vacuo. The residue was purified by flash column chromatography (petrol:Et2O 
98:2) to afford 4-prop-2-ynyloxy-but-1-ene 4.4 (1.31 g, 35%) as a pale yellow liquid; 
H (400 MHz, CDCl3) 2.32 - 2.44 (3H, m, C≡CH & CH2CH=CH2), 3.59 (2H, t, J 6.7 Hz, 
CH2CH2O), 4.15 (2H, s, CH2C≡CH), 5.06 (1H, d, J 10.6 Hz, CHEHZ=CH), 5.12 (1H, d, 
J 17.2 Hz, CHEHZ=CH), 5.76 - 5.89 (1H, m, CH2=CHCH2); C (100.5 MHz, CDCl3) 33.9 (t, 
CH2CH=CH2), 58.0 (t, CH2C≡CH), 69.3 (t, CH2CH2O), 74.2 (d, C≡CH), 79.8 (s, CH2C≡CH), 




Potassium hydroxide (5.05 g, 90 mmol) was suspended in DMSO (60 mL) at 0 °C. 4-Penten-
1-ol (2.58 mL, 30 mmol) was added and the mixture was stirred for 10 min. Propargyl bromide 
(2.27 mL, 30 mmol) was added and the mixture was stirred at RT for 3 h, then diluted with 
water (120 mL) and extracted with Et2O (3 x 60 mL). The combined organic extracts were 
washed with water (4 x 50 mL), washed with brine (50 mL), dried (MgSO4), filtered, and 
concentrated in vacuo. The residue was purified by flash column chromatography (petrol:Et2O 
98:2) to afford 5-prop-2-ynyloxy-pent-1-ene 78 (1.80 g, 48%) as a pale yellow liquid; 
H (400 MHz, CDCl3) 1.62 - 1.73 (2H, m, CH2CH2CH2), 2.11 (2H, q, J 7.0 Hz, CH2=CHCH2), 
2.39 (1H, t, J 2.3 Hz, C≡CH), 3.50 (2H, t, J 6.5 Hz, CH2O), 4.11 (2H, d, J 2.7 Hz, CH2≡CH), 
4.95 (1H, dd, JZ 10.2 Hz, Jgem 2.0 Hz, CHEHZ=CH), 5.01 (1H, dd, JE 17.0 Hz, Jgem 1.8 Hz, 
CHEHZ=CH), 5.79 (1H, ddt, JE 17.1 Hz, JZ 10.3 Hz, 2 x J 6.7 Hz, CH2=CHCH2). 
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2-Chloro-1,3-dimethylimidazolinium hexafluorophosphate 4.622 
 
2-Chloro-1,3-dimethylimidazolinium chloride 2.1 (20.00 g, 0.17 mol) and sodium 
hexafluophosphate (20.00 g, 0.17 mol) were dissolved in anhydrous MeCN under an 
atmosphere of nitrogen. The mixture was stirred for 0.5 h, then filtered through Celite® and 
concentrated in vacuo. The solid was precipitated (MeCN/Et2O) to afford 2-chloro-1,3-
dimethylimidazolinium 4.6 (26.03 g, 55%) as a white solid; m.p. 204-205 °C (MeCN) 
[lit. 210 °C (MeCN)]22; H (400 MHz, CD3CN)
22 3.13 (6H, s, 2 x CH3), 3.95 (4H, s, 2 x CH2); 
C (100.5 MHz, CD3CN)
22 34.1 , 49.8; F (376 MHz, CD3CN)
22 -73.0 (d, J 707 Hz, PF6); 
P (162 MHz, CD3CN) -144.7 (sept., J 707 Hz, PF6). 
 
2-Azido-1,3-dimethylimidazolinium hexafluorophosphate 4.722 
 
2-Chloro-1,3-dimethylimidazolinium chloride 4.6 (26.03 g, 0.093 mol) was dissolved in 
anhydrous MeCN (250 mL) at 0 °C under an atmosphere of nitrogen. Sodium azide (8.5 g, 
0.13 mol) was added to the reaction and the reaction was stirred for 3 h. The reaction was then 
filtered through Celite® washed with MeCN, concentrated in vacuo, and the solid was 
precipitated (MeCN/Et2O) to afford 2-azido-1,3-dimethylimidazolinium hexafluorophosphate 
4.7 (22.48 g, 85%) as a white solid; m.p. 206-207 °C (MeCN) [lit. 200-205 °C (MeCN)]22; 
H (400 MHz, CD3CN)
22 3.07 (6H, s, 2 x CH3), 3.81 (4H, s, 2 x CH2); C (100.5 MHz, CD3CN) 
32.8, 48.9, 110.0; F (376 MHz, CD3CN) -73.1 (d, J 707 Hz, PF6); P (162 MHz, 
CD3CN) -144.7 (sept., J 707 Hz, PF6). 
 






N-Acetyl-D-glucosamine 4.8 (500 mg, 2.26 mmol) and triethylamine (1.55 mL, 11.3 mmol) 
were dissolved in D2O/MeCN (4:1, 10 mL) and the reaction mixture was cooled to 0 °C. 
2-Azido-1,3-dimethylimidazolinium hexafluorophosphate 4.7 (1.925 g, 6.75 mmol) was added 
and the reaction mixture was stirred for 1 h. The reaction mixture was then acidified to pH 2 
by addition of HCl (1 M, 10 mL), stirred for 10 min, and then neutralised by the addition of 
NaHCO3 (sat. aqueous soln., 20 mL). The mixture was concentrated in vacuo. The residue was 
dissolved in tert-butanol/water (2:1, 25 mL) and 3-allyloxy-1-propyne 4.3 (0.45 mL, 
4.0 mmol), CuSO4.5H2O (112 mg, 0.45 mmol), and sodium ascorbate (178 mg, 0.9 mmol) 
were added. The reaction mixture was then heated to 50 °C and stirred for 16 h. The reaction 
mixture was then concentrated in vacuo and the residue was dissolved in EtOH (50 mL), 
filtered through Celite®, and concentrated in vacuo. The residue was dissolved in water 
(50 mL), and the aqueous layer was washed with CH2Cl2 (2 x 100 mL), filtered through a 
column of Amberlite® IR-120 (Na+ form, produced by treating the H+ form with 1 M aqueous 
NaOH solution and then washing with water until pH 7), and concentrated in vacuo. The 
residue was pre-absorbed onto silica and purified by flash column chromatography 
(CH2Cl2:MeOH 8:1) to afford 3-((1’-(2”-acetamido-2”-deoxy-β-D-glucopyranosyl)-[1’,2’,3’]-
triazo-4’-yl)methyloxy)-1-propene 4.9 (615 mg, 79%) as a white solid; m.p. 95-100 °C 
(CH2Cl2); [α]D
20 -5.9 (c, 1.0 in MeOH); υmax (neat) 3410 cm
-1 (OH), 1651 cm-1 (NHC=O); 
H (400 MHz, D2O) 1.80 (3H, s, NHC(O)CH3), 3.66 - 3.85 (4 H, m, H-3, H-4, H-5 & H-6), 
3.92 (1H, dd, J5,6’ 1.6 Hz, J6,6’ 12.5 Hz, H-6’), 4.04 (2H, d, J 6.3 Hz, CH2=CHCH2), 4.25 (1H, 
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t, J 10.0 Hz, H-2), 4.66 (2H, s, NCH=CCH2), 5.26 (1H, d, JZ 10.6 Hz, CHEHZ=CHCH2), 5.32 
(1H, d, JE 17.2 Hz, CHEHZ=CHCH2), 5.84 (1H, d, J1,2 9.8 Hz, H-1), 5.92 (1H, ddt, JE 17.2 Hz, 
JZ 10.6, 2 x J 5.9 Hz, CH2=CHCH2), 8.22 (1H, s, NCH=C); C (100.5 MHz, D2O) 21.5 (q, 
NHC(O)CH3), 55.3 (d, C-2), 60.3 (t, C-6), 61.8 (t, NCH=CCH2), 69.2 (d, C-4), 70.8 (t, 
CH2=CHCH2), 73.4 (d, C-3), 78.8 (d, C-5), 86.3 (d, C-1), 118.7 (t, CH2=CHCH2), 123.7 (d, 
NCH=C), 133.2 (d, CH2=CCH2), 144.0 (s, NCH=CCH2), 174.0 (s, NHC(O)CH3); HRMS (ESI-
TOF): calcd. for C14H23N4O6





N-Acetyl-D-galactosamine (111 mg, 0.5 mmol) and triethylamine (0.35 mL, 2.5 mmol) were 
dissolved in D2O/MeCN (4:1, 2 mL) and the reaction mixture was cooled to 0 °C. 2-Azido-
1,3-dimethylimidazolinium hexafluorophosphate 4.7 (428 mg, 1.5 mmol) was added and the 
reaction mixture was stirred for 1 h. The reaction mixture was then acidified to pH 2 by addition 
of aqueous HCl (1 M, 2.5 mL), stirred for 10 min, and then neutralised by the addition of 
NaHCO3 (sat. aqueous soln., 5 mL). The mixture was concentrated in vacuo. The residue was 
dissolved in tert-butanol/water (2:1, 6 mL) and 3-allyloxy-1-propyne 4.3 (0.11 mL, 2.0 mmol), 
CuSO4.5H2O (25 mg, 0.5 mmol), and sodium ascorbate (40 mg, 0.2 mmol) were added. The 
reaction mixture was then heated to 50 °C and stirred for 16 h. The reaction mixture was then 
concentrated in vacuo and the residue was dissolved in EtOH (20 mL), filtered through Celite®, 
and concentrated in vacuo. The residue was dissolved in water (10 mL), and the aqueous layer 
was washed with CH2Cl2 (3 x 20 mL), filtered through a column of Amberlite
® IR-120 (Na+ 
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form, produced by treating the H+ form with 1 M aqueous NaOH solution and then washing 
with water until pH 7), and concentrated in vacuo. The residue was pre-absorbed onto silica 
and purified by flash column chromatography (CH2Cl2:MeOH 8:1) to afford 3-((1’-(2”-
acetamido-2”-deoxy-β-D-galactopyranosyl)-[1’,2’,3’]-triazo-4’-yl)methyloxy)-1-propene 4.10 
(75.3 mg, 44%) as a white solid; [α]D
20 +6 (c, 1.0 in MeOH); υmax (neat) 3290 cm
-1 (OH), 
1652 cm-1 (NHC=O); H (400 MHz, D2O) 1.80 (3H, s, NHC(O)CH3), 3.79 - 3.84 (2H, m, H-6 
& H-6’), 3.95 - 4.02 (2H, m, H-3 & H-5), 4.05 (2H, d, J 5.9 Hz, CH2=CHCH2), 4.10 (1H, d, 
J3,4 3.1 Hz, H-4), 4.42 (1H, t, J 10.2 Hz, H-2), 4.67 (2H, s, CCH2O), 5.27 (1H, dd, JZ 10.6 Hz, 
Jgem 0.8 Hz, CHZHE=CH), 5.32 (1H, dd, JE 17.4 Hz, Jgem 1.4 Hz, CHZHE=CH), 5.78 (1H, d, 
J1,2 9.8 Hz, H-1), 5.92 (1H, ddt, JE 17.1 Hz, JZ 10.7 Hz, 2 x J 5.9 Hz, CH2=CH), 8.27 (1H, s, 
NCH=C); C (100.5 MHz, D2O) 21.6 (q, CH3), 52.0 (d, C-2), 60.8 (t, C-6), 61.8 (t, CCH2O), 
67.6 (d, C-4), 70.6 (d, C-3), 70.8 (t, CH2=CHCH2), 78.3 (d, C-5), 86.9 (d, C-1), 118.8 (t, 
CH2=CH), 123.6 (d, NCH=C), 133.3 (d, CH2=CH), 144.1 (s, NCH=CCH2), 174.2 (s, 
NHC(O)CH3); HRMS (ESI-TOF): calcd. for C14H23N4O6




Glucose (90.1 mg, 0.5 mmol) and triethylamine (0.35 mL, 2.5 mmol) were dissolved in 
D2O/MeCN (4:1, 2 mL) and the reaction mixture was cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 4.7 (428 g, 1.5 mmol) was added and the reaction 
mixture was stirred for 1 h. The reaction mixture was then concentrated in vacuo and the 
residue was dissolved in tert-butanol/water (2:1, 6 mL). 3-Allyloxy-1-propyne 4.3 (0.11 mL, 
1.0 mmol), CuSO4.5H2O (25.0 mg, 0.1 mmol), and sodium ascorbate (39.6 mg, 0.2 mmol) 
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were added. The reaction mixture was then heated to 50 °C and stirred for 16 h. The reaction 
mixture was then concentrated in vacuo and the residue was dissolved in EtOH (25 mL), 
filtered through Celite®, and concentrated in vacuo. The residue was dissolved in water 
(20 mL), and the aqueous layer was washed with CH2Cl2 (3 x 20 mL), filtered through a column 
of Amberlite® IR-120 (Na+ form, produced by treating the H+ form with 1 M aqueous NaOH 
solution and then washing with water until pH 7), and concentrated in vacuo. The residue was 
pre-absorbed onto silica and purified by flash column chromatography (CH2Cl2:MeOH 8:1) to 
afford 3-((1’-β-D-glucopyranosyl-[1’,2’,3’]-triazo-4’-yl)methyloxy)-1-propene 4.11 (100 mg, 
66%) as a colourless oil; [α]D
20 -3 (c, 1.0 in MeOH); υmax 3334 cm
-1 (OH); H (400 MHz, D2O) 
3.58 - 3.64 (1H, m, H-4), 3.67 - 3.80 (3H, m, H-3, H-5 & H-6’), 3.90 (1H, d, J6,6’ 10.6 Hz, 
H-6’), 3.99 (1H, t, J 9.2 Hz, H-2), 4.10 (2H, d, J 5.9 Hz, CHCH2), 4.70 (2H, s, CCH2O), 5.27 
(1H, d, JZ 10.6 Hz, CHZHE=CH), 5.33 (1H, d, JE 17.2 Hz, CHZHE=CH), 5.75 (1H, d, J1,2 9.4 Hz, 
H-1), 5.94 (1H, ddt, JE 17.0 Hz, JZ 10.6 Hz, 2 x J 6.2 Hz, CH2=CHCH2), 8.25 (1H, s, NCH=C); 
C (100.5 MHz, D2O) 60.3 (t, C-6), 62.0 (t, CCH2O), 68.9 (d, C-4), 71.1 (t, CH2=CHCH2), 72.2 
(d, C-2), 75.8 (d, C-3), 78.8 (d, C-5), 87.4 (d, C-1), 118.8 (t, CH2=CH), 124.3 (d, NCH=C), 
133.3 (d, CH2=CH), 144.2 (s, NCH=CCH2); HRMS (ESI-TOF): calcd. for C12H20N3O6
+: 
302.1347. Found: 302.1348 (MH+). 
 
  





Mannose (90.1 mg, 0.5 mmol) and triethylamine (0.35 mL, 2.5 mmol) were dissolved in 
D2O/MeCN (4:1, 2 mL) and the reaction mixture was cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 4.7 (428 g, 1.5 mmol) was added and the reaction 
mixture was stirred for 1 h. The reaction mixture was then concentrated in vacuo and the 
residue was dissolved in tert-butanol/water (2:1, 6 mL). 3-Allyloxy-1-propyne 4.3 (0.11 mL, 
1.0 mmol), CuSO4.5H2O (25.0 mg, 0.1 mmol), and sodium ascorbate (39.6 mg, 0.2 mmol) 
were added. The reaction mixture was then heated to 50 °C and stirred for 40 h. The reaction 
mixture was then concentrated in vacuo and the residue was dissolved in EtOH (25 mL), 
filtered through Celite®, and concentrated in vacuo. The residue was dissolved in water 
(20 mL), and the aqueous layer was washed with CH2Cl2 (3 x 20 mL), filtered through a column 
of Amberlite® IR-120 (Na+ form, produced by treating the H+ form with 1 M aqueous NaOH 
solution and then washing with water until pH 7), and concentrated in vacuo. The residue was 
pre-absorbed onto silica and purified by flash column chromatography (CH2Cl2:MeOH 8:1) to 
afford 3-((1’-α-D-mannopyranosyl-[1’,2’,3’]-triazo-4’-yl)methyloxy)-1-propene 4.12 
(120 mg, 80%) as a colourless oil; [α]D
20 +42 (c, 1.0 in MeOH); υmax 3353 cm
-1 (OH); 
H (400 MHz, D2O) 3.27 - 3.32 (1H, m, H-5), 3.75 - 3.85 (3H, m, H-4, H-6 & H-6’), 4.07 - 
4.16 (3H, m, H-3 & CHCH2O), 4.69 (2H, s, CCH2O), 4.79 (1H, t, J 3.1 Hz, H-2), 5.26 (1H, dd, 
JZ 10.6 Hz, Jgem 0.8 Hz, CHZHE=CH), 5.32 (1H, dd, JE 17.2 Hz, Jgem 1.6 Hz, CHZHE=CH), 5.93 
(1H, ddt, JE 17.0 Hz, JZ 10.6 Hz, 2 x J 6.2 Hz, CH2=CH), 6.12 (1H, d, J1,2 2.3 Hz, H-1), 8.19 
(1H, s, NCH=C); C (100.5 MHz, D2O) 60.4 (t, C-6), 62.0 (t, CCH2O), 66.5 (d, C-4), 68.2 (d, 
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C-2), 70.5 (d, C-3), 71.1 (t, CHCH2O), 76.1 (d, C-5), 86.7 (d, C-1), 118.7 (t, CH2=CH), 124.7 
(d, NCH=C), 133.4 (d, CH2=CH), 144.3 (s, NCH=CCH2); HRMS (ESI-TOF): calcd. for 
C12H20N3O6




Galactose (90.1 mg, 0.5 mmol) and triethylamine (0.35 mL, 2.5 mmol) were dissolved in 
D2O/MeCN (4:1, 2 mL) and the reaction mixture was cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 4.7 (428 g, 1.5 mmol) was added and the reaction 
mixture was stirred for 1 h. The reaction mixture was then concentrated in vacuo and the 
residue was dissolved in tert-butanol/water (2:1, 6 mL). 3-Allyloxy-1-propyne 4.3 (0.11 mL, 
1.0 mmol), CuSO4.5H2O (25.0 mg, 0.1 mmol), and sodium ascorbate (39.6 mg, 0.2 mmol) 
were added. The reaction mixture was then heated to 50 °C and stirred for 16 h. The reaction 
mixture was then concentrated in vacuo and the residue was dissolved in EtOH (25 mL), 
filtered through Celite®, and concentrated in vacuo. The residue was dissolved in water (20 
mL), and the aqueous layer was washed with CH2Cl2 (3 x 20 mL), filtered through a column 
of Amberlite® IR-120 (Na+ form, produced by treating the H+ form with 1 M aqueous NaOH 
solution and then washing with water until pH 7), and concentrated in vacuo. The residue was 
pre-absorbed onto silica and purified by flash column chromatography (CH2Cl2:MeOH 8:1) to 
afford 1,6-anhydro-β-D-galactose 4.13 (33.3 mg, 41%) as a colourless oil; H (400 MHz, 
D2O)
10 3.63 (1H, dd, J5,6 5.7 Hz, J6,6’ 7.2 Hz, H-6), 3.77 - 3.79 (1H, m, H-2), 3.90 - 3.93 (1H, 
m, H-3), 4.03 (1H, t, J 4.5 Hz, H-4), 4.29 (1H, d, J6,6’ 7.4 Hz, H-6’), 4.48 (1H, t, J 4.5 Hz, H-
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5), 5.38 (1H, s, H-1); C (100.5 MHz, D2O) 63.4 (t, C-6), 64.2 (d, C-4), 70.0 (d, C-3), 71.2 (d, 





Isomaltose (34.2 mg, 0.1 mmol) and triethylamine (0.07 mL, 0.5 mmol) were dissolved in 
D2O/MeCN (4:1, 0.4 mL) and the reaction mixture was cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 4.7 (85.5 g, 0.3 mmol) was added and the 
reaction mixture was stirred for 1 h. tert-Butanol (0.8 mL) was added to the reaction mixture, 
followed by 3-allyloxy-1-propyne 4.3 (0.02 mL, 0.2 mmol), CuSO4.5H2O (5.0 mg, 0.02 mmol), 
and sodium ascorbate (7.9 mg, 0.04 mmol). The reaction was heated to 50 °C and stirred for 
16 h, then concentrated in vacuo. The residue was dissolved in EtOH (5 mL), filtered through 
Celite®, and concentrated in vacuo. The residue was dissolved in water (5 mL), and the aqueous 
layer was washed with CH2Cl2 (3 x 10 mL), filtered through a column of Amberlite
® IR-120 
(Na+ form, produced by treating the H+ form with 1 M aqueous NaOH solution and then 
washing with water until pH 7), and concentrated in vacuo. The residue was pre-absorbed onto 
silica and purified by flash column chromatography (CH2Cl2:MeOH 4:1) to afford 3-((1’-(α-
D-glucopyranosyl-(1→4)-β-D-glucopyranosyl)-[1’,2’,3’]-triazo-4’-yl)methyloxy)-1-propene 
4.14 (34.7 mg, 75%) as a white solid; [α]D
20 +47 (c, 1.0 in MeOH); υmax 3258 cm
-1 (OH); 
H (400 MHz, D2O) 3.37 (1H, t, J 9.8 Hz, H-5b), 3.51 (1H, dd, J1,2 3.9 Hz, J2,3 10.2 Hz, H-2b), 
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3.59 - 3.76 (6H, m, H-3a, H-5a, H-3b, H-4b, H-6b & H-6’b), 3.76 - 4.00 (3H, m, H-4a, H-6a & 
H-6’a), 4.06 (1H, t, J 9.2 Hz, H-2a), 4.11 (2H, d, J 5.9 Hz, CH2=CHCH2), 4.71 (2H, s, CCH2O), 
4.91 (1H, d, J1,2 3.9 Hz, H-1b), 5.28 (1H, d, JZ 10.6 Hz, CHZHE=CH), 5.34 (1H, dd, JE 17.2 Hz, 
Jgem 1.6 Hz, CHZHE=CH), 5.77 (1H, d, J1,2 9.4 Hz, H-1a), 5.95 (1H, ddt, JE 17.0 Hz, JZ 10.6 Hz, 
2 x J 6.2 Hz, CH2=CH), 8.28 (1H, s, NCH=C); C (100.5 MHz, D2O) 60.0 (t, C-6b), 61.9 (t, 
CCH2O), 65.9 (t, C-6a), 69.0 (d, C-5a), 69.2 (d, C-5b), 71.1 (t, CH2=CHCH2), 71.3 (d, C-2b), 
71.6 (d, C-4b), 72.0 (d, C-2a), 72.9 (d, C-3b), 76.0 (d, C-3a), 77.5 (d, C-4a), 87.3 (s, C-1a), 98.0 
(s, C-1b), 118.8 (t, CH2=C), 124.5 (d, NCH=C), 133.3 (s, CH=CCH2); HRMS (ESI-TOF): 
calcd. for C18H30N3O11





N-Acetyl-D-glucosamine 4.8 (221 mg, 1 mmol) and triethylamine (0.70 mL, 5 mmol) were 
dissolved in D2O/MeCN (4:1, 4 mL) and the solution cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 4.7 (855 g, 3 mmol) was added and the reaction 
mixture was stirred for 1 h. The reaction mixture was then acidified to pH 2 by the addition of 
aqueous HCl (1 M, 5 mL), stirred for 10 min, and then neutralised by addition of NaHCO3 (sat. 
aqueous soln., 10 mL). The mixture was concentrated in vacuo. The residue was dissolved in 
tert-butanol/water (2:1, 10 mL) and 4-prop-2-ynyloxy-but-1-ene 4.4 (220 mg, 2 mmol), 
CuSO4.5H2O (50 mg, 0.2 mmol), and sodium ascorbate (80 mg, 0.4 mmol) were added. The 
reaction mixture was then heated to 50 °C and stirred for 16 h. The mixture was then 
concentrated in vacuo and the residue was dissolved in EtOH (25 mL), filtered through Celite®, 
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and concentrated in vacuo. The residue was dissolved in water (25 mL), and the aqueous layer 
was washed with CH2Cl2 (2 x 50 mL), filtered through a column of Amberlite
® IR-120 (Na+ 
form, produced by treating the H+ form with 1 M aqueous NaOH solution and then washing 
with water until pH 7), and concentrated in vacuo. The residue was pre-absorbed onto silica 
and purified by flash column chromatography (CH2Cl2:MeOH 8:1) to afford 4-((1’-(2”-
acetamido-2”-deoxy-β-D-glucopyranosyl)-[1’,2’,3’]-triazo-4’-yl)methyloxy)-1-butene 4.15 
(190 mg, 53%) as a white solid; υmax (neat) 3279 cm
-1 (OH), 1656 cm-1 (NHC=O); [α]D
20 -13.7 
(c, 1.0 in MeOH); H (400 MHz, D2O) 1.80 (3H, s, C(O)CH3), 2.32 (2H, q, J 6.5 Hz, 
CHCH2CH2O), 3.58 (2H, t, J 6.5 Hz, CHCH2CH2O), 3.65 - 3.85 (4H, m, H-3, H-4, H-5 & 
H-6), 3.93 (1H, d, J6,6’ 12.5 Hz, H-6’), 4.25 (1H, t, J 9.8 Hz, H-2), 4.65 (2H, s, CCH2O), 5.03 
- 5.16 (2H, m, CH2=CH), 5.74 - 5.89 (2H, m, H-1 & CH2=CH), 8.21 (1H, s, NCH=C); 
C (100.5 MHz, D2O) 21.6 (q, C(O)CH3), 33.0 (t, CHCH2CH2O), 55.3 (d, C-2), 60.4 (t, C-6), 
62.4 (t, CCH2O), 69.1 (t, CHCH2CH2O), 69.2 (d, C-4), 73.5 (d, C-3), 78.9 (d, C-5), 86.3 (d, 
C-1), 116.6 (t, CH2=CH), 123.7 (d, NCH=C), 135.3 (d, CH2=CH), 144.1 (CH=CCH2O), 174.0 
(q, C(O)CH3); HRMS (ESI-TOF): calcd. for C15H25N4O6





N-Acetyl-D-glucosamine 4.8 (221 mg, 1 mmol) and triethylamine (0.70 mL, 5 mmol) were 
dissolved in D2O/MeCN (4:1, 4 mL) and the solution cooled to 0 °C. 2-Azido-1,3-
dimethylimidazolinium hexafluorophosphate 4.7 (855 g, 3 mmol) was added and the mixture 
was stirred for 1 h. The reaction mixture was then acidified to pH 2 by addition of aqueous HCl 
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(1 M, 5 mL), stirred for 10 min, and then neutralised by the addition of NaHCO3 (sat. aqueous 
soln., 10 mL). The mixture was concentrated in vacuo. The residue was dissolved in 
tert-butanol/water (2:1, 10 mL) and 5-prop-2-ynyloxy-pent-1-ene 4.5 (248 mg, 2 mmol), 
CuSO4.5H2O (50 mg, 0.2 mmol), and sodium ascorbate (80 mg, 0.4 mmol) were added. The 
reaction mixture was then heated to 50 °C and stirred for 16 h. The reaction mixture was then 
concentrated in vacuo and the residue was dissolved in EtOH (25 mL), filtered through Celite®, 
and concentrated in vacuo. The residue was dissolved in water (25 mL), and the aqueous layer 
was washed with CH2Cl2 (2 x 50 mL), filtered through a column of Amberlite
® IR-120 (Na+ 
form, produced by treating the H+ form with 1 M aqueous NaOH solution and then washing 
with water until pH 7), and concentrated in vacuo. The residue was pre-absorbed onto silica 
and purified by flash column chromatography (CH2Cl2:MeOH 8:1) to afford 5-((1’-(2”-
acetamido-2”-deoxy-β-D-glucopyranosyl)-[1’,2’,3’]-triazo-4’-yl)methyloxy)-1-pentene 4.16 
(329 mg, 89%) as a pale yellow oil; [α]D
20 -9 (c, 1.0 in MeOH); υmax (neat) 3406 cm
-1 (OH), 
1656 cm-1 (NHC=O); H (400 MHz, D2O) 1.65 (2H, quin, J 6.9 Hz, CH2CH2CH2), 1.80 (3H, 
s, C(O)CH3), 2.07 (2H, q, J 7.0 Hz, CH2=CHCH2), 3.53 (2H, t, J 6.5 Hz, CH2CH2O), 3.65 - 
3.85 (4H, m, H-3, H-4, H-5 & H-6), 3.93 (1H, dd, J5,6’ 2.0 Hz, J6,6’ 12.1 Hz, H-6’), 4.26 (1H, t, 
J 10.0 Hz, H-2), 4.64 (2H, s, CCH2O), 4.94 - 5.06 (2H, m, CH2=CHCH2), 5.78 - 5.91 (2H, m, 
H-1 & CH2=CHCH2), 8.21 (1H, s, NCH=C); C (100.5 MHz, D2O) 21.6 (q, C(O)CH3), 27.7 (t, 
CH2CH2CH2), 29.4 (t, CH2=CHCH2), 55.2 (d, C-2), 60.4 (t, C-6), 62.3 (t, CCH2O), 69.2 (d, 
C-4), 69.4 (t, CH2CH2O), 73.5 (d, C-3), 78.9 (d, C-5), 86.3 (d, C-1), 114.7 (t, CH2=CH), 123.7 
(d, NCH=C), 138.6 (d, CH2=CHCH2), 144.2 (s, CH=CCH2O), 174.0 (s, C(O)CH3); HRMS 
(ESI-TOF): calcd. for C16H27N4O6
+: 371.1925. Found: 371.1925 (MH+). 
 
 







propene 4.9 (50 mg, 0.15 mmol) and N-[(9-fluorenylmethoxy)carbonyl]-L-cysteine 4.19 
(60 mg, 0.17 mmol) were dissolved in a mixture of sodium acetate buffer (0.7 mL, pH 4.0, 
0.6 M) and tert-butanol (1.3 mL). 2,2-Dimethoxy-2-phenylacetophenone (4.0 mg, 0.016 
mmol) was added, and the reaction mixture was stirred and irradiated in a Rayonet photoreactor 
(wavelength: 254 nm) for 2 h. A further portion of N-[(9-fluorenylmethoxy)carbonyl]-L-
cysteine 4.12 (60 mg, 0.17 mmol) was added, and the reaction mixture was stirred and 
irradiated for a further 2 h. The reaction mixture was then concentrated in vacuo and dissolved 
in anhydrous DMF (4.5 mL). Piperidine (0.5 mL, 6.8 mmol) was added, and the mixture stirred 
for 2 h. The mixture was concentrated in vacuo and the residue was purified by reverse phase 
flash column chromatography to afford S-(3’-((1’’-(2”’-Acetamido-2”’-deoxy-β-D-
glucopyranosyl)-[1’’,2’’,3’’]-triazo-4’’-yl)methyloxy)-1’-propyl)- L-cysteine 4.17 (58 mg, 
74%) as a colourless oil; [α]D
20 -15 (c, 0.9 in water); υmax 3245 cm
-1 (OH), 1628 cm-1 (NC=O); 
H (400 MHz, D2O) 1.80 (3H, s, NHC(O)CH3), 1.86 (2H, quin, J 6.7 Hz, CH2CH2CH2), 2.63 
(2H, t, J 6.8 Hz, CH2CH2S), 2.98 (1H, dd, J 14.9 Hz, J 7.8 Hz, CHCHH’S), 3.09 (2H, dd, 
J 14.9 Hz, J 4.3 Hz, CHCHH’S), 3.61 (2H, t, J 6.1 Hz, OCH2CH2), 3.65 - 3.85 (4H, m, H-3, 
H-4, H-5 & H-6), 3.86 - 3.97 (2H, m, CHCH2 & H-6’), 4.25 (1H, t, J 9.8 Hz, H-2), 4.64 (2H, 
s, CCH2O), 5.84 (1H, d, J1,2 9.8 Hz, H-1), 8.23 (1H, s, NCH=C); C (100.5 MHz, D2O) 21.6 
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(q, NHC(O)CH3), 27.9 (t, CH2CH2S), 28.3 (t, CH2CH2CH2), 32.0 (t, CHCH2S), 53.5 (d, 
CHCH2), 55.3 (d, C-2), 60.3 (t, C-6), 62.4 (t, CCH2O), 68.3 (t, OCH2CH2), 69.2 (d, C-4), 73.4 
(d, C-3), 78.8 (d, C-5), 86.3 (d, C-1), 123.7 (d, NCH=C), 144.1 (s, CH=CCH2), 172.7, 174.0 
(2 x s, 2 x C=O); HRMS (ESI-TOF): calcd. for C17H30N5O8S





Trifluoroacetic acid (0.19 mL, 2.5 mmol) and triisopropylsilane (0.37 mL, 2.5 mmol) were 
added to a solution of N-[(9-fluorenylmethoxy)carbonyl]-S-trityl-L-cysteine 4.18 (293 mg, 
0.5 mmol) in CH2Cl2 (5 mL) under an atmosphere of nitrogen. After 1 h, the reaction was 
concentrated in vacuo. The residue was redissolved in CH2Cl2 (20 mL) and concentrated in 
vacuo, and this process was repeated until a white solid was obtained in order to remove all 
trifluoroacetic acid. The solid was precipitated (CH2Cl2/petrol) to afford N-[(9-
fluorenylmethoxy)carbonyl]-L-cysteine 4.19 (142 mg, 83%) was a white solid; [α]D
20 -25 
(c, 2.0 in DMF) [lit. [α]D
20 -24.8 (c, 2.3 in DMF)]23; υmax (neat) 3310 cm
-1 (NH) 1701 cm-1, 
1688 cm-1 (NC=O & HOC=O); H (400 MHz, DMSO-d6)
23 2.65 - 2.76 (1H, m, CHH’SH), 2.82 
- 2.91 (1H, m, CHH’SH), 4.09 (1H, td, J 8.4 Hz, J 4.3 Hz, CHCH2SH), 4.21 (1H, t, J 7.0 Hz, 
CHCH2O), 4.26 - 4.31 (2H, m, CHCH2O), 7.25 - 7.35 (2H, m, 2 x Ar-H), 7.35 - 7.45 (2H, m, 
2 x Ar-H), 7.66 (1H, d, J 8.6 Hz, NH), 7.71 (2H, d, J 7.4 Hz, 2 x Ar-H), 7.87 (2H, d, J 7.4 Hz, 
2 x Ar-H); C (100.5 MHz, DMSO-d6)
23 25.9 (t, CH2SH), 47.1 (d, CHCH2O), 57.0 (d, 
CHCH2SH), 66.2 (t, CHCH2O), 120.6 (d, Ar-C), 125.7 (d, Ar-C), 127.5 (D, Ar-C), 128.1 (d, 
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Ar-C), 141.2 (s, Ar-C), 144.2 (s, Ar-C), 144.2 (s, Ar-C), 156.5 (s, OC(O)NH), 172.3 (s, 
COOH); HRMS (ESI-TOF): calcd. for C18H17NO4SNa






propene 4.9 (41 mg, 0.12 mmol) and cysteamine hydrochloride (42 mg, 0.36 mmol) were 
dissolved in sodium acetate buffer (2 mL, pH 4.0, 0.2 M). 2,2-Dimethoxy-2-
phenylacetophenone (3.1 mg, 0.012 mmol) was added, and the reaction mixture was stirred 
and irradiated in a Rayonet photoreactor (wavelength: 254 nm) for 6 h. The reaction mixture 
was then concentrated in vacuo and the residue purified by flash column chromatography 
(CH2Cl2:MeOH:NH3 75:25:1) to afford S-(3’-((1’’-(2”’-acetamido-2”’-deoxy-β-D-
glucopyranosyl)-[1’’,2’’,3’’]-triazo-4’’-yl)methyloxy)-1’-propyl)-1-thio-2-aminoethane 4.21 
(31.1 mg, 61%) as a colourless oil; υmax (neat) 3246 cm
-1 (broad, NH & OH), 1649 cm-1 (C=O); 
[α]D
20 -8 (c, 1.6 in MeOH); H (400 MHz, D2O) 1.80 (3H, s, C(O)CH3), 1.85 (2H, quin, 
J 6.7 Hz, OCH2CH2CH2S), 2.61 (2H, t, J 7.2 Hz, OCH2CH2CH2S), 2.82 (2H, t, J 6.7 Hz, 
SCH2CH2NH2), 3.19 (2H, t, J 6.7 Hz, SCH2CH2NH2), 3.61 (2H, t, J 6.1 Hz, OCH2CH2CH2S), 
3.65 - 3.85 (4H, m, H-3, H-4, H-5 & H-6), 3.93 (1H, dd, J5,6’ 1.6 Hz, J6,6’ 12.1, H-6’), 4.25 (1H, 
t, J 9.8 Hz, H-2), 4.65 (2H, s, CCH2O), 5.84 (1H, d, J1,2 9.8 Hz, H-1), 8.23 (1H, s, NCH=C); 
C (100.5 MHz, D2O) 21.6 (q, C(O)CH3), 27.2 (t, OCH2CH2CH2S), 28.1 (t, SCH2CH2NH2), 
28.3 (t, OCH2CH2CH2S), 38.2 (t, SCH2CH2NH2), 55.3 (d, C-2), 60.3 (t, C-6), 62.4 (t, CCH2O), 
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68.3 (t, OCH2CH2CH2S), 69.2 (d, C-4), 73.4 (d, C-3), 78.9 (d, C-5), 86.3 (d, C-1), 123.7 (d, 
NCH=C), 174.0 (s, C(O)CH3); HRMS (ESI-TOF): calcd. for C16H30N5O6S







propene 4.9 (20.5 mg, 0.06 mmol) and γ-L-glutamyl-L-cysteinylglycine 4.22 (18.4 mg, 
0.06 mmol) were dissolved in sodium acetate buffer (1 mL, pH 4.0, 0.2 M). 2,2-Dimethoxy-2-
phenylacetophenone (1.5 mg, 0.006 mmol) was added, and the reaction mixture was stirred 
and irradiated in a Rayonet photoreactor (wavelength: 254 nm) for 4 h. The reaction mixture 
was then concentrated in vacuo and the residue purified by reverse phase flash column 
chromatography (water) to afford S-(3’-((1’’-(2”’-acetamido-2”’-deoxy-β-D-glucopyranosyl)-
[1’’,2’’,3’’]-triazo-4’’-yl)methyloxy)-1’-propyl)-γ-L-glutamyl-L-cysteinylglycine 4.23 
(38.8 mg, quant.) as a colourless oil; [α]D
20 -10 (c, 0.7 in water); υmax 3246 cm
-1 (OH), 
1728 cm-1 (OC=O), 1641 (NHC=O); H (400 MHz, D2O) 1.79 (3H, s, C(O)CH3) 1.84 (2H, 
quin, J 5.9 Hz, CH2CH2CH2), 2.19 (2H, q, J 6.4 Hz, Q-CHCH2), 2.50 - 2.58 (2H, m, CH2CH2S), 
2.58 - 2.65 (2H, m, Q-CCH2), 2.84 (1H, dd, J 13.9 Hz, J 8.8 Hz, C-CHH’), 3.01 (1H, dd, 
J 14.3 Hz, J 4.9 Hz, C-CHH’), 3.60 (1H, t, J 6.1 Hz, OCH2CH2), 3.65 - 3.85 (4H, m, H-3, H-4, 
H-5 & H-6), 3.89 - 4.01 (4H, m, G-CH2, Q-CH & H-6’), 4.25 (1H, t, J 10.0 Hz, H-2), 4.54 (2H, 
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dd, J 8.6 Hz, J 5.1 Hz, C-CH), 4.64 (1H, s, CCH2O), 5.84 (1H, d, J1,2 9.8 Hz, H-1), 8.23 (1H, 
s, NCH=C); C (100.5 MHz, D2O) 25.7 (t, Q-CHCH2), 28.1 (t, CH2CH2S), 28.4 (t, 
CH2CH2CH2), 31.0 (t, Q-CCH2), 32.7 (t, C-CH2), 41.2 (t, G-CH2), 53.0 (d, Q-CH), 53.0 (d, 
C-CH), 55.3 (d, C-2), 60.4 (t, C-6), 62.4 (t, CCH2O), 68.3 (t, OCH2CH2), 69.2 (d, C-4), 73.4 
(d, C-3), 78.8 (d, C-5), 86.3 (d, C-1), 123.7 (d, NCH=C), 172.5, 172.8, 172.9, 174.0, 174.4 
(5 x s, 5 x C=O); HRMS (ESI-TOF): calcd. for C24H40N7O12S







propene 4.10 (20.5 mg, 0.06 mmol) and γ-L-glutamyl-L-cysteinylglycine 4.22 (18.4 mg, 0.06 
mmol) were dissolved in sodium acetate buffer (1 mL, pH 4.0, 0.2 M). 2,2-Dimethoxy-2-
phenylacetophenone (1.5 mg, 0.006 mmol) was added, and the reaction mixture was stirred 
and irradiated in a Rayonet photoreactor (wavelength: 254 nm) for 4 h. The reaction mixture 
was then concentrated in vacuo and the residue purified by reverse phase flash column 
chromatography (water) to afford S-(3’-((1’’-(2”’-acetamido-2”’-deoxy-β-D-
galactopyranosyl)-[1’’,2’’,3’’]-triazo-4’’-yl)methyloxy)-1’-propyl)-γ-L-glutamyl-L-
cysteinylglycine 4.24 (27.2 mg, 70%) as a white solid; [α]D
20 -9 (c, 0.5 in water); υmax 3362 cm
-1 
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(OH), 1637 cm-1 (C=O); H (400 MHz, D2O) 1.77 - 1.88 (5H, m, CH2CH2CH2 & C(O)CH3), 
2.13 (2H, q, J 7.3 Hz, Q-CHCH2CH2), 2.51 (2H, t, J 7.6 Hz, Q-CHCH2CH2), 2.60 (2H, t, 
J 7.2 Hz, CH2CH2S), 2.83 (1H, dd, J 14.1 Hz, J 9.0 Hz, C-CHH’), 3.03 (1H, dd, J 13.9 Hz, 
J 4.9 Hz, C-CHH’), 3.60 (2H, t, J 6.3 Hz, OCH2CH2), 3.72 - 3.77 (3H, m, Q-CH & G-CH2), 
3.79 - 3.84 (2H, m, H-6 & H-6’), 3.94 - 4.02 (2H, m, H-3 & H-5), 4.09 (1H, d, J3,4 2.7 Hz, 
H-4), 4.43 (1H, t, J 10.2 Hz, H-2), 4.54 (1H, dd, J 9.0 Hz, J 4.7 Hz, C-CH), 4.65 (2H, s, 
CCH2O), 5.78 (1H, d, J1,2 9.8 Hz, H-1), 8.27 (1H, s, NCH=C); C (100.5 MHz, D2O) 21.7 (q, 
C(O)CH3), 26.2 (t, Q-CHCH2CH2), 28.1 (t, CH2CH2S), 28.4 (t, CH2CH2CH2), 31.4 (t, 
Q-CHCH2CH2), 32.9 (t, C-CH2), 43.3 (t, G-CH2), 51.9 (d, C-2), 53.1 (d, C-CH), 54.1 (d, 
Q-CH), 60.9 (t, C-6), 62.5 (t, CCH2O), 67.7 (d, C-4), 68.3 (t, OCH2CH2), 70.7 (d, C-3), 78.3 
(d, C-5), 86.8 (d, C-1), 123.6 (d, NCH=C), 144.2 (s, CH=CCH2), 171.9, 173.9, 174.2, 174.8, 
176.1 (5 x s, 5 x C(O)); HRMS (ESI-TOF): calcd. for C24H40N7O12S






3-((1’-β-D-Glucopyranosyl-[1’,2’,3’]-triazo-4’-yl)methyloxy)-1-propene 4.11 (17.0 mg, 
0.06 mmol) and γ-L-glutamyl-L-cysteinylglycine 4.22 (17.0 mg, 0.06 mmol) were dissolved in 
sodium acetate buffer (1 mL, pH 4.0, 0.2 M). 2,2-Dimethoxy-2-phenylacetophenone (1.5 mg, 
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0.006 mmol) was added, and the reaction mixture was stirred and irradiated in a Rayonet 
photoreactor (wavelength: 254 nm) for 4 h. The reaction mixture was then concentrated in 
vacuo and the residue purified by reverse phase flash column chromatography (water) to afford 
S-(3’-((1’’-β-D-glucopyranosyl-[1’’,2’’,3’’]-triazo-4’’-yl)methyloxy)-1’-propyl)-γ-L-
glutamyl-L-cysteinylglycine 4.25 (30 mg, 93%) as a colourless oil; [α]D
20 -23 (c, 1.0 in water); 
υmax 3272 (OH), 1643, 1556 (C(O)N); H (400 MHz, D2O) 1.85 (2H, quin, J 7.0 Hz, 
CH2CH2CH2), 2.13 (2H, q, J 7.0 Hz, Q-CHCH2CH2), 2.50 (2H, t, J 7.0 Hz, Q-CHCH2CH2), 
2.60 (2H, t, J 6.8 Hz, CH2CH2S), 2.82 (1H, dd, J 14.1 Hz, J 9.0 Hz, C-CHH’), 3.03 (1H, dd, 
J 13.9 Hz, J 4.9 Hz, CHH’), 3.57 - 3.81 (9H, m, H-3, H-4, H-5, H-6, G-CH2, Q-CH & 
OCH2CH2), 3.89 (1H, d, J6,6’ 11.0 Hz, H-6’), 3.99 (1H, t, J 9.2 Hz, H-2), 4.54 (1H, dd, J 8.8 Hz, 
J 4.9 Hz, C-CH), 4.67 (2H, s, CCH2O), 5.75 (1H, d, J1,2 9.4 Hz, H-1), 8.26 (1H, s, NCH=C); 
C (100.5 MHz, D2O) 26.2 (t, Q-CHCH2CH2), 28.0 (t, CH2CH2S), 28.4 (t, CH2CH2CH2), 31.4 
(t, Q-CHCH2CH2), 32.9 (t, C-CH2), 43.4 (t, G-CH2), 53.1 (d, C-CH), 54.1 (d, Q-CH), 60.4 (t, 
C-6), 62.6 (t, CCH2O), 68.5 (t, OCH2CH2), 68.9 (d, C-4), 72.2 (d, C-2), 75.9 (d, C-3), 78.8 (d, 
C-5), 87.4 (d, C-1), 124.3 (d, NCH=C), 144.3 (s, NCH=C), 171.9, 174.9, 181.4 (3 x s, 
3 x C(O)); HRMS (ESI-TOF): calcd. for C22H37N6O12S
+: 609.2185. Found: 609.2204 (MH+). 
 
  






3-((1’-β-D-Mannopyranosyl-[1’,2’,3’]-triazo-4’-yl)methyloxy)-1-propene 4.12 (18.1 mg, 
0.06 mmol) and γ-L-glutamyl-L-cysteinylglycine 4.22 (18.1 mg, 0.06 mmol) were dissolved in 
sodium acetate buffer (1 mL, pH 4.0, 0.2 M). 2,2-Dimethoxy-2-phenylacetophenone (1.5 mg, 
0.006 mmol) was added, and the reaction mixture was stirred and irradiated in a Rayonet 
photoreactor (wavelength: 254 nm) for 4 h. The reaction mixture was then concentrated in 
vacuo and the residue purified by reverse phase flash column chromatography (water) to afford 
S-(3’-((1’’-α-D-mannopyranosyl-[1’’,2’’,3’’]-triazo-4’’-yl)methyloxy)-1’-propyl)-γ-L-
glutamyl-L-cysteinylglycine 4.26 (25.2 mg, 74%) as a colourless oil; [α]D
20 -3 (c, 1.0 in water); 
υmax 3217 cm
-1 (OH), 1634 (C=O); H (400 MHz, D2O) 1.84 (2H, quin, J 6.7 Hz, CH2CH2CH2), 
2.13 (3H, q, J 7.3 Hz, Q-CHCH2CH2), 2.51 (3H, t, J 7.8 Hz, Q-CHCH2CH2), 2.60 (2H, t, 
J 7.2 Hz, CH2CH2S), 2.82 (1H, dd, J 13.9 Hz, J 9.2 Hz, C-CHH’), 3.03 (1H, dd, J 14.3 Hz, 
J 4.9 Hz, C-CHH’), 3.25 - 3.34 (1H, m, H-5), 3.65 (2H, t, J 5.9 Hz, OCH2CH2), 3.72 - 3.85 
(6H, m., H-4, H-6, H-6’, Q-CH & G-CH2), 4.13 (1H, dd, J2,3 3.5 Hz, J3,4 9.0 Hz, H-3), 4.53 
(1H, dd, J 8.8 Hz, J 4.9 Hz, C-CH), 4.66 (2H, s, CCH2O), 4.78 - 4.82 (1H, m, H-2), 6.12 (1H, 
s, H-1), 8.20 (1H, s, NCH=C); C (100.5 MHz, D2O) 26.1 (t, Q-CHCH2CH2), 28.0 (t, 
CH2CH2S), 28.3 (t, CH2CH2CH2), 31.4 (t, Q-CHCH2CH2), 32.8 (t, C-CH2), 43.4 (t, G-CH2), 
53.1 (d, C-2), 54.1 (d, Q-CH), 60.4 (t, C-6), 62.5 (t, CCH2O), 66.5 (d, C-4), 68.2 (d, C-2), 68.4 
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(t, OCH2CH2), 70.4 (d, C-3), 76.1 (d, C-5), 86.7 (d, C-1), 124.7 (d, NCH=C), 144.4 (s, 
NCH=C), 171.9, 173.9, 174.8 (3 x s, 3 x C(O)); HRMS (ESI-TOF): calcd. for C22H37N6O12S
+: 






propene 4.14 (16.0 mg, 0.035 mmol) and γ-L-glutamyl-L-cysteinylglycine 4.22 (10.6 mg, 
0.035 mmol) were dissolved in sodium acetate buffer (0.5 mL, pH 4.0, 0.2 M). 2,2-Dimethoxy-
2-phenylacetophenone (0.9 mg, 0.0035 mmol) was added, and the reaction mixture was stirred 
and irradiated in a Rayonet photoreactor (wavelength: 254 nm) for 4 h. The reaction mixture 
was then concentrated in vacuo and the residue purified by HPLC (tR = 20.5 min, column: Luna 
5u C18 (100 Å) column (Phenomenex); gradient: 100% water for 10 min, followed by an 
increase to 40% MeOH over 5 min, then 40% MeOH for 10 min; column oven: 40 °C; flow 
rate: 2 mL/min; detection: UV 210 nm) to afford S-(5’-((1’’-(α-D-glucopyranosyl-(1→4)-β-D-
glucopyranosyl)-[1’’,2’’,3’’]-triazo-4’’-yl)methyloxy)-1’-pentyl)-γ-L-glutamyl-L-
cysteinylglycine 4.27 (20.1 mg, 76%) as a white solid; [α]D +18 (c, 0.7 in water); υmax 3306 cm
-1 
(OH), 1727 cm-1 (HOC=O), 1658 cm-1 (NHC=O); H (400 MHz, D2O) 1.82 (2H, quin, J 6.7 Hz, 
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OCH2CH2CH2S), 2.12 - 2.28 (2H, m, J 7.0 Hz, Q-CHCH2CH2), 2.51 - 2.63 (4H, m, CH2CH2S 
& QCHCH2CH2), 2.81 (1H, dd, J 14.1 Hz, J 8.6 Hz, C-CHH’), 2.98 (1H, dd, J 14.1, 5.5 Hz, 
C-CHH’), 3.31 - 3.39 (1H, m, H-5b), 3.47 (1H, dd, J1,2 3.5 Hz, J2,3 9.8 Hz, H-2b), 3.56 - 3.71 
(8H, m, H-3a, H-5a, H-3b, H-4b, H-6b, H-6’b & OCH2CH2), 3.81 (1H, d, J6,6’ 10.2 Hz, H-6a), 
3.85 - 3.94 (2H, m, H-4a & H-6’a), 3.96 (2H, s, G-CH2), 4.02 (1H, t, J 9.2 Hz, H-2a), 4.06 (1H, 
t, J 6.7 Hz, Q-CH), 4.51 (1H, dd, J 8.4 Hz, J 5.3 Hz, C-CH), 4.64 (2H, s, CCH2O), 4.86 (1H, 
d, J1,2 3.5 Hz, H-1b), 5.73 (1H, d, J1,2 9.4 Hz, H-1a), 8.23 (1H, s, NCH=C); C (100.5 MHz, 
D2O) 25.4 (t, Q-CHCH2CH2), 28.1 (t, CH2CH2S), 28.4 (t, Q-CHCH2CH2), 30.8 (t, 
Q-CHCH2CH2), 32.7 (t, C-CH2), 41.0 (d, G-CH2), 52.1 (t, Q-CH), 53.0 (d, C-CH), 60.0 (t, 
C-6b), 62.5 (t, CCH2O), 65.9 (t, C-6a), 68.5 (t, OCH2CH2), 69.0 (d, C-5a), 69.2 (d, C-5b), 71.3 
(d, C-2b), 71.6 (d, C-4b), 72.0 (d, C-2a), 72.9 (d, C-3b), 76.1 (d, C-3a), 77.5 (d, C-4a), 87.3 (d, 
C-1a), 98.0 (d, C-1b), 124.5 (d, NCH=C), 144.2 (s, NCH=CCH2), 171.4, 172.7, 172.8, 174.2 
(4 x s, 4 x C(O)); HRMS (ESI-TOF): calcd. for C28H47N6O17S








butene 4.26 (21.4 mg, 0.06 mmol) and γ-L-glutamyl-L-cysteinylglycine (18.4 mg, 0.06 mmol) 
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were dissolved in sodium acetate buffer (1 mL, pH 4.0, 0.2 M). 2,2-Dimethoxy-2-
phenylacetophenone (1.5 mg, 0.006 mmol) was added, and the reaction mixture was stirred 
and irradiated in a Rayonet photoreactor (wavelength: 254 nm) for 4 h. The reaction mixture 
was then concentrated in vacuo and the residue purified by reverse phase flash column 
chromatography (water) to afford S-(4’-((1’’-(2”’-acetamido-2”’-deoxy-β-D-
galactopyranosyl)-[1’’,2’’,3’’]-triazo-4’’-yl)methyloxy)-1’-butyl)-γ-L-glutamyl-L-
cysteinylglycine 4.28 (24.9 mg, 63%) as a white solid; [α]D
20 -16 (c, 1.1 in water); 
υmax 3246 cm
-1 (OH), 1637 cm-1 (NHC=O); H (400 MHz, D2O) 1.54 - 1.69 (4H, m, 
CH2CH2CH2CH2 & CH2CH2CH2CH2), 1.80 (3H, s, C(O)CH3), 2.14 (2H, q, J 7.0 Hz, 
Q-CHCH2CH2), 2.47 - 2.59 (4H, m, Q-CHCH2CH2 & CH2CH2S), 2.83 (1H, dd, J 13.9 Hz, 
J 9.2 Hz, C-CHH’), 3.04 (1H, dd, J 13.9 Hz, J 4.9 Hz, C-CHH’), 3.49 - 3.57 (2H, m, 
OCH2CH2), 3.65 - 3.85 (7H, m, H-3, H-4, H-5, H-6, Q-CH & G-CH2), 3.93 (1H, d, 
J6,6’ 12.1 Hz, H-6’), 4.25 (1H, t, J 10.0 Hz, H-2), 4.54 (1H, dd, J 9.0 Hz, J 4.7 Hz, C-CH), 4.64 
(2H, s, CCH2O), 5.84 (1H, d, J1,2 9.8 Hz, H-1), 8.22 (1H, s, NCH=C); C (100.5 MHz, D2O) 
21.6 (q, C(O)CH3), 25.2 (t, CH2CH2CH2O), 26.2 (t, Q-CHCH2CH2), 27.5 (t, OCH2CH2CH2), 
31.1 (t, CH2CH2S), 31.4 (t, Q-CHCH2CH2), 32.7 (t, C-CH2), 43.3 (t, G-CH2), 53.1 (d, C-CH), 
54.1 (d, Q-CH), 55.3 (d, C-2), 60.4 (t, C-6), 62.4 (t, CCH2O), 69.2 (d, C-4), 69.5 (t, OCH2CH2), 
73.5 (d, C-3), 78.9 (d, C-5), 86.3 (d, C-1), 123.7 (d, NCH=C), 144.2 (s, CH=CCH2), 171.9, 
173.9, 174.0, 174.9, 176.1 (5 x s, 5 x C(O)); HRMS (ESI-TOF): calcd. for C25H42N7O12S
+: 
664.2607. Found: 664.2623 (MH+). 
 
  







pentene 4.27 (22.3 mg, 0.06 mmol) and γ-L-glutamyl-L-cysteinylglycine (18.4 mg, 0.06 mmol) 
were dissolved in sodium acetate buffer (1 mL, pH 4.0, 0.2 M). 2,2-Dimethoxy-2-
phenylacetophenone (1.5 mg, 0.006 mmol) was added, and the reaction mixture was stirred 
and irradiated in a Rayonet photoreactor (wavelength: 254 nm) for 4 h. The reaction mixture 
was then concentrated in vacuo and the residue purified by reverse phase flash column 
chromatography (water) to afford S-(5’-((1’’-(2”’-acetamido-2”’-deoxy-β-D-
galactopyranosyl)-[1’’,2’’,3’’]-triazo-4’’-yl)methyloxy)-1’-pentyl)-γ-L-glutamyl-L-
cysteinylglycine 4.29 (30.4 g, 75%) as a white solid; [α]D
20 -15 (c, 1.0 in water); υmax 3245 cm
-1 
(OH), 1637 cm-1 (C=O); H (400 MHz, D2O) 1.38 (2H, quin, J 8.0 Hz, OCH2CH2CH2), 1.51 - 
1.63 (4H, m, OCH2CH2CH2 & CH2CH2CH2S), 1.81 (3H, s, NHC(O)CH3), 2.15 (2H, q, 
J 7.2 Hz, Q-CHCH2CH2), 2.49 - 2.61 (4H, m, Q-CHCH2CH2 & CH2CH2S), 2.85 (1H, dd, 
J 14.1 Hz, J 9.0 Hz, C-CHH’), 3.06 (1H, dd, J 14.1 Hz, J 4.7 Hz, C-CHH’), 3.53 (2H, t, 
J 6.7 Hz, OCH2CH2), 3.66 - 3.86 (7H, m, H-3, H-4, H-5, H-6, G-CH2 & Q-CH), 3.94 (1H, d, 
J 12.1 Hz, H-6’), 4.27 (1H, t, J 10.0 Hz, H-2), 4.56 (1H, dd, J 8.6 Hz, J 4.7 Hz, C-CH), 4.65 
(2H, s, CCH2O), 5.85 (1H, d, J1,2 9.8 Hz, H-1), 8.23 (1H, s, NCH=C); C (100.5 MHz, D2O) 
21.6 (q, NHC(O)CH3), 24.3 (t, OCH2CH2CH2), 26.2 (t, Q-CHCH2CH2), 28.0, 28.2 (2 x t, 
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OCH2CH2CH2 & CH2CH2CH2S), 31.4, 31.4 (2 x t, CH2CH2S & Q-CHCH2CH2), 32.8 (t, 
C-CH2), 43.3 (t, G-CH2), 53.1 (d, C-CH), 54.1 (d, Q-CH), 55.3 (d, C-2), 60.4 (t, C-6), 62.3 (t, 
CCH2O), 69.3 (d, C-4), 69.9 (t, OCH2CH2), 73.5 (d, C-3), 78.9 (d, C-5), 86.3 (d, C-1), 123.7 
(d, NCH=C), 144.3 (s, CH=CCH2), 172.0, 173.9, 174.0, 174.9, 176.1 (5 x s, 5 x C(O)); HRMS 
(ESI-TOF): calcd. for C26H44N7O12S
+: 678.2763. Found: 678.2782 (MH+). 
 
MUC1-GalNAc Neoglycopeptide 4.31 
 
3-((1’-(2”-Acetamido-2”-deoxy-β-D-galactopyranosyl)-[1’,2’,3’]-triazo-4’-yl)methyloxy)-1-
propene 4.10 (1.7 mg, 5.0 µmol) and modified MUC1 peptide 4.30 (0.9 mg, 0.5 µmol) were 
dissolved in sodium acetate buffer (50 µL, pH 4.0, 0.2 M). 2,2-Dimethoxy-2-
phenylacetophenone (0.1 mg, 0.4 µmol) was added, and the reaction mixture was stirred and 
irradiated in a Rayonet photoreactor (wavelength: 254 nm) for 4 h, and then analysed by HPLC 
(column: Prodigy 5u ODS3 (100 Å) column (Phenomenex); gradient: 5% MeCN in water for 
5 min, followed by an increase to 25% MeCN over 20 min; column oven: 40 °C; flow rate: 
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0.5 mL/min; detection: UV 210 nm) to reveal the presence of MUC1-GalNAc neoglycopeptide 
4.31 (80%); tR = 19.1 min; HRMS (ESI-TOF): calcd. for C93H148N29O33S
+: 2231.0510. Found: 
2231.0557 (MH+). 
 
Sialoglycan-linker conjugate 4.33 
Sialoglycan 4.32 (5.0 mg, 2.5 µmol) and triethylamine (24.4 µL, 175 µmol) were dissolved in 
D2O/MeCN (4:1, 90 µL) and the solution cooled to 0 °C. 2-Azido-1,3-dimethylimidazolinium 
hexafluorophosphate 4.7 (21.4 mg, 75 µmol) was added and the mixture was stirred for 6 h. 
The reaction mixture was then acidified to pH 2 by addition of aqueous HCl over 10 min (1 M, 
150 µL). After 20 min the reaction mixture was neutralised by the addition of NaHCO3 (sat. 
aqueous soln., 150 µL). The mixture was lyophilised and the residue was dissolved in 
tert-butanol/water (2:1, 150 µL) and 3-allyloxy-1-propyne 4.3 (5.6 µL, 50 µmol), CuSO4.5H2O 
(1.2 mg, 5 µmol), and sodium ascorbate (2.0 mg, 10 µmol) were added. The reaction mixture 
was then heated to 50 °C and stirred for 40 h. The reaction was then filtered and the mixture 
purified by HPLC (tR = 14.5 min; column: XBridge
® Glycan BEH Amide 3.5µm (130 Å) 
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column; gradient: 10% water in MeCN for 7 min, followed by an increase to 40% water over 
5 min, followed by 40% water in MeCN for 5 min; column oven: 40 °C; flow rate: 1 mL/min; 
detection: UV 210 nm) to afford sialoglycan-linker conjugate 4.33 (5.0 mg, 94%) as a white 
solid; [α]D
20 -10 (c, 0.25 in water); H (400 MHz, D2O) 4.05 (2H, d, J 5.9 Hz, CH2=CHCH2), 
4.67 (2H, s, NCH=CCH2), 5.26 (1H, d, JZ 10.2 Hz, CHEHZ=CH), 5.32 (1H, d, JE 17.2 Hz, 
CHEHZ=CH), 5.82 - 6.01 (2H, m, CH2=CH & H-1), 8.24 (1H, m, NCH=C); HRMS (ESI-TOF): 
calcd. for C82H133N8O57
+: 2141.7749. Found: 2141.7770 (MH+). 
 
MUC1-GlcNAc Neoglycopeptide 4.40 
 
3-((1’-(2”-Acetamido-2”-deoxy-β-D-glucopyranosyl)-[1’,2’,3’]-triazo-4’-yl)methyloxy)-1-
propene 4.9 (0.45 mg, 0.13 µmol) and modified MUC1 peptide 4.30 (0.25 mg, 0.0.13 µmol) 
were dissolved in sodium acetate buffer (15 µL, pH 4.0, 0.2 M). 2,2-Dimethoxy-2-
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phenylacetophenone (33 µg, 0.13 µmol, added as a solution in 1 µL DMF) was added, and the 
reaction mixture was stirred and irradiated in a Rayonet photoreactor (wavelength: 254 nm) for 
4 h, and then analysed by HPLC (column: Jupiter 5u C4 (300 Å) column (Phenomenex); 
gradient: 5% MeCN in water for 5 min, followed by an increase to 25% MeCN over 20 min; 
column oven: 40 °C; flow rate: 0.5 mL/min; detection: UV 210 nm) to reveal the presence of 
MUC1-GlcNAc neoglycopeptide 4.35 (77%); tR = 16.0 min; HRMS (ESI-TOF): calcd. for 
C93H148N29O33S
+: 2231.0510. Found: 2231.0532 (MH+). 
 
Sialoglycan oxazoline 4.4124 
 
Sialoglycan 4.32 (5.0 mg, 2.5 µmol) and triethylamine (35 µL, 250 µmol) were dissolved in 
water (100 µL) and the solution cooled to 0 °C. 2-Chloro-1,3-dimethylimidazolinium chloride 
2.1 (12.7 mg, 75 µmol) was added and the mixture was stirred for 6 h. The reaction was then 
purified by HPLC (tR = 14.5 min; column: XBridge
® Glycan BEH Amide 3.5µm (130 Å) 
column; gradient: 10% water in MeCN for 7 min, followed by an increase to 40% water over 
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5 min, followed by 40% water in MeCN for 5 min; column oven: 40 °C; flow rate: 1 mL/min; 
detection: UV 210 nm) to afford sialoglycan oxazoline 4.41 (3.1 mg, 63%) as a white solid; 
H (400 MHz, D2O) 2.01 (3H, s, CH3), 2.04 (12H, s, 4 x CH3), 4.94 (1H, s, 1 x H-1), 5.10 (1H, 
s, 1 x H-1), 6.07 (1H, d, J1,2 7.0 Hz, H-1a); HRMS (ESI-TOF): calcd. for C76H124N5O56
+: 
2002.7003. Found: 2002.7037 (MH+). 
 
MUC1-Sialoglycan Neoglycopeptide 4.4225 
 
 
MUC1-GlcNAc Neoglycopeptide 4.40 (0.2 mg, 0.1 µmol) and sialoglycan oxazoline 4.41 
(0.8 mg, 0.4 µmol) were dissolved in DMSO (4 µL). The mixture was heated to 37 °C and 
Endo M N175Q (10 mU, solution in sodium phosphate buffer (10 µL, pH 6.5, 0.1 M)) was 
added and the reaction was heated at 37 °C. Analysis by HPLC (column: Jupiter 5u C4 (300 
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Å) column (Phenomenex); gradient: 5% MeCN in water for 5 min, followed by an increase to 
25% MeCN over 20 min; column oven: 40 °C; flow rate: 0.5 mL/min; detection: UV 210 nm) 
indicated complete reaction after 1 h, and the presence of MUC1-sialoglycan neoglycopeptide 
4.42 (40%); tR = 15.1 min; HRMS (ESI-TOF): calcd. for C169H271N34O89S
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Experimental section for Chapter 5 
2-Nitro-N-(2-hydroxyethyl)aniline 5.426 
 
1-Chloro-2-nitrobenzene (0.79 g, 5 mmol) was dissolved in DMSO (10 mL) containing K2CO3 
(0.82 g, 6 mmol) under an atmosphere of nitrogen. Ethanolamine (0.48 mL, 15 mmol) was 
added and the reaction refluxed for 16 h, at which point t.l.c. (CH2Cl2:ethyl acetate, 2:1) 
indicated complete consumption of starting material (Rf 0.9) and formation of a single product 
(Rf 0.6). The reaction mixture was then cooled and diluted with water (50 mL) and then brine 
(50 mL). The resulting solution was extracted with Et2O (3 x 50 mL) and the combined organic 
extracts were dried (MgSO4), filtered and concentrated in vacuo. The residue was pre-absorbed 
onto silica and purified by flash column chromatography (CH2Cl2:ethyl acetate, 2:1) to afford 
2-nitro-N-(2-hydroxyethyl)aniline 5.4 (0.53 g, 58%) as an orange solid; m.p. 68-70 °C (EtOH) 
[lit. 71-73 °C (EtOH)]27; δH (400 MHz, CDCl3)
26 3.49 (2H, q, J 5.5 Hz, NHCH2CH2OH), 3.93 
(2H, t, J 5.5 Hz, NHCH2CH2OH), 6.64 (1H, t, J 7.8 Hz, Ar-H), 6.88 (1H, d, J 8.6 Hz, Ar-H), 
7.42 (1H, t, J 8.2 Hz, Ar-H), 8.13 (1H, d, J 8.6 Hz, Ar-H); δC (100.5 MHz, CDCl3)
26 45.0 (t, 
NHCH2CH2OH), 60.8 (t, NHCH2CH2OH), 113.8 (d, Ar-C), 115.6 (d, Ar-C), 126.9 (d, Ar-C), 
132.1(s, Ar-C), 136.3 (d, Ar-C), 145.5 (s, Ar-C); HRMS (ESI-TOF): calcd. for C8H11O3N2
+: 




2-Nitro-N-(2-hydroxyethyl)aniline 5.4 (1.00 g, 5.49 mmol) and 10% Pd on carbon (0.92 g) 
were dissolved in MeOH (20 mL) under an atmosphere of nitrogen. The mixture was cooled 
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to 0 °C and ammonium formate (1.73 g, 27.4 mmol) was added. The reaction was then warmed 
to room temperature and stirred for 1 h. At this point t.l.c. (CH2Cl2:ethyl acetate, 2:1) showed 
complete consumption of starting material (Rf 0.6) and formation of a single product (Rf 0.1). 
The reaction mixture was then filtered through Celite®, washing with MeOH. The filtrate was 
concentrated in vacuo. Brine (25 mL) was added and the mixture was extracted with CH2Cl2 
(3 x 20 mL). The organic extracts were combined, dried (MgSO4), filtered and concentrated in 
vacuo to afford 2-((2-hydroxyethyl)amino)aniline 5.5 (0.55 g, 66%) as a white solid; δH (400 
MHz, DMSO-d6)
26 3.07 (2H, q, J 5.9 Hz, NHCH2CH2OH), 3.59 (2H, q, J 5.6 Hz, 
NHCH2CH2OH), 4.30 (1H, m, OH), 4.40 (2H, s, NH2), 4.66 (1H, t, J 5.6 Hz, NH), 6.38-6.55 
(4H, m, 4 x Ar-H). 
 
1,10-Ethyleneisoalloxazinium chloride 5.726 
 
2-((2-Hydroxyethyl)amino)aniline 5.5 (0.50 g, 3.28 mmol) was dissolved in glacial acetic acid 
(10 mL). The resulting solution was heated to 50 °C in the dark and alloxan monohydrate 5.6 
(0.63 g, 3.94 mmol) was added, followed by boric acid (0.243 g, 3.94 mmol). The reaction was 
stirred for 16 h and then allowed to cool. The resulting precipitate was filtered off, washed with 
CH2Cl2 and dried under vacuum. The solid was then placed in the dark under an atmosphere 
of nitrogen. Thionyl chloride (7.5 mL) was added gradually, with constant stirring. The solution 
was then heated to 50 °C and stirred for 16 h. After this time the reaction was cooled, and the 
precipitate filtered off and washed with CH2Cl2 (12.5 mL). The crude product was dissolved 
in the minimum amount of 98% formic acid and then precipitated by the addition of Et2O to 
afford 1,10-ethyleneisoalloxazinium chloride 5.7 (0.29 g, 32%) as a brown solid; 
Chapter 6: Experimental 
288 
 
m.p. 238-240 °C (decomp.) [lit. 216-219 °C]26; δH (400 MHz, D2O)
26 4.77 (2H, t, J 9.6 Hz, 
CH2), 5.43 (2H, t, J 9.4 Hz, CH2), 8.03-8.13 (2H, m, 2 x Ar-H), 8.33 (1H, t, J 7.8 Hz, Ar-H), 
8.48 (1H, d, J 8.6 Hz, Ar-H); δC (100.5 Hz, D2O) 45.0 (t, CH2), 51.2 (t, CH2), 117.1 (d, Ar-C), 
129.9 (s, Ar-C), 132.1 (d, Ar-C), 132.7 (d, Ar-C), 140.6 (d, Ar-C), 140.8 (s, Ar-C), 143.5 (s, 
Ar-C), 159.0 (s, Ar-C); HRMS (ESI-TOF): calcd. for C12H9O2N4





NaOMe (0.54 g, 10 mmol) was added to a stirred solution of p-tolyl-2,3,4,6-O-acetyl-1-thio-
β-D-glucopyranoside 5.8 (6.82 g, 15 mmol) in MeOH (70 mL). After 1, h t.l.c. (ethyl 
acetate:MeOH 9:1) indicated complete consumption of starting material (Rf 0.9) and formation 
of a single product (Rf 0.3). Amberlite
® IR-120 (H+) resin was added and the mixture stirred 
for 15 min until the pH was neutral. The mixture was then filtered and concentrated in vacuo. 
The residue was pre-absorbed onto silica and purified by flash column chromatography (ethyl 
acetate:MeOH 9:1) to afford p-tolyl-1-thio-β-D-glucopyranoside 5.9 (3.07 g, 72%) as a white 
solid; m.p. 147-148 °C (EtOH) [lit. 147-148 °C (EtOH)]28; [α]D
20 -45 (c, 1.0 in MeOH) 
[lit. [α]D
20 -48 (c, 1.0 in MeOH)]29 ; δH (400 MHz, DMSO-d6)
29 2.26 (3H, s, CH3), 2.95-3.09 
(2H, m, H-2 & H-4), 3.13-3.22 (2H, m, H-3 & H-5), 3.42 (1H, dt, J6,6’ 11.7 Hz, J 5.6 Hz, H-6), 
3.66 (1H, dd, J6,6’ 11.7 Hz, J6’,OH-6 5.5 Hz), 4.50 (2H, m, H-1 & OH-6), 4.92 (1H, d, 
J4,OH-4 5.1 Hz, OH-4), 5.03 (1H, d, J3,OH-3 4.7 Hz, OH-3), 5.19 (1H, d, J2,OH-2 5.9 Hz, OH-2), 
7.11 (2H, d, J 8.2 Hz, 2 x Ar-H), 7.36 (2H, d, J 7.8 Hz, 2 x Ar-H); δC (100.5 MHz, DMSO-d6) 
21.0 (q, CH3), 61.5 (t, C-6), 70.3 (d, C-4), 72.8 (d, C-2), 78.6 (d, C-3), 81.4 (d, C-5), 87.9 (d, 
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C-1), 129.9 (d, Ar-C), 131.0 (d, Ar-C), 131.3 (s, Ar-C), 136.5 (s, Ar-C); HRMS (ESI-TOF): 
calcd. for C13H18O5SNa




p-Tolyl-1-thio-β-D-glucopyranoside 5.9 (0.858 g, 3 mmol) was dissolved in MeOH (8.1 mL). 
1,10-Ethyleneisoalloxazinium chloride 5.7 (0.0417 g, 0.15 mmol) was added followed by H2O2 
(0.21 mL, 50% w/w in water, 3.6 mmol), and the reaction was stirred for 6 h. The reaction 
mixture was concentrated in vacuo and the residue was pre-absorbed onto Florisil® and purified 
by flash column chromatography (CH2Cl2:MeOH 7:1) to afford p-tolyl-1-sulfinyl-β-D-
glucopyranoside 5.10 (0.669 g, 74%) as a pale orange solid (1:0.8 mixture of diastereoisomers); 
m.p. 70-71 °C (MeOH); υmax (neat) 1011 cm
-1 (S=O) δH (400 MHz, DMSO-d6) 2.35 (5.4H, s, 
CH3 a & CH3 b), 2.86 (0.8H, m, H-3a), 2.97 (1H, m, H-5b), 3.05-3.12 (1.8H, m, H-2a & H-4b), 
3.13-3.29 (2.6H, m, H-4a, H-5a & H-3b), 3.29-3.45 (2.8H, m, H-6a, H-6b & H-6’b), 3.49 (1H, 
m, H-2b), 3.64 (0.8H, m, H-6’a), 3.90 (1H, d, J1,2 9.8 Hz, H-1b), 4.09 (1H, t, J 5.5 Hz, OH-6b), 
4.3 (0.8H, d, J1,2 9.4 Hz, H-1a), 4.47 (0.8H, t, J 5.7 Hz, OH-6a), 4.95 (1.8H, d, J 5.1 Hz, OH-3a 
& OH-4b), 5.05 (0.8H, d, J 5.1 Hz, OH-4a), 5.10 (0.8H, d, J 5.5 Hz, OH-2a), 5.15 (1H, d, 
J 5.5 Hz, OH-3b), 5.68 (1H, d, J 5.9 Hz, OH-2b), 7.32 (3.6H, d, J 7.8 Hz, 2 x Ar-Ha & 2 x 
Ar-Hb), 7.52 (2H, d, J 7.8 Hz, 2 x Ar-Hb), 7.55 (1.6H, d, J 7.8 Hz, 2 x Ar-Ha); δC (100.5 MHz, 
DMSO-d6) 21.4 (q, CH3 a & CH3 b), 61.2 (t, C-6b), 61.3 (t, C-6b), 69.0 (d, C-2b), 69.8 (d, C-2a), 
69.9 (d, C-3a), 69.9 (d, C-4b), 78.1 (d, C-5a), 78.3 (d, C-3b), 81.7 (d, C-5b), 82.0 (d, C-4a), 93.6 
(d, C-1b), 94.6 (d, C-1a), 126.0 (d, 2 x Ar-Ca), 126.4 (d, 2 x Ar-Cb), 129.5 (d, 2 x Ar-Ca), 129.7 
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(d, 2 x Ar-Cb), 137.4 (s, Ar-Ca), 138.0 (s, Ar-Cb), 140.9 (s, Ar-Cb), 141.2 (s, Ar-Ca); HRMS 
(ESI-TOF): calcd. for C13H19O6S




p-Tolyl-1-thio-β-D-glucopyranoside 5.9 (2.86 g, 10 mmol) was dissolved in anhydrous DMF 
(35 mL) under an atmosphere of nitrogen. The solution was cooled to 0 °C and NaH (60% 
dispersion in mineral oil, 3.2 g, 80 mmol) was slowly added to the reaction mixture, followed 
by portionwise addition of benzyl bromide (7.2 mL, 60 mmol). The reaction mixture was then 
warmed to room temperature and stirred for 16 h, at which point t.l.c. (petrol:ethyl acetate 8:1) 
indicated complete consumption of starting material (Rf 0), and the formation of a single 
product (Rf 0.4). MeOH (30 mL) was added slowly to quench the reaction. The reaction mixture 
was concentrated in vacuo, and the residue was dissolved in Et2O (100 mL) and washed with 
water (30 mL). The aqueous layer was extracted with Et2O (2 x 30 mL) and the combined 
organic extracts were washed with brine (40 mL), dried (MgSO4), filtered and concentrated in 
vacuo. The residue was pre-absorbed onto silica and purified by flash column chromatography 
(petrol:ethyl acetate 8:1) to afford p-tolyl-2,3,4,6-O-benzyl-1-thio-β-D-glucopyranoside 5.11 
(5.13 g, 79%) as a colourless solid; m.p. 79-80 °C (EtOH) [lit. 78-79 °C]30; [α]D
20 -2.5 (c, 1.0 
in CHCl3) [lit. [α]D
20 -1.8 (c, 1.0 in CHCl3)]
30; δH (400MHz, CDCl3) 2.32 (3H, s, CH3), 3.50 
(2H, m, H-2 & H-3), 3.61-3.83 (5H, m, H-1, H-4, H-5, H-6 & H-6’), 4.52-4.65 (4H, m, H-1 & 
3 x CHH’Ph), 4.75 (1H, d, J 10.2 Hz, CHH’Ph), 4.81-4.95 (4H, m, 4 x CHH’Ph), 7.05 (2H, d, 
J 7.8 Hz, Ar-H), 7.19-7.45 (20H, m, 20 x Ar-H), 7.51 (2H, d, J 8.2 Hz, Ar-H); δC (100.5 MHz, 
CDCl3) 21.1 (q, CH3), 69.1 (t, C-6), 73.4 (t, CH2Ph), 75.0 (t, CH2Ph), 75.4 (t, CH2Ph), 75.8 (t, 
Chapter 6: Experimental 
291 
 
CH2Ph), 77.8 (d, C-4), 79.1 (d, C-2), 80.8 (d, C-2), 86.8 (d, C-5), 87.8 (d, C-1), 127.5, 127.7, 
127.7, 127.8, 127.8, 127.9, 128.2, 128.3, 128.4, 128.4, 129.6, 132.7, 137.7, 138.1, 138.1, 138.4, 
138.4, (30 x Ar-C); HRMS (ESI-TOF): calcd. for C41H42O5SNa





1,4-Dichloro-2-nitrobenzene 5.14 (24 g, 125 mmol) was dissolved in DMSO (250 mL) 
containing K2CO3 (20.5 g, 150 mmol) under an atmosphere of nitrogen. Ethanolamine (12 mL, 
375 mmol) was added and the reaction was refluxed for 16 h, at which point t.l.c. (CH2Cl2:ethyl 
acetate, 2:1) indicated complete consumption of starting material (Rf 0.9) and formation of a 
single product (Rf 0.6). The reaction mixture was then cooled and diluted with water (250 mL) 
and then brine (250 mL). The resulting solution was extracted with Et2O (3 x 250 mL) and the 
combined organic extracts were dried (MgSO4), filtered and concentrated in vacuo. The residue 
was crystallised from toluene to afford 2-nitro-4-chloro-N-(2-hydroxyethyl)aniline 5.15 
(12.30 g, 45%) as an orange solid; m.p. 105-107 °C (toluene) [lit. 107.5 °C (n-butanol)]31; 
δH (400 MHz, CDCl3) 3.49 (2H, t, J 5.1 Hz, NHCH2CH2OH), 3.94 (2H, t, J 5.5 Hz, 
NHCH2CH2OH), 6.86 (1H, d, J 9.4 Hz, Ar-H), 7.38 (1H, d, J 9 Hz, Ar-H), 8.16 (1H, s, Ar-H); 
δC (100.5 MHz, CDCl3) 45.0 (t, NHCH2CH2OH), 60.9 (t, NHCH2CH2OH), 115.2 (d, Ar-C), 
120.4 (s, Ar-C), 126.0 (d, Ar-C), 136.3 (d, Ar-C), 144.1 (s, Ar-C), 181.1 (s, Ar-C); HRMS 
(ESI-TOF): calcd. for C8H10ON2Cl
+: 217.0374. Found: 217.0373 (MH+). 
 
  





2-Nitro-4-chloro-N-(2-hydroxyethyl)aniline 5.15 (1.05g, 5 mmol) and tin (1.78 g, 15 mmol) 
were dissolved in water (15 mL) under an atmosphere of nitrogen. The solution was then heated 
to 100 °C and conc. HCl (9 mL) was added dropwise. The reaction was then cooled to 5 °C 
and stirred for 0.5 h. The pH was then increased to above 7 by the addition of 50% aqueous 
NaOH (5 mL) and the mixture was extracted with ethyl acetate (3 x 15 mL). The combined 
organic extracts were dried (MgSO4), filtered and concentrated in vacuo to afford 2-((2-
hydroxyethyl)amino)-5-chloroaniline 5.16 (0.9196 g, 99%) as a pale pink solid; δH (400 MHz, 
DMSO-d6) 3.05 (2H, t, J 5.9 Hz, NHCH2CH2OH), 3.57 (2H, t, J 5.9 Hz, NHCH2CH2OH), 6.37 
(1H, m, Ar-H), 6.46 (1H, m, Ar-H), 6.54 (1H, m, Ar-H). 
 










2-((2-Hydroxyethyl)amino)-5-chloroaniline 5.16 (9.89 g, 53 mmol) was dissolved in glacial 
acetic acid (160 mL). The resulting solution was heated to 50 °C in the dark and alloxan 
monohydrate 5.6 (10.2 g, 63.8 mmol) was added, followed by boric acid (3.93 g, 63.7 mmol). 
The reaction was stirred for 16 h and then allowed to cool. The resulting precipitate was filtered 
off, washed with CH2Cl2 and dried under vacuum. The solid was then placed in the dark under 
an atmosphere of nitrogen. Thionyl chloride (120 mL) was added gradually, with constant 
stirring. The solution was then heated to 50 °C and stirred for 16 h. After this time the reaction 
was cooled, and the precipitate filtered off and washed with CH2Cl2 (200 mL). The crude 
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product was dissolved in the minimum amount of 98% formic acid and then precipitated by 
the addition of Et2O to afford 7-chloro-1,10-ethyleneisoalloxazinium chloride 5.17 (15.43 g, 
94%) as a yellow solid; m.p. 170-200 °C (decomp.), HRMS (ESI-TOF): calcd. for 
C12H8O2N4Cl
+: 275.0336. Found: 275.0327 (M+). 
 
Ethyl 2,3,4,6-acetyl-1-thio-β-D-glucopyranoside 5.1932 
 
1,2,3,4,6-Penta-O-acetyl-β-D-glucopyranose 5.18 (5.86 g, 15 mmol) was dissolved in CH2Cl2 
(35 mL) and the resulting solution was cooled to 0 °C. Ethanethiol (1.98 mL, 27.5 mmol) was 
added, followed by dropwise addition of BF3.OEt2 (3.39 mL, 27.5 mmol) with constant stirring. 
The reaction was then warmed to room temperature, and after 2 h t.l.c. (petrol:Et2O 1:1) 
indicated complete consumption of starting material (Rf 0.2) and the formation of a single 
product (Rf 0.3). The reaction mixture was diluted with CH2Cl2 (40 mL), washed with aqueous 
NaHCO3 (sat. aqueous soln., 3 x 40 mL), followed by brine (2 x 20 mL) and the organic layer 
was then dried (MgSO4), filtered and concentrated in vacuo. The resulting solid was 
recrystallised from the minimum amount of hot EtOH to afford ethyl 2,3,4,6-acteyl-1-thio-β-
D-glucopyranoside 5.19 (3.67 g, 63%) as a colourless crystalline solid; m.p. 79-80 °C (EtOH) 
[lit: 81-82 °C (EtOH)]33; [α]D
20 -28 (c, 1.0 in CHCl3) [lit. [α]D
20 -27.1 (c, 1.0 in CDCl3)]
34; 
δH (400 MHz, CDCl3)
33 1.24 (3H, t, J 7.4 Hz, CH2CH3), 1.98 (3H, s, C(O)CH3), 2.00 (3H, s, 
C(O)CH3), 2.03 (3H, s, C(O)CH3), 2.05 (3H, s, C(O)CH3), 2.68 (2H, m, CH2CH3), 3.69 (1H, 
m, H-5), 4.11 (1H, m, H-6), 4.22 (1H, m, H-6’), 4.47 (1H, d, J1,2 10.2 Hz, H-1), 5.00 (1H, t, 
J 9.5 Hz, H-2), 5.05 (1H, t, 9.5 Hz, H-4), 5.20 (1H, t, J 9.4 Hz, H-3); δC (100.5 MHz, CDCl3) 
14.8 (q, CH2CH3), 20.5 (q, C(O)CH3), 20.6 (q, C(O)CH3), 20.7 (q, C(O)CH3), 20.7 (q, 
C(O)CH3), 24.1 (t, CH2CH3), 62.1 (t, C-6), 68.3 (d, C-4), 69.8 (d, C-2), 73.9 (d, C-3), 75.8 (d, 
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C-5), 83.5 (d, C-1), 169.3 (s, C(O)CH3), 169.4 (s, C(O)CH3),170.1 (s, C(O)CH3), 170.6 (s, 
C(O)CH3); HRMS (ESI-TOF): calcd. for C16H24O9SNa
+: 415.1033. Found: 415.1035 (MNa+). 
 
Phenyl 2,3,4,6-acetyl-1-thio-β-D-glucopyranoside 5.2035 
 
1,2,3,4,6-Penta-O-acetyl-β-D-glucopyranose 5.18 (5.86 g, 15 mmol) was dissolved in CH2Cl2 
(35 mL) and the resulting solution was cooled to 0 °C. Thiophenol (2.81 mL, 27.5 mmol) was 
added, followed by the dropwise addition of BF3.OEt2 (3.39 mL, 27.5 mmol) with constant 
stirring. The reaction was then warmed to room temperature, and after 2 h t.l.c. (petrol:Et2O 
1:1) indicated complete consumption of starting material (Rf 0.5) and formation of a single 
product (Rf 0.6). The reaction mixture was diluted with CH2Cl2 (40 mL), washed with aqueous 
NaHCO3 (sat. aqueous soln., 3 x 40 mL), followed by brine (2 x 20 mL) and the organic layer 
was then dried (MgSO4), filtered and concentrated in vacuo. The resulting solid was 
recrystallised from petrol:ethyl acetate to afford phenyl 2,3,4,6-acteyl-1-thio-β-D-
glucopyranoside 5.20 (4.80 g, 82%) as a colourless crystalline solid; m.p. 114-116 °C (ethyl 
acetate) [lit. 113-114 °C (ethyl acetate)]36; [α]D
20 -12 (c, 1.0 in CHCl3) [lit. [α]D
20 -16.5 (c, 1.0 
in CHCl3)]
34; H (400 MHz, CDCl3) 1.99 (3H, s, C(O)CH3), 2.01 (3H, s, C(O)CH3), 2.08 (3H, 
s, C(O)CH3), 2.08 (3H, s, C(O)CH3), 3.72 (1H, m, H-5), 4.13 - 4.25 (2H, m, H-6 & H-6’), 4.71 
(1H, d, J1,2 10.2 Hz, H-1), 4.97 (1H, t, J 9.8 Hz, H-2), 5.04 (1H, t, J 9.8 Hz, H-4), 5.22 (1H, t, 
J 9.0 Hz, H-3), 7.25 - 7.34 (3H, m, Ar-H x 3), 7.46 - 7.52 (2H, m, Ar-H x 2)36; C (100.5 MHz, 
CDCl3) 20.5 (q, C(O)CH3), 20.6 (q, C(O)CH3), 20.7 (q, C(O)CH3), 20.7 (q, C(O)CH3), 62.1 (t, 
C-6), 68.2 (d, C-4), 69.9 (d, C-2), 73.9 (C-3), 75.8 (C-5), 85.7 (C-1), 128.4, 128.9, 131.6, 133.1 
(Ar-C x 4), 169.2 (q, C(O)CH3), 169.4 (q, C(O)CH3), 170.1 (q, C(O)CH3), 170.5 (q, C(O)CH3); 
HRMS (ESI-TOF): calcd. for C20H24O9SNa
+: 463.1033. Found: 463.1039 (MNa+). 
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p-Methoxyphenyl 2,3,4,6-acetyl-1-thio-β-D-glucopyranoside 5.2137 
 
1,2,3,4,6-Penta-O-acetyl-β-D-glucopyranose 5.18 (5.86 g, 15 mmol) was dissolved in CH2Cl2 
(35 mL) and the resulting solution was cooled to 0 °C. p-Methoxythiophenol (3.38 mL, 27.5 
mmol) was added to the reaction, followed by dropwise addition of BF3.OEt2 (3.39 mL, 27.5 
mmol) with constant stirring. The reaction was warmed to room temperature, and after 2 h t.l.c. 
(petrol:Et2O 1:1) indicated complete consumption of starting material (Rf 0.5) and formation 
of a single product (Rf 0.6). The reaction mixture was diluted with CH2Cl2 (40 mL), washed 
with NaHCO3 (sat. aqueous soln., 3 x 40 mL), followed by brine (2 x 20 mL) and the organic 
layer was then dried (MgSO4), filtered and concentrated in vacuo. The resulting solid was pre-
absorbed onto silica and purified by flash column chromatography (petrol:ethyl acetate 2:1) to 
afford p-methoxyphenyl 2,3,4,6-acteyl-1-thio-β-D-glucopyranoside 5.21 (6.83 g, 97%) as a 
colourless solid; m.p. 95-96 °C (ethyl acetate) [lit. 92-93 °C (ethyl acetate)]28; [α]D
20 -22 (c, 1.0 
in CHCl3) [lit. [α]D
20 -24.3 (c, 2.0 in CHCl3)]
28; H (400 MHz, CDCl3)
28 1.97 (3H, s, C(O)CH3), 
2.00 (3H, s, C(O)CH3), 2.07 (3H, s, C(O)CH3), 2.09 (3H, s, C(O)CH3), 3.67 (1H, dt, 
J4,5 10.1 Hz, J5,6 3.6 Hz, J5,6’ 3.6 Hz, H-5), 3.81 (3H, s, OCH3), 4.16 - 4.20 (2H, m, H-6 & H-
6’), 4.55 (1H, d, J1,2 10.2 Hz, H-1), 4.88 (1H, t, J 9.6 Hz, H-2), 4.98 (1H, t, J 9.6 Hz, H-4), 5.19 
(1H, t, J 9.4 Hz, H-3), 6.84 (2H, d, J 8.6 Hz, Ar-H x 2), 7.43 (2H, d, J 8.6 Hz, Ar-H x 2); 
C (100.5 MHz, CDCl3)
28 20.5 (q, C(O)CH3), 20.6 (q, C(O)CH3), 20.7 (q, C(O)CH3), 20.8 (q, 
C(O)CH3), 55.3 (q, OCH3), 62.1 (t, C-6), 68.2 (d, C-4), 69.9 (d, C-2), 74.0 (d, C-3), 75.7 (d, 
C-5), 85.6 (d, C-1), 114.4 (d, Ar-C x 2), 120.8 (s, Ar-C), 136.5 (D, Ar-C x 2), 160.4 (s, Ar-C), 
169.2 (s, C(O)CH3), 169.4 (s, C(O)CH3), 170.2 (s, C(O)CH3), 170.5 (s, C(O)CH3); HRMS 
(ESI-TOF): calcd. for C21H26O10SNa
+: 493.1139. Found: 493.1142 (MNa+). 
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Ethyl 1-thio-β-D-glucopyranoside 5.2238 
 
NaOMe (0.32 g, 6 mmol) was added to a stirred solution of ethyl 2,3,4,6-acteyl-1-thio-β-D-
glucopyranoside 5.19 (3.53 g, 9 mmol) in MeOH (45 mL). After 1 h t.l.c. (ethyl acetate:MeOH 
9:1) indicated complete consumption of starting material (Rf 0.9) and formation of a single 
product (Rf 0.3). Amberlite
® IR-120 (H+) resin was added and the mixture stirred for 15 min 
until the pH was neutral. The mixture was then filtered and concentrated in vacuo. The residue 
was pre-absorbed onto silica and purified by flash column chromatography (ethyl 
acetate:MeOH 9:1) to afford ethyl 1-thio-β-D-glucopyranoside 5.22 (1.73 g, 86%) as a 
colourless oil; [α]D
20 -54 (c, 1.0 in water) [lit. [α]D
20 -55.1 (c, 1.0 in water)]39; H (400 MHz, 
D2O)
38 1.17 (3H, t, J 7.4 Hz, SCH2CH3), 2.56 - 2.74 (2H, m, SCH2CH3), 3.21 (1H, t, J 9.8 Hz, 
H-2), 3.26 - 3.42 (3H, m, H-3, H-4 & H-5), 3.59 (1H, dd, J5,6 5.5 Hz, J6,6’ 12.5 Hz, H-6), 3.79 
(1H, d, J6,6’ 12.1 Hz, H-6), 4.43 (1H, d, J1,2 9.8 Hz, H-1); C (100.5 MHz, D2O)
38 14.5 (q, 
SCH2CH3), 24.1 (t, SCH2CH3), 60.9 (t, C-6), 69.5 (d, C-4), 72.2 (d, C-2), 77.2 (d, C-3), 79.8 
(d, C-5), 85.0 (d, C-1); HRMS (ESI-TOF): calcd. for C8H16O5SNa





NaOMe (0.36 g, 6.67 mmol) was added to a stirred solution of phenyl 2,3,4,6-acteyl-1-thio-β-
D-glucopyranoside 5.20 (4.40 g, 10 mmol) in MeOH (50 mL). After 1 h t.l.c. (ethyl 
acetate:MeOH 9:1) indicated complete consumption of starting material (Rf 0.9) and formation 
of a single product (Rf 0.3). Amberlite
® IR-120 (H+) resin was added and the mixture stirred 
Chapter 6: Experimental 
297 
 
for 15 min until the pH was neutral. The mixture was then filtered and concentrated in vacuo. 
The residue was pre-absorbed onto silica and purified by flash column chromatography (ethyl 
acetate:MeOH 9:1) to afford phenyl-1-thio-β-D-glucopyranoside 5.23 (2.35 g, 86%) as a white 
solid; m.p. 128-129 °C (MeOH) [lit. 133 °C (MeOH)]40; [α]D
20 -65.3 (c, 1.0 in water) 
[lit. [α]D
20 -70.3 (c, 1.0 in water)]40; H (400 MHz, D2O)
41 3.24 (1H, t, J 9.0 Hz, H-2), 3.27 - 
3.45 (3H, m, H-3, H-4 & H-5), 3.60 (1H, dd, J5,6 5.9 Hz, J6,6’ 12.5 Hz, H-6), 3.75 - 3.81 (1H, 
m, H-6’), 4.68 (1H, d, J1,2 9.8 Hz, H-1), 7.24 - 7.34 (3H, m, Ar-H x 3), 7.47 (2H, d, J 7.8 Hz, 
Ar-H x 2); C (100.5 MHz, D2O)
41 60.7 (t, C-6), 69.3 (d, C-4), 71.7 (d, C-2), 77.2 (d, C-3), 79.8 
(d, C-5), 87.2 (d, C-1), 128.1, 129.3, 131.6, 131.9 (4 x Ar-C); HRMS (ESI-TOF): calcd. for 
C12H16O5SNa




NaOMe (0.47 g, 8.67 mmol) was added to a stirred solution of p-methoxyphenyl 2,3,4,6-acteyl-
1-thio-β-D-glucopyranoside 5.21 (6.11 g, 13 mmol) in MeOH (65 mL). After 1 h t.l.c. (ethyl 
acetate:MeOH 9:1) indicated complete consumption of starting material (Rf 0.9) and formation 
of a single product (Rf 0.3). Amberlite
® IR-120 (H+) resin was added and the mixture stirred 
for 15 min until the pH was neutral. The mixture was then filtered and concentrated in vacuo. 
The residue was pre-absorbed onto silica and purified by flash column chromatography (ethyl 
acetate:MeOH 9:1) to afford p-methoxyphenyl-1-thio-β-D-glucopyranoside 5.24 (3.22 g, 82%) 
as a colourless foam; [α]D
20 -33 (c, 1.0 in MeOH) [lit. [α]D
20 -41.0 (c, 1.0 in MeOH)]42; 
H (400 MHz, D2O)
43 3.14 (1H, t, J 9.4 Hz, H-2), 3.21 - 3.33 (2H, m, H-4 & H-5), 3.38 (1H, t, 
J 9.0 Hz, H-3), 3.59 (1H, dd, J6,6’ 12.5 Hz, J5,6 5.5 Hz, H-6), 3.71 (3H, s, OCH3), 3.73 - 3.79 
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(1H, m, H-6’), 4.49 (1H, d, J1,2 9.8 Hz, H-1), 6.87 (2H, d, J 9.0 Hz, Ar-H x 2), 7.43 (2H, d, 
J 9.0 Hz, Ar-H x 2); C (100.5 MHz, D2O)
43 55.4 (q, OCH3), 60.8 (t, C-6), 69.3 (d, H-4), 71.5 
(d, H-2), 77.2 (d, H-3), 79.8 (d, H-5), 87.7 (d, H-1), 114.8 (d, Ar-C x 2), 122.0 (s, Ar-C), 135.1 
(d, Ar-C x 2), 159.4 (s, Ar-C); HRMS (ESI-TOF): calcd. for C13H18O6SNa
+: 325.0716. Found: 
325.0711 (MNa+). 
 
Ethyl 1-sulfinyl-β-D-glucopyranoside 5.25 
 
Method 1 
Ethyl 1-thio-β-D-glucopyranoside 5.22 (0.672 g, 3 mmol) was dissolved in MeOH (8.1 mL). 
1,10-Ethyleneisoalloxazinium chloride 5.7 (0.0417 g, 0.15 mmol) was added followed by H2O2 
(0.21 mL, 50% w/w in water, 3.6 mmol), and the reaction was then stirred for 6 h. The reaction 
mixture was concentrated in vacuo and the residue produced was pre-absorbed onto Florisil® 
and purified by flash column chromatography (CH2Cl2:MeOH 7:1) to afford ethyl 1-sulfinyl-
β-D-glucopyranoside 5.25 (0.551 g, 76%) as an orange oil (1:1 mixture of diastereoisomers); 
υmax (neat) 1042 cm
-1 (S=O); H (400 MHz, D2O) 1.17 - 1.28 (6H, m, SCH2CH3a & SCH2CH3b), 
2.81 - 2.94 (2H, m, SCHH’CH3a
 & SCHH’CH3b), 3.04 - 3.19 (2H, m, SCHH’CH3a & 
SCHH’CH3b), 3.29 - 3.73 (10H, m, H-2a, H-2b, H-3a, H-3b, H-4a, H-4b, H-5a, H-5b, H-6a & 
H-6b), 3.83 (2H, dd, J5,6’ 6.5 Hz, J6,6’ 11.9 Hz, H-6’a & H-6’b), 4.17 (1H, d, J1,2 9.8 Hz, H-1b), 
4.47 (1H, d, J1,2 9.8 Hz, H-1a); C (100.5 MHz, D2O) 6.5 (q, SCH2CH3a & SCH2CH3b), 39.4 (t, 
SCH2CH3a), 40.1 (t, SCH2CH3b), 60.4 (t, C-6b), 60.7 (t, C-6a), 67.7 (d, C-2b), 68.6 (d, C-4b), 
68.8 (d, C-4a), 69.1 (d, C-2a), 76.9 (d, C-3b), 77.1 (d, C-3a), 80.2 (d, C-5b), 80.7 (d, C-5a), 87.7 
(d, C-1b), 90.4 (d, C-1a); HRMS (ESI-TOF): calcd. for C8H16O6SNa
+: 263.0560. Found: 
263.0563 (MNa+). 




Ethyl 1-thio-β-D-glucopyranoside 5.22 (0.672 g, 3 mmol) was dissolved in water (8.1 mL). 
1,10-Ethyleneisoalloxazinium chloride 5.7 (0.0417 g, 0.15 mmol) was added followed by H2O2 
(0.21 mL, 50% w/w in water, 3.6 mmol), and the reaction was then stirred for 6 h. The reaction 
mixture was freeze-dried and the residue produced was pre-absorbed onto Florisil® and purified 
by flash column chromatography (CH2Cl2:MeOH 7:1) to afford ethyl 1-sulfinyl-β-D-
glucopyranoside 5.25 (0.512 g, 71%) as an orange oil (1:1 mixture of diastereoisomers), 
identical in all respects to that produced by Method 1. 
 
Ethyl 2,3,4,6-acetyl-1-thio-α-D-mannopyranoside 5.2944 
 
1,2,3,4,6-Penta-O-acetyl-α-D-mannopyranose 5.28 (11.71 g, 30 mmol) was dissolved in 
CH2Cl2 (70 mL). Ethanethiol (3.96 mL, 55 mmol) was added, followed by the dropwise 
addition of BF3.OEt2 (6.77 mL, 55 mmol) with constant stirring. The reaction was stirred at 
room temperature, and after 24 h t.l.c. (petrol:ethyl acetate 2:1) indicated complete 
consumption of starting material (Rf 0.2) and formation of a single product (Rf 0.3). The 
reaction mixture was quenched with NaHCO3 (sat. aqueous soln., 2 x 100 mL), and then 
washed with brine (80 mL) and the organic layer was then dried (MgSO4), filtered and 
concentrated in vacuo. The solid was crystallised from CH2Cl2:petrol, and the mother liquors 
concentrated in vacuo to afford ethyl 2,3,4,6-acetyl-1-thio-α-D-mannopyranoside 5.29 (3.65 g, 
31%) as a colourless crystalline solid; m.p. 109-110 °C (CH2Cl2) [lit. 106-108 °C (EtOH)]
34; 
[α]D
20 +94 (c, 1.0 in CHCl3) [lit. [α]D
20
 +118.7 (c, 1.0 in CHCl3)]
34; H (400 MHz, CDCl3)
34 
1.30 (3H, t, J 7.4 Hz, SCH2CH3), 1.99 (3H, s, C(O)CH3), 2.05 (3H, s, C(O)CH3), 2.09 (3H, s, 
C(O)CH3), 2.16 (3H, s, C(O)CH3), 2.64 (2H, m, SCH2CH3), 4.10 (1H, dd, J6,6’ 12.1 Hz, 
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J5,6 1.6 Hz, H-6), 4.31 (1H, dd, J6,6’ 12.1 Hz, J5,6’ 5.1 Hz, H-6), 4.36 - 4.43 (1H, m, H-5), 5.23 
- 5.36 (4H, m, H-1, H-2, H-3 & H-4); C (100.5 MHz, CDCl3)
34 14.7 (q, SCH2CH3), 20.6 (q, 
C(O)CH3), 20.7 (q, C(O)CH3), 20.7 (q, C(O)CH3), 20.9 (q, C(O)CH3), 25.5 (t, SCH2CH3), 62.4 
(t, C-6), 66.4 (d, C-4), 68.9 (d, C-5), 69.5 (d, C-3), 71.2 (d, C-2), 82.3 (d, C-1), 169.7 (s, 
C(O)CH3), 169.7 (s, C(O)CH3), 170.0 (s, C(O)CH3), 170.6 (s, C(O)CH3); HRMS (ESI-TOF): 
calcd. for C16H24O9SNa
+: 415.1033. Found: 415.1051 (MNa+). 
 
Ethyl 1-thio-α-D-mannopyranoside 5.3045 
 
NaOMe (0.32 g, 6 mmol) was added to a stirred solution of ethyl 2,3,4,6-acetyl-1-thio-α-D-
mannopyranoside 5.29 (3.53 g, 9 mmol) in MeOH (45 mL). After 1 h t.l.c. (CH2Cl2:MeOH 
7:1) indicated complete consumption of starting material (Rf 0.8) and formation of a single 
product (Rf 0.1). Amberlite
® IR-120 (H+) resin was added and the mixture stirred for 15 min 
until neutral pH. The mixture was then filtered and concentrated in vacuo. The residue was pre-
absorbed onto silica and purified by flash column chromatography (CH2Cl2:MeOH 7:1) to 
afford ethyl 1-thio-α-D-mannopyranoside 5.30 (1.83 g, 91%) as a white solid; m.p. 105-106 °C 
(MeOH) [lit. 126-127 °C (EtOH)]46; [α]D
20
 +177.9 (c, 1.0 in water) [lit. [α]D
20 +20.2 (c, 0.85 in 
water)]46; H (400 MHz, D2O)
45 1.16 (3H, t, J 7.4 Hz, SCH2CH3), 2.47 - 2.67 (2H, m, 
SCH2CH3), 3.55 (1H, t, J 9.8 Hz, H-4), 3.62 - 3.69 (2H, m, H-3 & H-6), 3.73 - 3.79 (1H, m, 
H-6’), 3.84 - 3.90 (1H, m, H-5), 3.91 - 3.93 (1H, m, H-2), 5.20 (1H, s, H-1); C (100.5 MHz, 
D2O) 14.1 (q, SCH2CH3), 24.8 (t, SCH2CH3), 60.8 (t, C-6), 67.1 (d, C-4), 71.1 (d, C-3), 71.8 
(d, C-2), 73.0 (d, C-5), 84.2 (d, C-1); HRMS (ESI-TOF): calcd. for C8H16O5SNa
+: 247.0611. 
Found: 247.0606 (MNa+). 
 





Sodium acetate (45.9 g, 560 mmol) was suspended in acetic anhydride (320 mL). The resulting 
solution was stirred and heated to 120 °C. D-Galactopyranose 5.31 (50.44 g, 280 mmol) was 
added over 100 min. After a further 20 min the reaction mixture was cooled to room 
temperature, and then poured onto ice (400 mL). The resulting white precipitate was filtered 
off and recrystallised from EtOH to afford 1,2,3,4,6-penta-O-acetyl-β-D-galactopyranose 5.32 
(52.15 g, 48%); m.p. 139-140 °C (EtOH) [lit. 143-144 °C (EtOH)]48; [α]D
20 +23 (c, 1.0 in 
CHCl3) [lit. [α]D
20 +27.4 (c, 1.0 in CHCl3)]
48; H (400 MHz, CDCl3)
47 1.98 (3H, s, C(O)CH3), 
2.03 (6H, s, 2 x C(O)CH3), 2.11 (3H, s, C(O)CH3), 2.15 (3H, s, C(O)CH3), 4.04 (1H, t, J 6.7 Hz, 
H-5), 4.08 - 4.18 (2H, m, H-6 & H-6’), 5.07 (1H, dd, J2,3 10.4 Hz, J3,4 3.3 Hz, H-3), 5.32 (1H, 
dd, J2,3 10.2 Hz, J1,2 8.6 Hz, H-2), 5.41 (1H, d, J3,4 3.5 Hz, H-4), 5.69 (1H, d, J1,2 8.2 Hz, H-1); 
C (100.5 MHz, CDCl3)
47 20.5 (q, C(O)CH3), 20.6 (q, C(O)CH3), 20.6 (q, 2 x C(O)CH3), 20.8 
(q, C(O)CH3), 61.0 (t, C-6), 66.8 (d, C-4), 67.8 (d, C-2), 70.8 (d, C-3), 71.7 (d, C-5), 92.1 (d, 
C-1), 168.9 (s, C(O)CH3), 169.3 (s, C(O)CH3), 169.9 (s, C(O)CH3), 170.1 (s, C(O)CH3), 170.3 
(s, C(O)CH3); HRMS (ESI-TOF): calcd. for C16H22O11Na
+: 413.1054. Found: 413.1071 
(MNa+). 
 
Ethyl 2,3,4,6-acetyl-1-thio-β-D-galactopyranoside 5.3349 
 
1,2,3,4,6-Penta-O-acetyl-β-D-galactopyranose 5.32 (5.86 g, 15 mmol) was dissolved in CH2Cl2 
(35 mL) and the resulting solution cooled to 0 °C. Ethanethiol (1.98 mL, 27.5 mmol) was 
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added, followed by the dropwise addition of BF3.OEt2 (3.39 mL, 27.5 mmol) with constant 
stirring. The reaction was warmed to room temperature, and after 2 h t.l.c. (petrol:Et2O 2:1) 
indicated complete consumption of starting material (Rf 0.4) and the formation of a single 
product (Rf 0.5). The reaction mixture was diluted with CH2Cl2 (40 mL), washed with aqueous 
NaHCO3 (sat. aqueous soln., 3 x 40 mL), followed by brine (2 x 20 mL) and the organic layer 
was then dried (MgSO4), filtered and concentrated in vacuo. The resulting solid was 
recrystallised from the minimum amount of hot EtOH to afford ethyl 2,3,4,6-acetyl-1-thio-β-
D-galactopyranoside 5.33 (4.6 g, 78%) as a white solid; m.p. 74-76 °C (EtOH) [lit. 73-75 °C 
(Et2O)]
34; [α]D
20 -4 (c, 1.0 in CHCl3) [lit. [α]D
20 -9.2 (c, 1.0 in CHCl3)]
34; H (400 MHz, 
CDCl3)
34 1.28 (3H, t, J 7.4 Hz, SCH2CH3), 1.98 (3H, s, C(O)CH3), 2.04 (3H, s, C(O)CH3), 2.06 
(3H, s, C(O)CH3), 2.15 (3H, s, C(O)CH3), 2.64 - 2.81 (2H, m, SCH2CH3), 3.93 (1H, dd, 
J5,6 7.4 Hz, J5,6’ 5.9 Hz, H-5), 4.07 - 4.20 (2H, m, H-6 & H-6’), 4.49 (1H, d, J1,2 10.2 Hz, H-1), 
5.04 (1H, dd, J2,3 10.0 Hz, J3,4 3.3 Hz, H-3), 5.23 (1H, t, J 9.8 Hz, H-2), 5.42 (1H, d, J3,4 3.1 Hz, 
H-4); C (100.5 MHz, CDCl3)
34 14.8 (q, SCH2CH3), 20.6 (q, C(O)CH3), 20.6 (q, 2 x C(O)CH3), 
20.8 (q, C(O)CH3), 24.3 (SCH2CH3), 61.5 (t, C-6), 67.2 (d, C-2), 67.3 (d, C-4), 71.9 (d, C-3), 
74.4 (d, C-5), 84.1 (d, C-1), 169.5 (s, C(O)CH3), 170.0 (s, C(O)CH3), 170.2 (s, C(O)CH3), 
170.4 (s, C(O)CH3); HRMS (ESI-TOF): calcd. for C16H24O9SNa
+: 415.1033. Found: 415.1048 
(MNa+). 
 
Ethyl 1-thio-β-D-galactopyranoside 5.3450 
 
NaOMe (0.27 g, 5 mmol) was added to a stirred solution of ethyl 2,3,4,6-acetyl-1-thio-α-D-
galactopyranoside 5.33 (2.94 g, 7.5 mmol) in MeOH (40 mL). After 1 h t.l.c. (CH2Cl2:MeOH 
7:1) indicated complete consumption of starting material (Rf 0.7) and the formation of a single 
Chapter 6: Experimental 
303 
 
product (Rf 0.2). Amberlite
® IR-120 (H+) resin was added and the mixture stirred for 15 min 
until the pH was neutral. The mixture was then filtered and concentrated in vacuo. The residue 
was pre-absorbed onto silica and purified by flash column chromatography (CH2Cl2:MeOH 
7:1) to afford ethyl 1-thio-α-D-galactopyranoside 5.34 (1.46 g, 87%) as a white solid; 
m.p. 124-125 °C (MeOH) [lit. 122-123 °C (MeOH)]50; [α]D
20 -15 (c, 1.0 in water) 
[lit. [α]D
20 -23.5 (c, 1.1 in water)]50; H (400 MHz, D2O) 1.16 (3H, t, J 7.4 Hz, SCH2CH3), 2.56 
- 2.73 (2H, m, SCH2CH3), 3.44 (1H, t, J 9.8 Hz, H-2), 3.50 - 3.56 (1H, m, H-3), 3.56 - 3.68 
(3H, m, H-5, H-6 & H-6’), 3.86 (1H, s, H-4), 4.36 (1H, d, J1,2 9.8 Hz, H-1); C (100.5 MHz, 
D2O) 14.4 (q, SCH2CH3), 24.2 (t, SCH2CH3), 61.0 (t, C-6), 68.8 (d, C-2), 69.5 (d, C-3), 73.9 
(d, C-5), 78.8 (d, C-4), 85.5 (d, C-1); HRMS (ESI-TOF): calcd. for C8H16O5SNa
+: 247.0611. 
Found: 247.0602 (MNa+). 
 
Ethyl 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside 5.3644 
 
1,3,4,6-Tetra-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranoside 5.35 (12.0 g, 25 mmol) 
was dissolved in CH2Cl2 (100 mL). Ethanethiol (2.16 mL, 37.5 mmol) was added, followed by 
dropwise addition of BF3.OEt2 (4.62 mL, 37.5 mmol). The reaction was heated to reflux under 
an atmosphere of nitrogen for 3 h, at which point t.l.c. (petrol:ethyl acetate 1:1) indicated 
complete consumption of starting material (Rf 0.5) and formation of a single product (Rf 0.6). 
The reaction mixture was cooled to room temperature, diluted with CH2Cl2 (80 mL), quenched 
with aqueous NaHCO3 (sat. aqueous soln., 2 x 80 mL), washed with brine (40 mL), dried 
(MgSO4), filtered and concentrated in vacuo. The residue was pre-absorbed onto silica and 
purified by flash column chromatography (petrol:ethyl acetate 3:2) to afford ethyl 3,4,6-tri-O-
acetyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside 5.36 (10.24 g, 85%) as a colourless 
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solid; m.p. 116-118 °C (ethyl acetate) [lit. 118-119 °C (ethyl acetate)]34; [α]D
20 +42 (c, 1.0 in 
CHCl3) [lit. [α]D
20 +46.5 (c, 1.0 in CHCl3)]
34; H (400 MHz, CDCl3)
34 1.21 (3H, t, J 7.4 Hz, 
SCH2CH3), 1.85 (3H, s, C(O)CH3), 2.03 (3H, s, C(O)CH3), 2.10 (3H, s, C(O)CH3), 2.58 - 2.76 
(2H, m, SCH2CH3), 3.86 - 3.92 (1H, m, H-5), 4.17 (1H, dd, J6,6’ 11.7 Hz, J5,6 1.6 Hz, H-6), 4.30 
(1H, dd, J6,6’ 12.5 Hz, J5,6’ 4.7 Hz, H-6’), 4.39 (1H, t, J 10.4 Hz, H-2), 5.17 (1H, t, J 9.6 Hz, 
H-4), 5.48 (1H, d, J1,2 10.6 Hz, H-1), 5.82 (1H, t, J 9.6 Hz, H-3), 7.71 - 7.77 (2H, m, 2 x Ar-H), 
7.83 - 7.89 (2H, m, 2 x Ar-H); C (100.5 MHz, CDCl3)
34 14.9 (q, SCH2CH3), 20.4 (q, 
C(O)CH3), 20.6 (q, C(O)CH3), 20.8 (q, C(O)CH3), 24.3 (t, SCH2CH3), 53.7 (d, H-2), 62.3 (t, 
C-6), 68.9 (d, C-4), 71.5 (d, C-3), 75.9 (d, C-5), 81.2 (d, H-1), 123.7 (d, 2 x Ar-C), 134.3 (d, 
2 x Ar-C), 134.4 (s, 2 x Ar-C), 169.4 (s, C(O)CH3), 170.1 (s, C(O)CH3), 170.7 (s, C(O)CH3); 
HRMS (ESI-TOF): calcd. for C22H25NO9SNa
+: 502.1142. Found: 502.1164 (MNa+). 
 
Ethyl 3,4,6-tri-O-acetyl-2-deoxy-2-acetamido-1-thio-β-D-glucopyranoside 5.3751 
 
Ethyl 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside 5.36 (9.59 g, 
20 mmol) was dissolved in EtOH (100 mL) and H2NNH2.H2O (30.0 mL, 800 mmol) was 
added. The reaction was then refluxed for 16 h, at which point t.l.c. (petrol:ethyl acetate 1:1) 
indicated complete consumption of starting material (Rf 0.6) and the formation of a single 
product (Rf 0). The reaction mixture was then cooled, concentrated in vacuo and then co-
evaporated with toluene (3 x 100 mL). The residue was then dissolved in pyridine (80 mL) and 
acetic anhydride (40 mL) was added. After 16 h the reaction mixture was concentrated in 
vacuo, and the residue was dissolved in ethyl acetate. The solution was then washed with 
aqueous HCl (1M, 100 mL), filtered, washed with water (100 mL) and aqueous NaHCO3 (sat. 
aqueous soln., 100 mL). The organic phase was then dried (MgSO4), filtered and concentrated 
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in vacuo. The residue was then recrystallised (EtOH:petrol) to afford ethyl 3,4,6-tri-O-acetyl-
2-deoxy-2-acetamido-1-thio-β-D-glucopyranoside 5.37 (3.25 g, 42%) as a white crystalline 
solid; m.p. 175-176 °C (EtOH) [lit. 194-195 °C (EtOH)]38; [α]D
20 -48 (c, 1.0 in CHCl3) [lit. 
[α]D
20 -52 (c, 1.0 in CHCl3)]
52; H (400 MHz, CDCl3)
38 1.27 (3H, t, J 7.4 Hz, SCH2CH3), 1.96 
(3H, s, C(O)CH3), 2.02 (3H, s, C(O)CH3), 2.03 (3H, s, C(O)CH3), 2.08 (3H, s, C(O)CH3), 2.65 
- 2.79 (2H, m, SCH2CH3), 3.66 - 3.72 (1H, m, H-5), 4.05 - 4.16 (2H, m, H-2 & H-6), 4.23 (1H, 
dd, J6,6’ 12.1 Hz, J5,6’ 4.7 Hz, H-6’), 4.59 (1H, d, J1,2 10.2 Hz, H-1), 5.09 (1H, t, J 9.8 Hz, H-4), 
5.17 (1H, t, J 9.8 Hz, H-3), 5.51 (1H, d, JNH,2 9.4 Hz, NH); C (100.5 MHz, CDCl3)
48 14.7 (q, 
SCH2CH3), 20.6 (q, C(O)CH3), 20.7 (q, C(O)CH3), 20.7 (q, C(O)CH3), 23.3 (q, C(O)CH3), 
24.2 (t, SCH2CH3), 53.3 (d, C-2), 62.3 (t, C-6), 68.4 (d, C-4), 73.9 (d, C-3), 75.9 (d, C-5), 84.4 
(d, C-1), 169.3 (s, C(O)CH3), 170.0 (s, C(O)CH3), 170.7 (s, C(O)CH3), 171.1 (s, C(O)CH3); 
HRMS (ESI-TOF): calcd. for C16H25NO8SNa
+: 414.1193. Found: 414.1199 (MNa+). 
 
Ethyl 2-deoxy-2-acetamido-1-thio-β-D-glucopyranoside 5.38 
 
NaOMe (0.22 g, 4 mmol) was added to a stirred solution of ethyl 3,4,6-tri-O-acetyl-2-deoxy-
2-acetamido-1-thio-β-D-glucopyranoside 5.37 (3.13 g, 8 mmol) in MeOH (40 mL). After 1 h 
t.l.c. (CH2Cl2:MeOH 7:1) indicated complete consumption of starting material (Rf 0.7) and the 
formation of a single product (Rf 0.2). Amberlite
® IR-120 (H+) resin was added and the mixture 
stirred for 15 min until the pH was neutral. The mixture was then filtered and concentrated in 
vacuo. The resulting residue was pre-absorbed onto silica and purified by flash column 
chromatography (CH2Cl2:MeOH 7:1) to afford ethyl 2-deoxy-2-acetamido-1-thio-β-D-
glucopyranoside 5.38 (1.26 g, 59%) as a white solid; m.p. 118-120 °C (MeOH) [lit. 215 °C 
(MeOH)]53; [α]D
20 -43 (c, 1.0 in water) [lit. [α]D
20 -55 (c, 1.0 in water)]53; H (400 MHz, D2O)
38 
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1.12 (3H, t, J 7.4 Hz, SCH2CH3), 1.92 (3H, s, C(O)CH3), 2.51 - 2.71 (2H, m, SCH2CH3), 3.31 
- 3.38 (2H, m, H-4 & H-5), 3.39 - 3.47 (1H, m, H-3), 3.57 - 3.67 (2H, m, H-2 & H-6), 3.79 
(1H, d, J6,6’ 12.5 Hz, H-6’), 4.51 (1H, d, J1,2 10.6 Hz, H-1); C (100.5 MHz, D2O)
38 14.2 (q, 
SCH2CH3), 22.1 (q, C(O)CH3), 24.4 (t, SCH2CH3), 54.7 (d, C-2), 60.8 (t, C-6), 69.8 (d, C-4), 
75.1 (d, C-3), 79.8 (d, C-5), 83.9 (d, C-1), 174.4 (s, C(O)CH3); HRMS (ESI-TOF): calcd. for 
C10H19NO5SNa
+: 288.0876. Found: 288.0878 (MNa+). 
 
Ethyl β-D-galactopyranosyl-(1→4)-1-thio-β-D-glucopyranoside 5.4054 
 
2,3,4,6-Tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-1,2,3,6-tetra-O-acetyl-β-D-
glucopyranoside 5.39 (16.96 g, 25 mmol) was dissolved in CH2Cl2 (100 mL) and the resulting 
solution cooled to 0 °C. Ethanethiol (2.79 mL, 37.5 mmol) was added, followed by the 
dropwise addition of BF3.OEt2 (4.62 mL, 37.5 mmol) with constant stirring. The reaction was 
warmed to room temperature, and after 2 h t.l.c. (petrol:Et2O 2:1) indicated complete 
consumption of starting material (Rf 0.3) and formation of a single product (Rf 0.4). The 
reaction mixture was diluted with CH2Cl2 (100 mL), washed with NaHCO3 (sat. aqueous soln., 
3 x 100 mL), followed by brine (2 x 50 mL) and the organic layer was then dried (MgSO4), 
filtered and concentrated in vacuo. The resulting solid was then dissolved in MeOH (70 mL) 
and NaOMe (0.64 g, 11.9 mmol) was added. After 1 h, t.l.c (CH2Cl2:MeOH 7:1) indicated 
complete consumption of starting material (Rf 0.6) and the formation of a single product 
(Rf 0.2). Amberlite
® IR-120 (H+) resin was added and the mixture stirred for 15 min until 
neutral pH. The mixture was then filtered and concentrated in vacuo. The resulting solid was 
recrystallised from the minimum amount of hot EtOH to afford ethyl β-D-galactopyranosyl-
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(1→4)-1-thio-β-D-glucopyranoside 5.40 (4.06 g, 42%) as a white crystalline solid; m.p. 
185-187 °C (EtOH) [lit. 189-192 °C (EtOH)]54; [α]D
20 -8 (c, 1.0 in water) [lit. [α]D
20 -27.4 
(c, 0.5 in MeOH)]54; H (400 MHz, D2O)
54 1.17 (3H, t, J 7.4 Hz, SCH2CH3), 2.57 - 2.73 (2H, 
m, SCH2CH3), 3.26 (1H, t, J 9.2 Hz, H-2a), 3.40 - 3.46 (1H, m, H-2b), 3.49 - 3.71 (8H, m, H-3a, 
H-3b, H-4a, H-5a, H-5b, H-6a, H-6b & H-6’b), 3.81 (1H, d, J3,4 3.5 Hz, H-4b), 3.86 (1H, d, J6,6’ 
12.5 Hz, H-6’a), 4.34 (1H, d, J 7.8 Hz, H-1b), 4.46 (1H, d, J 9.8 Hz, H-1a); C (100.5 MHz, 
D2O) 14.5 (q, SCH2CH3), 24.1 (t, SCH2CH3), 60.2 (t, C-6a), 61.0 (t, C-6b), 68.5 (d, C-4b), 70.9 
(d, C-2b), 71.9 (d, C-2a), 72.5 (d, C-3a), 75.3 (d, C-5a), 75.7 (d, C-3b), 78.2 (d, C-4a), 78.6 (d, 
C-5b), 84.9 (d, C-1a), 102.8 (d, C-1b); HRMS (ESI-TOF): calcd. for C14H26O10SNa
+: 409.1139. 
Found: 409.1135 (MNa+). 
 
Ethyl 1-(R)-sulfinyl-α-D-mannopyranoside 5.41 
 
Method 1 
Ethyl 1-thio-α-D-mannopyranoside 5.30 (0.858 g, 3.83 mmol) was dissolved in MeOH 
(10.3 mL). 1,10-Ethyleneisoalloxazinium chloride 5.7 (0.0532 g, 0.19 mmol) was added 
followed by H2O2 (0.27 mL, 50% w/w in water, 4.6 mmol), and the reaction was then stirred 
for 6 h. The reaction mixture was concentrated in vacuo and the residue was pre-absorbed onto 
Florisil® and purified by flash column chromatography (CH2Cl2:MeOH 7:1) to afford ethyl 
1-(R)-sulfinyl-α-D-mannopyranoside 5.41 (0.645 g, 70%) as a pale orange oil; υmax (neat) 1036 
cm-1 (S=O); H (400 MHz, D2O) 1.26 (3H, t, J 7.4 Hz, SCH2CH3), 2.75 – 2.86 (1H, m, 
SCHH’CH3), 3.02 - 3.14 (1H, m, SCHH’CH3), 3.47 - 3.55 (1H, m, H-5), 3.60 (1H, dd, 
J6,6’ 12.5 Hz, J5,6 5.9 Hz, H-6), 3.67 (1H, t, J 9.8 Hz, H-4), 3.73 - 3.79 (1H, dd, J5,6’ 2.0 Hz, 
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J6,6’ 12.5 Hz, H-6’), 3.89 (1H, dd, J3,4 9.8 Hz, J2,3 3.5 Hz, H-3a & H-3b), 4.29 - 4.33 (1H, m, 
H-2), 4.71 (1H, s, H-1); C (100.5 MHz, D2O) 5.2 (q, SCH2CH3), 42.5 (t, SCH2CH3), 60.8 (t, 
C-6), 65.7 (d, C-4), 66.7 (d, C-2), 70.4 (d, C-3), 78.7 (d, C-5), 92.5 (d, C-1); HRMS (ESI-TOF): 
calcd. for C8H16O6SNa
+: 263.0560. Found: 263.0557 (MNa+). 
 
Method 2 
Ethyl 1-thio-α-D-mannopyranoside 5.30 (0.574 g, 2.56 mmol) was dissolved in water (6.9 mL). 
1,10-Ethyleneisoalloxazinium chloride 5.7 (0.0356 g, 0.13 mmol) was added followed by H2O2 
(0.18 mL, 50% w/w in water, 3.07 mmol), and the reaction was then stirred for 6 h. The reaction 
mixture was freeze-dried and the residue was pre-absorbed onto Florisil® and purified by flash 
column chromatography (CH2Cl2:MeOH 7:1) to afford ethyl 1-(R)-sulfinyl-α-D-
mannopyranoside 5.41 (0.303 g, 49%) as a pale orange oil, identical in all respects to the 
material produced by Method 1. 
 
Ethyl 1-sulfinyl-β-D-galactopyranoside 5.42 
 
Method 1 
Ethyl 1-thio-β-D-galactopyranoside 5.34 (0.858 g, 3.83 mmol) was dissolved in MeOH 
(10.3 mL). 1,10-Ethyleneisoalloxazinium chloride 5.7 (0.0532 g, 0.19 mmol) was added 
followed by H2O2 (0.27 mL, 50% w/w in water, 4.6 mmol), and the reaction was then stirred 
for 6 h. The reaction mixture was concentrated in vacuo and the residue was pre-absorbed onto 
Florisil® and purified by flash column chromatography (CH2Cl2:MeOH 7:1) to afford ethyl 1-
sulfinyl-β-D-galactopyranoside 5.42 (0.611 g, 66%) as a pale orange oil (1:0.7 mixture of 
diastereoisomers); υmax (neat) 1050 cm
-1 (S=O); H (400 MHz, D2O) 1.19 (3H, t, J 7.6 Hz, 
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SCH2CH3b), 1.24 (3H, t, J 8.2 Hz, SCH2CH3a), 2.82 - 2.95 (2H, m, SCHH’CH3a & 
SCHH’CH3b), 3.03 - 3.17 (2H, m, SCHH’CH3a & SCHH’CH3b), 3.58 - 3.92 (12H, m, H-2a, 
H-2b, H-3a, H-3b, H-4a, H-4b, H-5a, H-5b, H-6a, H-6b, H-6’a & H-6’b), 4.08 (1H, d, J1,2 9.8 Hz, 
H-1b), 4.40 (1H, d, J1,2 9.8 Hz, H-1a); C (100.5 MHz, D2O) 6.4 (q, SCH2CH3a), 6.5 (q, 
SCH2CH3b), 39.4 (t, SCH2CH3a), 40.2 (t, SCH2CH3b), 61.0 (t, C-6a), 61.2 (t, C-6b), 65.0 (d, 
C-2b), 66.5 (d, C-2a), 68.6 (d, C-3b), 68.8 (d, C-3a), 73.9 (d, C-4b), 73.9 (d, C-4a), 79.9 (d, C-5b), 
80.2 (d, C-5a), 88.4 (d, C-1b), 91.1 (d, C-1a); HRMS (ESI-TOF): calcd. for C8H16O6SNa
+: 
263.0560. Found: 263.0554 (MNa+). 
 
Method 2 
Ethyl 1-thio-β-D-galactopyranoside 5.34 (0.672 g, 3 mmol) was dissolved in water (8.1 mL). 
1,10-Ethyleneisoalloxazinium chloride 5.7 (0.0417 g, 0.15 mmol) was added followed by H2O2 
(0.21 mL, 50% w/w in water, 3.6 mmol), and the reaction was then stirred for 6 h. The reaction 
mixture was freeze-dried and the residue was pre-absorbed onto Florisil® and purified by flash 
column chromatography (CH2Cl2:MeOH 7:1) to afford ethyl 1-sulfinyl-β-D-galactopyranoside 
5.42 (0.456 g, 63%) as a pale orange oil (1:0.9 mixture of diastereoisomers), identical in all 
respects to the material produced by method 1. 
 
Ethyl β-D-galactopyranosyl-(1→4)-1-sulfinyl-β-D-glucopyranoside 5.44 
 
Ethyl β-D-galactopyranosyl-(1→4)-1-thio-β-D-glucopyranoside 5.40 (1.16 g, 3 mmol) was 
dissolved in MeOH (8.1 mL). 1,10-Ethyleneisoalloxazinium chloride 5.7 (0.0417 g, 
0.015 mmol) was added followed by H2O2 (0.21 mL, 50% w/w in water, 3.6 mmol), and the 
reaction was then stirred for 6 h. The reaction mixture was freeze-dried and the residue was 
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pre-absorbed onto Florisil® and purified by flash column chromatography (MeCN:MeOH 5:1) 
to afford ethyl β-D-galactopyranosyl-(1→4)-1-sulfinyl-β-D-glucopyranoside 5.44 (0.51 g, 
42%) as a colourless solid (1:1 mixture of diastereoisomers); m.p. 175-177 °C (MeOH); 
υmax (neat) 1056 cm
-1 (S=O); H (400 MHz, D2O) 1.17 - 1.29 (6H, m, SCH2CH3a & SCH2CH3b), 
2.83 - 2.94 (2H, m, SCHH’CH3a & SCHH’CH3b), 3.05 - 3.17 (2H, m, SCHH’CH3a & 
SCHH’CH3b), 3.44 (2H, s, H-2Ba & H-2Bb), 3.53 - 3.84 (20H, m), 3.86 - 3.94 (2H, m, H-6’Aa & 
H-6’Ab), 4.18 - 4.23 (1H, m, H-1Ab), 4.32 - 4.39 (2H, m, H-1Ba & H-1Bb), 4.46 - 4.51 (1H, m, 
H-1Aa); C (100.5 MHz, D2O) 6.5 (q, SCH2CH3a & SCH2CH3b), 39.5 (t, SCH2CH3a), 40.2 (t, 
SCH2CH3b), 60.0, 61.0, 61.0, 67.5, 68.5, 68.9, 70.9, 70.9, 72.5, 72.5, 75.3, 75.3, 75.4, 75.6, 
77.0, 77.2, 79.0, 79.6 (20 x C), 87.5 (d, C-1Ab), 90.3 (d, C-1Aa), 102.8 (d, C-1Ba & C-1Bb); 
HRMS (ESI-TOF): calcd. for C14H27O11S
+: 403.1269. Found: 403.1284 (MH+). 
 
Separation of Sulfoxide Diastereoisomers by HPLC 
The diastereoisomeric mixtures of gluco glycosyl sulfoxides 5.25 and galacto glycosyl 
sulfoxides 5.42 were separated by HPLC (column: Luna 5u C18 (100 Å) column 
(Phenomenex); eluent: 0.05% TFA in water; column oven: 40 °C; flow rate: 3.5 mL/min; 
detection: UV 210 nm) to afford single diastereoisomers: 
 
Ethyl 1-(R)-sulfinyl-β-D-glucopyranoside 5.25 RS 
 
tR = 12.0 min; H (400 MHz, D2O) 1.19 (3H, t, J 7.4 Hz, SCH2CH3), 2.82 - 2.93 (1H, m, 
SCHH’CH3), 3.05 - 3.17 (1H, m, SCHH’CH3), 3.37 (1H, t, J 9.4 Hz, H-4), 3.46 - 3.55 (2H, m, 
H-3 & H-5), 3.60 (1H, t, J 9.4 Hz, H-2), 3.69 (1H, dd, J6,6’ 12.5 Hz, J5,6 4.7 Hz, H-6), 3.83 (1H, 
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dd, J6,6’ 12.5 Hz, J5,6’ 1.6 Hz, H-6’), 4.16 (1H, d, J1,2 9.8 Hz, H-1); C (100.5 MHz, D2O) 6.5 
(q, SCH2CH3), 40.1 (t, SCH2CH3), 60.4 (t, C-6), 67.7 (d, C-2), 68.6 (d, C-4), 76.9 (d, C-3), 
80.2 (d, C-5), 87.7 (d, C-1); HRMS (ESI-TOF): calcd. for C8H16O6SNa
+: 263.0560. Found: 
263.0563 (MNa+). 
 
Ethyl 1-(S)-sulfinyl-β-D-glucopyranoside 5.25 SS 
 
tR = 10.9 min; H (400 MHz, D2O) 1.23 (3H, t, J 7.4 Hz, SCH2CH3), 2.81 - 2.93 (1H, m, 
SCHH’CH3), 3.04 - 3.15 (1H, m, SCHH’CH3), 3.32 (1H, t, J 9.0 Hz, H-4), 3.41 - 3.53 (2H, m, 
H-3 & H-5), 3.55 - 3.68 (2H, m, H-2 & H-6), 3.82 (1H, d, J6,6’ 12.5 Hz, H-6’), 4.46 (1H, d, 
J1,2 9.8 Hz, H-1); C (100.5 MHz, D2O) 6.5 (q, SCH2CH3), 39.4 (t, SCH2CH3), 60.7 (t, C-6), 
68.8 (d, C-4), 69.1 (d, C-2), 77.1 (d, C-3), 80.7 (d, C-5), 90.4 (d, C-1); HRMS (ESI-TOF): 
calcd. for C8H16O6SNa
+: 263.0560. Found: 263.0563 (MNa+). 
 
Ethyl 1-(R)-sulfinyl-β-D-galactopyranoside 23 RS 
 
tR = 6.9 min; H (400 MHz, D2O) 1.20 (3H, t, J 7.6 Hz, SCH2CH3), 2.85 - 2.96 (1H, m, 
SCHH’CH3), 3.07 - 3.18 (1H, m, SCHH’CH3), 3.62 - 3.70 (2H, m, H-5 & H-6), 3.72 – 3.80 
(2H, s, H-3 & H-6’), 3.84 - 3.92 (2H, m, H-2 & H-4), 4.09 (1H, d, J1,2 9.8 Hz, H-1); C (100.5 
MHz, D2O) 6.5 (q, SCH2CH3), 40.2 (t, SCH2CH3), 61.2 (t, C-6), 65.0 (d, C-2), 68.6 (d, C-3), 
73.9 (d, C-4), 79.9 (d, C-5), 88.4 (d, C-1), HRMS (ESI-TOF): calcd. for C8H16O6SNa
+: 
263.0560. Found: 263.0554 (MNa+). 
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Ethyl 1-(S)-sulfinyl-β-D-galactopyranoside 23 SS 
 
tR = 7.8 min; H (400 MHz, D2O) 1.25 (3H, t, J 7.6 Hz, SCH2CH3), 2.82 - 2.94 (1H, m, 
SCHH’CH3), 3.05 - 3.16 (1H, m, SCHH’CH3), 3.60 - 3.68 (2H, m, H-5 & H-6), 3.69 - 3.76 
(2H, m, H-3 & H-6’), 3.80 (1H, t, J 9.6 Hz, H-2), 3.90 (1H, d, J4,5 3.1 Hz, H-4), 4.41 (1H, d, 
J1,2 9.8 Hz, H-1); C (100.5 MHz, D2O) 6.4 (q, SCH2CH3), 39.4 (t, SCH2CH3), 61.0 (t, C-6), 
66.5 (d, C-2), 68.8 (d, C-3), 73.9 (d, C-4), 80.2 (d, C-5), 91.1 (d, C-1); HRMS (ESI-TOF): 
calcd. for C8H16O6SNa
+: 263.0560. Found: 263.0554 (MNa+). 
 
Glycosyl Sulfoxide Inhibition Studies 
Enzymes 
β-Glucosidase from almonds was obtained as a lyophilised powder (3.4 mg) which was 
dissolved in sodium phosphate buffer solution (600 µL, 0.05 M, pH 6.8).  
 
β-Galactosidase from Eschericia coli was obtained as a lyophilised powder (1.68 mg) which 
was dissolved in a buffer solution (600 µL, pH 7.0) containing Tris HCl (10 mM), MgCl2 
(10 mM) and β-mercaptoethanol (1 mM). A portion of the resulting solution (10 µL) was then 
diluted with the above buffer solution (40 µL) to obtain an appropriate concentration of 
enzyme. 
 
α-Mannosidase from jack beans was obtained as an ammonium sulphate suspension, which 
was diluted with sodium acetate buffer solution (400 µL, 0.1 M, pH 4.5). 
 




A stock solution of 60 mM o-nitrophenol β-D-glucopyranoside (0.36 g, 1.2 mmol) was 
prepared in sodium phosphate buffer (20 mL, 0.05 M, pH 6.8). Similar stock solutions of 
10 mM ethyl 1-sulfinyl-β-D-glucopyranoside 5.25, ethyl 1-(R)-sulfinyl-β-D-glucopyranoside 
5.25 RS and ethyl 1-(S)-sulfinyl-β-D-glucopyranoside 5.25 SS (48 mg, 0.20 mmol) were 
prepared in the same buffer solution (20 mL). A variety of volumes of each solution 
(100 – 500 µL of substrate, 0 – 500 µL of inhibitor) were mixed and the resulting solution made 
up to 1 mL with the previously mentioned buffer solution. The solution was then incubated at 
25 °C for 10 min. Enzyme solution (1 µL, as prepared above) was added, and the change in 
absorbance followed at 420 nm.  
 
ii) α-Mannosidase56 
A stock solution of 25 mM p-nitrophenol α-D-mannopyranoside (0.151 g, 0.50 mmol) was 
prepared in sodium acetate buffer solution (20 mL, 0.1 M, pH 4.5). A similar stock solution of 
40 mM ethyl 1-(R)-sulfinyl-β-D-mannopyranoside 5.41 (96 mg, 0.40 mmol) was prepared in 
the same buffer solution (10 mL). A variety of volumes of each solution (100 – 500 µL of 
substrate, 0 – 500 µL of inhibitor) were mixed and the resulting solutions made up to 1 mL 
with the previously mentioned buffer solution. The solution was then incubated at 37 °C for 
10 min. Enzyme solution (2 μL, as prepared above) was added, and the change in absorbance 
followed at 405 nm. 
 
iii) β-Galactosidase57 
A stock solution of 1.2 mM o-nitrophenol β-D-galactopyranoside (36 mg, 0.12 mmol) was 
prepared in sodium phosphate buffer solution (100 mL, 0.1 M, pH 7.0) containing 0.15 M 
NaCl. Similar stock solutions of 10 mM ethyl 1-sulfinyl-β-D-galactopyranoside 5.42, ethyl 
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1-(R)-sulfinyl-β-D-galactopyranoside 5.42 RS and ethyl 1-(R)-sulfinyl-β-D-galactopyranoside 
5.42 SS (48 mg, 0.20 mmol) were prepared in the same buffer solution (20 mL). A variety of 
volumes of each solution (100 – 500 µL of substrate, 0 – 500 µL of inhibitor) were mixed and 
the resulting solution made up to 1 mL with the previously mentioned buffer solution. The 
solution was then incubated at 37 °C for 10 min. Enzyme solution (1 µL, as prepared above) 
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